valsartan has been researched along with valine in 1720 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (0.70) | 18.7374 |
| 1990's | 112 (6.51) | 18.2507 |
| 2000's | 1013 (58.90) | 29.6817 |
| 2010's | 576 (33.49) | 24.3611 |
| 2020's | 7 (0.41) | 2.80 |
| Authors | Studies |
|---|---|
| Chow, L; De Gasparo, M; Levens, N | 2 |
| Cooper, ME; Komers, R | 1 |
| Bauer, JH; Reams, GP | 1 |
| Cohen, T; de Gasparo, M; Howald, H; Müller, P; Racine-Poon, A; Sioufi, A | 1 |
| Cumin, F; Kelly, M; Samani, NJ; Wood, JM | 1 |
| Lüscher, TF; Tschudi, MR | 1 |
| Argiolas, L; Marano, G | 1 |
| Criscione, L; Lüscher, TF; Novosel, D; Pfeiffer, K; Tschudi, MR | 1 |
| Bühlmayer, P; Criscione, L; de Gasparo, M; Ramjoué, HP; Whitebread, S; Wood, J | 1 |
| Levens, NR; Schnell, CR; Wood, JM | 1 |
| de Gasparo, M; Whitebread, S | 1 |
| Allegrini, P; Baum, HP; Cumin, F; de Gasparo, M; Drexler, H; Kästner, S; Laurent, D; Studer, R; Whitebread, S; Zierhut, W | 1 |
| Scheidegger, KJ; Struijker-Boudier, HA; van Essen, H; Wood, JM | 1 |
| Bodin, F; Cardoni, O; Corea, L; Fogari, R; Innocenti, P; Meilenbrock, S; Porcellati, C; Provvidenza, M; Sullivan, J | 1 |
| Cao, Z; Cooper, ME; Hulthén, UL; Johnston, CI; Rumble, JR | 1 |
| Davatz, A; Francotte, E; Richert, P | 1 |
| Angeli, P; Bodin, F; Fogari, R; Heath, R; Hereng, C; Holwerda, NJ; Oddou-Stock, P; Porcellati, C | 1 |
| Biollaz, J; Brunner, HR; Buclin, T; Csajka, C | 1 |
| Hirschhorn, W; Lloyd, P; Morgan, JM; Ortiz, M; Palmisano, M; Piraino, A; Prasad, PP; Spencer, S | 1 |
| Bühlmayer, P; De Gasparo, M; Flesch, G; Kriemler, HP; Müller, P; Waldmeier, F; Winkler, T | 1 |
| Avery, C; Benz, J; Chiang, YT; Gatlin, M; Henry, D; Oshrain, C | 1 |
| Brunner, LA; Colussi, DM; Lefèvre, GY; Parisot, C; Rossolino, ML | 1 |
| Millar, AB; Thickett, DR | 1 |
| Flesch, G; Lloyd, P; Müller, P | 1 |
| Hayashi, N; Inukai, T; Kometani, M; Nakao, K; Yamamoto, S | 2 |
| Hayashi, N; Kometani, M; Nakao, K; Yamamoto, S | 2 |
| Fujimura, Y; Hayashi, N; Kometani, M; Nakao, K; Yamamoto, S | 1 |
| Burrell, LM; Johnston, CI | 1 |
| Endlich, K; Steinhausen, M | 1 |
| Bodin, F; Faust, G; Freytag, F; Hegner, G; Meilenbrock, S; Sullivan, J | 1 |
| Cox, MH; de Gasparo, M; Hewett, KW; Mukherjee, R; O, SJ; Spinale, FG | 1 |
| Goa, KL; Markham, A | 1 |
| Bindschedler, M; de Gasparo, M; Degen, P; Flesch, G; Preiswerk, G | 1 |
| Cooper, ME; Cox, A; Dziadek, M; Gilbert, RE; Roe, CJ; Wu, LL | 1 |
| Allen, TJ; Cao, Z; Cooper, ME; Hulthen, UL; Youssef, S | 1 |
| Black, HR; Graff, A; Levine, J; Mallows, S; Ruff, D; Shi, Y; Shute, D; Stoltz, R | 1 |
| Benjamin, IS; Brookman, LJ; Flesch, G; Lloyd, P; Mullins, F; Palmer, KR; Rolan, PE; Sioufi, A; Waldmeier, F; Wyld, PJ | 1 |
| Franz, IW | 1 |
| Clair, MJ; de Gasparo, M; Hebbar, L; Iannini, JP; Krombach, RS; Melton, DM; Mukherjee, R; O, SJ; Spinale, FG; Whitebread, S | 1 |
| Clair, MJ; Cox, MH; de Gasparo, M; Hebbar, L; Iannini, JP; Melton, DM; Mukherjee, R; Spinale, FG; Thomas, PB; Whitebread, S | 1 |
| de Gasparo, M; Flesch, G; Gasparini, M; Howald, H; Müller, P | 1 |
| Czendlik, CH; Howald, H; Preiswerk, G; Sioufi, A | 1 |
| de Gasparo, M; Fenoy, FJ; García-Salom, M; Madrid, MI; Tornel, J | 2 |
| Baur, M; Bodin, F; Bremner, AD; Oddou-Stock, P | 1 |
| Brooks, DP; Feuerstein, GZ; Ohlstein, EH; Ruffolo, RR | 1 |
| Unger, T | 1 |
| Daemen, MJ; Leenders, PJ; Nelissen-Vrancken, MH; Scheidegger, KJ; Smits, JF; Wood, JM | 1 |
| Davis, S; Navarrete, AE; Webb, RL | 1 |
| Antonin, KH; Flesch, G; Racine-Poon, A; Schmidt, EK | 1 |
| Bakris, GL | 1 |
| Cardot, JM; Ezzet, F; Godbillon, J; Jaouen, A; Lloyd, P; Marfil, F; Sioufi, A | 1 |
| Leary, A; Lim, P; MacDonald, T; Naas, A; Shiels, P | 1 |
| Davis, S; de Gasparo, M; Navarrete, AE; Webb, RL | 1 |
| Bolshakova, TD; Fomina, IG; Kazakov, EN; Lyusov, VA; Mazayev, VP; Olbinskaya, LI; Orlov, VA; Spormann, DO; Sulimov, VA; Sullivan, J; Zvereva, TV | 1 |
| Clair, MJ; de Gasparo, M; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Spinale, FG; Whitebread, S; Zellner, JL | 1 |
| Julius, S; Mann, J | 1 |
| Botteri, F; Cifkova, R; Hradec, J; Oddou-Stock, P; Peleska, J; Pintérová, E; Rosolová, H; Thirlwell, J; Zeman, K | 1 |
| Dubey, RK; Flammer, J; Lüscher, TF | 1 |
| Barclay, BW; Navarrete, AE; Sahota, P; Webb, RL; Wosu, NJ | 1 |
| Kullberg, BJ; Netea, MG; Peeters, AC; Thien, T; van der Meer, JW | 1 |
| Harder, S; Kenedi, P; Rietbrock, N; Schmidt, A; Thürmann, PA | 1 |
| Ivleva, AIa | 1 |
| Bünten, B; Grabensee, B; Németh, R; Plum, J | 2 |
| Brunner, HR; Burnier, M; Fricker, AF; Meilenbrock, S; Nussberger, J | 1 |
| Angiolini, M; Belvisi, L; Poma, D; Salimbeni, A; Sciammetta, N; Scolastico, C | 1 |
| Benz, JR; Black, HR; Fitzsimmons, S; Graff, A; Reed, A; Shi, Y | 1 |
| Clair, MJ; de Gasparo, M; Hebbar, L; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Rios, G; Spinale, FG; Whitebread, S | 1 |
| McInnes, GT | 2 |
| Thürmann, PA | 3 |
| Mann, JF | 1 |
| Brunner, HR; Burnier, M; Maillard, M; Mazzolai, L; Nussberger, J; Rossat, J | 1 |
| Goldstein, S; Levine, TB; Mishima, T; Sabbah, HN; Sharov, VG; Shimoyama, H; Tanimura, M | 1 |
| Leary, AC; Lim, PO; MacDonald, TM; McMahon, AD; Shiels, P | 1 |
| Arai, Y; Hirose, N; Kawamura, M; Li, J | 1 |
| Ivleva, AIa; Moiseev, VS; Sokolova, MA | 1 |
| Gatlin, M; Hedner, T; Kobi, P; Oddou-Stock, P; Oparil, S; Rapelli, A; Rasmussen, K; Sullivan, J | 1 |
| Bandoh, T; Hori, S; Kimura, M; Mitani, H; Okada, T; Takimoto, M | 1 |
| Chiang, YT; Gatlin, M; Glazer, R; Pool, JL | 1 |
| Anand, I; Baruch, L; Cohen, IS; Cohn, JN; Judd, D; Ziesche, S | 1 |
| Langtry, HD; McClellan, KJ | 1 |
| Zakirova, AN; Zakirova, NE | 1 |
| Kirk, JK | 1 |
| Balaev, VV; Drozdova, GA; Frolov, VA; Mustiatsa, VF; Rieger, P | 1 |
| Cohn, JN; Glazer, RD; Hester, A; Spormann, D; Tognoni, G | 1 |
| Balaev, VV; Drozdova, GA; Frolov, VA; Mustiatsa, VF | 1 |
| Lippert, TH; Mueck, AO; Seeger, H | 2 |
| Julius, S | 1 |
| Cohn, JN | 3 |
| Gottdiener, JS | 1 |
| Kaplan, NM | 1 |
| Aragoncillo, P; Cachofeiro, V; de las Heras, N; DeGasparo, M; Lahera, V; Maeso, R; Mann, J; Navarro-Cid, J; Ruilope, LM; Vazquez-Pérez, S | 1 |
| Baicu, SC; Crawford, FA; de Gasparo, M; Hendrick, JW; King, MK; Loging, JA; New, RB; Spinale, FG | 1 |
| Bohlender, J; Dietz, R; Haass, M; Höhnel, K; Luft, FC; Scheuermann, M; Thibault, G; Willenbrock, R | 1 |
| Belz, GG; Butzer, R; Kober, S; Mang, C; Mutschler, E | 1 |
| Arwanto, A; Atmoko, R; Kabo, P; Markum, MS; Parsudi, I; Prabowo, P; Prodjosudjadi, W; Soemantri, D; Sukandar, E; Suprihadi, H | 1 |
| Spence, JD | 1 |
| van Veldhuisen, DJ; Voors, AA | 2 |
| Coca, A; Giner, V | 1 |
| Devereux, RB | 1 |
| Califf, RM; Cohn, JN | 1 |
| Pfeffer, MA | 2 |
| Brunner, HR; Burnier, M; Centeno, C; Daven, V; Maillard, MP; Mazzolai, L; Nussberger, J | 1 |
| De Gasparo, M; Fornes, P; Gervais, M; Giudicelli, JF; Richer, C | 1 |
| Lee, TH | 2 |
| Petkun, W | 1 |
| Bertocchi, F; Cuocolo, A; Damiano, M; Iovino, GL; Izzo, R; Mann, J; Storto, G; Trimarco, B | 1 |
| Arosio, E; Lucchese, L; Marchi, SD; Prior, M; Zannoni, M | 1 |
| Aldigier, JC; Botteri, F; Mann, JF; Oddou-Stock, P; Ponticelli, C; Ruilope, LM | 1 |
| Botteri, F; Cheung, R; Huff, MW; Lewanczuk, RZ; Muirhead, N; Oddou-Stock, P; Pecher, E; Rodger, NW | 1 |
| Cukon, S; Ennezat, PV; Hammer, A; Infeld, J; Jorde, UP; Le Jemtel, TH; Lisker, J; Sonnenblick, EH; Suryadevara, V | 1 |
| Blanco, M; Botero, R; Del Portillo, H; María, E; Matiz, H; Orejarena, H; Velez, JR | 1 |
| Blanc, J; Elghozi, JL; Lambert, G | 2 |
| Bonarjee, VV; Dickstein, K | 1 |
| Carey, RM; de Gasparo, M; Siragy, HM | 1 |
| Benedict, C; Bunt, AM; Conlin, PR; Ribeiro, AB; Saito, I; Spence, JD; Williams, B | 1 |
| Leung, M; Remick, RA | 1 |
| Casado, S; Farré, J; Gómez, J; Jiménez, A; López-Blaya, A; López-Farré, A; Montón, M; Núñez, A; Sánchez de Miguel, L; Zalba, LR | 1 |
| Achimastos, AD; Baibas, NM; Kalkana, CB; Mountokalakis, TD; Roussias, LG; Skeva, II; Stergiou, GS | 1 |
| de la Serna Higuera, C | 1 |
| Finckenberg, P; Lassila, M; Nurminen, ML; Pere, AK; Vapaatalo, H | 1 |
| DelGrande, D; Shetty, SS | 1 |
| Kiukaanniemi, K; Pelkonen, O; Taavitsainen, P | 1 |
| Breu, V; Dechend, R; Fiebeler, A; Ganten, D; Gulba, D; Haller, H; Luft, FC; Luther, T; Mackman, N; Mervaala, EM; Müller, DN; Park, JK; Schmidt, F; Schneider, W; Theuer, J | 1 |
| Laverty, R; Ledingham, JM | 3 |
| Ahonen, J; Finckenberg, P; Krogerus, L; Lassila, M; Nurminen, ML; Pere, AK; Vapaatalo, H | 1 |
| Birkenhäger, WH; de Leeuw, PW | 1 |
| Bedigian, MP; Neutel, JM | 1 |
| Feely, J; Mahmud, A | 2 |
| Carey, RM; Siragy, HM | 1 |
| Elliott, WJ | 1 |
| Basset, A; Blanc, J; Elghozi, JL | 1 |
| Clair, MJ; de Gasparo, M; Hendrick, JW; King, MK; Mandel, J; McElmurray, JH; Mukherjee, R; New, RB; Sampson, AC; Spinale, FG | 1 |
| Prat, H | 1 |
| Cooper, ME; Gilbert, RE; Huang, XR; Johnson, RJ; Lai, KN; Lan, HY; Wu, LL; Yang, N; Yu, XQ | 1 |
| Bichan, NA; Maslov, AP | 1 |
| Dubiel, RF; Littlejohn, T; Marbury, T; Mroczek, W; VanderMaelen, CP | 1 |
| Agarwal, R; Bakris, GL; Bolton, WK; Catanzaro, D; Hebert, L; Janssen, I; Richardson, D; Siomos, M | 1 |
| Califf, R; Edwards, S; Gallo, P; Henis, M; Leizorovicz, A; Maggioni, AP; McMurray, J; Neuhart, E; Pfeffer, MA; Rouleau, JL; Sellers, MA; Van De Werf, F; Velazquez, E | 1 |
| Horikoshi, S; Kimura, M; Nakamura, S; Shirato, I; Suzuki, Y; Thang, NT; Tomino, Y | 1 |
| Burkhardt, R; Geiger, H; Gossmann, J; Haak, T; Harder, S; Klinkhardt, U; Lenz, T; Scheuermann, EH; Sedlmeyer, A | 1 |
| Cohn, JN; Glazer, R; Spormann, D; Tognoni, G | 1 |
| Ganten, D; Geiger, H; Hartner, A; Hilgers, KF; Hugo, C; Mai, M; Mann, JF; Porst, M; Veelken, R; Wittmann, M | 1 |
| Cao, Z; Casley, D; Cooper, ME; Cox, A; Dean, R; Forbes, JM; Gilbert, RE; Kelly, DJ; Martinello, P | 1 |
| Andersen, SE; Pedersen, ST | 1 |
| Kano, H; Kohno, M; Minami, M; Mizushige, K; Nozaki, S; Ohmori, K; Yasunari, K; Yoshikawa, J | 1 |
| Iwao, H; Izumi, Y; Kawano, H; Kim, S; Kimoto, M; Yoshiyama, M; Zhan, Y | 1 |
| Sandmann, S; Unger, T; Yu, M | 1 |
| Burnier, M | 1 |
| Tepel, M; van der Giet, M; Zidek, W | 1 |
| Brattström, A; Götting, B; Peters, S; Rust, H; Trümmel, M | 1 |
| Ellis, SG | 1 |
| Buczko, W; Chabielska, E; Chłopicki, S; Gryglewski, RJ; Koda, M | 1 |
| Kulbertus, H | 1 |
| Corradi, L; Fogari, R; Marasi, G; Mugellini, A; Poletti, L; Zoppi, A | 1 |
| Basset, A; Blanc, J; Elghozi, JL; Hagège, A; Messas, E | 1 |
| Bertanelli, F; Leone, A; Mori, L | 1 |
| Cheng, ZJ; Fiebeler, A; Ganten, D; Ganten, U; Lapatto, R; Luft, FC; Mervaala, EM; Müller, DN; Nurminen, K; Tikkanen, I; Vapaatalo, H | 1 |
| Cheng, ZJ; Luft, FC; Mervaala, EM; Muller, D; Nurminen, K; Park, JK; Ruskoaho, H; Tikkanen, I; Vapaatalo, H; Vaskonen, T | 1 |
| Bieringer, M; Breu, V; Dechend, R; Fiebeler, A; Haller, H; Luft, FC; Müller, DN; Park, JK; Schmidt, F; Shagdarsuren, E | 1 |
| Arnaboldi, L; Calvio, AM; Corsini, A; de Gasparo, M; Mussoni, L; Parolari, A; Sironi, L; Tremoli, E | 1 |
| Fukuma, T; Hasegawa, T; Miki, T; Miura, T; Nakano, A; Shimamoto, K; Tsuchida, A | 1 |
| Vidt, DG | 1 |
| Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L | 1 |
| Ramahi, TM | 1 |
| Florin, M; Liu, KL; Lo, M; Sassard, J | 1 |
| Hannan, RD; Krum, H; Lim, S; See, F; Tzanidis, A; Ugoni, AM | 1 |
| Hauner, H; Lee, YM; Skurk, T | 1 |
| Casado, S; Gómez, J; Jiménez, A; Lopez-Bloya, A; López-Farré, A; Montón, M; Núñez, A; Rico, L; Sánchez de Miguel, L | 1 |
| Altinay, S; Göğer, NG; Ozkan, SA; Satana, E; Sentürk, Z | 1 |
| Beevers, DG; Beevers, M; Chung, NA; Lip, GY | 1 |
| Miller, AB; Srivastava, P | 1 |
| Hollenberg, NK | 2 |
| Cooper, ME; Gibbs, NJ; Kelly, DJ; Skinner, SL; Wilkinson-Berka, JL | 1 |
| Bonnefis-Boyer, S; Hébert, D; Laplante, A; Lasko, BH | 1 |
| Dinçer, I; Döven, O; Sayin, T | 1 |
| Hayashida, W; Yasaka, A | 1 |
| Magometschnigg, D | 1 |
| Fruhwald, FM; Kickenweiz, E; Klein, W; Zweiker, R | 1 |
| Coats, AJ | 1 |
| Bedigian, MP; Neutel, JM; Smith, DH; Weir, MR | 1 |
| Brunner, H; Ekman, S; Hansson, L; Henis, M; Julius, S; Kjeldsen, SE; Laragh, J; McInnes, G; Smith, B; Weber, M; Zanchetti, A | 1 |
| Bender, G; Hefner, L; Heidbreder, E; Lopau, K; Wanner, C | 1 |
| Benachi, A; Daikha-Dahmane, F; Gubler, MC; Laurent, N; Martinovic, J | 1 |
| Cao, H; Ke, YS; Yang, T | 1 |
| Huang, J; Xiang, Y | 1 |
| Allen, TJ; Bertram, JF; Cooper, ME; Gilbert, RE; Hulthen, UL; Kelly, DJ; Mifsud, SA; Wilkinson-Berka, JL | 1 |
| Carey, RM; de Gasparo, M; El-Kersh, M; Siragy, HM | 1 |
| Kolina, IB; Neverov, NI; Shilov, EM; Shvetsov, MIu; Stavrovskaia, EV; Zakharova, EV | 1 |
| Kozlovskaia, NL; Medvedeva, TIu; Miroshnichenko, NG; Okonova, EB; Plieva, OK; Rudenko, TE; Shonichev, DG; Shvetsov, MIu; Stavrovskaia, EV | 1 |
| Calhoun, DA; DeLucca, PT; Elliott, WJ; Gazdick, LP; Kerns, DE; Zeldin, RK | 1 |
| Hartner, A; Hilgers, KF; Mann, JF; Porst, M; Veelken, R | 1 |
| Alba, F; de Gasparo, M; Hermoso, F; Martínez, JM; Prieto, I; Ramírez, M; Ramírez, MJ; Vargas, F | 1 |
| Berlowitz, MS; Ennezat, PV; Hankins, SR; Latif, F; Le Jemtel, TH; Obeleniene, R; Tandon, S | 1 |
| De Gasparo, M; Domergue, V; Fornes, P; Giudicelli, JF; Richer, C | 1 |
| Bertocchi, F; Bonaduce, D; Carretta, R; Condorelli, M; Fogari, R; Malacco, E; Mann, J; Palatini, P | 1 |
| Benetos, A; de Gasparo, M; Labat, C; Lacolley, P; Lajemi, M; Safar, ME | 1 |
| Asmar, R; Ghobrial, H; Herpin, D; Mallion, JM; Poncelet, P; Vaïsse, B; Vaur, L | 1 |
| Lau, CP; Tipoe, GL; Wing-Hon Lai, K; Yu, CM | 1 |
| Auer, JW; Berent, R; Eber, B | 1 |
| Lewis, W; Stebbins, CL; Warren, JH; Wraa, CE | 1 |
| Ogihara, T; Rakugi, H | 2 |
| Aschwanden, R; Ferber, P; Sadecky, L; Waeber, B | 1 |
| Armstrong, PW; Borer, J; Fleming, T; Lipicky, R | 1 |
| Armaganijan, D; Franco, R; Madi, JC; Oigman, W | 1 |
| Shimoni, Y | 1 |
| Buenestado, J; Miñana, JM; Reñé, JM; Sesé, E | 1 |
| Akishita, M; Chen, R; de Gasparo, M; Horiuchi, M; Iwai, M; Li, Z; Nakagami, H; Suzuki, J; Wu, L | 1 |
| Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA | 1 |
| Hasegawa, T; Kuno, A; Miki, T; Miura, T; Nishino, Y; Shimamoto, K; Tsuchida, A | 1 |
| Komajda, M | 2 |
| Carey, RM; Howell, NL; Jin, XH; Siragy, HM | 1 |
| Cohn, JN; Tognoni, G | 1 |
| Cooper, ME; Cox, AJ; Gilbert, RE; Kelly, DJ; Tolcos, M; Wilkinson-Berka, JL | 1 |
| Akishita, M; Chen, R; de Gasparo, M; Horiuchi, M; Iwai, M; Nakagami, H; Suzuki, J; Wu, L | 1 |
| Lin, S; Wen, H | 1 |
| Adam, SA; Handrock, R; Kolloch, R; Schmidt, A; Weidinger, G | 1 |
| Cachofeiro, V; Cediel, E; de Las Heras, N; Lahera, V; Oubiña, MP; Ruilope, LM; Sanz-Rosa, D; Vázquez-Pérez, S | 1 |
| Brunner, HR; Burnier, M; Centeno, C; Maillard, MP; Nussberger, J; Würzner, G | 1 |
| Daneshtalab, N; Jamali, F; Lewanczuk, RZ | 1 |
| Bigler, H; Graf, P; Gruendl, E; Letzkus, M; Merz, M; Séchaud, R | 1 |
| Akesolo, U; Alonso, RM; González, L; Jiménez, RM | 1 |
| Bertocchi, F; Carretta, R; Di, SS; Dorigatti, F; Malacco, E; Mann, J; Palatini, P | 1 |
| de Gasparo, M; Feng, TC; Hua, RJ; Ji, YY; Ying, WY | 1 |
| McMurray, JJ | 3 |
| Lippert, C; Mueck, AO; Seeger, H; Wallwiener, D | 1 |
| Piérard, L | 1 |
| Bertram, D; Coote, JH | 1 |
| Baicu, SC; deGasparo, M; Goldberg, AT; Hendrick, JW; Joffs, C; King, MK; Krombach, RS; Multani, MM; Sample, JA; Spinale, FG | 1 |
| Erbaş, C; Erdine, S; Gültekin, N; Güven, O; Küçükoglu, MS; Mutlu, H; Okçün, B; Okuyan, E; Ozhan, H; Uner, S; Yigit, Z | 1 |
| Chen, Y; Li, W; Liu, W; Sun, N; Yu, Y | 1 |
| Barlera, S; Höglund, C; Latini, R; Staszewsky, L; Volpi, A; Wong, M | 1 |
| Haddy, FJ | 1 |
| Cayley, WE | 1 |
| Forfar, JC; Munir, S | 1 |
| Campbell, DJ | 2 |
| Rahman, AR; Rasool, AH; Rehman, A | 1 |
| Bruneval, P; Clozel, JP; de Gasparo, M; Hess, P; Nuesslein-Hildesheim, B | 1 |
| Casado, S; Gómez, J; Jiménez, A; López-Blaya, A; López-Farré, A; Montón, M; Núñez, A; Uriarte, AC; Velasco, S; Zalba, LR | 1 |
| Belz, GG; Breithaupt-Grögler, K; Butzer, R; Fuchs, W; Hausdorf, C; Mang, C | 1 |
| Becherer, A; Dudczak, R; Karanikas, G; Kletter, K; Wiesner, K | 1 |
| Carretta, R; Fogari, R; Salvetti, A; Veglio, F; Zoppi, A | 1 |
| Dendorfer, A; Dodt, C; Handrock, R; Muck, P; Struck, J; Trübger, D; Weidinger, G | 1 |
| Carey, RM; De Gasparo, M; El-Kersh, MA; Siragy, HM; Webb, RL | 1 |
| Corvol, P; Plouin, PF | 1 |
| Korlipara, K; Mancia, G; Silvert, B; van Rossum, P; Villa, G | 1 |
| Dunseath, G; Luzio, SD; Owens, DR | 1 |
| Halim, SA; Nouh, MS | 1 |
| Aviram, M; Hussein, O; Rosenblat, M; Shneider, J | 1 |
| Rapi, J | 1 |
| Dagistanli, FK; Erek, E; Kalender, B; Oztürk, M; Tunçdemir, M; Uysal, O; Yegenaga, I | 1 |
| Bonnet, F; Burns, WC; Candido, R; Cao, Z; Carey, RM; Cooper, ME; De Gasparo, M; Kawachi, H; Nesteroff, SP; Shimizu, F | 1 |
| Houghton, AR | 1 |
| Derosa, G; Fogari, R; Marasi, G; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A | 1 |
| Aizawa, Y; Ikarashi, T; Kaneko, S; Nakagawa, O; Souda, S; Suzuki, K | 1 |
| Fakouhi, K; He, W; Krause, S; Krum, H; Nolly, H; Roniker, B; Workman, D | 1 |
| Viberti, G; Wheeldon, NM | 1 |
| Benigni, A; Donadoni, C; Fassi, A; Gagliardini, E; Lepre, MS; Remuzzi, A; Remuzzi, G; Sangalli, F | 1 |
| Borovkov, NN; Sidorova, NV | 1 |
| Cherubini, A; Di Lenarda, A; Perkan, A; Salvatore, L; Sinagra, G | 1 |
| Sağlík, S; Tatar, S | 1 |
| Gordon, A; Helmers, C; Löfdahl, P; Pantev, E; Rydberg, E; Willenheimer, R | 1 |
| Faulds, DM; Wellington, K | 1 |
| Carretero, OA; Kapke, A; Liu, YH; Shesely, EG; Xu, J; Yang, F; Yang, XP | 1 |
| Krum, H; Martin, J | 1 |
| Barlera, S; Benza, RL; Chiang, YT; Cohn, JN; Gottlieb, SO; Kleemann, TD; Latini, R; Rosconi, F; Staszewsky, L; Vandervoort, PM; Volpi, A; Wong, M | 1 |
| Nesterov, IuI; Spoeva, VI; Tepliakov, AT | 1 |
| Andersson, OK; Elmfeldt, D; Friberg, PR; Fridman, KU; Wysocki, M | 1 |
| Buczko, W; Chabielska, E; Kalinowski, L; Malinski, T; Matys, T | 1 |
| Ito, S; Kanmatsuse, K; Komatsu, K; Sved, AF; Tsukamoto, K | 1 |
| Anand, I; Cohn, JN; Gottlieb, SO; Latini, R; Maggioni, AP; Tognoni, G | 1 |
| Greenberg, BH | 1 |
| Inagaki, K; Iwanaga, Y; Kihara, Y; Mochly-Rosen, D; Onozawa, Y; Sarai, N; Takenaka, H | 1 |
| André, E; Barberis, C; Colson, P; Guillon, G; Perrigault, PF; Ryckwaert, F | 1 |
| Kim, S | 1 |
| Sato, H | 1 |
| Clozel, JP; Clozel, M; de Gasparo, M; Germann, PG; Hess, P; Persohn, E; Roman, D; Webb, RL | 1 |
| Glazer, R; Gurrieri, P; McLeod, J; Prasad, PP; Yeh, CM | 1 |
| Fujita, T; Goto, A; Hara, C; Horita, S; Kunimi, M; Seki, G; Sugaya, T; Taniguchi, S; Uwatoko, S; Yamada, H; Zheng, Y | 1 |
| Anand, I; Bevilacqua, M; Cardano, P; Chiang, YT; Cohn, JN; Dunselman, PH; Holwerda, NJ; Judd, D; Latini, R; Maggioni, AP; Masson, S; Salio, M; Tognoni, G | 1 |
| Amedeo Modesti, P; Bertolozzi, I; Boddi, M; Cecioni, I; Coppo, M; Formigli, L; Perna, AM; Polidori, G; Serneri, GG; Vanni, S; Zecchi-Orlandini, S | 1 |
| Biswas, PN; Shakir, SW; Wilton, LV | 1 |
| Allcock, NM; Graham, MR | 1 |
| Edvinsson, L; Malmsjö, M; Pantev, E; Stenman, E; Wackenfors, A | 1 |
| Bedigian, MP; Falk, SA; Gengaro, PE; Gurevich, AK; Nemenoff, RA; Rizeq, M; Schrier, RW; Summer, SN; Weinberger, HD | 1 |
| Elmfeldt, D; Meredith, P; Olofsson, B | 1 |
| Gavish, D; Leibovitz, E; Lubimov, L; Shargorodsky, M; Zimlichman, R | 1 |
| Jacobi, J; John, S; Klingbeil, AU; Schmieder, RE; Schneider, MP; Weidinger, G | 1 |
| Isomura, Y; Kimura, M; Mitani, H | 1 |
| Calvillo, L; De Angelis, N; Fiordaliso, F; Funicello, M; Gobbi, M; Latini, R; Masson, S; Mennini, T | 1 |
| Cui, TX; Horiuchi, M; Iwai, M; Li, JM; Li, Z; Nakagami, H | 1 |
| Brom, HL; Rauwerda, JA; Vahl, AC; van Rij, GL; Vink, GQ; Yilmaz, EN | 1 |
| Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H | 1 |
| Alba, F; Banegas, I; de Gasparo, M; Hermoso, F; Prieto, I; Ramírez, M; Segarra, AB; Vargas, F | 1 |
| Bourdeix, I; Francillon, A; Ghannad, E; Gosse, P; Vaillant, J | 1 |
| Handrock, R; Jacobi, J; John, S; Klingbeil, AU; Schmieder, RE; Schneider, MP | 1 |
| Akbay, E; Altintas, E; Kiykim, A; Konca, K; Seyrek, E; Sezer, K; Sezgin, O; Tiftik, N | 1 |
| deBlois, D; Der Sarkissian, S; Duguay, D; Hamet, P; Marchand, EL | 1 |
| Eberhardt, W; Fierlbeck, W; Gauer, S; Geiger, H; Hartner, A; Hauser, IA | 1 |
| Hiratsuka, M; Ito, S; Kanmatsuse, K; Komatsu, K; Sved, AF; Tsukamoto, K | 1 |
| Handrock, R; Schmieder, RE | 1 |
| Anand, IS; Chiang, YT; Cohn, JN; Fisher, LD; Glazer, RD; Latini, R; Maggioni, AP; Masson, S; Tognoni, G | 1 |
| Aros, C; Bertocchi, F; Campbell, R; Fagiani, L; Perna, A; Perticucci, E; Remuzzi, A; Remuzzi, G; Ruggenenti, P; Sangalli, F; Viscarra, C | 1 |
| Mengden, T; Vetter, H; Weisser, B | 1 |
| Boonstra, PW; Buikema, H; Lübeck, RH; van Buiten, A; van Gilst, WH; van Veldhuisen, DJ; Voors, AA; Wagenaar, LJ | 1 |
| Allen, TJ; Burrell, LM; Cao, Z; Cooper, ME; Davis, BJ; Lassila, M | 1 |
| Chan, P; Cheng, JT; Liu, IM; Tzeng, TF; Wong, KL; Yang, TL | 1 |
| Andersen, S; Jacobsen, P; Jensen, BR; Parving, HH | 1 |
| Akino, M; Chiba, S; Kitabatake, A; Kumamoto, H; Matsui, Y; Mikami, T; Nan, J; Okamoto, H; Onozuka, H; Shimizu, T; Sugawara, T | 1 |
| Ke, YS; Tao, YY; Yang, H; Yu, GH | 1 |
| Abe, S; Aizawa, Y; Hanawa, H; Hayashi, M; Hui, L; Kashimura, T; Kato, K; Kodama, M; Nakazawa, M; Tachikawa, H; Watanabe, K; Yoshida, T | 1 |
| Campo, C; Praga, M; Rodicio, JL; Ruilope, LM; Segura, J | 1 |
| Chijiwa, T; Hashimoto, K; Horino, T; Hosokawa, T; Ito, H; Sasaoka, A; Tanimoto, N; Yoshida, T | 1 |
| Domínguez Ortega, FJ; Fuentes Gonzalo, MJ; Martínez Alonso, JC; Méndez Alcalde, J | 1 |
| Alhenc-Gelas, F; Chollet, C; Doucet, A; Helou, CM; Imbert-Teboul, M; Marchetti, J; Rajerison, R | 1 |
| Kohno, M | 1 |
| Abadir, P; Awad, A; Siragy, HM; Webb, R | 1 |
| Ito, S; Kanmatsuse, K; Katsunuma, N; Tsukamoto, K | 1 |
| Kubota, T; Takeshita, A | 1 |
| Alföldi, S | 1 |
| Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Düsing, R; Gohlke, P; Lottermoser, K; Unger, T; Vetter, H | 1 |
| Carretta, R; Fagan, T; Mallion, JM; Martinez, JF; Oddou, P; Teitelbaum, I; Trenkwalder, P; Tykarski, A | 1 |
| Carson, P; Cohn, JN; Tognoni, G | 1 |
| Terra, SG | 1 |
| Bessard, G; Caron, F; Cracowski, JL; Hakim, A; Hoffmann, P; Sessa, C; Stanke-Labesque, F | 1 |
| Balazovjech, I; Jezek, T | 1 |
| Genda, S; Ichikawa, Y; Kuno, A; Matsumoto, T; Miki, T; Miura, T; Sakamoto, J; Shimamoto, K; Tanno, M | 1 |
| Wilensky, RL | 1 |
| Brunner, H; Ekman, S; Hansson, L; Julius, S; Kjeldsen, SE; Laragh, JH; McInnes, G; Platt, F; Schork, AM; Smith, B; Weber, M; Zanchetti, A | 1 |
| Buganov, AA; Mamedova, SI; Novokrestova, SV; Salamatina, LV; Shesterikova, NV; Umanskaia, EL | 1 |
| Abe, Y; Fukui, T; Hitomi, H; Kimura, S; Kiyomoto, H; Kobori, H; Kohno, M; Nishiyama, A; Rahman, M; Shokoji, T; Yao, L; Zhang, GX | 1 |
| Ayala, DE; Calvo, C; Covelo, M; Domínguez, MJ; Fernández, JR; Hermida, RC; López, JE; Mojón, A | 1 |
| Femiano, F | 1 |
| Della Chiesa, A; Hess, OM; Meier, B; Pfiffner, D | 1 |
| Mutasim, DF | 1 |
| Guan, S; Wang, B | 1 |
| Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV | 1 |
| Alba, F; Banegas, I; Gasparo, Md; Hermoso, F; Prieto, I; Ramírez, M; Segarra, AB; Vargas, F | 1 |
| Califf, RM; Edwards, S; Gallo, P; Henis, M; Kober, L; Leimberger, JD; Maggioni, AP; McMurray, JV; Pfeffer, MA; Rouleau, JL; Sellers, MA; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Anand, IS; Chiang, YT; Cohn, JN; Glazer, R; Latini, R; Masson, S | 1 |
| Abadir, PM; Carey, RM; Siragy, HM | 1 |
| Barki-Harrington, L; Luttrell, LM; Rockman, HA | 1 |
| Aljada, A; Dandona, P; Garg, R; Ghanim, H; Hofmayer, D; Kumar, V; Mohanty, P; Syed, T; Tripathy, D | 1 |
| GIRAUD, G; PUECH, A | 1 |
| BERNARD, J | 1 |
| He, SX; Ling, HX; Sun, SY | 1 |
| LABORIE, P | 1 |
| BOULIN, R | 1 |
| Jugdutt, BI; Menon, V | 3 |
| Hashimoto, R; Kawahara, S; Matsuzaki, M; Umemoto, S | 1 |
| Gaspari, TA; Hannan, RE; Jones, ES; Widdop, RE | 1 |
| Shigemasa, M; Takami, T | 1 |
| Jermendy, G; Matos, L; Winkler, G | 2 |
| Ghali, JK | 1 |
| Arslan, A; Cihangiroğlu, M; Demir, A; Yalniz, M | 1 |
| Dominiak, P; Häuser, W | 1 |
| Arregui, B; Fenoy, FJ; López, B; Salom, MG; Valero, F | 1 |
| Bayraktutan, U | 1 |
| Bertocchi, F; Ceconi, C; De Tommasi, E; Ferrari, R; Francolini, G; Guida, P; Iacoviello, M; Massari, F; Pitzalis, MV; Rizzon, P; Romito, R | 1 |
| Vachiéry, JL | 1 |
| Deswal, A; Mann, DL | 1 |
| Califf, RM; Edwards, S; Henis, M; Køber, L; Leimberger, JD; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Sellers, MA; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, H; Zelenkofske, S | 1 |
| Hollomby, DJ; House, A; Jevnikar, AM; Muirhead, N | 1 |
| Bayraktutan, U; Ulker, S | 1 |
| Abe, M; Abe, T; Ito, S; Obara, N; Satoh, F; Tanemoto, M | 1 |
| Düsing, R; Lottermoser, K; Ulrich-Merzenich, G; Vetter, H | 1 |
| Iwasawa, H; Matsumoto, H; Nagaoka, Y; Nakao, T; Okada, T; Tomaru, R; Wada, T | 1 |
| Buczko, W; Chabielska, E; Domaniewski, T; Kucharewicz, I; Matys, T; Pawlak, R | 1 |
| Delles, C; Handrock, R; Klingbeil, AU; Schmieder, RE; Schneider, MP; Weidinger, G | 1 |
| Agelink, MW; Passenberg, P; Ullrich, H | 1 |
| Latini, R; Maggioni, AP; Masson, S; Staszewsky, L | 1 |
| Imanishi, S; Kurata, Y; Matsuda, H; Sato, R; Shibamoto, T | 1 |
| Borgnino, C; Capuano, V; Malacco, E; Palatini, P; Spagnuolo, V; Varì, N | 1 |
| Corradi, L; Fogari, R; Mugellini, A; Pasotti, C; Preti, P; Rinaldi, A; Zoppi, A | 1 |
| Goa, KL; Wellington, K | 1 |
| Fujita, T; Goto, A; Hirata, Y; Nagai, R; Nishimatsu, H; Oba, S; Omata, M; Satonaka, H; Suzuki, E; Takeda, R | 1 |
| Fogari, R; Marasi, G; Mugellini, A; Pasotti, C; Poletti, L; Preti, P; Rinaldi, A; Zoppi, A | 1 |
| Bedigian, MP; Lu, L; Robinson, AD; Sun, Y; Weber, KT; Zhang, J | 1 |
| Eguchi, K; Hoshide, S; Hoshide, Y; Ishikawa, J; Ishikawa, S; Kario, K; Morinari, M; Shimada, K | 1 |
| Doi, M; Kobayashi, S; Kohno, M; Matsuzaki, M; Oda, T; Ohkusa, T; Okuda, S; Tokuhisa, T; Yamamoto, T; Yano, M | 1 |
| Düsing, R | 1 |
| Franco, RJ; Goldflus, S; McQuitty, M; Oigman, W | 1 |
| Kanno, Y; Nakamoto, H; Okada, H; Sugahara, S; Suzuki, H | 2 |
| UZAN, M | 2 |
| Hukai, D; Ishii, C; Kanamori, T; Ohbayashi, Y; Ohnishi, M; Ohno, K; Okabayashi, T; Ozawa, T; Sakaguchi, T; Sichiri, G; Tanaka, T; Tsutamoto, T; Tsutsui, T; Wada, A; Yokohama, H | 1 |
| ROBINSON, RH | 1 |
| Pfeffer, M | 1 |
| Daneshtalab, N; Jamali, F; Lewanczuk, RZ; Russell, A | 1 |
| McAnulty, JH | 1 |
| Kupfer, Y; Moshenyat, R; Tessler, S | 1 |
| Jorde, UP | 1 |
| Düsing, R; Gohlke, P; Hertfelder, HJ; Lottermoser, K; Vetter, H | 1 |
| Delles, C; Handrock, R; Klingbeil, AU; Schäufele, T; Schmieder, RE; Schneider, MP | 1 |
| Katayama, S; Morita, T; Yagi, S | 1 |
| Avery, MA; Benson, SC; Chittiboyina, A; Desai, P; Ho, CI; Kurtz, TW; Pershadsingh, HA; Pravenec, M; Qi, N; Wang, J | 1 |
| Lai, KN; Lam, KY; Leung, JC; Li, PS; Wing-Hon Lai, K; Yu, CM | 1 |
| Liebson, PR | 1 |
| Azizi, M; Bissery, A; Lamarre-Cliche, M; Ménard, J | 1 |
| Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM | 1 |
| Chrysant, SG | 3 |
| McMurray, JJ; Swedberg, K | 2 |
| Cui, TX; Horiuchi, M; Iwai, M; Li, HS; Li, JM; Min, LJ; Okumura, M; Shiuchi, T; Wu, L | 1 |
| Schlosshan, D; Tan, LB; Williams, SG | 1 |
| Aizawa, Y; Kamimura, T; Kato, K; Soda, S; Suzuki, K | 1 |
| Anzai, T; Hashimoto, K; Himeno, H; Imai, K; Kawana, M; Kitakaze, M; Koretsune, Y; Maruyama, S; Masaoka, Y; Matsubara, H; Matsuoka, T; Miyao, Y; Miyatake, K; Miyauchi, T; Nakamura, Y; Nomura, F; Okamoto, H; Ozono, K; Sekiya, M; Shinohara, H; Shintani, U; Shiraki, T; Takaoka, H; Tsutamoto, T; Yasumura, Y; Yokoya, K; Yokoyama, H | 1 |
| Davidai, G; Lacourciere, Y; White, WB | 1 |
| Gottlieb, SO; Hennekens, CH; Lowry, DR; Malinin, AI; O'Connor, CM; Sane, DC; Serebruany, VL; Webb, RL | 1 |
| Crijns, HJ; Folkeringa, RJ; Pinto, YM | 1 |
| Bork, K; Dewald, G | 1 |
| Ambrosia, GB; Caiazza, A; Malacco, E; Mugellini, A; Palatini, P; Santonastaso, M; Spagnuolo, V | 1 |
| Ayala, DE; Calvo, C; Hermida, RC; Ruilope, LM | 1 |
| Isaka, N; Ito, M; Kaibuchi, K; Kongo, M; Kureishi, Y; Moriki, N; Nakakuki, T; Nakano, T; Okamoto, R; Seko, T | 1 |
| Bandinelli, M; Boddi, M; Cecioni, I; Chiavarelli, M; Coppo, M; Lisi, GF; Modesti, PA; Neri Serneri, GG; Papa, ML; Toscano, T | 1 |
| Li, Q; Liu, L; Xiao, J; Xu, Z; Zhao, S | 1 |
| Cooper, ME; Thomas, MC | 1 |
| Aknay, N; Anand, I; Barlera, S; Cohn, JN; Glazer, R; Hester, A; Latini, R; Staszewsky, L; Wong, M | 1 |
| Asada, A; Maeda, K; Nakamura, M; Watanabe, T; Yasunari, K; Yoshikawa, J | 1 |
| Angeli, F; Verdecchia, P | 1 |
| Iwasaka, T; Kijima, Y; Kishimoto, N; Kosaki, A; Mori, Y; Nishiue, T; Nose, A; Okigaki, M; Tokoro, T; Yamahara, H | 1 |
| Du, YC; Xu, JY; Zhang, SJ | 1 |
| Lindholm, LH | 1 |
| Brunner, HR; Ekman, S; Hansson, L; Hua, T; Julius, S; Kjeldsen, SE; Laragh, J; McInnes, GT; Mitchell, L; Plat, F; Schork, A; Smith, B; Weber, M; Zanchetti, A | 1 |
| Brunner, HR; Ekman, S; Hansson, L; Hua, T; Julius, S; Kjeldsen, SE; Laragh, JH; McInnes, GT; Mitchell, L; Plat, F; Schork, MA; Smith, B; Weber, MA; Zanchetti, A | 1 |
| Califf, RM; Friedman, JY; Gnanasakthy, A; Reed, SD; Schulman, KA; Velazquez, EJ | 1 |
| Luft, FC | 1 |
| Atlibatur Akbas, F; Ayer, M; Ergen, K; Ger, E; Kumbasar, B; Serez, K; Uzunoglu, S | 1 |
| Epstein, M; Hollenberg, NK | 1 |
| Suzuki, H | 1 |
| Hasenfuss, G | 1 |
| Birkenhäger, WH; Staessen, JA | 2 |
| Williams, B | 1 |
| Awad, AS; Carey, RM; Siragy, HM; Webb, RL | 2 |
| Solignac, M | 1 |
| Bertocchi, F; Gargiulo, A; Malacco, E; Palatini, P; Santonastaso, M; Spagnuolo, V; Varì, NA | 1 |
| Lindberg, M | 1 |
| Chen, R; Hata, R; Horiuchi, M; Ide, A; Iwai, M; Liu, HW; Okamoto, S; Sakanaka, M; Shiuchi, T | 1 |
| Stumpe, KO | 1 |
| Huang, CX; Jiang, H; Jiang, XJ; Liang, YH; Wang, JM; Zhou, Y | 1 |
| Banfi, C; Brioschi, M; Crippa, V; de Gasparo, M; Gelosa, P; Gianazza, E; Gianella, A; Guerrini, U; Nobili, E; Sironi, L; Tremoli, E | 1 |
| Chrysant, GS; Chrysant, SG | 2 |
| Davidai, G; Krzesinski, JM; Lacourcière, Y; Schumacher, H; White, WB | 1 |
| Bernaud, C; Boivin, JM; Fay, R; Radauceanu, A; Zannad, F | 1 |
| Nilsson, PM | 1 |
| Han, Z; Liang, X; Wang, H; Xing, Y; Zhou, J | 1 |
| Berkane, N; Carlier, P; Heim, N; Mathieu, E; Uzan, S; Verstraete, L | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Gross, V; Luft, FC; Obst, M | 1 |
| Lacourciere, Y; White, WB | 1 |
| Aguilar, D; Belenkov, YN; Califf, RM; Diaz, R; Francis, GS; Henis, M; Køber, L; Leimberger, JD; McMurray, JJ; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Varshavsky, S; Velazquez, EJ | 1 |
| Dahlöf, B; Kanae, K; Mochizuki, S; Shimizu, M; Tajima, N; Taniguchi, I; Yoshida, S | 1 |
| Anavekar, NS; Califf, RM; Dickstein, K; Kober, L; Leimberger, JD; Maggioni, A; McMurray, JJ; Nordlander, R; Pfeffer, MA; Rouleau, JL; Solomon, SD; Velazquez, EJ; White, HD; Zelenkofske, S | 1 |
| Jia, JD; Li, Q; Shen, FJ; Tang, SZ; Wang, BE; Wang, P; Ying, CH | 1 |
| Chihara, Y; Fujimori, T; Iidaka, K; Inada, H; Ishimitsu, T; Matsuoka, H; Ogihara, T; Ono, H; Ono, Y; Rakugi, H; Ueda, Y | 1 |
| Chen, R; Cui, TX; Gao, XY; Horiuchi, M; Iwai, M; Jinno, T; Li, Z; Liu, HW; Okumura, M; Suzuki, J; Tsuda, M; Wu, L | 1 |
| Nguyen, A; Sharma, S | 1 |
| Jugdutt, BI; Menon, V; Sawicki, G | 1 |
| Cheung, BM | 2 |
| Alderson, NL; Cooper, ME; Forbes, JM; Thomas, MC; Thorpe, SR | 1 |
| Fukuda, D; Sata, M; Takamoto, S; Yamamoto, T | 1 |
| Bahtyiar, G; Blendea, MC; Ferrario, CM; Jacobs, D; Kumar, P; McFarlane, SI; Ogrin, C; Sha, Q; Sowers, JR; Stas, S; Stump, CS | 1 |
| Jia, JD; Ma, H; Shen, FJ; Wang, BE; Zhu, YK | 1 |
| Colson, PH; Ryckwaert, F | 1 |
| Jugdutt, BI; Sawicki, G | 2 |
| Sever, P | 1 |
| Zidek, W | 2 |
| Berk, BC; Bisognano, JD | 1 |
| Einecke, D | 2 |
| Bertocchi, F; Dorigatti, F; Ferrara, R; Mugellini, A; Palatini, P; Spagnuolo, V; Varì, N | 1 |
| Kato, H; Munakata, M; Nagasaki, A; Nunokawa, T; Sakuma, T; Toyota, T; Yoshinaga, K | 1 |
| Abadir, P; Carey, RM; Siragy, HM; Xue, C | 1 |
| Chen, K; Joseph, J; Joseph, L; Li, D; Mehta, JL | 1 |
| Croom, KF; Keating, GM | 1 |
| Aknay, N; Carson, P; Chiang, YT; Cohn, JN; Farsang, C; Glazer, RD; Krum, H; Maggioni, AP | 1 |
| Strauss, M; Verma, S | 1 |
| Azizi, M; Bissery, A; Bura-Rivière, A; Camisasca, RP; Guyenne, TT; Ménard, J; Vaidyanathan, S | 1 |
| Hedner, T; Himmelmann, A; Kjeldsen, SE | 1 |
| Jackson, G | 1 |
| Bos-Thompson, MA; Boulot, P; Dechaud, H; Hillaire-Buys, D; Mazurier, E; Morin, D; Muller, F | 1 |
| He, Y; Savoia, C; Touyz, RM; Yao, G | 1 |
| Ruilope, LM; Segura, J | 2 |
| Delcroix, C; Ekhlas, A; Esnault, VL; Moutel, MG; Nguyen, JM | 1 |
| Takeuchi, M; Yamagishi, S | 1 |
| Gong, ZJ; Huang, YQ; Ruan, P; Song, SL | 1 |
| Brunel, P; Denolle, T; Fiquet, B; Girerd, X; Herpin, D; Moulin, B; Yau, C | 1 |
| Dubiel, R; Jones, M; Smith, DH | 1 |
| Aknay, N; Anand, I; Baruch, L; Cohn, JN; Glazer, RD; Hester, A; Heywood, JT; Krum, H; Vanhaecke, J | 1 |
| Xie, XW; Zhao, P | 1 |
| Fu, H; Li, Y; Lu, Z; Ma, Y; Xiao, J | 1 |
| Cumin, F; Menard, J; Schnell, CR; Webb, RL; Wood, JM | 1 |
| Koehler, B; Meyners, W; Peters, S; Trümmel, M; Westermann, K | 1 |
| Ripley, TL | 1 |
| Aknay, N; Baruch, L; Feliciano, N; Goedel-Meinen, L; Hester, A; Hofmann, M; Majahalme, SK; Prescott, MF | 1 |
| Ambrosi, P; Andrejak, M; Drici, MD; Herpin, D; Pithois-Merli, I | 1 |
| Anand, I; Barlera, S; Carbonieri, E; Cohn, J; Gonzini, L; Latini, R; Maggioni, AP; Opasich, C; Tavazzi, L | 1 |
| Eguchi, Y; Miura, Y; Oiso, Y; Ozaki, N; Taguchi, S; Tsunekawa, S; Yamamoto, N | 1 |
| Fujita, T; Imai, Y; Matsuoka, H; Nishigaki, M; Ogihara, T; Saruta, T; Shimada, K; Shimamoto, K | 1 |
| Itoh, T; Kajikuri, J; Katsuya, H; Kusama, N; Suzuki, Y; Watanabe, Y | 1 |
| Komuro, I; Kuwabara, Y | 1 |
| Chen, JZ; Wang, XX; Yuan, H | 1 |
| Duman, C; Duman, S; Oreopoulos, DG; Sen, S | 1 |
| Cimpanelli, M; Crespi, C; Gaudio, G; Grandi, AM; Guasti, L; Klersy, C; Riganti, G; Schizzarotto, A; Simoni, C; Venco, A | 1 |
| Efstathiou, S; Makris, T; Manolis, A; Papavasiliou, M; Stergiou, GS | 1 |
| Weber, MA | 1 |
| Fabbri, G; Maggioni, AP | 1 |
| Brandão, AA; Heintz, D; Kandra, A; Khder, Y; Ruilope, LM; Santonastaso, M; Stolt, P | 1 |
| Chu, GL; Ding, GH; Gao, P; Jia, RH; Liu, HY; Song, EF; Yang, DP | 1 |
| Deng, Q; Li, JQ; Li, QZ; Yi, GH; Zhao, SP | 1 |
| Aliavi, BA; Grachev, AV; Iakubov, MM; Kremkova, MM; Masri, MA | 1 |
| Colson, P; Foëx, P; Guillon, G; Ryckwaert, F | 1 |
| Kostis, WJ; Wilson, AC | 1 |
| Adani, GL; Baccarani, U; Boscutti, G; Bresadola, F; Gropuzzo, M; Mioni, G; Mioni, R; Montanaro, D; Risaliti, A; Sainz, M; Tulissi, P; Vallone, C | 1 |
| Erhardt, LR | 1 |
| Barlera, S; Carson, PE; Cerè, E; Cohn, JN; Glazer, R; Latini, R; Maggioni, AP; Masson, S; Singh, SN; Tognoni, G | 1 |
| Ardiles, LG; Aros, CA; Flores, CA; Jerez, V; Mezzano, SA; Muñoz, CC; Ramírez, JA; Schneider, HO; Valderrama, MG | 1 |
| Cohn, JN; Giardini, A; Glazer, R; Hester, A; Majani, G; Opasich, C; Tavazzi, L; Tognoni, G | 1 |
| Fukuhara, S; Iwasaka, T; Nishikawa, M; Nomura, S; Omoto, S; Shouzu, A | 1 |
| Anan, F; Hara, M; Nakagawa, M; Ooie, T; Saikawa, T; Takahashi, N; Yonemochi, H; Yoshimatsu, H; Yufu, K | 1 |
| Inoguchi, T; Kobayashi, K; Maeda, Y; Nakayama, M; Nawata, H; Sasaki, S; Sawada, F; Sonoda, N; Sonta, T; Sumimoto, H; Tsubouchi, H | 1 |
| Devine, AB; Dixon, LJ; El-Sherbeeny, NA; Hughes, SM; Leahey, WJ; McVeigh, GE; Plumb, RD | 1 |
| Han, YF; Ou, BR; Su, CJ | 1 |
| Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW | 1 |
| Anavekar, NS; Arnold, JM; Barvik, S; Bourgoun, M; Califf, RM; Ghali, JK; Khrakovskaya, M; McMurray, JV; Pfeffer, MA; Schwartz, Y; Skali, H; Solomon, SD; Velazquez, EJ; Warnica, JW | 1 |
| Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM | 1 |
| DI, J; Huang, ST; Lei, XY; Li, JM; Lu, YS | 1 |
| Khalil, N; Mancini, GB | 1 |
| Ando, H; Fujimura, A; Ioka, T; Sugimoto, K; Tsuruoka, S; Wakaumi, M; Yamamoto, H | 1 |
| Siragy, HM; Xue, C | 1 |
| Tokunaga, T | 1 |
| Duarte, AI; Gonçalves, LM; Monteiro, P; Providência, LA | 1 |
| Asayama, K; Hashimoto, J; Imai, Y; Kikuya, M; Metoki, H; Nishimura, T; Ohkubo, T; Totsune, K | 1 |
| Allsbrook, JS; Califf, RM; Masselink, LE; McMurray, JJ; Pfeffer, MA; Radeva, JI; Reed, SD; Schulman, KA; Sellers, MA; Velazquez, EJ; Weinfurt, KP | 1 |
| Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K | 1 |
| Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A | 2 |
| Aknay, N; Anand, IS; Chiang, YT; Cohn, JN; Florea, VG; Glazer, RD; Hester, A; Kuskowski, MA; Latini, R; Maggioni, AP; Opasich, C; Rector, TS | 1 |
| Dechend, R; Feldman, DL; Fiebeler, A; Garrelds, IM; Gratze, P; Jan Danser, AH; Luft, FC; Meiners, S; Müller, DN; Pilz, B; Shagdarsuren, E; Webb, RL; Wellner, M | 1 |
| Horiuchi, M; Ide, A; Ito, M; Iwai, M; Mogi, M; Okumura, M | 1 |
| Bavanandan, S; Chandran, A; Ismail, O; Morad, Z; Singaraveloo, M; Thayaparan, T | 1 |
| Dilek, I; Dogan, E; Durmus, A; Erkoc, R; Sayarlioglu, H; Topal, C | 1 |
| Liu, F; Xu, QY; Ye, YQ | 1 |
| Daley, W; Ferdinand, KC; Flack, JM; Jamerson, KA; Weir, MR; Zelenkofske, S | 1 |
| Cerulli, A; Frech, FH; Smith, DG | 1 |
| Anand, IS; Cohn, JN; Florea, VG; Glazer, R; Hester, A; Kuskowski, MA; Latini, R; Masson, S; Mocarelli, P; Rector, T; Signorini, S | 1 |
| Heljić, B; Velija-Asimi, Z | 1 |
| Ayala, DE; Calvo, C; Hermida, RC; López, JE | 1 |
| Chen, R; Horiuchi, M; Ide, A; Iwai, M; Li, Z; Min, LJ; Mogi, M; Okumura, M; Shiuchi, T; Suzuki, J; Tsuda, M | 1 |
| Ayala, DE; Calvo, C; Chayán, L; Fernández, JR; Fontao, MJ; Hermida, RC; López, JE; Mojón, A; Rodríguez, M; Soler, R | 1 |
| Palatini, P; Parati, G | 1 |
| Ayala, DE; Calvo, C; Covelo, M; Fernández, JR; Hermida, RC; López, JE; Mojón, A | 1 |
| Arosio, E; De Marchi, S; Lechi, A; Prior, M; Rigoni, A | 2 |
| Assouline, L; Hebert, D; Khder, Y; Lacourcière, Y; Poirier, L; Rehel, B; Stolt, P | 1 |
| Hatori, T; Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Sumino, H; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Chappell, MC; Ferrario, CM; Gallagher, PE; Tallant, EA | 1 |
| Iwasaki, K; Kawashita, H; Masuda, N; Nagae, Y; Nakashima, A; Niina, M; Saxer, C | 1 |
| Kawano, H; Koide, Y; Nakamizo, R; Seto, S; Toda, G; Yano, K | 1 |
| Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Nasonova, SN; Skvortsov, AA; Sychev, AV | 1 |
| Dohi, S; Fujiwara, H; Iida, H; Iida, M; Takenaka, M | 1 |
| Califf, RM; Diaz, R; Ertl, G; Hernandez, AF; Kilaru, R; Maggioni, AP; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Solomon, SD; van Gilst, W; Velazquez, EJ | 1 |
| Huang, ZY; Li, S; Liu, Z; Zhu, JH | 1 |
| Barrios Alonso, V; Calderón Montero, A; Escobar Cervantes, C | 1 |
| Hino, M; Nakamae, H; Nakamae, M; Nakane, T; Ohta, K; Terada, Y; Tsumura, K; Yamane, T | 1 |
| Arakawa, M; Murata, Y; Rikimaru, Y; Sasaki, Y | 1 |
| Boschmann, M; Engeli, S; Jordan, J; Kreuzberg, U; Luft, FC; Sharma, AM; Weidinger, G | 1 |
| Asmar, R; Bobrie, G; Delonca, J; Giacomino, A; Moulin, C; Postel-Vinay, N | 1 |
| Temple, R | 1 |
| Aylward, PE; Barvik, S; Califf, RM; Dalby, AJ; Huang, Z; Marin-Neto, JA; McMurray, JJ; Murin, J; Nordlander, RO; Pfeffer, MA; van Gilst, WH; Weaver, WD; White, HD; Zannad, F | 1 |
| Braszko, JJ | 1 |
| Liu, DS; Ye, JF | 1 |
| Fukuoka, T; Higaki, J; Manabe, S; Okura, T; Watanabe, S | 1 |
| Drexler, H; Landmesser, U | 1 |
| Horio, T; Inenaga, T; Kamide, K; Kawano, Y; Kubota, Y; Ogata, C; Sasaki, O; Sato, H; Suzuki, Y; Takiuchi, S | 1 |
| Mbah, CJ | 2 |
| Chen, YP; Dong, HR; Qiu, CB; Zhang, C | 1 |
| Hausberg, M; Hohage, H; Kosch, M | 1 |
| Akutsu, H; Iwa, Y; Kizawa, H; Kondoh, R; Nagane, Y; Terayama, Y; Tohgi, H; Utsugisawa, K | 1 |
| Bhatt, DL; Hennekens, CH; Malinin, AI; O'Connor, C; Pokov, AN; Sane, DC; Serebruany, VL; Tanguay, JF | 1 |
| Anabitarte, A; Caballero, A; Novoa Novoa, J; Palop, L; Plaza, C; Rodríguez Esparragón, F; Rodríguez Pérez, JC | 1 |
| Bellido, D; Nieto, J; Oteros, R; Rivera, F; Sánchez de la Nieta, MD; Vozmediano, C; Zarca, MA | 1 |
| Coleman, CI; Kalus, JS; White, CM | 1 |
| Bai, XJ; Qi, ZM; Wang, HX; Zhang, YJ | 1 |
| Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T | 1 |
| Klíma, J; Macek, J; Ptácek, P | 1 |
| Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tan, LB; Tognoni, G; Vago, T; Wong, M | 1 |
| Böger, RH; Maas, R; Quispe-Bravo, S; Schwedhelm, E; Skamira, C | 1 |
| Jacobsen, PK; Parving, HH; Rossing, P | 1 |
| Ganesan, A | 1 |
| Azizi, M; Guyene, TT; Ménard, J; Peyrard, S | 1 |
| Fujii, S; Furumoto, T; Goto, K; Inoue, M; Kaga, S; Kitabatake, A; Komatsu, H; Komuro, K; Onozuka, H; Taisei, M; Tsutsui, H; Yamada, S | 1 |
| Califf, R; Howlett, J; Køber, L; Maggioni, A; McMurray, J; Pfeffer, M; Pieper, K; Reed, S; Rouleau, J; Solomon, S; Swedberg, K; Van de Werf, F; Velazquez, E; White, H | 1 |
| Anavekar, N; McMurray, J; Pfeffer, M; Skali, H; Solomon, SD; Velazquez, E; Yerra, L; Zelenkofske, S | 1 |
| Ito, S; Kato, T; Mori, T; Nako, K; Ogawa, S; Takeuchi, K | 1 |
| Califf, RM; Diaz, R; Ertl, G; Køber, L; Leimberger, JD; Maggioni, AP; Mareev, V; McMurray, JJ; Opolski, G; Pfeffer, MA; Rouleau, JL; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; Zannad, F; Zelenkofske, S | 1 |
| Mitchell, A; Philipp, T; Rushentsova, U; Siffert, W; Wenzel, RR | 1 |
| Abts, M; Claus, V; Lataster, M | 1 |
| Iigaya, K; Kumagai, H; Onami, T; Saruta, T; Takimoto, C | 1 |
| Ito, S; Kageyama, N; Nakaya, Y; Nomura, M; Watanabe, T | 1 |
| Gómez, NA; Mejillón, JL; Vargas, PE; Zapatier, JA | 1 |
| Kjeldsen, SE; Mistry, NB; Westheim, AS | 1 |
| Akashiba, A; Ando, N; Inada, H; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Ohta, S; Ono, H; Takahashi, T; Tsukada, K; Yoshii, M | 1 |
| Kazdová, L; Kurtz, TW; Ogihara, T; Pravenec, M; Qi, NR; Sugimoto, K | 1 |
| Dudley, K; Ferran, C; Ganda, O; Hubbard, M; Khaodhiar, L; Lima, C; Scali, S; Shrikhande, G; Veves, A | 1 |
| Chen, H; Ding, RJ; Jia, SQ; Li, GH; Li, HW; Wang, L; Yao, DK; Zhao, L | 2 |
| Adachi, Y; Hirouchi, M; Hu, Z; Maeda, K; Sugiyama, Y; Yamashiro, W | 1 |
| Ma, X; Miao, Y; Sun, H; Tang, MX; Zhang, W; Zhang, Y; Zhong, M | 1 |
| Cheng, YL; Chow, KM; Fung, SK; Leung, CB; Li, PK; Mak, SK; Szeto, CC; Tang, AW; Wong, TY; Yu, AW; Yung, CY; Yung, JC | 1 |
| Ikeda, N; Inoue, T; Komiyama, N; Kyo, S; Matsumoto, K; Nishimura, S; Suzuki, H | 1 |
| Doğru-Abbasoğlu, S; Erbaş, B; Ozek, M; Uresin, Y | 1 |
| Delise, P; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Maggioni, AP; Staszewsky, L; Tognoni, G | 1 |
| Fujii, S; Hoshino, J; Kurabayashi, M; Mizuno, H; Nakamura, T; Saito, Y | 1 |
| Gong, HP; Li, L; Ma, X; Miao, Y; Sun, H; Zhang, W; Zhang, Y; Zhong, M | 1 |
| Fujino, A; Fujiwara, H; Hirano, M; Ieiri, I; Kitamura, Y; Kusuhara, H; Maeda, K; Otsubo, K; Sugiyama, Y; Watanabe, T; Yasuda, K | 1 |
| Hirata, Y; Hirono, Y; Sugiyama, T; Tateno, T; Tsuchiya, K; Yoshimoto, T | 1 |
| Ishikawa, H; Katayama, K; Koyabu, S; Murata, T; Nakano, T; Nomura, S | 1 |
| Endo, K; Koide, N; Miyashita, Y; Murano, T; Ohira, M; Oyama, T; Saiki, A; Shirai, K | 1 |
| Danielson, E; Glynn, RJ; Ridker, PM; Rifai, N | 1 |
| Adams, F; Boschmann, M; Engeli, S; Franke, G; Jordan, J; Klaua, S; Kreuzberg, U; Luft, FC; Scholze, J; Sharma, AM; Weidinger, G | 1 |
| Hirose, H; Komiya, N; Saisho, Y | 1 |
| Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Tsukuda, K | 1 |
| Baker, KM; Kumar, R | 1 |
| Berho, M; Elliot, SJ; Plati, AR; Potier, M; Striker, GE; Striker, LJ; Zeng, YJ; Zheng, F | 1 |
| De Ciuceis, C; Endemann, DH; Ko, EA; Pu, Q; Savoia, C; Schiffrin, EL; Touyz, RM | 1 |
| Chowdhury, NA; Cooper, SA; Ferrario, C; Gallagher, PE; Habibi, J; Hayden, MR; Link, CD; Sowers, JR; Stump, CS; Tallant, EA; Whaley-Connell, AT; Wiedmeyer, CE | 1 |
| Coca, A; Ekman, S; Girerd, X; Hua, T; Jamerson, K; Julius, S; Kjeldsen, SE; Larochelle, P; MacDonald, TM; Mancia, G; McInnes, GT; Schmieder, RE; Schork, MA; Stolt, P; Viskoper, R; Weber, MA; Widimský, J; Zanchetti, A | 1 |
| Aryana, A; Hilleman, DE; Maciejewski, S; Mohiuddin, SM; Mooss, AN; Packard, KA; Reyes, AP | 1 |
| Ichihara, A; Kaneshiro, Y; Sakoda, M; Takemitsu, T | 1 |
| Burghină, D; Cozma, D; Dan, R; Drăgulescu, SI; Petrescu, L; Riviş, AI; Suşan, M; Suşan, RM | 1 |
| Fukuoka, T; Gotoh, A; Higaki, J; Irita, J; Kurata, M; Manabe, S; Miyoshi, K; Okura, T; Uchida, K; Watanabe, S | 1 |
| Cheng, JL; Gao, RL; Jing, ZC; Wu, YJ; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Cesolari, JA; Laudanno, OM | 1 |
| Delles, C; Handrock, R; Harazny, J; Michelson, G; Oehmer, S; Schmieder, RE; Schwarz, T | 1 |
| Amerena, J; Balazovjech, I; Brunner, HR; Cassel, G; Herczeg, B; Hua, TA; Julius, S; Kjeldsen, SE; Koylan, N; Laragh, J; Magometschnigg, D; Majahalme, S; Martinez, F; McInnes, GT; Oigman, W; Schork, MA; Seabra Gomes, R; Weber, MA; Zanchetti, A; Zhu, JR | 1 |
| Sica, DA | 1 |
| Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S | 1 |
| Mittal, BV; Pendse, S; Rennke, HG; Singh, AK | 1 |
| Gong, Z; Huang, Y; Song, S; Xu, W | 1 |
| Arnold, JM; Artis, E; Aurigemma, G; Daley, WL; Janardhanan, R; Mulvagh, SL; Naqvi, TZ; Purkayastha, D; Solomon, SD; Thomas, JD; Zile, M | 1 |
| Dessì-Fulgheri, P; Sarzani, R | 1 |
| Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Nasonova, SN; Orlova, IaA; Skvortsov, AA; Sychev, AV | 1 |
| Even, P; Ferré, P; Lamandé, N; Quignard-Boulangé, A; Yvan-Charvet, L | 1 |
| Koçyiğit-Kaymakçoğlu, B; Rollas, S; Unsalan, S | 1 |
| Chen, N; Hao, L; Sun, G; Wang, W; Wu, K; Zhang, Y; Zhou, T | 1 |
| Califf, RM; Diaz, R; Kober, L; Maggioni, AP; Mareev, V; McMurray, JJ; Murin, J; Reed, SD; Schulman, KA; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Akdag, I; Filiz, G; Gullulu, M; Kahvecioglu, S; Savci, V | 1 |
| Huang, HF; Huo, LJ; Yang, BY | 1 |
| Egashira, K; Funakoshi, K; Ihara, Y; Nakano, K; Ohtani, K; Sata, M; Sunagawa, K; Zhao, G | 1 |
| Akasaka, T; Imanishi, T; Kobayashi, K | 1 |
| Davidai, G; Koval, SE; Murwin, D; Neutel, JM; Punzi, HA; White, WB | 1 |
| Higaki, J; Okura, T | 1 |
| Barker, TA; Berk, BC; Kennedy, AJ; Korshunov, VA; Massett, MP; Mohan, AM | 1 |
| Khan, F; Kumagai, N; Mahmood, J; Morioka, T; Oite, T; Okada, S | 1 |
| Ruilope, LM; Zanchetti, A | 1 |
| Liu, PP; Maggioni, A; Velazquez, EJ | 1 |
| Averbukh, Z; Berman, S; Efrati, S; Galperin, E; Malcev, E; Manevits, E; Rosenberg, R; Weissgarten, J | 1 |
| Chiang, CE; Coloma, R; Feig, P; Guptha, S; Ke, Y; Kim, D; Massaad, R; Sun, N; Tseng, CD; Vala, M; Watanabe, LA; Wei, M | 1 |
| Akishita, M; Horiuchi, M; Oishi, Y; Oshima, T; Ozono, R; Yoshizumi, M | 1 |
| Wagstaff, AJ | 1 |
| Brodin, LA; Govind, SC; Nowak, J; Ramesh, SS; Saha, SK | 1 |
| Iwanaga, T; Maeda, T; Ogihara, T; Sato, M; Tamai, I | 1 |
| Anand, I; Carretta, E; Cohn, J; Glazer, R; Ingrillì, F; Krum, H; Latini, R; Maggioni, AP; Masson, S; Pettinati, G; Tognoni, G | 1 |
| Battegay, E; Calvo-Vargas, C; Cieśliński, A; Degaute, JP; Holwerda, NJ; Hua, T; Julius, S; Kjeldsen, S; Kobalava, J; Laragh, JH; McInnes, GT; Pedersen, OL; Plat, F; Rudyatmoko, FP; Siamopoulos, KC; Störset, O; Weber, M; Zanchetti, A | 1 |
| Karotsis, AK; Mastorantonakis, SE; Stergiou, GS; Symeonidis, A | 1 |
| Akasaka, T; Goto, M; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Yoshida, K | 1 |
| Dzau, VJ; Matsushita, K; Okamoto, Y; Pratt, RE; Wu, Y | 1 |
| Sun, ZL; Wang, YJ; Xie, QY; Yang, TL | 1 |
| Aslam, S; Leone, A; Santha, T; Wilcox, C | 1 |
| Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Nahmias, C; Tomochika, H; Tsukuda, K | 1 |
| Bizot, MN; Denouel, J; Dieterich, HA; Dole, WP; Kemp, C; Vaidyanathan, S; Valencia, J; Yeh, CM; Zhao, C | 1 |
| Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Nasonova, SN; Skvortsov, AA; Sychev, AV | 2 |
| Ebrahimian, T; Gratton, JP; He, Y; Savoia, C; Schiffrin, EL; Touyz, RM | 1 |
| Bard, RL; Brook, R; Daley, W; Dellegrottaglie, S; Kariisa, M; Kehrer, C; Matlow, S; Pitt, B; Rajagopalan, S | 1 |
| Andrés, A; Bosch, I; Campo, C; Morales, E; Morales, JM; Ruilope, LM | 1 |
| Imamoto, S; Kuno, M; Mochizuki, S; Nagai, M; Okada, T; Seki, S; Taniguchi, I; Taniguchi, M | 1 |
| Alonso, RM; Ferreirós, N; Gonzalez, L; Ibarrondo, I; Iriarte, G; Jiménez, RM; Maguregi, MI | 1 |
| Koyabu, N; Kuwano, M; Murakami, H; Nakamura, T; Ohtani, H; Satoh, H; Sawada, Y; Tsujimoto, M; Uchiumi, T; Ushigome, F; Yamashita, F | 1 |
| Zoccali, C | 1 |
| Ago, T; Ibayashi, S; Iida, M; Ishikawa, E; Kamouchi, M; Kitazono, T; Ooboshi, H; Takada, J | 1 |
| Anavekar, NS; Arnold, JM; Bourgoun, M; Ghali, JK; Køber, L; Pfeffer, MA; Skali, H; Solomon, SD; Thune, JJ; Velazquez, EJ | 1 |
| Durante, A; Monacelli, F; Odetti, P; Poggi, A; Storace, D; Traverso, N; Viviani, GL | 1 |
| Bae, KS; Cho, JY; Chung, JY; Hong, KS; Jang, IJ; Lee, KH; Lim, HS; Oh, DS; Shin, SG; Yu, KS | 1 |
| Albini, TA; Foroozan, R; Lakhanpal, RR; Lopez, GA; McPherson, AR | 1 |
| Savoia, C; Schiffrin, EL; Touyz, RM; Volpe, M | 1 |
| Coll, JR; Estacio, RO; Schrier, RW; Tran, ZV | 1 |
| Kobalava, ZhD; Villeval'de, SV | 1 |
| Luan, B; Song, L | 1 |
| Brown, NJ; Gebretsadik, T; LeFebvre, J; Murphey, LJ; Petro, JR; Shintani, A | 1 |
| Brooks, VL; Freeman, KL | 1 |
| Imaizumi, S; Iwata, A; Kiya, Y; Kumagai, K; Matsuo, K; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Shirai, K; Zhang, B | 1 |
| Bokhari, S; Brinton, E; Israelian, Z; Meyer, C; Schmidt, J | 1 |
| Aldigier, JC; Azizi, M; Chiang, Y; Januszewicz, A; Pool, JL; Satlin, A; Schmieder, RE; Zidek, W | 1 |
| de Gasparo, M | 1 |
| Dahlöf, B | 1 |
| Ruilope, LM | 1 |
| Chan, P; Cheng, JT; Liu, IM; Tzeng, TF; Yang, TL | 1 |
| Andronescu, D; Bengus, A; Dragomir, P; Fierbinteanu-Braticevici, C; Negreanu, L; Tribus, L; Usvat, R | 1 |
| Chen, LF; Ke, YN; Li, N; Zhu, WL | 1 |
| Cai, Y; Chen, FP; Gong, LK; Li, XH; Liu, LL; Qi, XM; Ren, J; Wang, H; Wu, XF; Xiao, Y; Zhang, L | 1 |
| Fletcher, EL; Phipps, JA; Wilkinson-Berka, JL | 1 |
| Dallinga-Thie, GM; de Koning, EJ; Gaillard, CA; Rabelink, TJ; van Zonneveld, AJ; Westerink, JW; Willemsen, JM | 1 |
| Crikelair, N; Glazer, R; Kuturu, V; Levy, D; Rocha, R; Weir, MR | 1 |
| Chu, S; Dong, D; Gong, YT; Han, W; Li, BX; Li, WM; Li, Y; Liu, W; Sheng, L; Xue, JY; Yang, BF; Zhang, L | 1 |
| Birkenhäger, WH; Hansen, TW; Staessen, JA | 1 |
| Høegholm, A; Julius, S; Kjeldsen, SE; Mancia, G; Nielsen, ES; Pedersen, OL; Pickering, T; Refsgaard, J; Weber, M | 1 |
| Saito, I; Saruta, T | 1 |
| Hara, H; Kawai, R; Kawashita, H; Koseki, N; Masuda, N; Nagae, Y; Niina, M; Tanaka, M | 1 |
| Bianchetti, MG; Fossali, E; Ghiglia, S; Limoni, C; Meier, CM; Salice, P; Simonetti, GD | 1 |
| Gaskin, FS; Kamada, K; Korthuis, RJ; Yusof, M | 1 |
| Edelsberg, J; Jamerson, K; Khan, ZM; Kjeldsen, SE; Oster, G; Vincze, G; Weycker, D | 1 |
| Abu-Hijleh, M; Garadah, T; Golbahar, J; Gumaa, K; Kassab, S; Senok, S; Wazir, J | 1 |
| Jugdutt, BI | 1 |
| Chan, P; Chen, TH; Kao, PF; Ko, WC; Tomlinson, B; Yang, HY | 1 |
| Chen, S; Huang, H; Li, R; Liu, P; Tang, F; Wang, P; Zhang, H | 1 |
| Benetos, A; Cattan, V; Labat, C; Lacolley, P; Louis, H; Mercier, N; Safar, ME | 1 |
| Gosse, P | 1 |
| Gu, J; Jiang, Y; Li, H; Tang, Y; Wang, J; Wang, Y; Zhao, L | 1 |
| Aylward, PG; Califf, RM; Kober, L; McMurray, JJ; Pfeffer, MA; Pieper, KS; Skali, H; Solomon, SD; Stephenson, K; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Ott, P | 1 |
| Coleman, CI; Kluger, J; Makanji, S; White, CM | 1 |
| Assouline, L; de Champlain, J; Dubé, B; Karas, M; Larochelle, P; LeBlanc, AR; Nadeau, R | 1 |
| Giles, TD; Oparil, S; Silfani, TN; Walker, JF; Wang, A | 1 |
| Humbert, H; Pommier, F; Prasad, P; Reynolds, CV; Sunkara, G; Yeh, C | 1 |
| Chang, CJ; Hwang, TJ; Su, YP | 1 |
| Kashiwagi, A; Maegawa, H; Sawaguchi, M; Uzu, T | 2 |
| Acikel, C; Caglar, K; Celik, T; Eyileten, T; Oguz, Y; Sonmez, A; Vural, A; Yavuz, I; Yenicesu, M; Yilmaz, MI | 1 |
| Alvarado, R; Glazer, R; Graff, A; Huang, J; Pool, JL; Weinberger, M | 1 |
| Behlouli, H; Hudson, M; Humphries, K; Pilote, L; Sheppard, R; Tu, JV | 1 |
| Jaworski, K; Ninkovic, S; Tan, G; Wilkinson-Berka, JL | 1 |
| Itoh, Y; Mori, Y; Tajima, N | 1 |
| Esaki, M; Fujiwara, H; Fujiwara, T; Kanamori, H; Kondo, T; Li, L; Li, Y; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Ohno, T; Okada, H; Takemura, G | 1 |
| Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Maeyama, S; Mawatari, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Terauchi, Y; Wada, K; Yoneda, M | 1 |
| Cooper, SA; Ferrario, C; Govindarajan, G; Habibi, J; Hayden, MR; Karuparthi, PR; Link, D; Ma, L; Qazi, M; Sowers, JR; Stump, C; Wei, Y; Whaley-Connell, A | 1 |
| Cui, RZ; Liu, GQ; Mao, YM; Sun, GY; Sun, J; Zhang, SS; Zhao, HM | 1 |
| Ma, X; Miao, Y; Qi, TG; Sun, H; Zhang, W; Zhong, M | 1 |
| Dahlöf, B; Ikewaki, K; Kanae, K; Kawai, M; Mochizuki, S; Ogawa, K; Ohta, M; Okazaki, F; Seki, S; Shimizu, M; Tajima, N; Taniguchi, I; Taniguchi, M; Yamada, T; Yoshida, S; Yoshikawa, M | 1 |
| Chiang, YT; Fomina, I; Gamboa, R; Glazes, R; Kaczor, J; Kargiannis, S; Poldermans, D; Wernsing, M; Yen, J | 1 |
| Azuma, J; Dosaka, N; Iekushi, K; Katsuragi, N; Koibuchi, N; Morishita, R; Nagao, K; Ogihara, T; Sanada, F; Taniyama, Y | 1 |
| Bakris, GL; Glazer, R; Philipp, T; Smith, TR; Vaisse, B; Wernsing, M; Yen, J | 1 |
| Mitsuyama, S | 2 |
| Delea, TE; Frech-Tamas, F; Moynahan, A; Oster, G; Taneja, C; Thomas, SK | 1 |
| Chen, K; Clark, SE; Ferrario, CM; Habibi, J; Sowers, JR; Stump, CS; Uptergrove, GM; Wei, Y; Whaley-Connell, AT | 1 |
| Fujiwara, H; Hukunishi, M; Ito, Y; Kakami, M; Kawasaki, M; Matsuno, Y; Minatoguchi, S; Miyajima, K; Nishigaki, K; Takemura, G | 1 |
| Madelenat, P; Mahieu-Caputo, D; Popovic, I; Roger, N | 1 |
| Akazawa, H; Komuro, I; Kudo, Y | 1 |
| Ahmed, A; Husain, A; Perry, GJ | 1 |
| Arnold, JM; Aurigemma, GP; Bourgoun, M; Daley, WL; Fields, H; Hippler, SE; Janardhanan, R; Lacourcière, Y; Mulvagh, SL; Naqvi, TZ; Purkayastha, D; Solomon, SD; Thomas, JD; Verma, A; Zile, MR | 1 |
| Crikelair, N; Glazer, R; Levy, D; Meng, X; Rocha, R; Weir, MR | 1 |
| Cierco, M; Garrido, MR; Gutiérrez, A; Israel, A; Zavala, LE | 1 |
| Glazer, R; Jin, J; Philipp, T; Pospiech, R; Schneider, H; Smith, TR; Wernsing, M; Yen, J | 1 |
| Fukushima, H; Kobayashi, N; Matsuoka, H; Ohno, T; Yoshida, K | 1 |
| Müller, U; Scholze, J | 1 |
| Chen, B; Guan, GJ; Hou, XH; Li, XG; Liu, G; Liu, HY; Zhang, Y | 1 |
| Glazer, R; Jia, Y; Kariisa, M; Pitt, B; Prescott, MF; Radauceanu, A; Rajagopalan, S; Zannad, F | 1 |
| Azuma, K; Hirose, T; Ikeda, F; Kawamori, R; Mita, T; Ogihara, T; Otsuka, A; Tanaka, Y; Toyofuku, Y; Watada, H | 1 |
| Fang, H; Oparil, S; Patel, S; Satlin, A; Yarows, SA; Zhang, J | 1 |
| Inaba, M; Inukai, K; Izumida, T; Katayama, S; Noguchi, Y; Yagi, S; Yamaguchi, M; Yamamoto, H | 1 |
| Li, JX; Li, QZ; Liu, L; Zhao, SP; Zhou, HN | 1 |
| Jones, MR; Laragh, JH; Sealey, JE | 1 |
| Angeli, F; Reboldi, G; Verdecchia, P | 2 |
| Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Omvik, P; Rostrup, M | 1 |
| Wang, YP; Wang, YY; Xiao, ZX; Zhang, QY; Zhao, C | 1 |
| Abts, M; Kastrati, D; Schühlen, H | 1 |
| Fujita, T; Hishikawa, K; Imai, N; Marumo, T; Matsuzaki, Y; Okano, H; Shimosawa, T; Takase, O | 1 |
| Alonso, RM; Ferreirós, N; Ibarrondo, I; Iriarte, G; Itxaso Maguregui, M; Jiménez, RM | 1 |
| Fujimoto, M; Hashimoto, N; Imamura, H; Nakazawa, K; Ohta, T | 1 |
| Murakami, M; Nakagiri, A; Sunamoto, M | 1 |
| Azizi, M; Bissery, A; Bura-Rivière, A; Guyene, TT; Ménard, J | 1 |
| Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K | 3 |
| Acikel, C; Caglar, K; Cakir, E; Eyileten, T; Kurt, Y; Oguz, Y; Saglam, M; Sonmez, A; Tasar, M; Vural, A; Yenicesu, M; Yilmaz, MI | 1 |
| Goossen, LJ; Melzer, B | 1 |
| Liu, HM; Yang, YJ; Zhang, JH; Zhang, X | 1 |
| Cohn, JN; Duprez, DA; Florea, ND; Jones, K | 1 |
| Burstein, B; Calderone, A; Nattel, S; Qi, XY; Yeh, YH | 1 |
| Inoue, M; Ishida, S; Izumi-Nagai, K; Koto, T; Nagai, N; Oike, Y; Ozawa, Y; Satofuka, S; Tsubota, K; Umezawa, K; Yamashiro, K | 1 |
| Daley, WL; Hollenberg, NK; Kandra, A; Parving, HH; Remuzzi, G; Ritter, S; Rocha, R; Viberti, G; Zelenkofske, S | 1 |
| Ashiya, M; Smith, RE | 1 |
| Bai, A; Bianchi, R; Cuccovillo, I; De Angelis, N; Fiordaliso, F; Latini, R; Masson, S; Razzetti, R; Salio, M; Serra, DM | 1 |
| Ikeda, T; Kamiyama, E; Kasuya, A; Kurihara, A; Takei, M; Yoshigae, Y | 1 |
| Ichikawa, Y | 1 |
| Ogawa, H; Sakamoto, T; Shintomi, Y; Yoshimura, M | 1 |
| Azuma, K; Hashimoto, T; Ishigami, T; Lopez-Ilasaca, M; Masuda, S; Matsuda, M; Sakai, M; Shigenaga, A; Tamura, K; Tanaka, Y; Tsurumi-Ikeya, Y; Umemura, S; Wakui, H | 1 |
| Feng, Y; Jiang, L; Li, F; Liu, M; Nie, J; Yang, M; Zhang, H; Zhang, W | 1 |
| Gowda, KV; Mandal, U; Pal, TK; Selvan, PS; Solomon, WD | 1 |
| Han, Q; Lei, J; Liao, YD; Wang, ZH; Xu, H; Zhang, YY | 1 |
| Fujino, M; Imaizumi, S; Kanazawa, T; Karnik, SS; Kiya, Y; Matsuo, Y; Miura, S; Saku, K | 1 |
| Oparil, S; Patel, S; Satlin, A; Yarows, SA; Zhang, J | 1 |
| Davidson, J; Koval, S; Lacourcière, Y; Sharma, AM | 1 |
| Adachi, T; Hirakawa, N; Kamezaki, F; Kouzuma, R; Nagatomo, T; Otsuji, Y; Shibata, K; Tasaki, H; Tsutsui, M; Yamashita, K | 1 |
| Handrock, R; Hilsmann, U; Klebs, S; Neumann, G; Schweizer, J | 1 |
| Conen, D; Everett, BM; Glynn, RJ; Ridker, PM | 1 |
| Dong, YF; Ichijo, H; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Ogawa, H; Shintaku, H; Tokutomi, Y; Yamamoto, E; Yamashita, T | 1 |
| Sun, NL; Wang, HY; Zhu, JR | 1 |
| Dagenais, NJ; Dryden, WF; Hanafy, S; Jamali, F | 1 |
| Bartholomew, S; Chen, L; Ho, L; Humala, N; Pasinetti, GM; Qian, X; Rosendorff, C; Seror, I; Wang, J; Zhao, W; Zhao, Z | 1 |
| Bissessor, N; White, H | 1 |
| Victor, RG | 1 |
| Campestrini, J; Dole, K; Dole, WP; He, YL; Howard, D; Ligueros-Saylan, M; Marion, A; Pommier, F; Sabo, R; Sunkara, G; Wang, Y; Zhao, C | 1 |
| Guan, YY; Liu, YJ; Lu, HH; Sheng, ZQ; Wang, Y; Zhang, L | 1 |
| Appleyard, CB; Ferder, L; Rivera, E; Santiago, OI | 1 |
| Califf, RM; Howlett, J; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Signorovitch, J; Solomon, SD; Thune, JJ; Velazquez, EJ; Zelenkofske, S | 1 |
| Choi, JI; Hong, SJ; Joo, HJ; Lim, DS; Lim, SY; Park, SM; Shim, WJ; Shin, SY | 1 |
| Koji, Y; Shiina, K; Tomiyama, H; Yamada, J; Yamashina, A; Yoshida, M | 1 |
| Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T | 1 |
| Achard, JM; Boutitie, F; Fournier, A; Gueyffier, F; Temmar, M | 1 |
| Deswal, A; Mann, DL; Ramasubbu, K | 1 |
| Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tognoni, G; Wong, M | 1 |
| Forrester, MB | 1 |
| Al-Khatib, SM; Califf, RM; Kober, L; Lokhnygina, Y; McMurray, JJ; Solomon, SD; Thomas, KL; Velazquez, EJ | 1 |
| Gaballa, MA; Goldman, S; Guarraia, D; Johnson, N; Thai, H | 1 |
| Rupp, H | 1 |
| Chen, WD; Huang, YY; Li, LH; Wang, YW; Xu, HH; Yang, LC; Yang, YL; Zhang, DY; Zhu, XJ | 1 |
| Horiuchi, M; Inaba, S; Iwai, M; Mogi, M; Tomono, Y | 1 |
| Huang, J; Siragy, HM | 2 |
| Amiri, F; Brassard, P; Iglarz, M; Javeshghani, DM; Pu, Q; Schiffrin, EL; Webb, RL | 1 |
| Bartels, V; Hausberg, M; Kosch, M; Lang, D; Levers, A; Pavenstädt, H; Rahn, KH | 1 |
| Belsey, JD | 1 |
| Chrysant, SG; Davidai, G; Guthrie, R; Koval, SE; Murwin, D; White, WB | 1 |
| Breekveldt-Postma, NS; Erkens, JA; Herings, RM; Khan, ZM; Siiskonen, SJ; Vincze, G | 1 |
| Krzesinski, JM; Scheen, AJ | 1 |
| Plosker, GL; Robinson, DM | 1 |
| Du, X; Gu, J; Jiang, Y; Li, H; Liu, M; Zhang, D; Zhao, L | 1 |
| Balakhonova, TV; Chernova, NA; Fomicheva, OA; Karpov, IuA; Kuznetsova, TV; Masenko, VP; Pogorelova, OA; Rogoza, AN; Soboleva, GN | 1 |
| Lin, CS; Pan, CH; Wen, CH | 1 |
| Hua, TA; Julius, S; Kjeldsen, SE; McInnes, GT; Schmieder, RE; Zanchetti, A | 1 |
| Dessì-Fulgheri, P; Rappelli, A; Sarzani, R | 1 |
| Alonso, RM; Ferreirós, N; Iriarte, G; Jiménez, RM; Ortíz, E | 1 |
| Chrysant, SG; Dattani, D; Hoppe, UC; Hsu, H; Murray, AV; Patel, S; Zhang, J | 1 |
| Kushibiki, M; Okumura, K; Osanai, T; Tomita, H; Yamada, M | 1 |
| Allemann, Y; Barbier, M; Ferber, P; Fraile, B; Izzo, JL; Lambert, M | 1 |
| Hashimoto, K; Horino, T; Inoue, K; Kagawa, T; Matsumoto, R; Morita, T; Takao, T | 1 |
| Akizuki, O; Inayoshi, A; Kitayama, T; Kusaka, H; Matsubara, M; Sasaki, K; Shirakura, S; Yao, K | 1 |
| Ayala, DE; Calvo, C; Hermida, RC; Khder, Y | 1 |
| Hayashi, N; Ito, N; Iwamoto, Y; Katsuya, T; Ogihara, T; Ohishi, M; Rakugi, H; Shiota, A; Takagi, T; Tatara, Y | 1 |
| Jin, D; Kimura, M; Kirimura, K; Miyazaki, M; Sakonjo, H; Takai, S; Tanaka, K | 1 |
| Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A | 1 |
| Anavekar, NS; Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Solomon, SD; Velazquez, E; White, H | 1 |
| Daimon, M; Fujita, M; Komuro, I; Kuwabara, Y; Mizuma, H; Nakayama, K; Narumi, H; Shindo, S | 1 |
| Anderson, RE; Califf, RM; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Thune, JJ; Velazquez, E; White, HD | 1 |
| Liu, Y; Meng, QH; Wang, L; Zhu, S | 1 |
| Asai, S; Ishikawa, K; Nishida, Y; Sugahara-Kobayashi, M; Takahashi, Y | 1 |
| Liu, ZY; Sun, GY; Zhang, SS | 1 |
| Peters, S | 1 |
| Hirooka, Y; Ito, K; Kimura, Y; Sagara, Y; Sunagawa, K | 1 |
| Botha, J; DeAngelis, L; Ferber, P; Kandra, A; Karalliedde, J; Mirenda, V; Smith, A; Viberti, G | 1 |
| Brborić, J; Cudina, O; Janković, I; Karljiković-Rajić, K; Vladimirov, S | 1 |
| Downie, LE; Fletcher, EL; Pianta, MJ; Vingrys, AJ; Wilkinson-Berka, JL | 1 |
| Croce, G; Desideri, G; Ferri, C | 1 |
| Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C | 1 |
| Hattori, N; Liu, M; Miyamoto, N; Tanaka, R; Urabe, T; Zhang, N | 1 |
| Chen, N; Shi, H; Shi, W; Wang, W; Yu, H; Zhang, B | 1 |
| Ansari, A; Brachmann, J; Handrock, R; Klebs, S; Mahla, G | 1 |
| Califf, RM; Francis, GS; Huang, Z; Lewis, EF; McMurray, JJ; Pfeffer, MA; Prisant, LM; Thomas, KL; Velazquez, EJ; Weaver, WD | 1 |
| Havranek, EP | 1 |
| Clark, SE; Ferrario, CM; Ibdah, JA; Morris, EM; Sowers, JR; Thyfault, JP; Uptergrove, GM; Wei, Y; Whaley-Connell, AT | 1 |
| Imamura, Y; Ishida, S; Kurihara, T; Nagai, N; Noda, K; Oike, Y; Okano, H; Ozawa, Y; Shinoda, K; Tsubota, K | 1 |
| Ikee, R; Kobayashi, S; Maesato, K; Mano, T; Moriya, H; Ohtake, T; Oka, M | 1 |
| Danielson, E; Everett, BM; Glynn, RJ; Ridker, PM | 1 |
| Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M; Störset, O | 1 |
| Curnew, GP; Leclerc, JM; Rehel, B; Tardif, JC | 1 |
| Ge, Y; Huang, Y; Kohan, DE | 1 |
| Baier, M; Bambauer, R; Handrock, R; Kirchertz, EJ; Leidig, M; Leinung, D; Schmieder, RE; Szabã, T | 1 |
| Baumhäkel, M; Böhm, M; Müller, U | 1 |
| Calhoun, DA; Purkayastha, D; Samuel, R; Taylor, AA; White, WB; Zappe, DH | 1 |
| el-Alamin, MM; Habib, IH; Toubar, SS; Weshahy, SA | 1 |
| Corradi, L; Derosa, G; Ferrari, I; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A | 1 |
| Ferguson, KL; Greller, HA; Hoffman, RS; Nelson, LS; Smith, SW | 1 |
| Ahad, A; Ali, MM; Aqil, M; Rizwan, M; Sultana, Y | 1 |
| Galle, J | 1 |
| Fukuda, M | 1 |
| Sinaiko, AR | 1 |
| Bagga, A; de Paula Meneses, R; Flynn, JT; Gupte, J; Han, G; Mattheyse, L; Meyers, KE; Neto, JP; Shi, V; Solar-Yohay, S; Zurowska, A | 1 |
| Calhoun, DA; Coenen, PD; Glazer, RD; Grosso, A; Pettyjohn, FS; Zhao, Y | 1 |
| Elenkova, A; Kirilov, G; Lozanov, V; Mitev, V; Orbetzova, M; Shigarminova, R; Zacharieva, S | 1 |
| Anthony Schork, M; Coca, A; Girerd, X; Hua, TA; Jamerson, K; Julius, S; Kjeldsen, SE; Larochelle, P; Macdonald, T; Mancia, G; McInnes, GT; Schmieder, RE; Viskoper, R; Weber, MA; Widimsky, J; Zanchetti, A | 1 |
| Ishii, T; Kaneki, M; Sakurai, S; Tsujibayashi, T; Yoshitomi, Y | 1 |
| He, XX; Liang, QS; Zhan, CY; Zhou, DX | 1 |
| Mourad, JJ; Waeber, B | 1 |
| Chen, ZJ; Fu, P; Huang, SM; Tang, WX; Tao, Y | 1 |
| Enomoto, D; Fukuoka, T; Higaki, J; Irita, J; Jotoku, M; Koresawa, M; Kurata, M; Miyoshi, K; Okura, T; Watanabe, S | 1 |
| Dal Pan, GJ; Governale, LA; Hammad, TA; McAdams, MA; Swartz, L | 1 |
| Koide, N; Miyashita, Y; Murano, T; Saiki, A; Shirai, K; Watanabe, F | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kitabata, H; Kuroi, A; Mochizuki, S; Muragaki, Y; Takarada, S; Tanimoto, T; Tsujioka, H; Yoshida, K | 1 |
| Chen, B; Guan, GJ; Hou, XH; Li, XG; Liu, G; Liu, JL; Zhang, Y | 1 |
| Araki, R; Ikeda, N; Inoue, T; Kanno, Y; Shoda, J; Sugahara, S; Suzuki, H; Takenaka, T | 1 |
| Crikelair, N; Nash, DT; Zappe, D | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tamamaki, N; Tokutomi, Y; Yamamoto, E | 1 |
| Hashimoto, K; Horino, T; Inoue, K; Iwasaki, Y; Kagawa, T; Matsumoto, R; Morita, T; Taguchi, T; Takao, T; Terada, Y | 1 |
| Deák, L; Farsang, C; Haller, H; Handrock, R; Klebs, S; Meier, M; Menne, J; Sieder, C | 1 |
| Baumgart, P; Ferber, P; Le Breton, S; Reimund, B; Tuomilehto, J; Tykarski, A | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, A; Tsujioka, H; Yoshida, K | 1 |
| Sun, NL; Tu, YM; Zhao, Y; Zhu, JR | 1 |
| Izumi, N; Nagaoka, T; Sato, E; Takahashi, A; Yokota, H; Yoshida, A | 1 |
| Chen, YH; Chen, YY; Qi, CJ; Yuan, L | 1 |
| Baker, AB; Beigel, R; Chatzizisis, YS; Coskun, AU; Daley, W; Edelman, ER; Feldman, CL; Gerrity, RG; Jonas, M; Maynard, C; Stone, BV; Stone, PH | 1 |
| Cheng, Q; de Gasparo, M; Law, PK; Leung, PS | 1 |
| Lee, BJ; Lee, ES; Piao, ZZ; Tran, HT | 1 |
| Abadir, PM; Abdel-Rahman, EM; Siragy, HM | 1 |
| Dahlöf, B; Matsubara, H; Sawada, T; Takahashi, T; Yamada, H | 1 |
| Brixner, DI; Jackson, KC; Keskinaslan, A; Nelson, RE; Sheng, X | 2 |
| Li, JX; Liu, L; Xu, DY; Zhao, SP; Zhou, HN | 1 |
| Chen, L; Chen, S; Wang, W; Yan, J | 1 |
| Crikelair, N; Lastra, G; Levy, DG; Rocha, R; Seifu, Y; Sowers, JR | 1 |
| He, Y; Huang, Q; Jiang, J; Li, M; Liu, X; Ma, D; Wang, S; Xu, G; Yao, Y; Zhou, J; Zou, R | 1 |
| Bethel, MA; Califf, RM; Haffner, SM; Holman, R; Hua, TA; Huntsman-Labed, A; McMurray, J | 1 |
| Bethel, M; Boolell, M; Califf, RM; Duggal, A; Haffner, SM; Holman, RR; McMurray, J | 1 |
| Fujikawa, K; Saito, I; Saruta, T | 1 |
| Imanishi, M; Kitabayashi, C; Konishi, Y; Maeda, I; Miyazaki, M; Morikawa, T; Nishiyama, A; Okada, N; Okumura, M; Takai, S; Ueda, M; Yoshioka, K | 1 |
| Faedda, R; Loriga, G; Ruggenenti, P; Sanna, M; Satta, AE; Vidili, G | 1 |
| Lu, J; Sun, L; Yu, XJ; Zang, WJ; Zhang, CH | 1 |
| Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A | 1 |
| Bozkurt, D; Cetin, P; Duman, S; Ertilav, M; Hur, E; Nar, H; Sezak, M; Sipahi, S | 1 |
| Baranova, E; Ferber, P; Kandra, A; Okopien, B; Rump, LC; Weisskopf, M | 1 |
| Imaizumi, T; Kai, H; Kuwahara, F; Mizoguchi, M; Mizuta, Y; Nakaura, H; Osada, K; Tahara, N | 1 |
| Chang, YM; Feng, CH; Lu, CY; Tseng, WL | 1 |
| Aoki, M; Fujiwara, Y; Makino, H; Miyake, T; Morishita, R; Nishimura, M; Shiraya, S; Yamakawa, S | 1 |
| Haider, DG; Jungbauer, A; Kapiotis, S; Mueller, M; Storka, A; Vojtassakova, E; Wolzt, M | 1 |
| Furuno, M; Higaki, J; Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Mogi, M; Okayama, H; Senba, I; Tomono, Y | 1 |
| Akashiba, A; Ishimitsu, T; Matsuoka, H; Ono, H; Ono, Y | 1 |
| Fu, L; Gao, Y; Han, Y; Li, Y; Ma, D; Shen, J; Wang, F; Wang, Y; Xie, R; Zhou, P | 1 |
| Harbig, J; Jaworski, K; Miller, AG; Tan, G; Wilkinson-Berka, JL | 1 |
| Bader, M; Carretero, OA; Rhaleb, NE; Shesely, EG; Xu, J; Yang, JJ; Yang, XP | 1 |
| Hamamoto, Y; Honjo, S; Ikeda, H; Koshiyama, H; Nabe, K; Wada, Y | 1 |
| Fang, H; Oparil, S; Patel, S; Yarows, SA; Zhang, J | 1 |
| Hirose, H; Itoh, H; Komiya, N; Saisho, Y; Saito, I | 1 |
| Belousov, DIu; Belousov, IuB; Shestakova, MV | 1 |
| Chen, JD; Li, YH; Liu, KY; Lu, GJ; Wang, T; Yin, KS | 1 |
| Dai, Y; Deng, W; Su, L; Yin, YH | 1 |
| Chen, JS; Cheng, DR; Cheng, Z; Ji, SM; Li, LS; Liu, ZH; Sha, GZ; Wen, JQ | 1 |
| Jiang, B; Liu, ZH; Qu, FZ | 1 |
| Deedwania, PC; Fonseca, VA; Haffner, SM; Hsueh, WA; Keeling, L; Sica, DA; Sowers, JR; Zappe, DH | 1 |
| Baumhäkel, M; Müller, U | 1 |
| Hatzitolios, A; Ntaios, G; Savopoulos, C | 1 |
| Al Qahtani, M; Alzahrani, M; Haider, A; Palker, V; Saeed, AB; Salih, SB | 1 |
| Ding, LJ; Huang, QJ; Ji, H; Li, YQ; Shen, Y; Yang, YL; Zhuang, P | 1 |
| Hawkins, NM; Huang, Z; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Pieper, KS; Solomon, SD; Swedberg, K; Velazquez, EJ | 1 |
| Batisky, DL; Blumer, J; Shi, V; Solar-Yohay, S; Sunkara, G; Wells, T | 1 |
| Chaplin, S; Papo, NL; Scuffham, PA; Taylor, M | 1 |
| Glazer, RD; Kavoliuniene, A; Miglinas, M; Prak, H; Sinkiewicz, W; Wernsing, M; Yen, J | 1 |
| Ansari, A; Braun, N; Handrock, R; Klebs, S; Ulmer, HJ | 1 |
| Akpinar, E; Brunel, P; Calvo, C; Keeling, L; Salvetti, A; Schrader, J; Weisskopf, M | 1 |
| Ali, NA; Jawad, AM; Salman, AA | 1 |
| Edelsberg, J; Kartashov, A; Keskinaslan, A; Levy, DG; Oster, G; Weycker, D | 1 |
| Borbas, E; Handrock, R; Klebs, S; Schaetzl, R; Trenkwalder, P | 1 |
| Ram, CV | 1 |
| Glazer, RD; Philipp, T; Pospiech, R; Zhao, Y | 1 |
| Aoyama, I; Bomsztyk, K; Komers, R; Koopmeiners, JS; Naito, M; Schnaper, HW; Shenoy, A | 1 |
| Averinen, RK; Gupta, PD; Mutalik, S; Nayak, UY; Nayak, Y; Reddy, SM; Shavi, GV; Udupa, N | 1 |
| Clark, SE; Ferrario, CM; Ibdah, JA; Li, W; Sowers, JR; Thyfault, JP; Uptergrove, GM; Wei, Y; Whaley-Connell, AT | 1 |
| Georgescu, EF; Ionescu, R; Mogoanta, L; Niculescu, M; Vancica, L | 1 |
| Araki, SI; Haneda, M; Isshiki, K; Kanasaki, M; Kashiwagi, A; Koya, D; Kume, S; Sakaguchi, M; Sugiomoto, T; Uzu, T; Yokomaku, Y | 1 |
| Argyropoulos, D; Durdagi, S; Grdadolnik, SG; Hayes, JM; Katsiaras, V; Kyrikou, I; Mavromoustakos, T; Papadopoulos, MG; Potamitis, C; Vatougia, G; Zervou, M; Zoumpoulakis, P | 1 |
| Ichihara, A; Itoh, H; Kaneshiro, Y; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M | 1 |
| Chang, NC; Lee, TM | 1 |
| Ezan, E; Levi, M; Pruvost, A; Wuerzner, G | 1 |
| Mullangi, R; Ramani, AV; Sengupta, P | 1 |
| Akiyoshi, Y; Miyamoto, S; Morishima, M; Ono, K; Wang, Y | 1 |
| Bayir, Y; Halici, Z; Keles, MS; Suleyman, H | 1 |
| Düsing, R; Handrock, R; Klebs, S; Tousset, E; Vrijens, B | 1 |
| Rosa, EM; Viecceli, C | 1 |
| Iwasaka, T; Kawamura, A; Masue, Y; Sugiura, T; Yokoe, H; Yuasa, F | 1 |
| Chiang, AN; Hou, HH; Hsiao, SH; Kou, YR; Lee, TS; Pan, CC; Shyue, SK; Su, KH; Tsai, JY; Wu, YL | 1 |
| Feldman, D; Wexler, R | 1 |
| Huang, CX; Jiang, H; Li, GS; Okello, E; Tang, YH; Wang, X; Zhao, QY | 1 |
| Azuma, K; Dejima, T; Ishigami, T; Kokuho, T; Masuda, S; Mitsuhashi, H; Okano, Y; Ozawa, M; Shigenaga, A; Sugano, T; Tamura, K; Tokita, Y; Toya, Y; Tsurumi-Ikeya, Y; Uchino, K; Umemura, S; Wakui, H | 1 |
| Geshi, E; Katagiri, T; Mochizuki, S; Nakano, H; Nanjyo, S; Sato, N; Shibata, T; Suzuki, H; Takano, T; Tanaka, K; Yagi, H; Yamazaki, J | 1 |
| Abraham, I; Brié, H; Denhaerynck, K; Hermans, C; Lee, C; MacDonald, K; Van der Niepen, P; Vancayzeele, S; Woestenburg, A | 1 |
| Arnold, JM; Bourgoun, M; Califf, RM; Ghali, JK; Kober, L; McMurray, JJ; Meris, A; Pfeffer, MA; Skali, H; Solomon, SD; Velazquez, EJ; Verma, A | 1 |
| Davidai, G; Schumacher, H; White, WB | 1 |
| Barlera, S; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Lucci, D; Maggioni, AP; Staszewsky, L; Tognoni, G | 1 |
| Gillis, AM | 1 |
| Furukata, S; Ishimitsu, T; Matsuoka, H; Minami, J; Ohno, E | 1 |
| Chen, LH; Ding, JW; Jiang, H; Li, S; Yang, J; Zhang, XD | 1 |
| Brennan, AM; Chan, JL; Danias, PG; Khaodhiar, L; Lima, C; Manning, WJ; Mantzoros, CS; Veves, A | 1 |
| Black, HR; Lacourcière, Y; Purkayastha, D; Samuel, R; Wright, JT; Zappe, D | 2 |
| Kuji, T; Masuda, S; Okano, Y; Tamura, K; Tochikubo, O; Umemura, S | 1 |
| Miura, T; Yuda, S | 1 |
| Falvey, H; Lowy, A; Müller, E; Nixon, RM | 1 |
| Levesque, S; Meloche, S; Pelletier, GB; Racine, N; Ross, H; Voisin, L; White, M; Whittom, L | 1 |
| Kapadia, CJ; Shrivastava, AR; Ursekar, B | 1 |
| Koehler, B; Peters, S; Rählert-Sommer, A; Selbig, D; Steffen, H; Trümmel, M | 1 |
| Habtemariam, B; Jarugula, V; Kern, S; Pillai, G; Sallas, W; Sunkara, G | 1 |
| Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Mogi, M; Senba, I; Tomono, Y | 1 |
| Ayala, C; Clavijo, S; Contreras, Y; del Rosario Brunetto, M; Delgado, Y; Estela, JM; Gallignani, M; Martin, VC; Ovalles, F; Torres, D | 1 |
| Bhuiyan, MA; Hossain, M; Ishiguro, M; Miura, S; Nagatomo, T; Nakamura, T; Ozaki, M | 1 |
| Ceylan, C; Gencoglan, G; Kazandi, AC | 1 |
| Arimura, T; Iwata, A; Kawamura, A; Kiya, Y; Miura, S; Nishikawa, H; Saku, K; Sugihara, M; Takamiya, Y; Uehara, Y | 1 |
| Black, HR | 1 |
| Calhoun, DA; Chiang, YT; Glazer, RD; Lacourcière, Y | 1 |
| Boj, M; Camprubí, M; Hernandez-Flix, S; Solà, R | 1 |
| Behnisch, B; Heilmann, T; Peters, S; Richter, C | 1 |
| Barranco, E; Geiger, H; Gorostidi, M; Taylor, A; Xiang, Z; Zhang, J; Zhang, X | 1 |
| Califf, RM; Maggioni, AP; McMurray, JJ; Moukarbel, GV; Pfeffer, MA; Scheiman, JM; Signorovitch, JE; Solomon, SD; Velazquez, EJ; White, HD | 1 |
| Prabhakar, M; Reddy, AR; Reddy, PP; Reddy, VP; Sampath, A; Thirupathi, A; Yakambaram, B | 1 |
| Califf, RM; Diaz, R; Leimberger, JD; Lewis, EF; Lokhnygina, Y; McMurray, JJ; Murin, J; Pfeffer, MA; Velazquez, EJ | 1 |
| Dong, YF; Fukuda, M; Kaneko, T; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakagata, N; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E | 1 |
| Furuyama, M; Hashimoto, T; Hayasaka, K; Matsunaga, A; Ogino, D; Toyoda, K | 1 |
| Lim, PO; MacDonald, TM; Tzemos, N | 1 |
| Flack, JM; Hilkert, R | 1 |
| Vivencio, B | 1 |
| Aoki, T; Hashimoto, N; Ishibashi, R; Kataoka, H; Miyake, T; Morishita, R; Nishimura, M; Takagi, Y | 1 |
| Smit, MD; Van Gelder, IC | 1 |
| Tomoda, H | 1 |
| Alonso, RM; Ferreirós, N; Gonzalez, O; Iriarte, G; Jiménez, RM; Maguregui, MI | 1 |
| Ikeda, H; Jin, D; Miyazaki, M; Sakonjo, H; Takai, S | 1 |
| Harada, N; Okajima, K; Shimozawa, N | 1 |
| Wang, Q; Wu, G; Zhao, W | 1 |
| Kondrack, R; Mohiuddin, S | 1 |
| Li, D; Ma, S; Tang, B; Yang, D; Yang, Y | 1 |
| Chihara, K; Dan, T; Izuhara, Y; Kurokawa, K; Miyata, T; Ohtomo, S; Robert, A; Tominaga, N; Van Ypersele de Strihou, C | 1 |
| Dahlöf, B; Matsubara, H; Sawada, T; Yamada, H | 1 |
| Bangalore, S; Messerli, FH; Ruschitzka, F | 1 |
| Braga, MF; Leiter, LA | 1 |
| Patil, K; Rane, V; Shinde, D | 1 |
| Inoue, M; Iwano, H; Kaga, S; Komatsu, H; Matsuno, K; Mikami, T; Nishida, M; Okada, M; Onozuka, H; Shimizu, C; Tsutsui, H; Yamada, S; Yokoyama, S | 1 |
| Glazer, RD; Macarie, CE; Romanova, J; Schunkert, H; Vintila, MM; Wernsing, M; Yen, J | 1 |
| Takami, T | 1 |
| Andrews, CD; Brunel, P; MacDonald, TM; Parthasarathy, HK; Pieske, B; Struthers, AD; Weisskopf, M | 1 |
| Huang, YL; Li, JJ; Qu, XF; Shen, JX; Wang, GZ; Xi, Y; Xiu, CH; Yue, L | 1 |
| Frampton, JE; Scott, LJ | 1 |
| Anand, IS; Bishu, K; Cohn, JN; Ishani, A; Kuskowski, MA; Rector, TS | 1 |
| Anand, IS; Cohn, JN; Holwerda, NJ; Kuskowski, M; Rector, TS; Thomas, S | 1 |
| Hollenberg, NK; Meng, X; Parving, HH; Remuzzi, G; Viberti, G; Weir, MR; Zappe, DH | 1 |
| Andraus, MH; Azevedo, CP; Borges, BC; Borges, NC; Moreira, RF; Moreno, RA; Salvadori, MC | 1 |
| Ecder, T; Kashihara, N; Locatelli, F; Palmer, BF | 1 |
| Almeida, S; Farré, A; Filipe, A; Neves, R; Spínola, AC; Trabelsi, F | 1 |
| Al-Khatib, SM; Califf, RM; McMurray, JJ; Pfeffer, MA; Piccini, JP; Pieper, K; Solomon, SD; Van de Werf, F; Velazquez, EJ; Zhang, M | 1 |
| Downie, LE; Fletcher, EL; Hatzopoulos, KM; Kalloniatis, M; Pianta, MJ; Vingrys, AJ; Wilkinson-Berka, JL | 1 |
| Crikelair, N; Glazer, R; Levy, D; Pool, JL | 1 |
| Fan, H; Liu, X; Wang, A; Yuan, H; Zhu, X | 1 |
| Ferber, P; Papst, CC; Zappe, D | 1 |
| Li, J; Shi, R; Yang, C; Zhu, X | 1 |
| Hotta, H; Ishikawa, S; Itoh, T; Kim, SJ; Kuno, A; Maeda, T; Miki, T; Miura, T; Satoh, T; Shimamoto, K; Tanno, M; Terashima, Y; Togashi, N; Yano, T | 1 |
| Bailey, J; Black, HR; Samuel, R; Zappe, D | 1 |
| Hedner, T; Kjeldsen, SE; Narkiewicz, K | 1 |
| Han, LH; Jiang, B; Jiang, WP; Li, HX; Liu, ZH; Qu, FZ; Zou, C | 1 |
| Iannazzo, S; Pradelli, L; Zaniolo, O | 1 |
| Deeks, ED | 1 |
| Cascais, AC; Funk, C; Lavé, T; Poirier, A | 2 |
| Guan, Q; Pang, X; Sun, D; Xie, L; Zeng, D; Zhang, H | 1 |
| Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B | 1 |
| Hall, AS; Strauss, MH | 1 |
| Chen, X; Dong, J; Jiang, L; Jiang, W; So, Y; Xin, H | 1 |
| Chen, FM; Fu, GS; Wang, H; Wang, YJ | 1 |
| Lacourcière, Y; Poirier, L; Samuel, R | 1 |
| Bellocci, F; Crea, F; Giubilato, G; Ierardi, C; Pieroni, M; Santangeli, P; Vitulano, N | 1 |
| Masuda, S; Okano, Y; Ozawa, M; Tamura, K; Tochikubo, O; Umemura, S | 1 |
| Chen, CC; Hsieh, IC; Hsieh, MJ; Lee, CH; Wang, JL | 1 |
| Calhoun, DA; Jamerson, KA; Palmer, BF; Purkayastha, D; Samuel, R; Zappe, DH | 1 |
| Calhoun, DA; Crikelair, NA; Glazer, RD; Yen, J | 1 |
| Yarows, SA | 1 |
| Cheng, S; Li, H; Li, J; Li, X; Qi, C; Xu, G; Yuan, L | 1 |
| Biala, A; Eriksson, O; Finckenberg, P; Kaheinen, P; Lapatto, R; Lempiäinen, J; Louhelainen, M; Luft, FC; Martonen, E; Mattila, I; Merasto, S; Mervaala, E; Muller, DN; Oresic, M | 1 |
| Frank, H; Heemann, U; Pscherer, S | 1 |
| Chen, YD; Feng, QZ; Li, TD | 1 |
| Carter, JD; Cole, BK; Keller, SR; Nadler, JL; Nunemaker, CS; Wu, R | 1 |
| Delić-Brkljacić, D; Gaćina, P; Galesić, K; Ivanac, G; Manola, S; Pintarić, H; Radeljić, V; Stambuk, K | 1 |
| Burnier, M; Coltamai, L; Maillard, M; Simon, A; Vogt, B | 1 |
| Ekhlas, A; Esnault, VL; Moranne, O; Nguyen, JM | 1 |
| Hu, Z; Jiang, B; Li, X; Peng, T; Xia, Q; Yang, X | 1 |
| El-Setouhy, DA; Ibrahim, HK | 1 |
| Huang, J; Ke, YN; Zhu, JR | 1 |
| Jiang, L; Li, F; Liu, M; Wang, L; Xiao, N; Yang, M | 1 |
| Bai, B; Cui, TQ; Hou, JN; Jiang, LS; Mu, CL; Zhao, CP | 1 |
| Dastani, HB; Kahler, KH; Latremouille-Viau, D; Signorovitch, J; Wu, EQ; Yu, AP; Zhang, J | 1 |
| Johnston, A | 1 |
| Corradi, L; Derosa, G; Fogari, R; Malamani, G; Mugellini, A; Preti, P; Zoppi, A | 1 |
| Habuchi, T; Inoue, T; Kagaya, H; Miura, M; Ohkubo, T; Saito, M; Satoh, S; Suzuki, T | 1 |
| Bourgoun, M; Califf, RM; Ghali, JK; Hassanein, AH; Hung, CL; Køber, L; Pfeffer, MA; Shin, SH; Solomon, SD; Uno, H; Velazquez, EJ; Verma, A | 1 |
| Chiang, YT; Crikelair, NA; Glazer, RD; Weinberger, MH | 1 |
| Dixit, AR; Patel, SG; Rajput, SJ | 1 |
| Bethel, MA; Califf, RM; Gerlock, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Krum, H; McMurray, JJ; Zuurman, L | 1 |
| Hatazawa, J; Hougaku, H; Kajimoto, K; Kato, H; Kimura, Y; Kitagawa, K; Oku, N; Sakaguchi, M; Sakoda, S; Tanaka, M | 1 |
| Li, X; Qi, CJ; Xu, GL; Yuan, L | 1 |
| Adachi, M; Aritomi, S; Hayata, M; Kakizoe, Y; Kitamura, K; Ko, T; Konda, T; Miyoshi, T; Shiraishi, N; Tomita, K; Uchimura, K; Wakida, N | 1 |
| Nathan, DM | 1 |
| Belenkov, Y; Bethel, MA; Boolell, M; Buckley, BM; Buse, JB; Califf, RM; Chacra, AR; Charbonnel, B; Chiang, FT; Chow, CC; Davies, MJ; Deedwania, P; Diem, P; Einhorn, D; Fonseca, V; Fulcher, GR; Gaciong, Z; Gaztambide, S; Giles, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Hua, TA; Ilkova, H; Jenssen, T; Kahn, SE; Krum, H; Laakso, M; Leiter, LA; Levitt, NS; Mareev, V; Martinez, F; Masson, C; Mazzone, T; McMurray, JJ; Meaney, E; Nesto, R; Pan, C; Prager, R; Raptis, SA; Rutten, GE; Sandstroem, H; Schaper, F; Scheen, A; Schmitz, O; Sinay, I; Soska, V; Stender, S; Tamás, G; Tognoni, G; Tuomilehto, J; Villamil, AS; Vozár, J | 2 |
| Derosa, G; Fogari, R; Mugellini, A; Preti, P; Zoppi, A | 1 |
| Feihl, F; Waeber, B | 2 |
| Böhm, M; Dukat, A; Gong, J; Lacourcière, Y; Lefkowitz, MP; Ruilope, LM | 1 |
| DUHOT, E; FONTAN, M; MINET, J | 1 |
| Fu, L; Gao, Q; Li, Y; Ma, D | 1 |
| Bhuiyan, MA; Hossain, M; Nagatomo, T; Nakamura, T; Ozaki, M | 1 |
| Islambulchilar, Z; Nemati, M; Valizadeh, H; Zakeri-Milani, P | 1 |
| Li, X; Zhou, Q | 1 |
| Choi, HG; Kim, JO; Kim, YI; Li, DX; Oh, DH; Seo, YG; Yan, YD; Yang, KY; Yong, CS | 1 |
| Binger, KJ; Campbell, DJ; Cooper, ME; Fletcher, EL; Hatzopoulos, KM; Heine, R; Miller, AG; Tan, G; Wilkinson-Berka, JL | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E | 1 |
| Aihara, K; Akimoto, Y; Daida, H; Kasai, T; Kawamura, M; Kojima, S; Miyauchi, K; Miyazaki, S; Miyazaki, T; Sumiyoshi, M; Suwa, S; Takagi, A | 1 |
| Dittmann, S; Farr, M; Funke, C; Horstkotte, D; Niehaus, K; Piper, C; Überla, K; Werner, B | 1 |
| Guo, L; Hu, Z; Jiang, B; Li, XH; Pei, F; Peng, T; Song, J; Xia, Q; Yang, XD | 1 |
| Batolar, LS; Iqbal, M; Khuroo, A; Monif, T; Sharma, PL; Tandon, M | 1 |
| Achouba, A; Boutouyrie, P; Laurent, S; Trunet, P | 1 |
| Cagnoni, F; D'Ospina, A; Demichele, E; Destro, M; Peros, E; Preti, P; Ricci, AR; Zaninelli, A | 1 |
| Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Shintani, S | 1 |
| Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J | 1 |
| Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Vahtola, E | 1 |
| Suzuki, H; Takenaka, T | 1 |
| Kamal, F; Morioka, T; Oite, T; Piao, H; Yanakieva-Georgieva, N | 1 |
| Blanco-Colio, LM; Carrero, JJ; Celik, T; Egido, J; Eyileten, T; Martín-Ventura, JL; Moreno, JA; Saglam, M; Sonmez, A; Yaman, H; Yenicesu, M; Yilmaz, MI | 1 |
| Fukuda, N; Fukushima, H; Hirata, H; Ishimitsu, T; Kobayashi, E; Kobayashi, N; Koguchi, W; Machida, Y; Mamada, Y; Suzuki, N; Tabei, K; Takeshima, H; Yokotsuka, F | 1 |
| Chen, X; Chen, ZG; Cheng, B; Gu, YF; Liu, HW; Liu, WZ; Wu, HJ | 1 |
| Barlera, S; Cosmi, F; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Lombardi, F; Maggioni, AP; Zeni, P | 1 |
| Arsenault, J; Cabana, J; Escher, E; Guillemette, G; Lanthier, L; Lavigne, P; Leduc, R; Lehoux, J | 1 |
| Bernheim, A; Brunner-La Rocca, HP; Kiowski, W; Kuster, GM; Morgenthaler, NG; Mueller, B; Nietlispach, F; Rickli, H; Riesen, W; Rüter, F; Schindler, R; Schuetz, P | 1 |
| Dahlöf, B; Ikewaki, K; Mochizuki, S; Rosano, G; Shimizu, M; Tada, N; Taniguchi, I; Yoshida, H; Yoshimura, M | 1 |
| Cardenas, P; Hong, H; Ke, Y; Wang, R; Zhang, Y; Zhu, D; Zhu, J | 1 |
| Brown, RE; Imran, SA; Wilkinson, M | 1 |
| Gong, C; Huang, JF; Huang, SL; Jiang, XJ; Luo, M; Zhang, ZF; Zhao, Y | 1 |
| Gao, Q; Liu, Z; Qin, W; Shen, W; Wang, J; Wang, S; Zeng, C; Zhang, M; Zheng, C; Zhu, X | 1 |
| Kondo, K; Nomura, Y; Oiso, Y; Ozaki, N; Sobajima, H | 1 |
| Deedwania, PC; Egan, BM; Jialal, I; Ofili, EO; Purkayastha, D; Raij, L; Samuel, R; Sowers, JR; Zappe, DH | 1 |
| Scheen, AJ | 1 |
| Biggi, A; Cabassi, A; De Iaco, G; Iori, M; Magnani, G; Montanari, A; Musiari, L; Novarini, A; Pelà, GM; Pelloni, I; Pinelli, S | 1 |
| Baguet, JP; Barone-Rochette, G; Launois, SH; Lévy, P; Pépin, JL; Tamisier, R | 1 |
| Eto, T; Imai, Y; Imaizumi, T; Ito, S; Kikuchi, K; Kimura, G; Matsuoka, H; Ogihara, T; Rakugi, H; Saruta, T; Shimada, K; Shimamoto, K; Takishita, S; Ueshima, H | 1 |
| Fliser, D; Frank, H; Heemann, U; Pscherer, S | 1 |
| Rudolph, A; Weintraub, HS | 1 |
| Dörffel, Y; Kappert, K; Kintscher, U; Kümmel, A; Martus, P; Marx, N; Schimkus, J; Schneider, A; Scholze, J; Stoppelhaar, M; Unger, T; Walcher, D; Winkler, R | 1 |
| Asmar, R; Brudi, P; Di Giovanni, R; Kandra, A; Mengden, T; Parati, G | 1 |
| Biro, S; Ikeda, Y; Kono, S; Otonari, T; Saikawa, T; Sasaki, J | 1 |
| Bode, C; Braunwald, E; Cannon, CP; Lopez-Sendon, J; Lukashevich, V; Maboudian, M; McCabe, CH; Morrow, DA; Ogorek, M; Oude Ophuis, AJ; Rifai, N; Ruda, M; Ruzyllo, W; Scirica, BM; Swedberg, K | 1 |
| Becker, HF; Canisius, S; Greulich, T; Heitmann, J; Koehler, U; Reinke, C; Schmidt, AC; Vogelmeier, C | 1 |
| Lin, S; Peng, W; Tang, R; Veeraragoo, P; Wu, R; Zhou, Q | 1 |
| Lin, S; Shi, H; Zheng, Z | 1 |
| Belenkov, Y; Califf, RM; Finn, PV; Kenchaiah, S; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Shamshad, F; Soler-Soler, J; Solomon, SD; Swedberg, K; Varshavsky, S; Velazquez, EJ | 1 |
| Abraham, I; Brié, H; Chen, HC; Fidel, GE; Hermans, C; Ko, ML; Lee, CS; MacDonald, K; Reel, S; Van der Niepen, P; Vancayzeele, S | 1 |
| Chen, JW; Fang, J; Gao, J; Huang, HQ; Liu, PQ; Tang, FT; Wang, P; Xu, SW; Zhou, SG | 1 |
| Krishnaiah, Ch; Kumar, R; Mukkanti, K; Reddy, AR | 1 |
| Ayala, DE; Fernández, JR; Fontao, MJ; Hermida, RC; Mojón, A | 2 |
| Braga, AN; Denadai, AM; dos Santos, RA; Jensen, CE; Santos, CF; Sinisterra, RD | 1 |
| Derosa, G; Ferrari, I; Fogari, R; Mugellini, A; Preti, P; Zoppi, A | 1 |
| Desilva, VR; Enomoto, D; Higaki, J; Irita, J; Jotoku, M; Kurata, M; Miyoshi, K; Nagao, T; Okura, T | 1 |
| Battaglia, G; Cambareri, F; Carminati, S; Cravedi, P; David, S; Ene-Iordache, B; Gaspari, F; Granata, A; Ledda, F; Loriga, G; Motterlini, N; Perna, A; Remuzzi, G; Rota, S; Rubis, N; Ruggenenti, P; Satta, A; Stucchi, N; Tonelli, M | 1 |
| Hilleman, DE; Malesker, MA | 1 |
| Chang, J; Fellers, T; Kahler, KH; Orloff, J; Tsaneva, M; Wu, EQ; Xie, J; Yang, W; Yu, AP | 1 |
| Chang, CH; Chiu, YT; Ku, CL; Shu, KH; Wen, MC; Wu, MJ; Wu, WP | 1 |
| Asmar, R; Bilo, G; Di Giovanni, R; Kandra, A; Mengden, T; Parati, G | 1 |
| Bangalore, S; Messerli, FH | 1 |
| Kamide, K; Maekawa, Y; Ohishi, M; Onishi, M; Rakugi, H; Takeya, Y; Tatara, Y; Yamamoto, K | 1 |
| Luan, FL | 1 |
| Kario, K; Yano, Y | 1 |
| Anand, IS; Deswal, A; Kereiakes, DJ; Purkayastha, D; Zappe, DH | 1 |
| Han, HK; Im, YB; Lee, HK; Lee, W; Park, YJ | 1 |
| Mastaitis, JW; Mobbs, CV; Poplawski, MM | 1 |
| Bilo, G; Mancia, G; Parati, G; Schumacher, H | 1 |
| Fukamachi, S; Kawakami, C; Nakamura, M; Sawada, Y; Sugita, K; Tokura, Y; Yoshiki, R | 1 |
| Kazawa, T; Kuroki, N; Kuwabara, M; Maruki, T; Odagaki, Y; Toyoshima, R; Yamashita, H; Yoda, H | 1 |
| Huo, LJ; Liu, Y; Zhang, SJ | 1 |
| Carretero, OA; Liao, TD; Liu, TS; Peng, H; Reudelhuber, TL; Shesely, EG; Xu, J; Yang, JJ; Yang, XP | 1 |
| Cooley, C; Kalra, A; Palaniswamy, C; Zanotti-Cavazzoni, SL | 1 |
| Ayalasomayajula, S; Bhad, P; Jarugula, V; Karan, R; Leon, S; Riviere, GJ; Sunkara, G | 1 |
| Allhoff, T; Anand, IS; Cohn, JN; Drexler, H; Jantzen, F; Kempf, T; Kuskowski, M; Rector, TS; Tapken, H; Wollert, KC | 1 |
| Epstein, BJ | 1 |
| Crikelair, N; Destro, M; Glazer, R; Yen, J | 1 |
| Belal, TS; Shaalan, RA | 1 |
| Mehta, S; Shah, RP; Singh, S | 1 |
| Aritomi, S; Koganei, H; Konda, T; Mitsui, A; Nitta, K; Ogawa, T; Wagatsuma, H | 1 |
| Fujita, M; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H | 1 |
| Manome, Y; Nishida, N; Sawabe, T; Taniyama, K | 1 |
| Fukuda, N; Maeshima, A; Matsumoto, K; Matsumoto, T; Nojima, Y; Soma, M; Ueno, T; Yamamoto, C; Yoshida, Y | 1 |
| Ge, J; Gong, H; Komuro, I; Li, L; Lin, L; Wu, J; Zhou, N; Zou, Y | 1 |
| Barlera, S; Carbonieri, E; Disertori, M; Favero, C; Franzosi, MG; Gulizia, M; Latini, R; Maggioni, AP; Masson, S; Pirelli, S; Pulitano, G; Staszewsky, L; Struck, J; Vago, T; Zdunek, D | 1 |
| Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, J; Signorovitch, JE; Solomon, SD; Swedberg, K; Thune, JJ; Velazquez, E | 1 |
| Giles, T; Hilkert, R; Ofili, EO; Oparil, S; Pitt, B; Samuel, R; Seifu, Y; Sowers, JR | 1 |
| Cheng, X; Lin, S; Wu, R; Zhou, Q | 1 |
| Chrysant, SG; Dattani, D; Hoppe, UC; Murray, AV; Patel, S; Ritter, S; Zhang, J | 1 |
| Hosoya, T; Ishii, T; Kawamura, T; Tsuboi, N | 1 |
| Bengel, FM; Bravo, PE; Dannals, RF; Fukushima, K; Higuchi, T; Javadi, MS; Lautamäki, R; Mathews, WB; Szabo, Z; Xia, J | 1 |
| Barrios, V; Escobar, C | 1 |
| Asmar, R; Oparil, S | 1 |
| Bouma, BJ; Groenink, M; Mulder, BJ; Pieper, PG; Roos-Hesslink, JW; Sieswerda, GT; van der Bom, T; van Dijk, AP; Vliegen, HW; Winter, MM; Zwinderman, AH | 1 |
| Anand, IS; Angelici, L; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Prescott, M; Solomon, S; Tognoni, G | 1 |
| Akhtari, S; Andalib, A; Curnew, G; Leclerc, JM; Rigal, R; Tardif, JC; Vaillancourt, M | 1 |
| Chiu, YH; Hsu, BG; Ke, CY; Lee, CJ; Lin, NT; Subeq, YM | 1 |
| Fogari, R; Zoppi, A | 1 |
| Chaiyakunapruk, N; Cheewasithirungrueng, N; Dilokthornsakul, P; Jeanpeerapong, N; Nimpitakpong, P; Srisupha-olarn, W; Thanarungroj, A | 1 |
| Aizawa, Y; Suzuki, K | 1 |
| Carrington, MJ; Jennings, GL; Kurstjens, N; Stewart, S; Swemmer, C | 1 |
| Lee, T | 1 |
| Chazova, IE; Dongre, N; Vigdorchik, AV | 1 |
| Calhoun, DA; Crikelair, N; Glazer, RD; Lacourcière, Y; Yen, J | 1 |
| Huang, J; Matavelli, LC; Siragy, HM | 1 |
| Konta, T; Kubota, I; Miyamoto, T; Miyashita, T; Nishiyama, S; Nitobe, J; Shishido, T; Takasaki, S; Takeishi, Y; Watanabe, T | 1 |
| Friedrich, D; Gortner, L; Herkenrath, P; Hoppe, B; Hünseler, C; Kattner, E; Körber, F; Lindner, U; Müller, A; Oberthuer, A; Paneitz, A; Roth, B; Schaible, T; Schmitt, K; Welzing, L | 1 |
| Bakris, GL; Cao, C; Kupfer, S; Perez, A; Sica, D; Weber, MA; White, WB | 1 |
| Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T | 2 |
| Furuno, M; Higaki, J; Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Mogi, M; Okayama, H; Senba, I | 1 |
| Armstrong, SR; Budman, J; Cheruvu, M; Hegde, LG; Hegde, SS; Hill, CM; Klein, U; Lane, CE; Olsufka, R; Park, T; Renner, T; Sandvik, ER; Thibodeaux, H; Yu, C | 1 |
| Chae, DW; Do, JY; Huh, W; Jang, HR; Kim, DJ; Kim, SG; Kim, YG; Lee, JE; Lee, YJ; Oh, HY | 1 |
| Cacho-Nerin, F; Chatzigeorgiou, P; Hodzic, A; Laggner, P; Mavromoustakos, T; Pabst, G; Potamitis, C; Rappolt, M; Siapi, E; Viras, K | 1 |
| Blaak, EE; Diamant, M; Goossens, GH; Hermans, MM; Moors, CC; van der Zijl, NJ | 1 |
| Dong, Z; Ge, Z; Geng, J; Kang, W; Liu, G; Sun, Y; Wu, T; Zhang, Y | 1 |
| Deng, S; Li, H; Qin, DL; Zhang, Z; Zhou, M | 1 |
| Bouabidi, A; Bouklouze, A; Bourichi, H; El Guezzar, M; El Karbane, M; Hubert, P; Rozet, E; Talbi, M; Ziemons, E | 1 |
| Arya, DS; Bharti, S; Goyal, S; Sahoo, KC; Sharma, AK | 1 |
| Choi, KH; Han, DS; Han, SH; Kang, EW; Kang, SW; Lee, HC; Yoo, TH; Yoon, HS; Yoon, SJ | 1 |
| Lakshmi, KS; Lakshmi, S | 1 |
| Imig, JD; Khan, AH | 1 |
| Guan, QG; Pang, XF; Sun, DM; Xie, LN; Zeng, DY; Zhang, HS | 1 |
| Bekki, H; Fukami, K; Homma, T; Nakata, M; Nohara, M; Okuda, S; Sone, M; Yamagishi, S; Yamamoto, K | 1 |
| Kimura, S; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H | 2 |
| Behar, B; Meyers, KE | 1 |
| Curt, V; Hao, YM; Huang, J; Sun, NL; Tu, Y; Zhang, Y; Zhu, JR | 1 |
| Ahad, A; Ali, A; Aqil, M; Kohli, K; Mujeeb, M; Sultana, Y | 2 |
| Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Sakata, A; Tsukuda, K | 1 |
| Chen, ZY; Huang, Y; Lau, CW; Leung, FP; Tian, XY; Wong, WT; Yao, X; Yung, LH; Yung, LM | 1 |
| Abraham, I; Aerts, A; Brié, H; Hermans, C; Lee, C; MacDonald, K; Vancayzeele, S | 1 |
| Dongre, N; Lai, WT; Park, JE; Wang, J | 1 |
| Kato, T; Kinouchi, H; Wakai, T; Yagi, T; Yoshioka, H | 1 |
| Aderibigbe, A; Anisiuba, BC; Ba, SA; Boombhi, HJ; Ijoma, CK; Kamdem, MK; Kaptue, J; Kingue, S; Kolo, PM; Lemogoum, D; M'buyamba-Kabangu, JR; Mipinda, JB; Ndiaye, MB; Odili, AN; Omotoso, BA; Richart, T; Staessen, JA; Thijs, L; Ulasi, II | 1 |
| Blumer, J; Han, G; Litwin, M; Meneses, R; Meyers, KE; Neto, JP; Shi, V; Solar-Yohay, S; Vande Walle, J; Wells, T | 1 |
| Dohi, Y; Fujii, T; Hayashi, Y; Ishibashi, K; Kihara, Y; Kurisu, S; Okada, T; Okimoto, T; Otsuka, M; Tadehara, F; Yamamoto, H | 1 |
| Bianchini, RM; Castellano, PM; Kaufman, TS | 1 |
| Campo, G; Cangiano, E; Carrà, G; Ceconi, C; Ferrari, R; Fortini, C; Francolini, G; Marchesini, J; Miccoli, M; Tavazzi, L | 1 |
| Derbentseva, EA; Dralova, OV; Maksimov, MA; Ostroumova, OD; Starodubtsev, AK | 1 |
| Circelli, M; Cremonesi, G; Fogari, R; Mugellini, A | 1 |
| Higashi, K; Hiroo, K; Kushiyama, T; Oda, T; Yamamoto, K | 1 |
| Chen, J; Huang, L; Le, X; Meng, J; Tang, Y; Wang, M; Wu, P; Yu, P | 1 |
| Derbentseva, EA; Dralova, OV; Ermolaeva, AS; Maksimov, ML; Starodubtsev, AK | 1 |
| Brown, L; Sernia, C | 1 |
| Cohen, DL; Townsend, RR | 1 |
| Tullus, K | 1 |
| Jin, D; Miyazaki, M; Takai, S | 1 |
| Hirooka, Y; Hoka, S; Ito, K; Kishi, T; Nakagaki, T; Sunagawa, K | 1 |
| Dejima, T; Fujikawa, T; Haku, S; Kanaoka, T; Kondoh, S; Konno, Y; Maeda, A; Mitsuhashi, H; Mizushima, S; Moriya, T; Ogawa, N; Ohsawa, M; Okano, Y; Ozawa, M; Suzuki, D; Tamura, K; Tanaka, K; Toyoda, M; Umemura, S; Umezono, T; Wakui, H; Yamakawa, T; Yanagi, M | 1 |
| Ahn, CM; Choi, SC; Hong, SJ; Kim, JS; Lim, DS; Park, JH | 1 |
| Vértes, A | 1 |
| Ha, NS; Lee, BJ; Park, JB; Tran, PH; Tran, TT | 1 |
| Bains, J; Smith, WB | 1 |
| Andrews, LM; Baser, O; Wang, L; Xie, L | 1 |
| Matsuura, K; Mori, Y; Tanaka, T; Utsunomiya, K; Yokoyama, J | 1 |
| Cushman, WC; Duprez, DA; Izzo, JL; Purkayastha, D; Samuel, R; Weintraub, HS; Zappe, D | 2 |
| Bakris, GL; Cao, C; Handley, A; Kupfer, S; Perez, A; Sica, D; Weber, MA; White, WB | 1 |
| Jing, L; Lu, LX; Sang, Y; Yuan, L; Zhang, QH; Zhou, LJ | 1 |
| Aparasu, RR; Ashton, CM; Chen, H; Desai, RJ; Deswal, A; Johnson, ML; Mehta, HB; Morgan, RO | 1 |
| Hemmelder, MH; Janssen, WM; Lambers Heerspink, HJ; Laverman, GD; Navis, G; Slagman, MC; Waanders, F; Woittiez, AJ | 1 |
| Akhter, N; Alom, MM; Bhuiyan, NI; Rozario, RJ | 1 |
| Duprez, D; Ferdinand, KC; Purkayastha, D; Samuel, R; Wright, RF | 1 |
| Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Nako, H; Ogawa, H; Sueta, D; Tokutomi, Y; Toyama, K; Yamamoto, E | 1 |
| Higashikuni, Y; Hirata, Y; Iwata, H; Nagai, R; Sata, M; Takaoka, M; Tanaka, K | 1 |
| Barlera, S; Bianconi, L; Disertori, M; Fabbri, G; Favero, C; Franzosi, MG; Latini, R; Lombardi, F; Lucci, D; Maggioni, AP; Quintarelli, S; Staszewsky, L | 1 |
| Hollenberg, NK; Meng, X; Parving, HH; Remuzzi, G; Weir, MR; Zappe, DH | 1 |
| Katono, K; Kubota, M; Masuda, N; Otani, S; Takakura, A; Yamamoto, M | 1 |
| Blaak, EE; Diamant, M; Goossens, GH; Ijzerman, RG; Moors, CC; Serné, EH; van der Zijl, NJ | 1 |
| Bagmanova, NKh; Fediunina, EIu; Karaulova, IuL; Kobalava, ZhD; Kotovskaia, IuV | 1 |
| Dralova, OV; Ermolaeva, AS; Maksimov, ML | 1 |
| Biala, A; Finckenberg, P; Korpi, A; Levijoki, J; Loytainen, M; Martonen, E; Mervaala, E | 1 |
| Eringa, EC | 1 |
| de Leeuw, PW | 1 |
| Cheng, YN; Gao, JJ; Jiao, B; Wang, YS; Zhang, QZ | 1 |
| Hu, DY; Jiang, LQ | 1 |
| Bertocchi, F; Bicego, D; Correale, E; Disertori, M; Emanuelli, C; Fabbri, G; Franzosi, MG; Gramenzi, S; Latini, R; Maggioni, AP; Masson, S; Nicolis, EB; Proietti, G; Pulitanò, G; Raimondi, E; Staszewsky, L; Taddei, F; Tognoni, G; Wong, M | 1 |
| Abraham, I; Brié, H; Cholette, M; Ciesielski, G; Hermans, C; Kinsey, K; Lee, C; MacDonald, K; Pacheco, C; Reel, S; Song, M; Speaks, P; Van der Niepen, P; Vancayzeele, S; Yee, B | 1 |
| Janic, M; Lunder, M; Sabovic, M | 1 |
| Maksimov, ML; Mochkin, IA; Starodubtsev, AK | 1 |
| Abraham, I; Aerts, A; Brié, H; Coen, N; Hermans, C; Lee, C; Lins, R; Macdonald, K; Mecum, N; Shen, YM; Vancayzeele, S | 1 |
| Chen, C; Le, X; Sun, S; Tang, Y; Wang, M; Yin, Y | 1 |
| Egan, BM; Purkayastha, D; Raij, L; Samuel, R; Sowers, JR; Zappe, DH | 1 |
| Han, G; Lieberman, K; Meyers, KE; Shi, V; Solar-Yohay, S | 1 |
| Acar, G; Akçay, A; Altun, B; Kaya, H; Köroğlu, S; Sökmen, A | 1 |
| Ho, C; Kajiya, T; Kurtz, TW; Vilardi, R; Wang, J | 1 |
| Birnbaum, Y; Castillo, AC; Perez-Polo, JR; Qian, J; Ye, Y | 1 |
| Hasegawa, H; Kobayashi, Y; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H | 1 |
| Chang, J; Kahler, KH; Sun, P; Zhang, J | 1 |
| Grosso, A; Kadwa, M; Litwin, M; Pezous, N; Schaefer, F; Turi, S; Zachwieja, J; Zurowska, A | 1 |
| Guo, LL; Li, M; Wang, AH | 1 |
| Nagahama, M; Seki, M | 1 |
| Inoue, A; Kuwano, T; Mitsutake, R; Miura, S; Morii, J; Saku, K; Shiga, Y; Uehara, Y | 1 |
| Akazawa, H; Asano, T; Fujishiro, M; Fukushima, T; Iwashita, M; Kamata, H; Kikuchi, T; Komuro, I; Kumamoto, S; Kurihara, H; Kushiyama, A; Nakatsu, Y; Nishimura, F; Ohno, H; Sakoda, H; Tsuchiya, Y | 1 |
| Belgamwar, VS; Pardeshi, CV; Rajput, PV; Tekade, AR | 1 |
| Biskupiak, J; Qian, C; Quah, R; Ram, CV; Ramaswamy, K; Russo, PA; Ryan, A | 1 |
| Baker, TM; Brede, Y; Brown, RE; Falvey, H; Goh, J; Johnston, A | 1 |
| Choi, HG; Kim, DW; Kim, JO; Kim, KK; Lee, BJ; Sung, JH; Yan, YD; Yong, CS | 1 |
| Feng, M; Huang, GL; Zhang, Y; Zhong, LN | 1 |
| Cambi, GE; De Rita, F; Faggian, G; Lucchese, G; Luciani, GB; Mazzucco, A; Modesti, PA | 1 |
| Kordikowski, A; Lorente, LT; Xivillé, NR | 1 |
| Baek, H; Cho, YR; Choi, SY; Hong, TJ; Hur, SH; Hwang, JY; Kim, KS; Kim, YD; Lee, SG; Park, JS; Park, K; Park, TH; Yang, TH | 1 |
| Skotnikov, AS; Skotnikova, EV; Vertkin, AL; Vilkovyskiĭ, FA; Zviagintseva, EI | 1 |
| Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S; Xu, L | 1 |
| Chen, RH; Jiao, KL; Li, YG; Yu, Y; Zhang, PP | 1 |
| Christogiannis, LG; Elisaf, MS; Kostapanos, MS; Milionis, HJ; Tellis, CC; Tselepis, AD | 1 |
| Gandhi, HP; Giridhar, R; Naik, PP; Yadav, MR | 1 |
| Li, B; Oite, T; Qi, SH; Song, SM; Wang, CC; Xing, L; Yang, BF | 1 |
| Chumachek, EV; Lediaeva, AA; Mazina, GG; Nedogoda, SV; Salasiuk, AS; Tsoma, VV | 1 |
| Cai, J; Cheng, K; Huang, Z; Ming, Y; Yang, G; Ye, Q; Yuan, H; Zhou, P; Zuo, X | 1 |
| Brown, NJ; Gamboa, JL; Ikizler, TA; Luther, JM; Pretorius, M; Todd-Tzanetos, DR; Yu, C | 1 |
| Peng, XD; Yang, ZH | 1 |
| Di Virgilio, AL; Etcheverry, SB; Nascimento, OR; Williams, PA | 1 |
| Duprez, D; Ferdinand, K; Purkayastha, D; Samuel, R; Wright, R | 1 |
| Sestito, A | 1 |
| Ahmad, S; Ferrario, CM; Moniwa, N; Varagic, J; VonCannon, JL | 1 |
| Ichimiya, S; Ikeda, N; Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Ohno, M; Shintani, S; Sone, T; Watarai, M; Yamashita, K | 1 |
| Kalantar-Zadeh, K; Zaritsky, JJ | 1 |
| Astarcı, HM; Azak, A; Can, M; Ceri, M; Duranay, M; Huddam, B; Karaca, G; Koçak, G; Sert, M | 1 |
| Ofili, EO; Purkayastha, D; Samuel, R; Sowers, JR; Zappe, DH | 1 |
| Hasegawa, H; Kameda, Y; Kobayashi, Y; Komuro, I; Kubota, A; Takano, H | 1 |
| Kandiloglu, G; Ozturk, G; Senturk, B; Turk, BG; Turkmen, M | 1 |
| Chen, J; Cheng, Z; He, L; Hu, G; Hu, Y; Li, Q; Li, Y; Wu, C | 1 |
| Boulton, DW; Chang, M; Griffen, SC; Kasichayanula, S; LaCreta, FP; Liu, X; Shyu, WC | 1 |
| Binger, KJ; Deliyanti, D; Miller, AG; Samson, AL; Tan, G; Wilkinson-Berka, JL | 1 |
| Gong, J; Guo, X; Liao, H; Zhang, W | 1 |
| Corbalan, JJ; Jacob, RF; Jacoby, A; Kubant, R; Louka, F; Malinski, T; Mason, RP | 1 |
| Bassi, R; Caldara, R; De Cobelli, F; Del Maschio, A; Fiorina, P; Gremizzi, C; Mello, A; Perseghin, G; Secchi, A; Vergani, A | 1 |
| Amigoni, M; Califf, R; Køber, L; Levine, RA; McMurray, JJ; Meris, A; Pfeffer, MA; Solomon, SD; Thune, JJ; Velazquez, E; Verma, A | 1 |
| Gurbuz, S; Kucukler, N; Kurt, IH; Topaloglu, C; Yalcin, F | 1 |
| Cushman, WC; Duprez, DA; Izzo, JL; Purkayastha, D; Samuel, R; Weintraub, HS; Zappe, DH | 1 |
| Albayrak, A; Bayir, Y; Ferah, I; Halici, Z; Kabalar, E; Karakus, E; Keles, MS; Keles, O; Unal, B | 1 |
| Koide, M; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H | 1 |
| Bao, HG; Chen, YQ; Li, PH; Li, T; Ma, L; Wang, ZG; Zhang, WZ | 1 |
| Chang, KC; Chen, IC; Chen, ZC; Hou, CJ; Hsu, KL; Huang, CH; Hung, YJ; Lee, JD; Lei, MH; Liao, PY; Liou, CW; Wang, J; Yeh, TC | 1 |
| Altieri, PI; Cangiano, JL; Crespo, MJ; Escobales, N | 1 |
| Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A | 1 |
| Chen, H; Li, H; Liu, Z; Tang, L; Yang, B; Yi, R | 1 |
| Janić, M; Jug, B; Lunder, M; Sabovič, M | 1 |
| Chen, HY; Chen, LF; Fang, Q; Wang, W; Xu, Z; Yan, XW | 1 |
| Bilić, M; Galesić, K; Horvatić, I; Ljubanović, D; Munjas-Samarin, R | 1 |
| Bae, KS; Jin, S; Jung, JA; Kim, MJ; Kim, YH; Lim, HS; Noh, YH | 1 |
| Sawada, T | 1 |
| Kumagai, H; Matsubara, H; Oda, T; Ohshima, N; Senda, M; Tadano, H; Takechi, H; Uchida, T; Watanabe, A; Yamamoto, K | 1 |
| Okeahialam, BN | 1 |
| Croxtall, JD | 1 |
| Abe, S; Furusho, Y; Hamasaki, S; Ikeda, Y; Kajiya, S; Kihara, K; Lee, S; Minagoe, S; Miyata, M; Nakamura, S; Ohba, I; Sasaki, T; Tateishi, S; Tei, C; Torii, H | 1 |
| Bozcali, E; Dedeoglu, DB; Karpuz, H; Karpuz, V; Suzer, O | 1 |
| Aono, J; Higaki, J; Horiuchi, M; Inoue, K; Iwai, M; Nagai, T; Nishimura, K; Ogimoto, A; Okayama, H; Suzuki, J | 1 |
| Chen, J; Li, C; Xu, W; Zhou, X | 1 |
| Ferrario, CM; Habibi, J; Hayden, MR; Locher, B; Nistala, R; Pulakat, L; Sinak, C; Sowers, JR; Whaley-Connell, A | 1 |
| Pancholi, SS; Sharma, RN | 1 |
| Ebina, T; Hibi, K; Kimura, K; Kosuge, M; Kusama, I; Morita, S; Nozawa, N; Okuda, J; Ozaki, H; Tsukahara, K; Umemura, S; Yano, H | 1 |
| Cao, F; Li, W; Liu, B; Shen, M; Sun, D; Wang, S; Zhang, Z | 1 |
| Auleley, GR; Boutron, I; Konrat, C; Ravaud, P; Ricordeau, P; Trinquart, L | 1 |
| Sun, CX; Tao, CW; Wu, ZB; Yu, QG; Zhang, Y | 1 |
| Fan, J; Hoffman, MR; Qin, Y; Ren, H; Xu, G; Zhang, M | 1 |
| Joffe, MM; Yang, W | 1 |
| Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A | 1 |
| Alessi, T; Giles, TD; Purkayastha, D; Zappe, D | 1 |
| Liew, R | 1 |
| Chen, B; Du, G; Guo, J; Li, X; Qiang, G; Shi, L; Xuan, Q; Yang, H; Yang, X; Zhang, H; Zhang, L; Zhou, D; Zu, M | 1 |
| Durik, M; Roks, AJ; Sevá Pessôa, B | 1 |
| de Leeuw, PW; Neef, C; van der Kuy, PH; van Iperen, HP; van Onzenoort, HA; Verberk, WW | 1 |
| Ikeda, M; Ohta, M; Tajiri, Y; Yamato, H | 1 |
| Horiguchi, CS; Makino, H; Miyoshi, T; Murakami, K; Nakamura, Y; Ogawa, D; Sasaki, M; Uchida, HA; Wada, J | 1 |
| Nabbi, R; Riess, ML; Woehlck, HJ | 1 |
| Barrios, V; de la Sierra, A | 1 |
| Gao, P; Grosso, A; Sun, N; Wang, R; Yang, K; Zhang, Y; Zhu, D | 1 |
| Galetin, A; Houston, JB; Kenworthy, KE; Ménochet, K | 1 |
| Babu, PR; Challa, SR; Challa, VR; Johnson, B; Maheswari, C | 1 |
| Fan, YY; Hitomi, H; Kitada, K; Kobori, H; Lei, B; Masaki, T; Mori, H; Nakano, D; Nishiyama, A | 1 |
| Cao, QR; Cui, JH; Lee, BJ; Liu, Y; Xu, WJ; Yang, M | 1 |
| Aydogan, U; Cakir, E; Iyisoy, A; Parlak, A; Saglam, K | 1 |
| Ando, H; Fujimura, A; Hosohata, K; Saito, T; Ushijima, K | 1 |
| Cao, C; He, H; Jiang, L; Li, F; Liu, M; Mao, J; Yang, M | 1 |
| Burchill, LJ; Burrell, LM; Dean, RG; Griggs, K; Patel, SK; Velkoska, E | 1 |
| Chen, F; Li, Z; Wang, C; Wang, X | 1 |
| Deedwania, PC; Egan, BM; Purkayastha, D; Samuel, R; Sowers, JR; Zappe, DH | 1 |
| Alili, R; Blaak, EE; Clément, K; Cleutjens, JP; Diamant, M; Essers, Y; Goossens, GH; Jocken, JW; Moors, CC; van der Zijl, NJ; Venteclef, N | 1 |
| Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY | 1 |
| Kaynar, K; Konca, C; Ozkan, G; Ulusoy, S | 1 |
| Hatou, S; Imada, T; Inaba, T; Ishida, S; Kawakami, Y; Nakamura, S; Ogawa, Y; Ozawa, Y; Shimmura, S; Tsubota, K; Yaguchi, S | 1 |
| Harada, M; Otani, M; Otsuki, M; Wei, L; Yamamoto, M | 1 |
| Cebe, P; Gaweł, A; Pyda, M; Skotnicki, M | 1 |
| Cheng, CI; Fu, M; Hsiao, CC; Peng, SY; Wang, FS; Wu, SC; Yip, HK | 1 |
| Chen, CS; Cheng, SM; Hsieh, CM; Huang, LC; Huang, SC; Mar, GY; Ueng, KC | 1 |
| Carrera, E; Casagrande, D; Hayoz, D; Périard, D; Rey, MA; Vesin, JM | 1 |
| Baschiera, F; Botha, J; Brunel, P; Lacy, PS; Prescott, MF; Williams, B | 1 |
| Imanishi, M; Kitabayashi, C; Konishi, Y; Maeda, I; Masada, M; Morikawa, T; Nishiyama, A; Okada, N; Shirahashi, N; Wilcox, CS | 1 |
| Lee, BJ; Park, JB; Tran, PH; Tran, TT | 1 |
| Lacourcière, Y | 1 |
| Chen, JZ; Wang, L; Xue, JL; Zhang, D; Zhao, L | 1 |
| Afantitis, A; Baldus, J; Christodouleas, D; Fotakis, C; Glaubitz, C; Hodzic, A; Kritsi, E; Mali, G; Mavromoustakos, T; Megariotis, G; Melagraki, G; Ntountaniotis, D; Pabst, G; Papadopoulos, MG; Potamitis, C; Rappolt, M; Zervou, M; Zoumpoulakis, P | 1 |
| Aksak, S; Albayrak, A; Albayrak, F; Gundogdu, C; Halici, Z; Karakus, E; Kiki, I; Ozturk, B; Polat, B; Sipal, S | 1 |
| Bransford, T; Gong, J; Kraigher-Krainer, E; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, B; Shah, A; Shi, V; Solomon, SD; Takeuchi, M; Voors, A; Zile, M | 1 |
| Lu, JY; Qin, XT; Sheng, HZ; Yu, XH; Zhu, JH | 1 |
| Cao, G; Deng, Y; Ding, X; Li, H; Xu, X; Zhang, X; Zhuang, X | 1 |
| Benge, CD; Muldowney, JA | 1 |
| Brunner, HR; Hua, TA; Jia, Y; Julius, S; Kjeldsen, SE; Mancia, G; McInnes, GT; Schork, A; Weber, MA; Zanchetti, A; Zappe, DH | 1 |
| Volpe, M | 1 |
| Burgin, K; Daiber, A; Daub, S; Gori, T; Hausding, M; Knorr, M; Kröller-Schön, S; Münzel, T; Oelze, M; Rümmler, R; Sartor, D; Scherhag, A; Schreiner, J; Schuff, A; Schulz, E; Wenzel, P | 1 |
| Bai, WW; Sun, HL; Xiang, GD; Yue, L; Zhao, LS | 1 |
| Beg, S; Patra, ChN; Rao, ME; Singh, HP; Swain, S | 1 |
| Dohi, K; Hiraoka, N; Hoshino, K; Ito, M; Kitai, T; Kumagai, N; Nakamori, S; Nakamura, M; Okamoto, S; Onishi, K; Oota, M; Ueda, Y; Yamada, T; Yazu, T | 1 |
| Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T | 1 |
| Baker, KM; Chandel, N; Feldman, DL; Kumar, R; Seqqat, R; Thomas, CM; Yong, QC | 1 |
| Choi, HG; Kim, JO; Marasini, N; Poudel, BK; Tran, TH; Yong, CS | 1 |
| Baek, I; Haesler, E; Hayoz, D; Joly, MP; Kandra, A; Mazzolai, L; Meyer, MA; Periard, D; Zappe, DH | 1 |
| Kalaitzidis, R; Karasavvidou, D; Pappas, K; Siamopoulos, KC; Spanos, G | 1 |
| Baek, SH; Dong, YG; Ihm, SH; Ke, YN; Ma, SP; Yuan, H | 1 |
| Abe, M; Baba, S; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Takashima, H; Yoshida, Y | 1 |
| An, Y; Li, YH; Liu, P; Man, YL; Ren, BB; Wang, QX | 1 |
| Arslan, E; Ay, SA; Balta, S; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Sağlam, K; Turker, T; Unlu, M; Yaman, H | 1 |
| Endoh, M; Ideura, T; Kamata, K; Kimura, K; Suzuki, D; Tamura, K; Toya, Y; Umemura, S; Yasuda, T; Yoshimura, A | 1 |
| Aritomi, S; Jin, D; Miyazaki, M; Niinuma, K; Takai, S | 1 |
| Ando, H; Fujimura, A; Ishikawa-Kobayashi, E; Maekawa, T; Nozawa, M; Shiga, T; Takuma, M; Ushijima, K | 1 |
| Akhan, M; Arslan, E; Arslan, Z; Ay, SA; Balta, S; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Saglam, K; Sarlak, H | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Awaiye, K; Jose, B; Joshi, P; Tan, A; Trabelsi, F | 1 |
| Border, WA; Cheung, AK; Gu, C; Huang, Y; Noble, NA; Zhou, G | 1 |
| Ahmad, S; Brosnihan, KB; Ferrario, CM; Gomez, RA; Groban, L; Kato, J; Kitamura, K; Lopez, ML; Moniwa, N; Nagata, S; Simington, SW; Varagic, J; VonCannon, JL; Wang, H | 1 |
| Al Balushi, KA; Al-Zakwani, I; Habib, JQ | 1 |
| Goto, SN; Mizuno, Y; Takagi, H; Umemoto, T; Yamamoto, H | 1 |
| Redington, AN; Roche, SL | 1 |
| Bouma, BJ; Groenink, M; Mulder, BJ; Pieper, PG; Roos-Hesselink, JW; Sieswerda, GT; van der Bom, T; van Dijk, AP; Vliegen, HW; Winter, MM; Zwinderman, AH | 1 |
| Dikkeschei, BD; Dullaart, RP; Kwakernaak, AJ; Lambert, G; Laverman, GD; Navis, G; Petrides, F; Slagman, MC; Waanders, F | 1 |
| Bugaj, V; Kohan, DE; Mironova, E; Ramkumar, N; Rees, S; Roos, KP; Stockand, JD | 1 |
| Che, E; Jiang, T; Ma, Q; Sun, C; Sun, H; Wang, S; Zheng, X | 1 |
| Chen, Z; Li, CC; Liu, X; Lou, T; Peng, H; Wang, C; Ye, ZC; Zhang, J | 1 |
| Huang, J; Huang, Y; Wang, T | 1 |
| Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM | 1 |
| Arslan, Z; Balta, S; Bozoglu, E; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Kocak, N; Kurt, O; Naharci, I; Sarlak, H; Seyit Ahmet, AY | 1 |
| Adourian, A; Anand, IS; Cohn, JN; Kuskowski, M; Muntendam, P; Rector, TS | 1 |
| Kothari, C; Mehta, P; Sharma, M; Sherikar, O | 1 |
| Akhan, M; Altun, B; Arslan, E; Ay, SA; Balta, S; Bulucu, F; Cakar, M; Demirkol, S; Karaman, M; Koc, B; Kurt, O; Unlu, M | 1 |
| Ahad, A; Aqil, M; Kohli, K; Mujeeb, M; Sultana, Y | 2 |
| De Mello, WC | 1 |
| Avachat, AM; Bhosale, SS | 1 |
| Aoyama, T; Goto, M; Goto, N; Hiei, K; Iwasa, M; Kawai, N; Kida, K; Kobayashi, H; Kojima, S; Minagawa, T; Minatoguchi, S; Oda, M; Sugishita, F; Takai, K; Tanaka, R; Watanabe, I; Yamamoto, N; Yasue, T | 1 |
| Alessi, T; Bakris, GL; Oparil, S; Purkayastha, D; Sowers, JR; Yadao, AM | 1 |
| Goto, SN; Mizuno, Y; Niwa, M; Takagi, H; Umemoto, T | 1 |
| Ardhanari, S; DeMarco, VG; Ferrario, CM; Habibi, J; Hayden, MR; Krueger, C; Pulakat, L; Rehmer, N; Sowers, JR; Whaley-Connell, A | 1 |
| Califf, RM; Giles, T; Haffner, SM; Hernandez, AF; Krum, H; Leiter, LA; Martinez, FA; Mazzone, T; McMurray, JJ; Rutten, GE; Standl, E; Sun, JL; Thomas, L; Tognoni, G; Wong, YW | 1 |
| Brancati, FL; Califf, RM; Chatterjee, R; Edelman, D; Svetkey, L; Thomas, L | 1 |
| Cheng, J; Li, C; Li, PY; Mao, L; Wen, J; Yang, Y; Yue, XL | 1 |
| Owen, A; Riley, RJ; Soars, AC; Soars, MG; White, P; Williamson, B | 1 |
| Chen, C; Dai, R; Hong, M; Lin, R; Wu, B; Wu, H | 1 |
| Bode, C; Braunwald, E; Brunel, PC; Hoffman, EB; Morrow, DA; Prescott, MF; Ren, F; Rifai, N; Scirica, BM; Swedberg, K; Udell, JA | 1 |
| Bagga, A; Coppo, R; Kadwa, M; Schaefer, F; Schlosshauer, R; Senguttuvan, P; Zhang, Y | 1 |
| Freytag, S; Hagendorff, A; Klebs, S; Müller, A | 1 |
| Baek, IH; Kwon, KI; Lee, BY; Lee, ES | 1 |
| Blaak, EE; Diamant, M; Goossens, GH; Moors, CC; van der Zijl, NJ | 1 |
| Arslan, E; Ay, SA; Balta, S; Bozoglu, E; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Kurt, O; Naharci, MI | 1 |
| Abraham, I; Bowles, J; Brié, H; Hermans, C; Lee, C; Macdonald, K; Piotrowski, K; Vancayzeele, S | 1 |
| Barlera, S; Cappellini, G; Cosmi, F; Disertori, M; Fabbri, G; Favero, C; Franzosi, MG; Latini, R; Maggioni, AP; Moroni, LA; Quintarelli, S; Staszewsky, L | 1 |
| McKinley, MJ | 1 |
| Crane, JA; Ebrahimi, B; Eirin, A; Jordan, KL; Krier, JD; Lerman, A; Lerman, LO; Li, ZL; Pawar, AS; Tang, H; Textor, SC; Zhang, X; Zhu, XY | 1 |
| Amano, T; Harada, K; Ichimiya, S; Ishii, H; Kanashiro, M; Kobayashi, M; Kurebayashi, N; Marui, N; Murohara, T; Sone, T; Suzuki, S; Tsuboi, H; Uetani, T; Yoshikawa, D | 1 |
| Devraj, R; Mangamoori, LN; Parvataneni, DM | 1 |
| Cambi, GE; De Rita, F; Faggian, G; Franzoi, M; Lucchese, G; Luciani, GB; Mazzucco, A; Modesti, PA | 1 |
| Cong, XD; Dai, DZ; Dai, Y; Shi, FH; Wu, Y; Zhang, YM | 1 |
| Dorhout, B; van der Meer, P; Voors, AA | 1 |
| Cong, XD; Dai, DZ; Dai, Y; Ding, MJ; Liu, GL; Zhang, YM | 1 |
| Aksenova, AV; Chazova, IE; Elfimova, EM; Galitsin, PV; Litvin, AY; Rogoza, AN; Sukmarova, ZN | 1 |
| Hang, P; Li, Y; Sun, D; Sun, L; Wang, X; Xu, W; Yun, F; Zhao, H; Zhao, J | 1 |
| Eckert, S; Freytag, SB; Klebs, SH; Müller, A | 1 |
| Calhoun, DA; Crikelair, N; Glazer, RD; Jia, Y; Lacourcière, Y | 1 |
| Ge, Y; Hou, J; Jin, B; Li, S; Liu, Z; Shi, M; Xie, H; Zhang, H | 1 |
| Darwish, HW; El-Zeany, BA; Hassan, SA; Salem, MY | 2 |
| El-Maraghy, SA; Motawi, TK; Senousy, MA | 1 |
| Hatou, S; Imada, T; Ishida, S; Kawakami, Y; Kawakita, T; Miyashita, H; Mori, T; Nakamura, S; Ogawa, Y; Okamoto, S; Ozawa, Y; Satofuka, S; Shimmura, S; Tsubota, K; Yaguchi, S; Yaguchi, T; Yoshida, S | 1 |
| Cohn, JN; Gimpelewicz, C; Hua, TA; Kandra, A; Krum, H; Latini, R; Lesogor, A; Massie, B; Tognoni, G; Zalewski, A | 1 |
| Hedaya, MA; Helmy, SA | 1 |
| Anisiuba, BC; Ba, SA; Boombhi, HJ; Ezeala-Adikaibe, B; Ijoma, CK; Jacobs, L; Kaptue, J; Kingue, S; Kolo, PM; Lemogoum, D; M'Buyamba-Kabangu, JR; Mipinda, JB; Ndiaye, MB; Odili, A; Omotoso, BA; Osakwe, CE; Staessen, JA; Thijs, L; Ulasi, II | 1 |
| Boncelj, M; Eržen, B; Janež, A; Janić, M; Kanc, K; Lunder, M; Šabović, M; Savić, V | 1 |
| Chang, KH; Dikalova, AE; Engberding, N; Griendling, KK; Jo, H; Koga, M; Lassègue, B; Long, JS; Seidel-Rogol, B | 1 |
| Alajbegovic, A; Alajbegovic, L; Alajbegovic, S; Ambeskovic, M; Deljo, D; Sukalo, A; Vranic, JD | 1 |
| Choi, H; Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Oh, PC; Quon, MJ; Sakuma, I; Shin, EK | 1 |
| Bobkova, IN; Chebotareva, NV; Kozlovskaia, LV; Li, OA; Nanchikeeva, ML; Plieva, OK | 1 |
| Normile, D | 2 |
| Bahng, MY; Chae, D; Kim, Y; Lee, D; Park, K; Roh, H; Son, H; Son, M | 1 |
| Lee, BJ; Tran, PH; Tran, TT | 1 |
| D'Angelo, A; Derosa, G; Fogari, R; Gualtierotti, R; Mugellini, A; Zoppi, A | 1 |
| Califf, RM; Chiang, FT; Giles, TD; Haffner, SM; Holman, RR; Mazzone, T; McMurray, JJ; Preiss, D; Rutten, GE; Standl, E; Sun, JL; Thomas, LE; Tognoni, G | 1 |
| Berktaş, M; Boyacı, B; Kızılırmak, P; Yalçın, MR | 1 |
| Mahony, C | 1 |
| Gnudi, L; Hill, B; Karalliedde, J; Maltese, G; Viberti, G | 1 |
| Chae, SC; Jeong, MH; Kim, DS; Kim, KS; Lee, H; Oh, BH | 1 |
| Wei, JR; Zhang, YL | 1 |
| Singh, S; Singh, SK; Srivastava, AK; Vuddanda, PR | 1 |
| Anyfanti, P; Douma, S; Doumas, M; Ferro, A; Garypidou, V; Gavriilaki, E; Gkaliagkousi, E; Markala, D; Papadopoulos, N; Petidis, K; Triantafyllou, A; Yiannaki, E | 1 |
| Chung, A; Hoe, HS; Lee, NJ; Pak, DT; Saavedra, JM; Scott Turner, R; Sohn, YI | 1 |
| Chiga, M; Iwamoto, T; Kita, S; Lin, SH; Mori, T; Oi, K; Rai, T; Sasaki, S; Sohara, E; Susa, K; Takahashi, D; Uchida, S; Yang, SS; Zeniya, M | 1 |
| Kami, M; Shibuya, K; Tanimoto, T | 1 |
| Abraham, I; Aerts, A; Brié, H; Denhaerynck, K; Hermans, C; MacDonald, K; Sun, D; Van Camp, Y; Vancayzeele, S; Villa, L | 1 |
| Brown, A; Burrell, LM; Carrington, MJ; Jennings, GL; Kurstjens, NP; Nelson, M; Stewart, S; Stocks, NP; Swemmer, CH | 1 |
| Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K | 1 |
| Barreira, JC; Iotti, A; Laborde, HA; Rivero, MA; Zazzetti, F | 1 |
| Hillebrand, O; Idzik, K; Licha, T; Nödler, K; Schiperski, F; Strathmann, M; Zirlewagen, J | 1 |
| Cai, Y; He, L; He, X; He, Y; Luo, J; Wu, X; Zhang, G; Zhang, Z | 1 |
| Allen, RR; Ghushchyan, V; Kaila, S; Nair, KV; Saseen, JJ | 1 |
| Akasaka, H; Miura, T; Saitoh, S; Shimamoto, K; Yoshida, H | 1 |
| Guan, G; Li, P; Lv, W; Qi, D; Wang, J; Zhang, Y | 1 |
| Gold, KA; Gomez, DR; Levy, LB; Liao, Z; Nguyen, QN; O'Reilly, M; Wang, H; Xu, T; Zhuang, Y | 1 |
| Bethel, MA; Califf, RM; Chang, F; Disertori, M; Giles, TD; Haffner, SM; Holman, RR; Latini, R; Maggioni, AP; McMurray, JJ; Rutten, GE; Standl, E; Staszewsky, L; Sun, JL; Thomas, L; Tognoni, G | 1 |
| Asai, S; Kanou, N; Nakayama, T; Nishida, Y; Susa, N; Takahashi, Y | 1 |
| Claggett, B; Gupta, DK; Kraigher-Krainer, E; Lefkowitz, MP; McMurray, JJ; Packer, M; Pieske, B; Santos, A; Shah, AM; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Araki, E; Goto, R; Igata, M; Kawasaki, S; Kawashima, J; Kitano, S; Kondo, T; Matsumura, T; Matsuyama, R; Miyagawa, K; Motoshima, H; Ono, K | 1 |
| Feng, Z; Hou, S; Hu, H; Liang, Y; Shi, W; Shi, X; Wang, L; Wang, W; Xia, Y; Xu, L; Yan, H; Ye, Z; Zhang, B; Zhang, L; Zhong, W | 1 |
| Cheung, AK; Huang, Y; Liu, X; Zhou, G | 1 |
| Baker, KM; Chandel, N; Kumar, R; Seqqat, R; Thomas, CM; Yong, QC | 1 |
| Chen, MY; Cheng, KS; Hong, YH; Hsieh, WY; Ko, L; Kuan, TC; Liao, YC; Lin, CS; Wu, CL; Yen, CY | 1 |
| Amini, M; Gheissari, A; Javanmard, SH; Khalili, N; Shirzadi, R | 1 |
| Coakley, C; Hough, A; Parra, D; Shah, S | 2 |
| Mir, TS; Mueller, GC; Stark, V; Steiner, K; Stierle, L; von Kodolitsch, Y; Weil, J | 1 |
| Achouba, A; Beaussier, H; Boutouyrie, P; Laurent, S | 1 |
| Ahad, A; Ali, A; Aqil, M | 1 |
| Bethel, MA; Califf, RM; Charbonnel, B; Diem, P; Haffner, SM; Holman, R; Horton, ES; Krum, H; Leiter, LA; Mareev, V; McMurray, JJ; Reyes, EM; Schaper, F; Shah, BR; Shen, L; Soska, V; Sun, JL; Thomas, L; Wojdyla, D | 1 |
| Huo, X; Liu, K; Liu, Q; Ma, X; Meng, Q; Peng, J; Sun, H; Sun, P; Wang, C | 1 |
| Chen, H; Hu, X; Jiang, Z; Li, J; Liu, X; Steinhoff, G; Wang, L; Xu, Y; Yu, H; Zhang, Z | 1 |
| Bader, M; Baltatu, OC; Campos, LA; Louie, P; Schumacher, C; Zaugg, CE | 1 |
| Giannakopoulos, P; Lazarczyk, MJ | 1 |
| Huang, QF; Li, Y; Wang, JG | 1 |
| Campbell, DJ; Koid, SS; Ziogas, J | 1 |
| Born, J; Derad, I; Lehnert, H; Marshall, L; Nitschke, M; Sayk, F | 1 |
| Blair, G | 1 |
| Bruder-Nascimento, T; Callera, GE; Cau, SB; Chinnasamy, P; Riascos-Bernal, DF; Sibinga, NE; Tostes, RC; Touyz, RM | 1 |
| Donova, T; Koshtikova, K; Manov, E; Naidenov, S; Rangelov, Y; Runev, N; Shabani, R; Vitlyanova, K | 1 |
| Chen, Q; Fang, Y; Li, S; Lv, S; Tian, X; Zhou, H | 1 |
| Caffrey, JL; Chang, CH; Lai, MS; Lin, JW; Wu, LC | 1 |
| Cho, HJ; Ki, MH; Kim, DD; Kim, JE; Kim, RS; Tae Kim, G; Yoon, IS | 1 |
| Bai, X; Chen, X; Jin, B; Li, X; Shan, H; Yu, K; Zhang, S; Zhao, X | 1 |
| Bales, CW; Bethel, MA; Califf, RM; Davies, MJ; Haffner, SM; Holman, RR; Huffman, KM; Kraus, WE; McMurray, JJ; Sun, JL; Thomas, L; Tuomilehto, J; Yates, T | 1 |
| Hasan, AU; Hashimoto, T; Ishihara, N; Ishihara, Y; Kamitori, K; Kohno, M; Noma, T; Ohmori, K; Tokuda, M; Yamaguchi, F | 1 |
| Chen, G; He, QY; Pan, SF; Pan, SQ; Shen, C; Zhang, XM | 1 |
| Feng, GF; Han, H; Hu, XD; Liu, Y; Qian, YH; Shi, LL; Yang, WN | 1 |
| Anand, IS; Cohn, JN; Kuskowski, M; Rector, TS; Snider, J | 1 |
| Miyake, S; Nagai, N; Narimatsu, T; Ozawa, Y; Tsubota, K | 1 |
| Komano, H; Liu, J; Liu, S; Maeda, T; Tanabe, C; Zou, K | 1 |
| Bransford, T; Claggett, B; Jhund, PS; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, B; Shi, V; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Batman, A; Can, B; Celebi, A; Hulagu, S; Korkmaz, U; Sali, M; Senturk, O; Yilmaz, H | 1 |
| Califf, RM; Kober, L; Lewis, EF; Li, Y; Pfeffer, MA; Reed, SD; Rouleau, JL; Schulman, KA; Solomon, SD; Velazquez, EJ; Weinfurt, KP; White, HD | 1 |
| Basile, G; Epifanio, A; Mandraffino, R; Trifirò, G | 1 |
| Jing, J; Qu, X; Tu, Z; Zheng, C; Zheng, Z | 1 |
| Beránek, J; Heng, JY; Punčochová, K; Stěpánek, F | 1 |
| Crane, JA; Jordan, KL; Lerman, A; Lerman, LO; Li, ZL; Pawar, AS; Textor, SC; Zhang, X | 1 |
| Chang, F; Gui-Yi, Y; Mao-Huan, L; Shu-Xian, Z; Wei, W; Zhi-Bin, H | 1 |
| Burrell, LM; Carrington, MJ; de Looze, FJ; Esterman, A; Harris, M; Hung, J; Jennings, GL; Kurstjens, NP; Stewart, S; Stocks, NP; Swemmer, CH | 1 |
| Chou, YM; Ghasemi, O; Iyer, RP; Jin, YF; Levin, DB; Lindsey, ML; Lopez, EF; Ramirez, TA; Zamilpa, R; Zhang, J | 1 |
| Kamimura, R; Kawana, S; Nishisako, R; Urabe, T | 1 |
| Akimoto, T; Fujita, D; Hirata, Y; Kiyosue, A; Komuro, I; Morishita, Y; Myojo, M; Nagai, R; Nagata, D; Satonaka, H; Takahashi, M | 1 |
| Georgianos, PI; Sarafidis, PA; Zebekakis, PE | 1 |
| Ping, G; Qian, W; Song, G; Zhaochun, S | 1 |
| Douma, S; Gavriilaki, E; Gkaliagkousi, E; Nikolaidou, B; Triantafyllou, G | 1 |
| Pawar, H; Varkhade, C | 1 |
| Baek, IH; Cho, W; Choo, GH; Ha, ES; Hwang, SJ; Kim, JS; Kim, MS | 1 |
| Basile, J; Bharucha, DB; Chen, W; Giles, TD; Gradman, AH; Pattathil, M; Weber, MA | 1 |
| Fletcher, EL; Hatzopoulos, KM; Vessey, KA; Wilkinson-Berka, JL | 1 |
| Asner, R; Bayer, A; Kopf, W; Letzel, M; Schüssler, W; Sengl, M; Weiß, K | 1 |
| Ar, I; Ilerigelen, B; Kızılırmak, P | 1 |
| Huo, Y; Lei, L; Mao, Y; Meng, L; Qi, Y; Su, J; Tang, C | 1 |
| Ha, JW; Jung, HO; Park, JB; Rhee, MY | 1 |
| Bell, PD; Bissler, JJ; Bunni, M; Dillon, J; Dixon, BP; Hellmann, AR; Ramkumar, T; Reichert, RJ; Sampson, JR; Siroky, BJ; Tsuchihashi, Z; Yin, H | 1 |
| Sakaida, H; Sano, T; Suzuki, H; Taki, W; Toma, N; Umeda, Y; Yamamoto, A | 1 |
| McCurry, J | 1 |
| Gislason, GH; Kristensen, SL; Køber, L; Lamberts, M; Selmer, C; Torp-Pedersen, C; von Kappelgaard, LM | 1 |
| Palmer, OM; Rhoads, DD; Sivak, RA | 1 |
| Ding, HY; Guo, W; Li, GR; Li, XX; Yu, YG; Zhi, L | 1 |
| Cai, S; Li, Y; Liu, X; Ren, B; Sun, T; Wang, Q; Xu, Q; Yu, H; Zhou, J | 1 |
| Hasegawa, Y; Katayama, T; Kim-Mitsuyama, S; Koibuchi, N; Ma, M; Maeda, M; Nakagawa, T; Ogawa, H; Sueta, D; Toyama, K; Uekawa, K; Waki, H | 1 |
| Howard, A; Kopp, JB; Levi, M; Li, C; Qiu, L; Solis, N; Wang, W; Wang, X | 1 |
| Amiya, E; Hirata, Y; Hosoya, Y; Kawarasaki, S; Nagai, R; Nakao, T; Omori, K; Ozeki, A; Tahara, Y; Takata, M; Watanabe, A; Watanabe, M; Watanabe, S; Yamada, N | 1 |
| Che, E; Gao, J; Han, J; Song, Y; Sun, B; Zhang, M; Zhang, Y | 1 |
| Kartashova, EA; Romantsov, MG; Sarvilina, IV | 1 |
| Chang, KC; Ha, YM; Kang, YJ; Kim, HJ; Park, EJ; Park, SW | 1 |
| Aguilar, JA; Hodgkinson, P; Pyda, M; Skotnicki, M | 1 |
| Costa, AP; Costa, As; Junior, AS; Muratori, MC; Reis, AM; Viana, GE | 1 |
| Choovichian, P; Leelasiri, K; Satirapoj, B; Supasyndh, O | 1 |
| Kobalava, ZhD; Kotovskaia, IuV; Kravtsova, OA; Lobzhanidze, TV | 1 |
| Harada, E; Hattori, T; Matsuura, N; Murohara, T; Nagasawa, K; Nagata, K; Niinuma, K; Takahashi, K; Takatsu, M; Watanabe, S | 1 |
| Bauer, CA; Grimme, S | 1 |
| Černe, D; Drevenšek, G; Janić, M; Lunder, M; Marc, J; Šabovič, M; Zupan, J | 1 |
| Claggett, BL; Jhund, PS; Kraigher-Krainer, E; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, BM; Prescott, MF; Shah, AM; Shi, V; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Licha, T; Nödler, K; Tsakiri, M | 1 |
| Xu, C; Xu, J; Zhao, L | 1 |
| Guo, ZA; Li, Y; Liu, G; Meng, FC; Peng, SL; Yu, CJ | 1 |
| Jang, K; Lee, H; Lee, J; Lim, KS; Shin, D; Yu, KS | 1 |
| Li, X; Li, Y; Lu, J; Peng, Y; Shen, Q; Wang, Y; Yin, D | 1 |
| Chen, F; Cheng, G; Fang, Y; Guo, Y; Li, H; Liu, D; Liu, F; Liu, L; Liu, Z; Margetts, P; Tang, L; Zhao, Z | 1 |
| Cao, QR; Cui, JH; Liu, Y; Shi, LL; Xu, WJ | 1 |
| Ahmet Ay, S; Balta, S; Celık, T; Demırkol, S; Dınc, M; Fıcı, F; Grassı, G; Iyısoy, A; Karaman, M; Kılıc, S; Kurt, G; Ozturk, C; Quartı-Trevano, F; Tas, A; Unal, HU; Yılmaz, MI | 1 |
| Baek, IH; Kim, MS | 1 |
| Dimitriadis, F; Higashi, Y; Nakamura, K; Nemoto, T; Saito, M; Shimizu, S; Shimizu, T; Taniuchi, K; Ueba, T; Yanagita, T; Yawata, T | 1 |
| Califf, RM; Katz, M; Lopes, RD; McMurray, JJ; Sun, JL; Thomas, L | 1 |
| Jadhav, P; Pawar, HA | 1 |
| Bai, L; Chen, Q; Chen, Y; Du, XJ; Luo, P; Tian, XM; Tian, XZ | 1 |
| Flavahan, NA; Flavahan, S; Leung, SW; Vanhoutte, PM; Xu, A; Zhao, Y | 1 |
| Finck, A; Giles, TD; Li, H; Neutel, JM; Punzi, H; Weiss, RJ | 1 |
| Chang, JP; Chang, TH; Chen, MC; Ho, WC; Hsiao, CC; Hsu, SD; Huang, HD; Liu, WH; Wang, FS | 1 |
| Jo, CH; Simoni, J; Wesson, DE | 1 |
| Musko, M; Sznitowska, M | 1 |
| Bathgate-Siryk, A; Dabul, S; Garcia, D; Koch, WJ; Lymperopoulos, A; McDonald, P; Rengo, G; Sturchler, E; Walklett, K | 1 |
| Cai, F; Chen, XN; Jiang, MH; Shen, WF; Wang, HY; Wang, LJ; Wang, XF; Wu, F; Yang, Q; Zhang, FR | 1 |
| Bramlage, P; Ferrero, C; Gomez, T; Minguet, J; Sutton, G | 1 |
| İkitimur, B; Karadağ, B; Kılıçkıran Avcı, B; Öngen, Z | 1 |
| Ecder, T | 1 |
| Kızılırmak, P; Üresin, AY | 1 |
| Güleç, S | 1 |
| Bathgate-Siryk, A; Dabul, S; Jafferjee, M; Koch, WJ; Lymperopoulos, A; McDonald, P; Sturchler, E; Valero, TR | 1 |
| Hegazy, MA; Lotfy, HM; Mohamed, EH; Mowaka, S | 1 |
| Assaad-Khalil, SH; Cho, B; DiTommaso, S; Kitchlew, AR; Najem, R; Shete, A; Sison, J; Ueng, KC | 1 |
| Giles, TD; Sander, GE | 1 |
| Chen, J; Hu, YJ; Peng, DF; Tang, SY | 1 |
| Farmakis, D; Filippatos, G; Lekakis, J; Parissis, J | 1 |
| Cheng, WP; Lo, HM; Shyu, KG; Wang, BW | 1 |
| Ardiana, F; Indrayanto, G | 1 |
| Bai, F; Chang, P; Li, X; Lin, X; Wang, Q; Xu, H; Yang, M; Yu, J; Zhang, X; Zhang, Z; Zhao, F; Zhao, X | 1 |
| Akhter, N; Huda, S | 1 |
| Li, KY; Zhang, YJ | 1 |
| Ebeid, W; El-Bagary, R; Elkady, E; Elzahr, A; Patonay, G; Salim, M | 1 |
| Anraku, Y; Inami, S; Inoue, T; Kato, T; Kikegawa, Y; Nakamoto, A; Node, K; Suzuki, A; Toyoda, S; Tsukada, K | 1 |
| Morrow, T | 1 |
| Chai, J; Guo, G; Hao, D; Song, F; Zhao, Y | 1 |
| Abraham, I; Alkhatib, N; Brié, H; Denhaerynck, K; Hamarneh, D; MacDonald, K; Vancayzeele, S | 1 |
| Fujiwara, T; Hoshide, S; Kanegae, H; Kario, K; Tomitani, N | 1 |
| Chan, TH; Tsoi, MF; Yung Cheung, BM | 1 |
| Cortés-Ríos, J; Rodriguez-Fernandez, M | 1 |
| Abdelrahim, MEA; Hanna, SM; Mahmoud, HB; Rabea, HM | 1 |
| Hirata, T; Ishii, T; Kokuba, S; Nakamura, K; Shiohira, H; Tayag, JCS | 1 |
| Liang, H; Tang, T; Xie, M | 1 |
161 review(s) available for valsartan and valine
| Article | Year |
|---|---|
The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs.
Topics: Acrylates; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Losartan; Pyridines; Quinolines; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 1995 |
Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Humans; Imidazoles; Losartan; Renin; Tetrazoles; Valine; Valsartan | 1997 |
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Imidazoles; Kidney Diseases; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 1997 |
Valsartan. A review of its pharmacology and therapeutic use in essential hypertension.
Topics: Antihypertensive Agents; Cardiomegaly; Humans; Hypertension; Receptors, Angiotensin; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 1997 |
Angiotensin II receptor blockers in hypertension and renal disease.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Kidney Diseases; Losartan; Tetrazoles; Valine; Valsartan | 1998 |
[New prospects in the treatment of arterial hypertension. Antagonist of angiotensin II valsartan (diovan)].
Topics: Angiotensin II; Antihypertensive Agents; Humans; Hypertension; Safety; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1998 |
Angiotensin II antagonism in clinical practice: experience with valsartan.
Topics: Age Factors; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Drug Synergism; Humans; Kidney Diseases; Racial Groups; Sex Factors; Tetrazoles; Valine; Valsartan | 1999 |
Valsartan and the kidney: present and future.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Humans; Hypertension; Kidney Diseases; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 1999 |
Valsartan/hydrochlorothiazide.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Drug Combinations; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin-II receptor antagonists: their place in therapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 1999 |
Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation.
Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypertension; Tetrazoles; Valine; Valsartan | 1999 |
Clinical advantage of valsartan.
Topics: Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Humans; Hypertension; Losartan; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin II receptor antagonists in the treatment of hypertension.
Topics: Algorithms; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Hypertension; Irbesartan; Losartan; Receptors, Angiotensin; Telmisartan; Tetrazoles; Valine; Valsartan | 1999 |
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Heart Diseases; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 1999 |
Therapeutic options in minimizing left ventricular hypertrophy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hypertension; Hypertrophy, Left Ventricular; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
Cardiac protection: evolving role of angiotensin receptor blockers.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Middle Aged; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2000 |
Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Prognosis; Receptors, Angiotensin; Renin-Angiotensin System; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2000 |
[Use of angiotensin II receptor blockaders in heart failure].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Heart Failure; Humans; Irbesartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2000 |
Angiotensin II antagonists for hypertension: are there differences in efficacy?
Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Humans; Hypertension; Irbesartan; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2000 |
[Use of angiotensin-II-antagonists in hypertension].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Hypertension; Losartan; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2000 |
Prospective trials of angiotensin receptor blockers: beyond blood pressure control.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Losartan; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2000 |
Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2000 |
Angiotensin II type 1 receptor blockers.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Binding, Competitive; Biphenyl Compounds; Blood Pressure; Drug Design; Humans; Irbesartan; Losartan; Peptidyl-Dipeptidase A; Protein Binding; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin-Angiotensin System; Saralasin; Tetrazoles; Valine; Valsartan | 2001 |
Valsartan: a novel angiotensin type 1 receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2000 |
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Cardiovascular Diseases; Humans; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Metabolic Clearance Rate; Patient Selection; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes; Treatment Outcome; Valine; Valsartan | 2001 |
Angiotensin II AT(1) receptor antagonists and platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Coronary Disease; Coronary Thrombosis; Humans; Losartan; P-Selectin; Platelet Activation; Platelet Aggregation; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Thromboxane; Tetrazoles; Thrombosis; Thromboxane A2; Valine; Valsartan | 2001 |
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Heart Failure; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2001 |
[Angiotensin receptor blockers--significance for the therapy of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Austria; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Losartan; Prodrugs; Telmisartan; Tetrazoles; Therapeutic Equivalency; Thiophenes; Valine; Valsartan | 2001 |
[Angiotensin I receptor blockers for heart failure].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Austria; Benzimidazoles; Biphenyl Compounds; Contraindications; Cough; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2001 |
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles; Valine; Valsartan | 2001 |
[Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2001 |
Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2001 |
[Angiotensin II receptor blockers: current status and future prospects].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Diseases; Humans; Hypertension; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
[Irbesartan: a new possibility in the treatment of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Controlled Clinical Trials as Topic; Drug Administration Schedule; Enalapril; Half-Life; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2002 |
Angiotensin II receptor antagonists in chronic heart failure: where do they fit?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
[Treatment of heart failure: an update].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Benzazepines; Bosentan; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; Double-Blind Method; Heart Failure; Heart-Assist Devices; Humans; Metoprolol; Multicenter Studies as Topic; Placebos; Propanolamines; Prospective Studies; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2002 |
Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension.
Topics: Antihypertensive Agents; Databases, Bibliographic; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
[Tendency and prospect of the development of new ARBs].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Humans; Losartan; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2002 |
[Acute myocardial infarction].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Coronary Restenosis; Female; Humans; Losartan; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2002 |
The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Irbesartan; Losartan; Male; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Renin-angiotensin system inhibition: how much is too much of a good thing?
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Drug Therapy, Combination; Humans; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
[Pharmacological treatment of heart failure].
Topics: Acute Disease; Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Infusions, Intravenous; Pyridazines; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2003 |
[Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Losartan; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[Diurnal blood pressure control in the optimal treatment of hypertension].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Circadian Rhythm; Humans; Hypertension; Irbesartan; Losartan; Telmisartan; Tetrazoles; Valine; Valsartan | 2003 |
Angiotensin-receptor blockers: revival of the systemic prevention of restenosis?
Topics: Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Clinical Trials as Topic; Coronary Restenosis; Humans; Receptors, Angiotensin; Stents; Tetrazoles; Valine; Valsartan | 2003 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diastole; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Placebos; Prognosis; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2003 |
[Angiotensin receptor blockers in chronic heart failure].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Failure; Humans; Hypertension; Japan; Losartan; Myocardial Infarction; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2003 |
Angiotensin AT2 receptors: cardiovascular hope or hype?
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Cardiovascular Physiological Phenomena; Humans; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vasodilation | 2003 |
[Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Humans; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2003 |
[Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Complications; Heart Failure; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2003 |
Valsartan for the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Valsartan: in chronic heart failure.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Agents; Drug Administration Schedule; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Nephropathies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2004 |
Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT).
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan | 2003 |
Blockade of the renin-angiotensin system: better late than never.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Complications; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Peritoneal Dialysis, Continuous Ambulatory; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2004 |
Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
Angiotensin type 1 receptor blockers in chronic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Clinical Trials as Topic; Diabetic Nephropathies; Humans; Kidney Diseases; Losartan; Tetrazoles; Valine; Valsartan | 2004 |
VALUE: to the heart of the matter.
Topics: Antihypertensive Agents; Heart Failure; Humans; Hypertension; Risk Factors; Tetrazoles; Valine; Valsartan | 2004 |
VALUE and supremacy of blood pressure control for cardiovascular protection.
Topics: Antihypertensive Agents; Humans; Hypertension; Myocardial Infarction; Stroke; Tetrazoles; Valine; Valsartan | 2004 |
Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Clinical experience with angiotensin receptor blockers with particular reference to valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Drug Interactions; Drug Therapy, Combination; Humans; Hypertension; Tetrazoles; Valine; Valsartan | 2004 |
Fetal toxicity of valsartan and possible reversible adverse side effects.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Female; Humans; Hypertension; Kidney; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Tetrazoles; Ultrasonography; Valine; Valsartan | 2004 |
The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes.
Topics: Animals; Antihypertensive Agents; Diabetes Mellitus, Experimental; Glycation End Products, Advanced; Tetrazoles; Valine; Valsartan | 2004 |
The VALUE trial: a commentary.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Drug Administration Schedule; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.
Topics: Amniotic Fluid; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; beta 2-Microglobulin; Child, Preschool; Female; Follow-Up Studies; Gestational Age; Humans; Hypertension; Infant; Infant, Newborn; Male; Pregnancy; Pregnancy Complications, Cardiovascular; Prenatal Exposure Delayed Effects; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 2005 |
Hope in Life and Value of blood pressure control.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan in chronic heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Drug Therapy, Combination; Female; Formularies, Hospital as Topic; Heart Failure; Humans; Liver Diseases; Male; Patient Education as Topic; Pregnancy; Randomized Controlled Trials as Topic; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 2005 |
[The best of clinical pharmacology in 2004].
Topics: Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Complications; Humans; Obesity; Tetrazoles; Valine; Valsartan | 2005 |
valsartan in elderly isolated systolic hypertension (VALISH) study: rationale and design.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Incidence; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
[Ace inhibitors and angiotensin II receptor antagonists for therapy of chronic heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Enalapril; Heart Failure; Humans; Indoles; Lisinopril; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2005 |
A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Drug Therapy, Combination; Drug Tolerance; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
[Use of the antihypertensive agent Diovan after acute myocardial infarction].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
[ARB II in chronic heart failure. Coincidences and divergences. Class effect?].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Losartan; Systole; Tetrazoles; Valine; Valsartan | 2005 |
Update on the efficacy of angiotensin receptor blockers in treatment of hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Captopril; Diabetes Complications; Drug Evaluation; Humans; Hypertension; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Chronic heart failure: an overview of conventional treatment versus novel approaches.
Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cardiac Glycosides; Erythropoietin; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Pacemaker, Artificial; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2005 |
The impact of suppressing the renin-angiotensin system on atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Combined Modality Therapy; Electric Countershock; Enalapril; Humans; Indoles; Losartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Secondary Prevention; Tetrazoles; Valine; Valsartan | 2006 |
Solid-phase synthesis in the twenty-first century.
Topics: Alkadienes; Boron Compounds; Combinatorial Chemistry Techniques; Guanidines; Hydantoins; Mesylates; Molecular Structure; Peptides, Cyclic; Pharmaceutical Preparations; Piperazines; Tetrazoles; Valine; Valsartan | 2006 |
[Molecular mechanisms underlying proteinuria reduction and protection of nephrin and podocytes by ARB].
Topics: Actinin; Actins; Adaptor Proteins, Signal Transducing; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cytoskeletal Proteins; Humans; Intracellular Signaling Peptides and Proteins; Kidney Failure, Chronic; Membrane Proteins; Podocytes; Proteins; Proteinuria; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2006 |
The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus; Drug Administration Schedule; Heart Failure; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2006 |
The pleiotropic effects of angiotensin receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Diabetes Mellitus; Heart; Humans; Kidney; Losartan; Platelet Aggregation; Stroke; Tetrazoles; Uric Acid; Valine; Valsartan | 2006 |
Therapeutic potential of angiotensin receptor blockers in hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Coronary Disease; Female; Humans; Hypertension; Losartan; Male; Meta-Analysis as Topic; Myocardial Infarction; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Survival Analysis; Tetrazoles; Valine; Valsartan | 2006 |
[VALUE].
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Double-Blind Method; Endpoint Determination; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Tetrazoles; Valine; Valsartan | 2006 |
[VALISH].
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Endpoint Determination; Evidence-Based Medicine; Humans; Hypertension; Japan; Prospective Studies; Systole; Tetrazoles; Valine; Valsartan | 2006 |
Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension.
Topics: Antihypertensive Agents; Drug Interactions; Humans; Hydrochlorothiazide; Hypertension; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism?
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arginine; Biomarkers; Calcium; Calcium Channel Blockers; Humans; Kidney Failure, Chronic; Risk Factors; Tetrazoles; Valine; Valsartan | 2006 |
[Combination therapy in contemporary strategy of treatment of arterial hypertension. Review of data on efficacy and safety of fixed combination valsartan and hydrochlorothiazide].
Topics: Angiotensin II Type 1 Receptor Blockers; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Tetrazoles; Valine; Valsartan | 2006 |
New basic science initiatives with the angiotensin II receptor blocker valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atherosclerosis; Cell Proliferation; Endothelium, Vascular; Humans; Inflammation; Tetrazoles; Valine; Valsartan; Vasoconstriction; Ventricular Remodeling | 2000 |
Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Vessels; Humans; Hypertrophy, Left Ventricular; Kidney Diseases; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Complications; Diabetic Neuropathies; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Kidney Diseases; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 2000 |
Rationale for angiotensin II receptor blocker therapy in chronic heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Heart Failure; Humans; Long-Term Care; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Myocardial Infarction; Renin-Angiotensin System; Survival; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2000 |
Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension.
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2007 |
Valsartan in the treatment of heart attack survivors.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Secondary Prevention; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2006 |
A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Drug Therapy, Combination; Humans; Hypertension; Telmisartan; Tetrazoles; Valine; Valsartan | 2006 |
[Val-HeFT trial--evidence for valsartan in heart failure].
Topics: Adolescent; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2007 |
[ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Contraindications; Heart Failure; Humans; Hypertension; Imidazoles; Losartan; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Myocardial Infarction; Severity of Illness Index; Survival Rate; Tetrazoles; Valine; Valsartan | 2007 |
Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2007 |
Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Pathophysiology of target-organ disease: does angiotensin II remain the key?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Progression; Humans; Hypertension; Losartan; Myocardial Infarction; Renin; Renin-Angiotensin System; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Anti-angiotensin therapy: new perspectives.
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Fumarates; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Catecholamines; Humans; Hypertension; Imidazoles; Norepinephrine; Stroke; Tetrazoles; Thiophenes; Valine; Valsartan | 2007 |
[A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Drug Combinations; Humans; Hypertension; Tetrazoles; Valine; Valsartan | 2007 |
Amlodipine/Valsartan: fixed-dose combination in hypertension.
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Drug Combinations; Drug Synergism; Humans; Hypertension; Tetrazoles; Valine; Valsartan | 2008 |
Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension; Life Style; Tetrazoles; Valine; Valsartan | 2008 |
Reduction of proteinuria with angiotensin receptor blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biomarkers; Cardiovascular Diseases; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Determining the most appropriate components for a composite clinical trial outcome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies.
Topics: Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Placebos; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2009 |
Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Dose-Response Relationship, Drug; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Single-pill combination of amlodipine and valsartan in the management of hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Combinations; Humans; Hypertension; Patient Compliance; Tetrazoles; Valine; Valsartan | 2009 |
Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Tetrazoles; Valine; Valsartan | 2009 |
Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Progression; Endothelium, Vascular; Humans; Ramipril; Renin-Angiotensin System; Rosiglitazone; Tetrazoles; Thiazolidinediones; Valine; Valsartan; Vasodilation; Ventricular Function | 2009 |
Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Drug Combinations; Drug Interactions; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2009 |
Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cytoprotection; Humans; Hypertension; Hypertension, Renal; Kidney; Kidney Failure, Chronic; Models, Biological; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Valsartan: more than a decade of experience.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Hypotension; Meta-Analysis as Topic; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2009 |
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Saralasin; Secondary Prevention; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2009 |
Valsartan plus hydrochlorothiazide for first-line therapy in hypertension.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diuretics; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Patient Compliance; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2009 |
Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Fumarates; Humans; Kidney Diseases; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2010 |
Aliskiren/valsartan (Valturna) for hypertension.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Combinations; Drug Interactions; Fumarates; Humans; Hypertension; Randomized Controlled Trials as Topic; Renin; Tetrazoles; Valine; Valsartan | 2009 |
[Recent clinical evidences of RAS inhibitors on chronic kidney diseases].
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Fumarates; Kidney Diseases; Losartan; Tetrazoles; Valine; Valsartan | 2010 |
The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Drug Interactions; Drug Therapy, Combination; Fumarates; Humans; Hypertension; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2010 |
Combination therapy for managing difficult-to-treat patients with stage 2 hypertension: focus on valsartan-based combinations.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Black or African American; Calcium Channel Blockers; Diuretics; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Obesity; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2011 |
A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Confidence Intervals; Diastole; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Renin-Angiotensin System; Risk; Systole; Telmisartan; Tetrazoles; Valine; Valsartan | 2010 |
Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Databases, Factual; Female; Humans; Losartan; Male; Ramipril; Randomized Controlled Trials as Topic; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: case report and literature review.
Topics: Aged, 80 and over; Angioedema; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Hypertension; Tetrazoles; Time Factors; Valine; Valsartan | 2012 |
Aliskiren and valsartan combination therapy for the management of hypertension.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Fumarates; Humans; Hypertension; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2010 |
Dual-acting angiotensin receptor-neprilysin inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Volume; Endopeptidases; Heart Failure; Humans; Hypertension; Neprilysin; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Vasoconstriction | 2011 |
Valsartan-amlodipine-hydrochlorothiazide: the definitive fixed combination?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Medication Adherence; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
A drug safety evaluation of valsartan.
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Child; Drug Therapy, Combination; Humans; Hypertension; Risk Factors; Tetrazoles; Valine; Valsartan | 2011 |
Valsartan use in pediatric hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Child; Humans; Hypertension; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hypertension; Program Evaluation; Risk Assessment; Risk Factors; Tetrazoles; Translational Research, Biomedical; Treatment Outcome; Valine; Valsartan | 2011 |
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Indans; Irbesartan; Losartan; Nitrobenzenes; Obesity; Olmesartan Medoxomil; Piperazines; Ramipril; Tetrazoles; Valine; Valsartan | 2011 |
Update on pathophysiology and treatment of hypertension in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antihypertensive Agents; Blood Pressure; Geriatric Assessment; Humans; Hypertension; Prevalence; Risk Factors; Tetrazoles; United States; Valine; Valsartan | 2011 |
Valsartan plus hydrochlorothiazide: a review of its use since its introduction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Diuretics; Drug Combinations; Drug Costs; Drug Synergism; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Renal Insufficiency; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2011 |
[Hypertension, obesity, erectile dysfunction. What kind of drug to choose].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Erectile Dysfunction; Humans; Hypertension; Male; Obesity; Renin-Angiotensin System; Risk Factors; Tetrazoles; Valine; Valsartan | 2011 |
[Application of AT1-angiotensin II receptor blocker valsartan in clinical practice].
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Drug Monitoring; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Renal Insufficiency; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Water-Electrolyte Balance | 2011 |
Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Design; Fumarates; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Medication Adherence; Olmesartan Medoxomil; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tetrazoles; Valine; Valsartan | 2011 |
[Medical and social implications of sexual dysfunction and safety of antihypertensive therapy in hypertensive patients].
Topics: Adult; Aged; Androgens; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Erectile Dysfunction; Female; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Hypertension therapy and cardiovascular protection. Effects of angiotensin II receptor block with Valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Patient Compliance; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2011 |
[Recent advance in kidney and hypertension research].
Topics: Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Agonists; Catheter Ablation; Cerebrovascular Circulation; Chronic Disease; Diabetic Nephropathies; Drug Therapy, Combination; Evidence-Based Medicine; Fumarates; Humans; Hypertension; Imidazoles; Kidney; Kidney Diseases; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2012 |
[Almanac 2011: Cardiac arrhythmias and pacing. Review of selected studies that have driven recent advances in clinical cardiology -- by the Editors of the Network Task Force of the European Society of Cardiology].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiac Resynchronization Therapy; Catheter Ablation; Clinical Trials as Topic; Death, Sudden, Cardiac; Defibrillators, Implantable; Evidence-Based Medicine; Humans; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Tetrazoles; Thromboembolism; Treatment Outcome; Valine; Valsartan; Ventricular Fibrillation | 2012 |
The renin-angiotensin system, bone marrow and progenitor cells.
Topics: Adipogenesis; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bone Marrow; Erythropoiesis; Hematopoiesis; Humans; Kidney; Mesenchymal Stem Cells; Metabolic Syndrome; Myocytes, Cardiac; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Stem Cells; Tetrazoles; Valine; Valsartan | 2012 |
Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2012 |
Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diuretics; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Randomized Controlled Trials as Topic; Telmisartan; Tetrazoles; Valine; Valsartan | 2013 |
The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan | 2012 |
Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.
Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypertension; Telmisartan; Tetrazoles; Valine; Valsartan | 2012 |
Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Confidence Intervals; Cross-Over Studies; Double-Blind Method; Humans; Hypertension; Hypertension, Renal; Imidazoles; Interleukin-6; Obesity; Prospective Studies; Publication Bias; Randomized Controlled Trials as Topic; Stents; Telmisartan; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2013 |
A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Publication Bias; Randomized Controlled Trials as Topic; Telmisartan; Tetrazoles; Valine; Valsartan | 2013 |
The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Obesity, Abdominal; Risk Factors; Tetrazoles; Valine; Valsartan | 2013 |
Overview of clinical use and side effect profile of valsartan in Chinese hypertensive patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; China; Drug Therapy, Combination; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2013 |
LCZ696 : a new paradigm for the treatment of heart failure?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Clinical Trials, Phase II as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Prospective Studies; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2015 |
Renin-angiotensin system blockade in the treatment of heart failure and the role of valsartan in this treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Renal and metabolic effects of valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Humans; Protective Agents; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan | 2014 |
Hypertension and valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Combinations; Humans; Hypertension; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Valsartan after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Angiotensin II Type 1 Receptor Blockers; Animals; Benzopyrans; Blood Pressure; Drug Combinations; Ethanolamines; Humans; Hypertension; Nebivolol; Tetrazoles; Valine; Valsartan | 2015 |
Valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Chemistry, Pharmaceutical; Humans; Molecular Structure; Technology, Pharmaceutical; Tetrazoles; Valine; Valsartan | 2015 |
Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Essential Hypertension; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Network Meta-Analysis; Telmisartan; Tetrazoles; Valine; Valsartan | 2023 |
571 trial(s) available for valsartan and valine
| Article | Year |
|---|---|
Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Heart Rate; Humans; Male; Placebos; Renin; Reproducibility of Results; Systole; Tetrazoles; Valine; Valsartan | 1994 |
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
Topics: Adult; Aged; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Dizziness; Double-Blind Method; Drug Administration Schedule; Edema; Female; Headache; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1996 |
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril.
Topics: Adult; Age Factors; Aged; Angiotensin II; Antihypertensive Agents; Double-Blind Method; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1996 |
The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects.
Topics: Adult; Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Area Under Curve; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Humans; Linear Models; Male; Receptors, Angiotensin; Reference Values; Tetrazoles; Time Factors; Valine; Valsartan | 1997 |
Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cough; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Lisinopril; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1997 |
Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man.
Topics: Administration, Oral; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biological Availability; Capsules; Cross-Over Studies; Dose-Response Relationship, Drug; Humans; Injections, Intravenous; Male; Middle Aged; Pilot Projects; Solutions; Tetrazoles; Valine; Valsartan | 1997 |
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1997 |
Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide.
Topics: Administration, Oral; Adult; Angiotensin II; Antihypertensive Agents; Area Under Curve; Blood Pressure; Cross-Over Studies; Diuretics; Drug Synergism; Furosemide; Humans; Male; Middle Aged; Renin; Tetrazoles; Valine; Valsartan | 1997 |
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Lisinopril; Male; Middle Aged; Safety; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1997 |
Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Area Under Curve; Blood Pressure; Cross-Over Studies; Double-Blind Method; Half-Life; Heart Rate; Humans; Male; Metabolic Clearance Rate; Middle Aged; Tetrazoles; Valine; Valsartan | 1997 |
Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Antihypertensive Agents; Area Under Curve; Atenolol; Blood Pressure; Cross-Over Studies; Drug Interactions; Exercise; Half-Life; Heart Rate; Humans; Male; Metabolic Clearance Rate; Renin; Tetrazoles; Valine; Valsartan | 1997 |
Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lisinopril; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1997 |
An interaction study with cimetidine and the new angiotensin II antagonist valsartan.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cimetidine; Cross-Over Studies; Drug Interactions; Histamine H2 Antagonists; Humans; Male; Reference Values; Tetrazoles; Valine; Valsartan | 1998 |
The ELITE study. Evaluation of Losartan in the Elderly Study.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Captopril; Creatine; Cross-Over Studies; Electrocardiography; Heart; Humans; Losartan; Male; Tetrazoles; Valine; Valsartan | 1998 |
Valsartan in heart failure patients previously untreated with an ACE inhibitor.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Hemodynamics; Humans; Least-Squares Analysis; Lisinopril; Male; Matched-Pair Analysis; Middle Aged; Renin-Angiotensin System; Tetrazoles; Time Factors; Valine; Valsartan | 1998 |
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
Topics: Aged; Amlodipine; Angiotensin II; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Prospective Studies; Research Design; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1998 |
Valsartan and atenolol in patients with severe essential hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1998 |
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1998 |
Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.
Topics: Aged; Albuminuria; Angiotensin II; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Creatinine; Dextrans; Double-Blind Method; Erythrocyte Count; Female; Glomerular Filtration Rate; Humans; Hypertension, Renal; Inulin; Kidney Failure, Chronic; Kidney Glomerulus; Male; Middle Aged; Molecular Weight; p-Aminohippuric Acid; Particle Size; Potassium; Prospective Studies; Proteinuria; Renal Circulation; Tetrazoles; Valine; Valsartan | 1998 |
Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Enalapril; Humans; Indomethacin; Kidney; Male; Natriuresis; Reference Values; Renal Circulation; Single-Blind Method; Tetrazoles; Valine; Valsartan | 1998 |
Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Headache; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1998 |
Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertrophy, Left Ventricular; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Double-Blind Method; Humans; Irbesartan; Losartan; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Time Factors; Valine; Valsartan | 1999 |
Angiotensin II receptor subtype I antagonism and diastolic cardiac filling in man.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Cardiovascular Agents; Cross-Over Studies; Diastole; Double-Blind Method; Echocardiography; Heart Failure; Hemodynamics; Humans; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 1999 |
[The hypotensive effect and tolerance of valsartan (Diovan) in hypertension in a general clinical practice].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Quality of Life; Tetrazoles; Time Factors; Valine; Valsartan | 1999 |
A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Diastole; Dizziness; Double-Blind Method; Female; Headache; Humans; Hypertension; Losartan; Male; Middle Aged; Patient Dropouts; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
Dose-response efficacy of valsartan, a new angiotensin II receptor blocker.
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Posture; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Hemodynamics; Hormones; Humans; Lisinopril; Middle Aged; Single-Blind Method; Tetrazoles; Time Factors; Valine; Valsartan | 1999 |
[Diovan efficacy and tolerance in mild and moderate hypertension].
Topics: Adult; Angiotensin II; Antihypertensive Agents; Blood Pressure; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Safety; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation.
Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypertension; Tetrazoles; Valine; Valsartan | 1999 |
Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Renal Circulation; Tetrazoles; Valine; Valsartan | 1999 |
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Drug Interactions; Heart Ventricles; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Organ Size; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Research Design; Tetrazoles; Valine; Valsartan | 1999 |
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Chromatography, High Pressure Liquid; Confounding Factors, Epidemiologic; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Half-Life; Humans; Irbesartan; Losartan; Male; Radioligand Assay; Reference Values; Tetrazoles; Time Factors; Valine; Valsartan | 1999 |
A comparison of valsartan and captopril in patients with essential hypertension in Indonesia.
Topics: Adult; Aged; Antihypertensive Agents; Captopril; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Double-Blind Method; Humans; Hypertension; Irbesartan; Losartan; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Reproducibility of Results; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 1999 |
Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril.
Topics: Adult; Angiography; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Double-Blind Method; Enalapril; Exercise Test; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Radionuclide Imaging; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1999 |
Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Creatinine; Drug Combinations; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Pilot Projects; Potassium; Proteinuria; Safety; Tetrazoles; Valine; Valsartan | 2000 |
The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1999 |
Efficacy and safety of valsartan compared with enalapril at different altitudes.
Topics: Adult; Altitude; Antihypertensive Agents; Colombia; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Safety; Tetrazoles; Valine; Valsartan | 2000 |
Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Cross-Over Studies; Diastole; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Humans; Hypertension; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Systole; Tetrazoles; Time Factors; Valine; Valsartan | 2000 |
Efficacy of valsartan in patients aged > or =65 years with systolic hypertension.
Topics: Aged; Antihypertensive Agents; Double-Blind Method; Female; Humans; Hypertension; Male; Placebos; Tetrazoles; Valine; Valsartan | 2000 |
[Antihypertensive effects of valsartan. National multicentric study].
Topics: Analysis of Variance; Antihypertensive Agents; Case-Control Studies; Chi-Square Distribution; Female; Follow-Up Studies; Humans; Male; Prospective Studies; Tetrazoles; Valine; Valsartan | 2000 |
[Diovan effectiveness in combined treatment of severe arterial hypertension].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Clonidine; Diuretics; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Humans; Hypertension; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Valine; Valsartan | 2000 |
A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Humans; Hypertension; Male; Middle Aged; Patient Compliance; Single-Blind Method; Telmisartan; Tetrazoles; Valine; Valsartan | 2000 |
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cross-Over Studies; Female; Glomerular Filtration Rate; Humans; Kidney; Lisinopril; Male; Middle Aged; Potassium; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 2000 |
Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: a placebo-controlled study in healthy volunteers.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Endothelins; Humans; Infusions, Intravenous; Male; Nitric Oxide; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2000 |
Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.
Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Sex Factors; Tetrazoles; Valine; Valsartan | 2000 |
Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Angiotensin Receptor Antagonists; Antihypertensive Agents; Coronary Disease; Female; Humans; Male; Middle Aged; Recurrence; Stents; Tetrazoles; Valine; Valsartan | 2001 |
Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study.
Topics: Adult; Antihypertensive Agents; Carbazoles; Carvedilol; Cross-Over Studies; Double-Blind Method; Humans; Hypertension; Male; Middle Aged; Propanolamines; Sexual Behavior; Tetrazoles; Valine; Valsartan | 2001 |
Treatment of hypertension with valsartan combined with spironolactone.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Spironolactone; Tetrazoles; Valine; Valsartan | 2000 |
Canadian valsartan study in patients with mild-to-moderate hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Canada; Chronotherapy; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Racial Groups; Sex Factors; Single-Blind Method; Tetrazoles; Valine; Valsartan | 2001 |
Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Black People; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Pilot Projects; Prospective Studies; Sodium Chloride Symporter Inhibitors; Sodium, Dietary; Tetrazoles; Valine; Valsartan | 2001 |
Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation.
Topics: Aged; Aged, 80 and over; Algorithms; Antihypertensive Agents; Clinical Protocols; Coronary Disease; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Risk Factors; Tetrazoles; Valine; Valsartan | 2001 |
[Experience in the use of valsartan with the aim to inhibit progression of kidney failure in patients with chronic glomerulonephritis].
Topics: Adult; Antihypertensive Agents; Chronic Disease; Female; Follow-Up Studies; Glomerulonephritis; Humans; Hypertension; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Proteinuria; Tetrazoles; Time Factors; Valine; Valsartan | 2001 |
Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
Topics: Adult; Antihypertensive Agents; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Tetrazoles; Treatment Outcome; Uric Acid; Valine; Valsartan | 2001 |
Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects.
Topics: Administration, Oral; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Female; Humans; Male; Random Allocation; Tetrazoles; Time Factors; Valine; Valsartan | 2001 |
A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2001 |
[Antihypertensive effect of valsartan 80 mg and hydrochlorothiazide 12.5 mg evaluated by ambulatory blood pressure monitoring].
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2001 |
Central and peripheral effects of angiotensin II on the cardiovascular response to exercise.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Blood Pressure; Enalapril; Epinephrine; Exercise; Female; Heart Rate; Humans; Male; Norepinephrine; Receptor, Angiotensin, Type 1; Stroke Volume; Tetrazoles; Valine; Valsartan; Vascular Resistance | 2001 |
Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Diuretics; Drug Combinations; Drug Resistance; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan | 2001 |
Valsartan alone and as part of combination therapy in general practice in Brazil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Chlorthalidone; Drug Therapy, Combination; Family Practice; Female; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Tetrazoles; Valine; Valsartan | 2001 |
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Probability; Quality of Life; Stroke Volume; Survival Analysis; Tetrazoles; Valine; Valsartan | 2001 |
Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Kinetics; Male; Middle Aged; Tetrazoles; Therapeutic Equivalency; Treatment Outcome; Valine; Valsartan | 2001 |
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Humans; Irbesartan; Losartan; Male; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design.
Topics: Adult; Area Under Curve; Capsules; Cross-Over Studies; Dosage Forms; Female; Humans; Least-Squares Analysis; Male; Middle Aged; Tablets; Tetrazoles; Therapeutic Equivalency; Valine; Valsartan | 2002 |
Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Drug Combinations; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Prospective Studies; Tetrazoles; Time Factors; Valine; Valsartan | 2002 |
The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; Hemodynamics; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Tetrazoles; Therapeutic Equivalency; Treatment Outcome; Ultrasonography; Valine; Valsartan | 2002 |
Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val-HeFT).
Topics: Angiotensin Receptor Antagonists; Double-Blind Method; Echocardiography; Heart Failure; Humans; Quality Assurance, Health Care; Quality Control; Reproducibility of Results; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2002 |
Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Flow Velocity; Carotid Arteries; Cross-Over Studies; Double-Blind Method; Femoral Artery; Hemodynamics; Humans; Male; Pulse; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Reference Values; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2002 |
The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Irbesartan; Losartan; Male; Receptor, Angiotensin, Type 1; Reference Values; Tetrazoles; Valine; Valsartan | 2000 |
Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition.
Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Arteries; Blood Pressure; Captopril; Cross-Over Studies; Drug Synergism; Drug Therapy, Combination; Humans; Hypertension; Middle Aged; Pulse; Tetrazoles; Valine; Valsartan | 2002 |
ACE inhibition is superior to angiotensin receptor blockade for renography in renal artery stenosis.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Humans; Hypertension, Renovascular; Male; Middle Aged; Radioisotope Renography; Radiopharmaceuticals; Renal Artery Obstruction; Reproducibility of Results; Sensitivity and Specificity; Technetium Tc 99m Mertiatide; Tetrazoles; Valine; Valsartan | 2002 |
Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Chronic Disease; Drug Interactions; Female; Humans; Hypertension; Indomethacin; Lisinopril; Male; Middle Aged; Osteoarthritis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Muscle, Skeletal; Receptor, Angiotensin, Type 1; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2002 |
An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Humans; Hypertension; Irbesartan; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes.
Topics: Adolescent; Adult; Antihypertensive Agents; Cross-Over Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Tetrazoles; Valine; Valsartan | 2002 |
Efficacy and tolerability of valsartan in patients with mild to moderate essential hypertension.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Probability; Reference Values; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Atenolol; Coitus; Double-Blind Method; Humans; Hypertension; Male; Middle Aged; Testosterone; Tetrazoles; Valine; Valsartan | 2002 |
Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2002 |
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Patient Dropouts; Renin-Angiotensin System; Spironolactone; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2002 |
Safety and efficacy of valsartan versus enalapril in heart failure patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2002 |
[Efficacy and tolerance of ACE inhibitor invoril and angiotensin I At-receptor blocker diovan in patients with stages I-II of arterial hypertension].
Topics: Adult; Aged; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Drug Tolerance; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Valine; Valsartan | 2002 |
Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension; Infusions, Intravenous; Losartan; Male; Middle Aged; Receptor, Angiotensin, Type 1; Renal Circulation; Renin; Tetrazoles; Valine; Valsartan | 2002 |
Pharmacokinetics of multiple doses of valsartan in patients with heart failure.
Topics: Angiotensin Receptor Antagonists; Area Under Curve; Cardiac Output, Low; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Tetrazoles; Valine; Valsartan | 2002 |
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Survival Rate; Tetrazoles; Time; Valine; Valsartan | 2002 |
AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Aorta; Blood Pressure; Diastole; Diuretics; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Pulse; Radial Artery; Receptor, Angiotensin, Type 1; Sodium Chloride Symporter Inhibitors; Systole; Tetrazoles; Valine; Valsartan | 2002 |
[Tolerance to valsartan in office practice in 3,197 hypertensive patients (the VALSE study)].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Female; Humans; Hypertension; Male; Middle Aged; Office Visits; Prospective Studies; Tetrazoles; Valine; Valsartan | 2000 |
Effect of AT1 receptor blockade on endothelial function in essential hypertension.
Topics: Acetylcholine; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Cohort Studies; Diuretics; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Forearm; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; omega-N-Methylarginine; Receptor, Angiotensin, Type 1; Regional Blood Flow; Rest; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2003 |
[Control of systolic blood pressure in the VALUE trial after 12 months].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Europe; Female; Germany; Humans; Hypertension; Male; Middle Aged; Prognosis; Reference Standards; Risk Factors; Tetrazoles; Valine; Valsartan | 2003 |
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Biomarkers; Double-Blind Method; Follow-Up Studies; Heart Failure; Humans; Kinetics; Natriuretic Peptide, Brain; Norepinephrine; Prognosis; Survival Analysis; Tetrazoles; Valine; Valsartan | 2003 |
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
Topics: Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Chronic Disease; Cross-Over Studies; Dextrans; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Male; Middle Aged; Prospective Studies; Proteinuria; Renal Circulation; Tetrazoles; Valine; Valsartan | 2003 |
[Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Safety; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan | 2003 |
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Drug Synergism; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2003 |
Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardenolides; Digoxin; Female; Humans; Hypertension; Male; Middle Aged; Saponins; Tetrazoles; Valine; Valsartan | 2003 |
Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Drug Therapy, Combination; Female; Humans; Kidney Diseases; Male; Middle Aged; Pilot Projects; Proteinuria; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2003 |
Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Stroke Volume; Sympathetic Nervous System; Tetrazoles; Treatment Outcome; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
Differential effect of acute angiotensin II type 1 receptor blockade on the vascular and adrenal response to exogenous angiotensin II in humans.
Topics: Adrenal Glands; Adult; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Endothelins; Heart Rate; Humans; Hydrocortisone; Injections, Intravenous; Interleukin-6; Male; Renin; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan; Vasoconstrictor Agents | 2003 |
Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan | 2003 |
Effect of Valsartan on hospitalization: results from Val-HeFT.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2003 |
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial in Slovakia.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Risk Factors; Slovakia; Tetrazoles; Valine; Valsartan | 2003 |
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk.
Topics: Algorithms; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cohort Studies; Double-Blind Method; Drug Utilization; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Risk; Tetrazoles; Valine; Valsartan | 2003 |
[Efficiency of diovan (valsartane) in arterial hypertension patients].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Endopeptidases; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2003 |
Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diastole; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2003 |
Sexual activity in hypertensive men.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Coitus; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Prospective Studies; Sexual Behavior; Sodium Chloride Symporter Inhibitors; Surveys and Questionnaires; Tetrazoles; Valine; Valsartan | 2003 |
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Cardiac Output, Low; Chronic Disease; Double-Blind Method; Follow-Up Studies; Humans; Tetrazoles; Valine; Valsartan | 2003 |
Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blotting, Western; C-Reactive Protein; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Proteins; Isoquinolines; Leukocytes; Male; Monocytes; Neutrophils; NF-kappa B; Quinapril; Reactive Oxygen Species; Simvastatin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2003 |
[Clinical observation of the therapeutic effect of valsartan for renal hypertension in 64 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Urea Nitrogen; Creatinine; Electrolytes; Humans; Hypertension, Renal; Middle Aged; Proteinuria; Tetrazoles; Valine; Valsartan | 2003 |
Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Ankle; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brachial Artery; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Male; Nifedipine; Pulsatile Flow; Tetrazoles; Thiazepines; Treatment Outcome; Valine; Valsartan | 2003 |
Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Disease Progression; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; Lisinopril; Male; Middle Aged; Norepinephrine; Tetrazoles; Valine; Valsartan | 2003 |
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[Effects of angiotensin II on inflammation mediators in healthy subjects].
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cytokines; Humans; Inflammation Mediators; Interleukin-6; Male; Renin-Angiotensin System; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan; Vascular Cell Adhesion Molecule-1 | 2003 |
Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension.
Topics: Amlodipine; Antihypertensive Agents; Double-Blind Method; Glomerular Filtration Rate; Humans; Hypertension; Microcirculation; Middle Aged; Renal Circulation; Tetrazoles; Valine; Valsartan | 2003 |
A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Sodium Chloride Symporter Inhibitors; Systole; Tetrazoles; Valine; Valsartan | 2003 |
Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Hormone Replacement Therapy; Humans; Hypertension; Libido; Middle Aged; Postmenopause; Sexual Behavior; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cognition; Enalapril; Female; Humans; Hypertension; Male; Memory; Tetrazoles; Valine; Valsartan | 2004 |
Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chronotherapy; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II; Antihypertensive Agents; Blood Pressure; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Orgasm; Patient Satisfaction; Penile Erection; Sexual Behavior; Surveys and Questionnaires; Tetrazoles; Valine; Valsartan | 2003 |
Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brazil; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Racial Groups; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2003 |
A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Blood Flow Velocity; Blood Pressure; Compliance; Creatinine; Double-Blind Method; Echocardiography; Elasticity; Humans; Hypertrophy, Left Ventricular; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Tetrazoles; Valine; Valsartan | 2003 |
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Coronary Disease; Delayed-Action Preparations; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan.
Topics: Administration, Oral; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Area Under Curve; Arthritis, Rheumatoid; Blood Pressure; Chromatography, High Pressure Liquid; Down-Regulation; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nitrites; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors; Valine; Valsartan | 2004 |
Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans.
Topics: Administration, Oral; Adolescent; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Area Under Curve; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Diet, Sodium-Restricted; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Furosemide; Genetic Variation; Humans; Juxtaglomerular Apparatus; Male; Renin; Renin-Angiotensin System; Reproducibility of Results; Tetrazoles; Valine; Valsartan | 2004 |
The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Double-Blind Method; Heart Failure; Hospitalization; Humans; Risk Factors; Severity of Illness Index; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling | 2004 |
Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Drug Synergism; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Failure; Heart Function Tests; Humans; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Receptors, Angiotensin; Renin; Tetrazoles; Valine; Valsartan | 2004 |
Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Canada; Circadian Rhythm; Cross-Over Studies; Diastole; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Receptors, Angiotensin; Systole; Telmisartan; Tetrazoles; Treatment Outcome; United States; Valine; Valsartan | 2004 |
Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study).
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diuretics; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2004 |
Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Tablets; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People | 2004 |
Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component.
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chymases; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Coronary Circulation; Cytokines; Female; Gene Expression Profiling; Humans; Male; Microcirculation; Middle Aged; Mitral Valve Stenosis; Myocardium; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Preoperative Care; Ramipril; Renin-Angiotensin System; RNA, Messenger; Serine Endopeptidases; Tetrazoles; Valine; Valsartan; Vasculitis | 2004 |
Simvastatin reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension.
Topics: Aged; Angiotensin II; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Hypertension; Inflammation; Interleukin-1; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Simvastatin; Tetrazoles; Valine; Valsartan | 2004 |
Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Creatinine; Female; Humans; Hypertension; Japan; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Cavity; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Proteinuria; Retrospective Studies; Tetrazoles; Urine; Valine; Valsartan | 2004 |
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.
Topics: Antihypertensive Agents; Echocardiography; Heart Failure; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Survival Analysis; Tetrazoles; United States; Valine; Valsartan; Ventricular Remodeling | 2004 |
Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
Topics: Amlodipine; Antihypertensive Agents; Cross-Sectional Studies; Double-Blind Method; Echocardiography; Female; Flow Cytometry; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Monocytes; Prospective Studies; Reactive Oxygen Species; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Ultrasound evaluation of valsartan therapy for renal cortical perfusion.
Topics: Adult; Air; Angiotensin Receptor Antagonists; Female; Humans; Image Enhancement; Kidney Cortex; Male; Microspheres; Renal Circulation; Tetrazoles; Ultrasonography; Valine; Valsartan | 2004 |
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diuretics; Double-Blind Method; Endpoint Determination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Risk Factors; Sodium Chloride Symporter Inhibitors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Follow-Up Studies; Health Care Costs; Health Resources; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
[AT(1) blocker for post-infarct therapy. VALIANT Study].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cause of Death; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Survival Analysis; Syndrome; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
[Results of the VALIANT trial in post-myocardial infarction].
Topics: Adult; Aftercare; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Body Mass Index; Captopril; Cause of Death; Coronary Angiography; Double-Blind Method; Echocardiography; Female; Hospitalization; Humans; Male; Myocardial Infarction; Patient Selection; Proportional Hazards Models; Risk Factors; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chi-Square Distribution; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Italy; Lisinopril; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Sustained antihypertensive activity of telmisartan compared with valsartan.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastole; Double-Blind Method; Female; Half-Life; Humans; Hypertension; Male; Middle Aged; Placebos; Single-Blind Method; Systole; Telmisartan; Tetrazoles; Valine; Valsartan | 2004 |
Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Time Factors; Valine; Valsartan | 2004 |
JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Ischemia; Quality of Life; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2004 |
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Chronic Disease; Creatinine; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Survival Rate; Tetrazoles; Valine; Valsartan | 2004 |
Heart attack patients with complications. Treat with valsartan, captopril, or both?
Topics: Aged; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Topics: Aged; Aged, 80 and over; Ambulatory Care Facilities; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Patient Selection; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Blood Flow Velocity; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Female; Humans; Hypertension; Male; Middle Aged; Nifedipine; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Quality of Life; Risk Factors; Single-Blind Method; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Topics: Administration, Oral; Adolescent; Adult; Aldosterone; Amides; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Drug Synergism; Feedback, Physiological; Fumarates; Humans; Male; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2004 |
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
Topics: Adult; Aged; Antihypertensive Agents; Cross-Over Studies; Diet, Sodium-Restricted; Diuretics; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Proteinuria; Ramipril; Reference Values; Risk Assessment; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Monitoring, Physiologic; Olmesartan Medoxomil; Single-Blind Method; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2005 |
Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Adult; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Neurotransmitter Agents; Quality of Life; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Function, Left | 2004 |
Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial).
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Severity of Illness Index; Sex Distribution; Tetrazoles; United States; Valine; Valsartan | 2005 |
Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice.
Topics: Aged; Anemia; Antihypertensive Agents; Cause of Death; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hemoglobins; Humans; Male; Middle Aged; Multivariate Analysis; Prevalence; Prognosis; Prospective Studies; Registries; Risk; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypertension; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2005 |
Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Chlorthalidone; Cross-Over Studies; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2005 |
24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Female; Humans; Hypertension; Interleukin-1; Leukocytes, Mononuclear; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2005 |
[A comparative assessment of valsartan and lisinopril effects on systolic and diastolic function of the left ventricular in patients with acute Q-infarction].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diastole; Electrocardiography; Female; Follow-Up Studies; Humans; Lisinopril; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Creatinine; Enalapril; Follow-Up Studies; Humans; Hypertension; Kidney Function Tests; Kidney Transplantation; Losartan; Proteinuria; Ramipril; Renal Artery; Renin-Angiotensin System; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
Valsartan-induced hematocrit changes in renal transplant patients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Drug Therapy, Combination; Female; Hematocrit; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Potassium; Tetrazoles; Valine; Valsartan | 2005 |
Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Placebos; Quality of Life; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People | 2005 |
Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Biomarkers; Cytokines; Diabetes Mellitus, Type 2; Endothelial Cells; Female; Humans; Hypertension; Male; Middle Aged; Monocytes; Tetrazoles; Valine; Valsartan | 2006 |
Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Ankle; Aorta; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Japan; Male; Middle Aged; Natriuretic Peptide, Brain; Perindopril; Prospective Studies; Pulse; Tetrazoles; Valine; Valsartan | 2005 |
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Electrocardiography; Female; Heart Ventricles; Hospitalization; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Obesity; Risk Factors; Tetrazoles; Valine; Valsartan | 2005 |
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Area Under Curve; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Double-Blind Method; Humans; Male; Middle Aged; Renin; Saliva; Sensory Thresholds; Taste; Tetrazoles; Valine; Valsartan; Zinc | 2005 |
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Ambulatory Care; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Costs; Global Health; Health Care Costs; Health Resources; Heart Failure; Hospital Costs; Hospitalization; Humans; Myocardial Infarction; Prospective Studies; Quality of Life; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients.
Topics: Aged; Antihypertensive Agents; Felodipine; Female; Humans; Hypertension; Insulin Resistance; Leptin; Male; Middle Aged; Obesity; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Female; Heart Failure; Hemoglobins; Humans; Logistic Models; Male; Middle Aged; Morbidity; Multivariate Analysis; Prevalence; Prognosis; Survival Analysis; Tetrazoles; Valine; Valsartan | 2005 |
A comparison of valsartan and perindopril in the treatment of essential hypertension in the malaysian population.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Follow-Up Studies; Humans; Hypertension; Malaysia; Male; Middle Aged; Perindopril; Prevalence; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Urea Nitrogen; Creatinine; Erythropoietin; Female; Follow-Up Studies; Glomerular Filtration Rate; Hemoglobins; Humans; Kidney Failure, Chronic; Male; Middle Aged; Potassium; Tetrazoles; Uric Acid; Valine; Valsartan | 2005 |
A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Black People; Blood Pressure; Calcium Channel Blockers; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Prospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; C-Reactive Protein; Female; Heart Failure; Humans; Male; Middle Aged; Morbidity; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; Tetrazoles; Valine; Valsartan | 2005 |
The effects of valsartan on lipid profile in normotensive type 2 diabetic patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Lipids; Middle Aged; Tetrazoles; Valine; Valsartan | 2005 |
Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Double-Blind Method; Drug Administration Schedule; Female; Fibrinogen; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2005 |
Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects.
Topics: Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Drug Administration Schedule; Female; Humans; Hypertension; Male; Prospective Studies; Tetrazoles; Valine; Valsartan | 2005 |
Treatment of non-dipper hypertension with bedtime administration of valsartan.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Female; Forearm; Hand Strength; Heart Rate; Humans; Hypertension; Imidazoles; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Skin; Stress, Psychological; Tetrazoles; Thiophenes; Time Factors; Treatment Outcome; Valine; Valsartan | 2005 |
Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group tri
Topics: Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Patient Compliance; Tetrazoles; Valine; Valsartan | 2005 |
Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Female; Heart; Heart Failure; Humans; Male; Mediastinum; Middle Aged; Natriuretic Peptide, Brain; Observer Variation; Radionuclide Imaging; Radiopharmaceuticals; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan | 2006 |
Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Collagen Type I; Female; Fibrosis; Humans; Male; Middle Aged; Myocardium; Tetrazoles; Valine; Valsartan | 2005 |
[Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect o
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Renin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2005 |
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Natriuretic Factor; Biomarkers; Cyclophosphamide; Doxorubicin; Female; Hemodynamics; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Prednisone; Tetrazoles; Valine; Valsartan; Vincristine | 2005 |
Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Obesity; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan | 2005 |
A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Male; Middle Aged; Musculoskeletal Diseases; Prospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarct
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Captopril; Cardiovascular Diseases; Cause of Death; Heart Failure; Humans; Middle Aged; Morbidity; Mortality; Myocardial Infarction; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
[Effects of benazepril combined with valsartan on congestive heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2005 |
Haemodynamic effects of AT1 inhibition and Ca2+-channel blockade in hypertensive patients during isometric stress.
Topics: Amlodipine; Analysis of Variance; Antihypertensive Agents; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method; Female; Forearm; Hand Strength; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Plethysmography; Tetrazoles; Valine; Valsartan; Vascular Resistance | 2006 |
Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial.
Topics: Aged; Antihypertensive Agents; Blood Platelets; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Male; Severity of Illness Index; Tetrazoles; Valine; Valsartan | 2006 |
[Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study].
Topics: Adult; Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypertension; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2005 |
Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Circadian Rhythm; Diabetic Nephropathies; Humans; Renin-Angiotensin System; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan | 2006 |
Conformational changes in prorenin during renin inhibition in vitro and in vivo.
Topics: Adolescent; Adult; Amides; Antihypertensive Agents; Cross-Over Studies; Double-Blind Method; Fumarates; Humans; Immunoradiometric Assay; Male; Protein Conformation; Renin; Sodium; Tetrazoles; Valine; Valsartan | 2006 |
Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Diabetic Nephropathies; Female; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Single-Blind Method; Tetrazoles; Trichlormethiazide; Valine; Valsartan | 2006 |
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Captopril; Cardiac Output, Low; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein beta3 subunit (GNB3) C825T polymorphism.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin-1; Genotype; Heterotrimeric GTP-Binding Proteins; Humans; Laser-Doppler Flowmetry; Male; Microcirculation; Norepinephrine; Polymorphism, Genetic; Regional Blood Flow; Skin; Tetrazoles; Valine; Valsartan; Vasoconstriction; Vasoconstrictor Agents | 2006 |
Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Female; Glomerulonephritis; Humans; Middle Aged; Nephrosclerosis; Proteinuria; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan | 2005 |
Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biopsy, Needle; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Male; Microcirculation; Middle Aged; Probability; Prospective Studies; Reference Values; Regional Blood Flow; Risk Assessment; Severity of Illness Index; Skin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Female; Glomerulonephritis, IGA; Hong Kong; Humans; Male; Tetrazoles; Valine; Valsartan | 2006 |
Valsartan cardio-renal protection in patients undergoing coronary angiography complicated with chronic renal insufficiency (VAL-CARP) trial: rationale and design.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Patient Selection; Protective Agents; Renal Artery Obstruction; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan | 2006 |
Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Double-Blind Method; Echocardiography; Humans; Italy; Prospective Studies; Recurrence; Research Design; Tetrazoles; Valine; Valsartan | 2006 |
Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Arteries; Blood Pressure; Female; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Plethysmography; Prospective Studies; Pulse; Tetrazoles; Valine; Valsartan | 2005 |
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
Topics: Adult; Animals; Antihypertensive Agents; Area Under Curve; Cells, Cultured; Cross-Over Studies; Dogs; Haplotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Metabolic Clearance Rate; Organic Anion Transporters; Polymorphism, Genetic; Pravastatin; Tetrazoles; Thiazepines; Valine; Valsartan | 2006 |
Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypertension; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2006 |
Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; C-Reactive Protein; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Inflammation; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2006 |
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Ethanol; Fatty Acids, Nonesterified; Female; Glucose; Glucose Tolerance Test; Glycerol; Humans; Hypertension; Insulin; Kinetics; Lactic Acid; Lipids; Male; Metabolism; Middle Aged; Muscle, Skeletal; Obesity; Tetrazoles; Valine; Valsartan | 2006 |
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Atenolol; Biopsy; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diastole; Female; Humans; Hypertension; Male; Middle Aged; Organ Culture Techniques; Subcutaneous Tissue; Systole; Tetrazoles; Time; Treatment Outcome; Valine; Valsartan | 2006 |
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Risk Factors; Tetrazoles; Valine; Valsartan | 2006 |
Randomized, double-blind, crossover comparison of amlodipine and valsartan in african-americans with hypertension using 24-hour ambulatory blood pressure monitoring.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Black or African American; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypertension; Male; Tetrazoles; Valine; Valsartan | 2006 |
Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carotid Arteries; Endothelium, Vascular; Female; Humans; Hypertension; Male; Middle Aged; Pulse; Tetrazoles; Valine; Valsartan; Vascular Resistance | 2006 |
Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2005 |
Valsartan and retinal endothelial function in elderly hypertensive patients.
Topics: Aged; Aged, 80 and over; Blood Flow Velocity; Cholesterol, LDL; Endothelium, Vascular; Hemodynamics; Humans; Hypertension; Male; Middle Aged; omega-N-Methylarginine; Retinal Artery; Tetrazoles; Valine; Valsartan | 2006 |
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiac Output, Low; Diabetes Mellitus; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Incidence; Male; Middle Aged; Risk; Tetrazoles; Valine; Valsartan | 2006 |
[Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADK
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiac Output, Low; Chronic Disease; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling | 2006 |
Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Placebos; Telmisartan; Tetrazoles; United States; Valine; Valsartan | 2006 |
Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ versus Amlodipine in stage II hypertensive patients (VASt) trial.
Topics: Amlodipine; C-Reactive Protein; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Interleukin-6; Lipoproteins, LDL; Tetrazoles; Tissue Plasminogen Activator; Valine; Valsartan | 2006 |
Blockade of renin-angiotensin system reduces QT dispersion and improves intracellular Ca/Mg status in hemodialysis patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Calcium; Cilazapril; Female; Heart Rate; Humans; In Vitro Techniques; Kidney Failure, Chronic; Magnesium; Male; Middle Aged; Renal Dialysis; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2006 |
Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: results of a multicentre open-label trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Blood Pressure; Drug Combinations; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan | 2006 |
Acute administration of a single dose of valsartan improves left ventricular functions: a pilot study to assess the role of tissue velocity echocardiography in patients with systemic arterial hypertension in the TVE-valsartan study I.
Topics: Adult; Aged; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Dose-Response Relationship, Drug; Echocardiography, Doppler, Color; Female; Heart Rate; Humans; Hypertension; Image Processing, Computer-Assisted; Male; Middle Aged; Myocardial Contraction; Pilot Projects; Research Design; Stroke Volume; Sweden; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Function, Left | 2006 |
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Female; Heart Arrest; Heart Failure; Humans; Hypertension; Male; Middle Aged; Proportional Hazards Models; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Chlorthalidone; Diltiazem; Drug Therapy, Combination; Felodipine; Female; Humans; Hypertension; Lisinopril; Male; Middle Aged; Office Visits; Sodium Chloride Symporter Inhibitors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Effects of valsartan and indapamide on plasma cytokines in essential hypertension.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Chemokine CCL2; Chemokine CCL3; Chemokine CCL4; Cytokines; Diuretics; Female; Humans; Hypertension; Indapamide; Macrophage Inflammatory Proteins; Male; Middle Aged; P-Selectin; Tetrazoles; Valine; Valsartan | 2006 |
Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Arginine; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Female; Humans; Hypertension, Renal; Kidney Failure, Chronic; Male; Methylation; Middle Aged; Oxidative Stress; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2006 |
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; Drug Therapy, Combination; Electrocardiography, Ambulatory; Follow-Up Studies; Heart Failure; Humans; Quinapril; Severity of Illness Index; Stroke Volume; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; Drug Therapy, Combination; Electrocardiography, Ambulatory; Exercise Test; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Quinapril; Stroke Volume; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Angiotensin receptor blockade improves vascular compliance in healthy normotensive elderly individuals: results from a randomized double-blind placebo-controlled trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Brachial Artery; Compliance; Cross-Over Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Prognosis; Reference Values; Tetrazoles; Valine; Valsartan; Vasoconstriction | 2006 |
Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diastole; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Kidney Transplantation; Male; Middle Aged; Placebos; Postoperative Complications; Safety; Systole; Tetrazoles; Valine; Valsartan | 2006 |
Angiotensin II type 1 receptor 1166A/C polymorphism in association with blood pressure response to exogenous angiotensin II.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Female; Gene Frequency; Genotype; Humans; Male; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2007 |
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vascular Resistance; Vasodilation | 2007 |
Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Colorado; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2006 |
Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Bradykinin; Bradykinin B2 Receptor Antagonists; Cross-Over Studies; Cyclic GMP; Diet, Sodium-Restricted; Female; Heart Rate; Humans; Hypertension; Male; Receptor, Bradykinin B2; Renin; Sodium; Tetrazoles; Valine; Valsartan | 2007 |
Do valsartan and losartan have the same effects in the treatment of coronary artery disease?
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Case-Control Studies; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Stenosis; Dose-Response Relationship, Drug; Female; Humans; Intercellular Adhesion Molecule-1; L-Selectin; Losartan; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2007 |
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fumarates; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
The effect of valsartan, an angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in liver cirrhosis.
Topics: Adult; Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Creatinine; Female; Hemodynamics; Humans; Hypertension, Portal; Kidney; Liver Cirrhosis; Male; Metanephrine; Middle Aged; Natriuresis; Portal System; Renin; Romania; Single-Blind Method; Sodium; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2006 |
Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
Topics: Adult; Age Factors; Aged; Amlodipine; Ankle; Blood Pressure; Cross-Over Studies; Drug Therapy, Combination; Edema; Female; Humans; Hypertension; Male; Middle Aged; Placebos; Prospective Studies; Single-Blind Method; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Denmark; Female; Heart Rate; Humans; Hypertension; Italy; Male; Middle Aged; Office Visits; Randomized Controlled Trials as Topic; Reproducibility of Results; Research; Risk Factors; Tetrazoles; United States; Valine; Valsartan | 2007 |
Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nifedipine; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Palatability of angiotensin II antagonists among nephropathic children.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Child; Child, Preschool; Female; Humans; Irbesartan; Kidney Diseases; Losartan; Male; Patient Compliance; Patient Satisfaction; Smell; Taste; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blotting, Northern; Dizziness; Double-Blind Method; Exanthema; Female; Gene Expression Regulation, Enzymologic; Humans; Hypertension; Male; Middle Aged; Patient Dropouts; RNA, Messenger; Superoxide Dismutase; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Research Design; Risk Factors; Stroke Volume; Survival Analysis; Survivors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; Catecholamines; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Posture; Rest; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Olmesartan Medoxomil; Severity of Illness Index; Single-Blind Method; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects.
Topics: Adult; Antihypertensive Agents; Confidence Intervals; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Hypolipidemic Agents; Male; Probability; Reference Values; Risk Factors; Sensitivity and Specificity; Simvastatin; Single-Blind Method; Tetrazoles; Time Factors; Valine; Valsartan | 2007 |
Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART).
Topics: Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Japan; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
Topics: Adiponectin; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Body Mass Index; Calcium Channel Blockers; Doxazosin; Female; Humans; Hypertension; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Metoprolol; Middle Aged; Predictive Value of Tests; Prospective Studies; Ramipril; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2007 |
Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Coronary Disease; Endpoint Determination; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Lisinopril; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Black People; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Research Design; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Collagen Type I; Collagen Type III; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Lipid Peroxidation; Long QT Syndrome; Male; Oxidative Stress; Prospective Studies; Tetrazoles; Valine; Valsartan | 2007 |
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Echocardiography; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valine; Valsartan | 2007 |
[Role of the renin-angiotensin system on the sympathetic response induced by the cold pressor test in humans].
Topics: Acrylates; Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cold Temperature; Double-Blind Method; Female; Humans; Imidazoles; Losartan; Male; Receptors, Angiotensin; Renin-Angiotensin System; Sympathetic Nervous System; Tetrazoles; Thiophenes; Valine; Valsartan | 2007 |
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hyperten
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Headache; Humans; Hypertension; Male; Middle Aged; Nasopharyngitis; Tetrazoles; Valine; Valsartan | 2007 |
Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
Topics: Antihypertensive Agents; Biomarkers; Blood Pressure Monitoring, Ambulatory; C-Reactive Protein; Chemokine CCL2; Double-Blind Method; Drug Combinations; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Simvastatin; Tetrazoles; Valine; Valsartan | 2007 |
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
Topics: Amides; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Fumarates; Humans; Hypertension; Male; Middle Aged; Renin; Tetrazoles; Valine; Valsartan | 2007 |
Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Diabetic Nephropathies; Drug Therapy, Combination; Humans; Hypertension; Kidney; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fibrinolysis; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Lipids; Male; Middle Aged; P-Selectin; Plasminogen Activator Inhibitor 1; Postprandial Period; Tetrazoles; Tissue Plasminogen Activator; Valine; Valsartan; Vasculitis | 2007 |
Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Blood Pressure; Circadian Rhythm; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Imidazoles; Irbesartan; Male; Middle Aged; Olmesartan Medoxomil; Prognosis; Radioimmunoassay; Reference Values; Renin; Renin-Angiotensin System; Single-Blind Method; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2007 |
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Tetrazoles; Valine; Valsartan | 2007 |
[The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Female; Genetic Predisposition to Disease; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Tetrazoles; Time Factors; Transforming Growth Factor beta1; Treatment Outcome; Valine; Valsartan | 2007 |
[Intensive blood pressure reduction in patients with increased cardiovascular risk with high-dose combination therapy of 160 mg valsartan plus 25 mg hydrochlorothiazide. Results of the MACHT II observational study].
Topics: Antihypertensive Agents; Death, Sudden, Cardiac; Drug Administration Schedule; Drug Therapy, Combination; Female; Germany; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Risk Assessment; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
Topics: Adult; Amides; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Fumarates; Humans; Male; Renin; Sodium; Tetrazoles; Valine; Valsartan | 2007 |
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; Female; Glomerular Filtration Rate; Hemorheology; Humans; Insulin Resistance; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Proteinuria; Ramipril; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Vasodilation | 2007 |
Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Comorbidity; Coronary Artery Disease; Disease Progression; Double-Blind Method; Exercise Test; Female; Fluorescein Angiography; Health Status Indicators; Heart Diseases; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Pilot Projects; Predictive Value of Tests; Tetrazoles; Valine; Valsartan | 2007 |
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Female; Humans; Hypertension; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diastole; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Male; Middle Aged; Obesity; Placebos; Single-Blind Method; Systole; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Angiotensin receptor blocker improves coronary flow velocity reserve in hypertensive patients: comparison with calcium channel blocker.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Flow Velocity; Blood Pressure; Calcium Channel Blockers; Coronary Circulation; Echocardiography; Female; Humans; Hyperemia; Hypertension; Male; Middle Aged; Nifedipine; Tetrazoles; Valine; Valsartan | 2007 |
Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combination.
Topics: Benzimidazoles; Biphenyl Compounds; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Prospective Studies; Tetrazoles; Valine; Valsartan | 2007 |
Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination; Epidemiologic Methods; Female; Humans; Hydrochlorothiazide; Hypertension; Intercellular Adhesion Molecule-1; Male; Middle Aged; Tetrazoles; Valine; Valsartan; Vascular Cell Adhesion Molecule-1 | 2008 |
[Therapeutic efficacy of valsartan and valsartan/HCTZ in mild to moderate hypertensive patients].
Topics: Adult; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
Topics: Adamantane; Administration, Oral; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Half-Life; Headache; Humans; Male; Middle Aged; Nausea; Nitriles; Pyrrolidines; Ramipril; Tablets; Tetrazoles; Valine; Valsartan; Vildagliptin | 2008 |
Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Stenosis; Drug-Eluting Stents; Female; Humans; Hypertension; Immunosuppressive Agents; Interleukin-6; Male; Middle Aged; Single-Blind Method; Sirolimus; Telmisartan; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2007 |
Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; Endothelium, Vascular; Female; Forearm; Humans; Hyperemia; Hypertension; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cause of Death; Confidence Intervals; Creatinine; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Inflammation; Male; Middle Aged; Norepinephrine; Pulmonary Disease, Chronic Obstructive; Survival Rate; Tetrazoles; Treatment Outcome; Troponin T; Valine; Valsartan | 2007 |
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
Topics: Aged; Amiodarone; Captopril; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Severity of Illness Index; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction | 2008 |
A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Brachial Artery; Carotid Arteries; Dose-Response Relationship, Drug; Double-Blind Method; Elasticity; Endothelium, Vascular; Female; Humans; Hypertension; Male; Metoprolol; Middle Aged; Sympathetic Nervous System; Tetrazoles; Tunica Intima; Tunica Media; Ultrasonography; Valine; Valsartan | 2008 |
Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2008 |
[Influence of valsartan, fluvastatin extended release and their combination on arterial pressure, parameters of lipid metabolism, and endothelial function in patients with hypertensive disease].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cholesterol; Delayed-Action Preparations; Endothelium, Vascular; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2007 |
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Drug Therapy, Combination; Female; Humans; Hypertension; Incidence; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Retreatment; Tetrazoles; Valine; Valsartan | 2008 |
Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cholesterol; Enalapril; Female; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Prospective Studies; Severity of Illness Index; Tetrazoles; Uric Acid; Valine; Valsartan | 2008 |
Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Proteinuria; Tetrazoles; Valine; Valsartan | 2007 |
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hypertension; Male; Middle Aged; Propafenone; Prospective Studies; Secondary Prevention; Tetrazoles; Valine; Valsartan | 2008 |
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Creatinine; Diabetes Complications; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
Valsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary results.
Topics: 3-Iodobenzylguanidine; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Data Interpretation, Statistical; Endpoint Determination; Female; Follow-Up Studies; Humans; Hypertension; Informed Consent; Male; Middle Aged; Patient Selection; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Research Design; Risk Factors; Sample Size; Tetrazoles; Ultrasonography; Valine; Valsartan | 2008 |
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Adult; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Sex Factors; Smoking; Survivors; Tetrazoles; Valine; Valsartan | 2008 |
Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Topics: Administration, Inhalation; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Double-Blind Method; Female; Humans; Hypertension; Kidney; Kidney Diseases; Male; Middle Aged; Prospective Studies; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2008 |
Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Sex Factors; Stents; Tetrazoles; Valine; Valsartan | 2008 |
Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Asian People; Biomarkers; Blood Pressure; Brachial Artery; Calcium Channel Blockers; Deoxyguanosine; Dinoprost; Endothelium, Vascular; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Regional Blood Flow; Tetrazoles; Valine; Valsartan; Vasodilation | 2008 |
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 2008 |
Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2008 |
Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Blockers; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypertension; Incidence; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4).
Topics: Aged; Antihypertensive Agents; Blood Pressure; Canada; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Patient Compliance; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Cross-Over Studies; Female; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
[Valsartan improves symptoms and quality of life in patients with chronic heart failure].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Data Interpretation, Statistical; Diastole; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Outpatients; Practice Guidelines as Topic; Prospective Studies; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2008 |
Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTAT
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Chi-Square Distribution; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Least-Squares Analysis; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Double-Blind Method; Electrocardiography; Female; Humans; Male; Peptide Fragments; Procollagen; Ramipril; Recurrence; Tetrazoles; Valine; Valsartan | 2008 |
Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years.
Topics: Administration, Oral; Age Factors; Angiotensin II Type 1 Receptor Blockers; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Infant; Male; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Diuretics; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Follow-Up Studies; Humans; Hypertension; Middle Aged; Multivariate Analysis; Regression Analysis; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Female; Humans; Incidence; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2008 |
Achieving BP goals with valsartan and HCTZ alone and in combination: pooled analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Placebos; Retrospective Studies; Tetrazoles; Valine; Valsartan | 2008 |
Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hypertension, Renal; Lisinopril; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2008 |
Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART).
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2008 |
Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Asian People; Blood Pressure; China; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
Effect of systemic administration of valsartan, an angiotensin II type 1 receptor blocker, on retinal circulation in healthy humans.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Arterioles; Blood Flow Velocity; Blood Pressure; Humans; Intraocular Pressure; Male; Regional Blood Flow; Retinal Vessels; Tetrazoles; Valine; Valsartan; Young Adult | 2009 |
Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Hypertension; Japan; Male; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2009 |
[Effect of valsartan on postprandial plasma inflammatory factors in patients with essential hypertension].
Topics: Adult; Aged; Antihypertensive Agents; C-Reactive Protein; Dietary Fats; Female; Humans; Hypertension; Male; Middle Aged; P-Selectin; Tetrazoles; Triglycerides; Valine; Valsartan | 2008 |
Initial combination therapy compared with monotherapy in diabetic hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Determining the most appropriate components for a composite clinical trial outcome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cyclohexanes; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Research Design; Tetrazoles; Valine; Valsartan | 2008 |
Evidence for abundant presence of chymase-positive mast cells in the kidneys of patients with immunoglobulin A nephropathy: effect of combination therapy with prednisolone and angiotensin II receptor blocker valsartan.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Antihypertensive Agents; Biopsy; Chymases; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Humans; Kidney; Linear Models; Male; Mast Cells; Prednisolone; Renal Circulation; Severity of Illness Index; Tetrazoles; Ultrasonography, Doppler; Valine; Valsartan | 2008 |
Renal hemodynamics and renoprotection.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Female; Humans; Hypertension, Renal; Male; Middle Aged; Proteinuria; Renal Circulation; Renin; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hypertension; Insulin; Male; Middle Aged; Obesity; Overweight; Prospective Studies; Tetrazoles; Valine; Valsartan | 2008 |
Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hypertension; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Tetrazoles; Valine; Valsartan | 2008 |
Long-term treatment with valsartan improved cyclic variation of the myocardial integral backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Echocardiography; Female; Fibrosis; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardium; Prospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
Topics: Aged; Amides; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Fumarates; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2008 |
[Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Humans; Hypertension; Irbesartan; Kidney Diseases; Tetrazoles; Valine; Valsartan | 2008 |
Therapeutic effect of Tripterygium wilfordii on proteinuria associated with sirolimus in renal transplant recipients.
Topics: Adult; Antihypertensive Agents; China; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Plant Extracts; Proteinuria; Sirolimus; Tetrazoles; Tripterygium; Valine; Valsartan; Young Adult | 2008 |
Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Metabolic Syndrome; Middle Aged; Prediabetic State; Risk Factors; Tetrazoles; Valine; Valsartan; Young Adult | 2008 |
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atherosclerosis; Cause of Death; Confidence Intervals; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Prognosis; Proportional Hazards Models; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Survival Rate; Tetrazoles; Time Factors; Valine; Valsartan | 2009 |
Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension.
Topics: Administration, Oral; Adolescent; Age Factors; Antihypertensive Agents; Area Under Curve; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Infant; Male; Tetrazoles; Valine; Valsartan | 2009 |
Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy.
Topics: Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Single-Blind Method; Tetrazoles; Valine; Valsartan | 2009 |
Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Cohort Studies; Drug Combinations; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Patient Compliance; Prospective Studies; Tetrazoles; Valine; Valsartan | 2009 |
The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg.
Topics: Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Edema; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Resistance; Drug Therapy, Combination; Felodipine; Female; Humans; Hypertension; Male; Middle Aged; Ramipril; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Long-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension study.
Topics: Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Placebos; Tetrazoles; Valine; Valsartan | 2009 |
Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.
Topics: Alanine Transaminase; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Aspartate Aminotransferases; Benzimidazoles; Benzoates; Blood Pressure; Fatty Liver; Female; Humans; Hypertension; Liver Function Tests; Male; Middle Aged; Patient Selection; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Japan; Losartan; Male; Middle Aged; Prospective Studies; Sodium; Sodium, Dietary; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan.
Topics: Adult; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Carotid Arteries; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Tetrazoles; Thiazides; Valine; Valsartan | 2009 |
Effect of nicorandil on proteinuria in well controlled hypertensive patients.
Topics: Aged; Antihypertensive Agents; Case-Control Studies; Creatinine; Diuretics, Osmotic; Double-Blind Method; Endothelin-1; Female; Humans; Isosorbide; Male; Middle Aged; Nicorandil; Prospective Studies; Proteinuria; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2009 |
Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Medication Adherence; Middle Aged; Tetrazoles; Valine; Valsartan | 2009 |
Augmented sympathoinhibitory effect of valsartan when added to angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteries; Baroreflex; Drug Synergism; Enalapril; Female; Heart; Hemodynamics; Humans; Lung; Male; Middle Aged; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2009 |
Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Natriuretic Peptides; Peritoneal Dialysis, Continuous Ambulatory; Pulse; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2009 |
Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asian People; Disease Progression; Female; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study).
Topics: Aged; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Linear Models; Logistic Models; Male; Middle Aged; Outcome Assessment, Health Care; Patient Compliance; Practice Patterns, Physicians'; Professional Competence; Tetrazoles; Time Factors; Valine; Valsartan | 2009 |
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Europe; Female; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Recurrence; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography; United States; Valine; Valsartan; Ventricular Remodeling | 2008 |
Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension.
Topics: Adult; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Racial Groups; Sex Factors; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Valsartan for prevention of recurrent atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Cardiomegaly; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double-Blind Method; Female; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recurrence; Tetrazoles; Valine; Valsartan | 2009 |
Pretreatment levels of plasma renin activity predict ambulatory blood pressure response to valsartan in essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Humans; Hypertension; Japan; Predictive Value of Tests; Prospective Studies; Radioimmunoassay; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Effect of valsartan on left ventricular anatomy and systolic function and aortic elasticity.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Aorta; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Young Adult | 2009 |
Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Autonomic Nervous System; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Circadian Rhythm; Dose-Response Relationship, Drug; Female; Health Surveys; Heart Rate; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Quality of Life; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Female; Heart; Heart Transplantation; Humans; Hypertension; Male; Middle Aged; Myocardium; Potassium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Signal Transduction; Tetrazoles; Valine; Valsartan | 2009 |
Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Single-Blind Method; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Fumarates; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2009 |
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Female; Gastrointestinal Hemorrhage; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2009 |
Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Chemical Analysis; Blood Pressure; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Forearm; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Nitric Oxide Donors; Nitric Oxide Synthase Type III; Nitroprusside; omega-N-Methylarginine; Regional Blood Flow; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2009 |
Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Hypertension; Kaplan-Meier Estimate; Male; Prospective Studies; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Placebos; Tetrazoles; Treatment Failure; Treatment Outcome; Valine; Valsartan | 2009 |
Evaluation of arterial stiffness in morning hypertension under high-dose valsartan compared to valsartan plus low-dose diuretic.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Ankle Brachial Index; Blood Flow Velocity; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Pulsatile Flow; Tetrazoles; Trichlormethiazide; Valine; Valsartan | 2009 |
A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Exercise Tolerance; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Diseases; Male; Middle Aged; Proteinuria; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria.
Topics: Adolescent; Adult; Aged; Albuminuria; Antihypertensive Agents; Black or African American; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult | 2010 |
Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics.
Topics: Administration, Oral; Adult; Chlorthalidone; Chromatography, High Pressure Liquid; Cross-Over Studies; Female; Humans; Hydrochlorothiazide; Losartan; Male; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tetrazoles; Therapeutic Equivalency; Valine; Valsartan | 2009 |
Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
Topics: Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Area Under Curve; Biological Availability; Blood Pressure; Chromatography, Liquid; Cross-Over Studies; Drugs, Generic; Europe; Female; Humans; Legislation, Drug; Male; Middle Aged; Tablets; Tandem Mass Spectrometry; Tetrazoles; Therapeutic Equivalency; Valine; Valsartan; Young Adult | 2009 |
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Death, Sudden, Cardiac; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Recurrence; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2010 |
Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; South America; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2009 |
Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Heart Rate; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Quality of Life; Sympathetic Nervous System; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety.
Topics: Adolescent; Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Tetrazoles; Valine; Valsartan | 2009 |
Influence of ATII blockers and calcium channel blockers on renal vascular resistance in patients with essential hypertension.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Croatia; Female; Humans; Hypertension; Hypertension, Renovascular; Kidney; Male; Middle Aged; Regression Analysis; Tetrazoles; Ultrasonography, Doppler, Duplex; Valine; Valsartan; Vascular Resistance | 2009 |
Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Imidazoles; Irbesartan; Kidney Tubules; Losartan; Single-Blind Method; Tetrazoles; Valine; Valsartan | 2010 |
Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Chronic Disease; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Proteinuria; Ramipril; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
A comparative study of the renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Proteinuria; Renal Circulation; Tetrazoles; Valine; Valsartan | 2009 |
[Efficacy and safety of the single pill combination of valsartan 80 mg plus amlodipine 5 mg in mild to moderate essential hypertensive patients without adequate blood pressure control by monotherapy].
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2009 |
[Impact of antihypertensive medication timing on degree and stability of blood pressure lowering in patients with essential hypertension].
Topics: Antihypertensive Agents; Blood Pressure; Drug Administration Schedule; Drug Therapy, Combination; Felodipine; Humans; Hypertension; Tetrazoles; Valine; Valsartan | 2009 |
Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Ankle Joint; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Drug Therapy, Combination; Edema; Female; Heart Rate; Humans; Hypertension; Imidazoles; Male; Middle Aged; Norepinephrine; Prospective Studies; Tetrazoles; Valine; Valsartan | 2010 |
Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Area Under Curve; Benzimidazoles; Benzoates; Biphenyl Compounds; Drug Interactions; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Placebo Effect; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2010 |
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patient Selection; Phenylalanine; Prediabetic State; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Treatment Failure; Valine; Valsartan | 2010 |
Effect of valsartan on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine.
Topics: Adult; Aged; Amlodipine; Anthracenes; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2010 |
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; Neprilysin; Tetrazoles; Valine; Valsartan | 2010 |
Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Humans; Intestinal Absorption; Male; Tablets; Tetrazoles; Therapeutic Equivalency; Valine; Valsartan; Young Adult | 2010 |
Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Indoles; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling | 2010 |
[Renal protective effects of benidipine and valsartan in primary hypertension patients with proteinuria].
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Calcium Channel Blockers; Dihydropyridines; Female; Glomerular Filtration Rate; Humans; Hypertension; Male; Middle Aged; Proteinuria; Tetrazoles; Valine; Valsartan | 2010 |
Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.
Topics: Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Drugs, Generic; Half-Life; Humans; India; Least-Squares Analysis; Male; Tablets; Tetrazoles; Therapeutic Equivalency; Valine; Valsartan; Young Adult | 2010 |
Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Probability; Prospective Studies; Severity of Illness Index; Single-Blind Method; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult | 2010 |
Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Diabetes Complications; Humans; Hypertension; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2010 |
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; C-Reactive Protein; Calcium Channel Blockers; Chi-Square Distribution; Cytokine TWEAK; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Serum Amyloid P-Component; Tetrazoles; Time Factors; Treatment Outcome; Tumor Necrosis Factors; Turkey; Valine; Valsartan; Vasodilation | 2010 |
Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Diuretics; Electrophysiologic Techniques, Cardiac; Female; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Recurrence; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Role of RAS inhibition in the regulation of Cu/Zn-SOD in the cardiac and peripheral arterial beds in humans.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Renin-Angiotensin System; Superoxide Dismutase; Tetrazoles; Valine; Valsartan | 2010 |
Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Female; Humans; Hypertension; Male; Middle Aged; Risk Reduction Behavior; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Amlodipine; Antihypertensive Agents; Asian People; Double-Blind Method; Drug Combinations; Drug Resistance; Female; Humans; Hypertension; Male; Middle Aged; Tablets; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult | 2010 |
Effects of combined therapy of Xuezhikang Capsule and Valsartan on hypertensive left ventricular hypertrophy and heart rate turbulence.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Capsules; Combined Modality Therapy; Drug Combinations; Drugs, Chinese Herbal; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Hypolipidemic Agents; Integrative Medicine; Male; Medicine, Chinese Traditional; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypertension; Insulin Resistance; Lipids; Male; Middle Aged; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Mass Index; Calcium Channel Blockers; Diuretics; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; Hydrochlorothiazide; Hypertension; Insulin; Male; Middle Aged; Obesity; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
[NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
Topics: Angiotensin II Type 1 Receptor Blockers; Belgium; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Contribution of bradykinin B2 receptors to the inhibition by valsartan of systemic and renal effects of exogenous angiotensin II in salt-repleted humans.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Bradykinin; Bradykinin B2 Receptor Antagonists; Female; Glomerular Filtration Rate; Humans; Indicators and Reagents; Inulin; Kidney; Male; p-Aminohippuric Acid; Receptor, Bradykinin B2; Renal Circulation; Sodium; Tetrazoles; Valine; Valsartan | 2010 |
Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea.
Topics: Angiotensin II Type 1 Receptor Blockers; Comorbidity; Continuous Positive Airway Pressure; Cross-Over Studies; Female; Humans; Hypertension; Intention to Treat Analysis; Male; Middle Aged; Sleep Apnea, Obstructive; Tetrazoles; Valine; Valsartan | 2010 |
Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Male; Medical History Taking; Patient Selection; Proportional Hazards Models; Reference Values; Stroke; Systole; Tetrazoles; Valine; Valsartan | 2010 |
Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Interleukin-6; Lipids; Male; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2010 |
Use of automated blood pressure measurements in clinical trials and registration studies: data from the VALTOP Study.
Topics: Adult; Automation; Blood Pressure Determination; Clinical Trials as Topic; Female; Humans; Hypertension; Male; Observer Variation; Reproducibility of Results; Sphygmomanometers; Tetrazoles; Valine; Valsartan | 2010 |
Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; beta 2-Microglobulin; Blood Pressure; Blood Urea Nitrogen; Collagen Type IV; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Kidney; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2010 |
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.
Topics: Acute Coronary Syndrome; Aged; Amides; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Female; Fumarates; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2010 |
Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Benzopyrans; Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nebivolol; Polysomnography; Sleep Apnea Syndromes; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Female; Follow-Up Studies; Heart Failure; Heart Rupture, Post-Infarction; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2010 |
Gender-specific, multi-level determinants of outcomes of antihypertensive treatment: a sub-analysis of the Belgian PREVIEW study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Belgium; Blood Pressure; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Patients; Physicians; Prospective Studies; Sex Characteristics; Tetrazoles; Treatment Failure; Treatment Outcome; Valine; Valsartan | 2011 |
Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Circadian Rhythm; Drug Chronotherapy; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Sleep; Tetrazoles; Valine; Valsartan | 2010 |
Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Comorbidity; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2010 |
Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; C-Reactive Protein; Female; Humans; Hypertension; Male; Middle Aged; Osteopontin; Tetrazoles; Valine; Valsartan | 2011 |
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Pressure; Chi-Square Distribution; Chronic Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Kidney Diseases; Lipids; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2010 |
Effectiveness and safety of high-dose valsartan monotherapy in hypertension treatment: the ValTop study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Female; Hawaii; Humans; Hypertension; Imidazoles; Imidazolidines; Kidney; Kidney Diseases; Male; Middle Aged; Proteinuria; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2010 |
Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Creatinine; Cystatin C; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Potassium; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
[Clinical evaluation of valsartan on portal hypertension in patients with hepatic cirrhosis].
Topics: Female; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Tetrazoles; Valine; Valsartan | 2010 |
Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension.
Topics: Adolescent; Adult; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2011 |
Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Biomarkers; Diabetic Angiopathies; Female; Growth Differentiation Factor 15; Heart Failure; Humans; Hypertension; Male; Middle Aged; Placebos; Prognosis; Regression Analysis; Risk Assessment; Risk Factors; Severity of Illness Index; Tetrazoles; Valine; Valsartan | 2010 |
Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Female; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Biomarkers; Epidemiologic Methods; Female; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptides; Prognosis; Secondary Prevention; Tetrazoles; Troponin T; Valine; Valsartan | 2011 |
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
Topics: Age Factors; Aged; Captopril; Cause of Death; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Recurrence; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2011 |
Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Tetrazoles; Valine; Valsartan | 2011 |
24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Drug Combinations; Ethnicity; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Racial Groups; Regression Analysis; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amides; Antihypertensive Agents; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Fumarates; Humans; Hydrochlorothiazide; Hypertension; Incidence; Male; Middle Aged; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Young Adult | 2010 |
Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender.
Topics: Adolescent; Adult; Age Factors; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Male; Middle Aged; Prospective Studies; Sex Characteristics; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult | 2010 |
Rationale and design of a trial on the effect of angiotensin II receptor blockers on the function of the systemic right ventricle.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Female; Follow-Up Studies; Heart Atria; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Stroke Volume; Tetrazoles; Tomography, X-Ray Computed; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Right; Ventricular Function, Right | 2010 |
Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Aged; Biomarkers; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Predictive Value of Tests; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Evaluation of dosing time-related anti-hypertensive efficacy of valsartan in patients with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2011 |
Optimising management of hypertension in primary care: the Valsartan Intensified Primary Care Reduction of Blood Pressure (Viper-Bp) study.
Topics: Blood Pressure; Cohort Studies; Data Collection; Disease Management; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Pilot Projects; Primary Health Care; Tetrazoles; Valine; Valsartan | 2011 |
Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Bangladesh; Blood Pressure; Blood Pressure Monitoring, Ambulatory; China; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Egypt; Female; Heart Rate; Humans; Hypertension; Malaysia; Male; Middle Aged; Pakistan; Product Surveillance, Postmarketing; Russia; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2011 |
Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets).
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; C-Reactive Protein; Diabetes Complications; Female; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2011 |
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
Topics: Adult; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Oxadiazoles; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial.
Topics: Angiotensin Receptor Antagonists; Blood Glucose; Double-Blind Method; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2011 |
Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Brachial Artery; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Prognosis; Prospective Studies; Tetrazoles; Valine; Valsartan; Vascular Resistance; Vascular Stiffness; Vasodilation | 2011 |
Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
Topics: Adiponectin; Age Factors; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Drug Substitution; Drug Therapy, Combination; Female; Humans; Hypertension; Japan; Male; Prospective Studies; Telmisartan; Tetrazoles; Time Factors; Treatment Outcome; Up-Regulation; Valine; Valsartan | 2011 |
Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy--sub-analysis of the KYOTO HEART study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Risk Factors; Tetrazoles; Valine; Valsartan | 2011 |
Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Calcium Channel Blockers; China; Double-Blind Method; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypertension; Korea; Male; Middle Aged; Tetrazoles; Thailand; Treatment Outcome; Valine; Valsartan; Young Adult | 2011 |
Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial.
Topics: Adult; Africa South of the Sahara; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Black People; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diuretics; Drug Combinations; Female; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Male; Methyldopa; Middle Aged; Research Design; Risk Factors; Tetrazoles; Valine; Valsartan | 2011 |
Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Headache; Humans; Hypertension; Incidence; Longitudinal Studies; Male; Prospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Beneficial effects of valsartan on target lesion revascularization after percutaneous coronary interventions with bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Coronary Artery Disease; Coronary Restenosis; Dose-Response Relationship, Drug; Endpoint Determination; Female; Follow-Up Studies; Humans; Japan; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Prospective Studies; Stents; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antigens, CD34; Apoptosis; Bone Marrow Cells; Case-Control Studies; Cells, Cultured; Endothelial Cells; Female; Humans; Male; Middle Aged; Myocardial Infarction; Perindopril; Single-Blind Method; Stem Cells; Tetrazoles; Umbilical Veins; Valine; Valsartan | 2011 |
[Antihypertensive and nephroprotective effectiveness of AT1-angiotensin II receptor blocker valsartan in average therapeutic and maximal daily dose in patients with arterial hypertension and chronic kidney disease].
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Chronic Disease; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Hypertension; Kidney; Kidney Diseases; Male; Middle Aged; Receptor, Angiotensin, Type 1; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan; Vascular Resistance | 2011 |
[The Shiga Microalbuminuria Reduction Trial].
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Middle Aged; Prospective Studies; Rats; Tetrazoles; Valine; Valsartan | 2010 |
Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.
Topics: Adiponectin; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Benzimidazoles; Benzoates; C-Reactive Protein; Coronary Stenosis; Diabetes Mellitus, Type 2; Disease Progression; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Hypertension; Interleukin-6; Male; Middle Aged; Neointima; Prospective Studies; Single-Blind Method; Sirolimus; Telmisartan; Tetrazoles; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Ultrasonography, Interventional; Valine; Valsartan | 2011 |
Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; Female; Glucose; Glucose Tolerance Test; Humans; Hyperinsulinism; Hypertension; Insulin Resistance; Male; Obesity; Telmisartan; Tetrazoles; Valine; Valsartan | 2011 |
Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Tetrazoles; Valine; Valsartan | 2011 |
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
Topics: Age Factors; Aged; Antihypertensive Agents; Benzimidazoles; Biological Availability; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypertension; Male; Middle Aged; Oxadiazoles; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Chronic Disease; Combined Modality Therapy; Cross-Over Studies; Diet, Sodium-Restricted; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Kidney Diseases; Lisinopril; Male; Middle Aged; Patient Compliance; Proteinuria; Sodium Chloride, Dietary; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXA
Topics: Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Treatment Outcome; United States; Valine; Valsartan | 2011 |
Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Prospective Studies; Sleep; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Incidence; Italy; Male; Prognosis; Prospective Studies; Recurrence; Tetrazoles; Valine; Valsartan | 2011 |
Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2011 |
Valsartan-induced improvement in insulin sensitivity is not paralleled by changes in microvascular function in individuals with impaired glucose metabolism.
Topics: Adipokines; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Capillaries; Cytokines; Diabetes Mellitus, Type 2; Female; Humans; Inflammation Mediators; Insulin Resistance; Male; Microvessels; Middle Aged; Tetrazoles; Valine; Valsartan | 2011 |
[Efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Combinations; Drug Monitoring; Drug Synergism; Female; Humans; Hypertension; Inpatients; Male; Medication Adherence; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy.
Topics: Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Atrial Function, Left; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Echocardiography, Doppler; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recovery of Function; Risk Assessment; Secondary Prevention; Severity of Illness Index; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Reduction of age-associated arterial wall changes by low-dose valsartan.
Topics: Adult; Age Factors; Aging; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Brachial Artery; Carotid Artery, Common; Double-Blind Method; Heart Rate; Humans; Male; Pulse Wave Analysis; Slovenia; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography; Valine; Valsartan; Vascular Diseases; Vascular Stiffness; Vasodilation | 2012 |
Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: ValVET primary results.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Obesity; Office Visits; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
The efficacy and safety of valsartan in obese and non-obese pediatric hypertensive patients.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Child; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; International Cooperation; Male; Obesity; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
[Comparative effects of nebivolol and valsartan on atrial electromechanical coupling in newly diagnosed stage 1 hypertensive patients].
Topics: Antihypertensive Agents; Atrial Fibrillation; Benzopyrans; Echocardiography, Doppler; Ethanolamines; Female; Humans; Hypertension; Male; Middle Aged; Nebivolol; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Cause of Death; Creatinine; Death, Sudden; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: ancillary results of the KYOTO HEART Study.
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Female; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2012 |
Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Child; Drug-Related Side Effects and Adverse Reactions; Enalapril; Female; Humans; Hypertension; Male; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
[Effects of benazepril and valsartan on erythropoietin levels in patients with essential hypertension].
Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Erythropoietin; Female; Hemoglobins; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2011 |
The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Clinical Protocols; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Sample Size; Single-Blind Method; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cross-Over Studies; Diuretics; Drug Interactions; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2011 |
Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Cholesterol; Female; Humans; Hydrochlorothiazide; Hypertension; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Tetrazoles; Triglycerides; Valine; Valsartan | 2013 |
[Comparative efficacy of original and generic valsartan arterial hypertension].
Topics: Antihypertensive Agents; Blood Pressure; Drug Monitoring; Drugs, Generic; Female; Humans; Hypertension; Male; Middle Aged; Risk Factors; Severity of Illness Index; Single-Blind Method; Tetrazoles; Therapeutic Equivalency; Treatment Outcome; Valine; Valsartan | 2011 |
Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.
Topics: Adult; Amlodipine; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Pressure; Cyclosporine; Cytochrome P-450 CYP3A; Double-Blind Method; Drug Interactions; Female; Genotype; Humans; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Male; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Prospective Studies; Tetrazoles; Valine; Valsartan | 2011 |
Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Coagulation; CD40 Ligand; Cross-Over Studies; Cytokines; Double-Blind Method; Female; Hemodynamics; Humans; Inflammation; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Ramipril; Renal Dialysis; Renin; Tetrazoles; Valine; Valsartan | 2012 |
Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2011 |
Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study.
Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypertension; Japan; Male; Middle Aged; Morbidity; Prospective Studies; Risk Factors; Survival Rate; Tetrazoles; Valine; Valsartan | 2012 |
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Black or African American; Blood Glucose; Diuretics; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hyperglycemia; Hypertension; Insulin; Intention to Treat Analysis; Male; Middle Aged; Obesity, Abdominal; Prediabetic State; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People | 2013 |
Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Humans; Hypertension; Imidazoles; Japan; Losartan; Male; Middle Aged; Prospective Studies; Telmisartan; Tetrazoles; Valine; Valsartan | 2012 |
Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
Topics: Adult; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Simvastatin; Sodium-Glucose Transporter 2 Inhibitors; Tetrazoles; Valine; Valsartan; Warfarin | 2012 |
31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients.
Topics: Adult; Angiotensin Receptor Antagonists; Female; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Magnetic Resonance Spectroscopy; Male; Middle Aged; Phosphates; Tetrazoles; Valine; Valsartan | 2012 |
Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction.
Topics: Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Disease Progression; Echocardiography, Doppler, Color; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Monitoring, Physiologic; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Reference Values; Reproducibility of Results; Risk Assessment; ROC Curve; Severity of Illness Index; Sex Factors; Statistics, Nonparametric; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2012 |
Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity.
Topics: Age Factors; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Renin; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan | 2012 |
Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study).
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Incidence; Japan; Male; Prospective Studies; Risk Factors; Stroke; Survival Rate; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2012 |
Efficacy and safety of valsartan in hypertensive Taiwanese patients: post-marketing surveillance study.
Topics: Aged; Antihypertensive Agents; Asian People; Blood Pressure; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypertension; Male; Middle Aged; Product Surveillance, Postmarketing; Taiwan; Tetrazoles; Valine; Valsartan | 2011 |
Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2012 |
The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial.
Topics: Adult; Aging; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Blood Flow Velocity; Brachial Artery; Carotid Arteries; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pulsatile Flow; Tetrazoles; Valine; Valsartan; Vascular Stiffness | 2012 |
Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Humans; Kidney; Middle Aged; Prospective Studies; Proteinuria; Ramipril; Tetrazoles; Valine; Valsartan | 2011 |
Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers.
Topics: Adult; Antihypertensive Agents; Cross-Over Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Quinolines; Reference Values; Republic of Korea; Tetrazoles; Valine; Valsartan | 2012 |
[Series: Clinical study from Japan and its reflections; KYOTO HEART study].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Humans; Hypertension; Japan; Prospective Studies; Research Design; Tetrazoles; Valine; Valsartan | 2012 |
Effects of valsartan on fibrinolysis in hypertensive patients with metabolic syndrome.
Topics: Adipocytes; Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Apolipoproteins E; Biomarkers; Cardiovascular Diseases; Disease Models, Animal; Female; Fibrinolysis; Humans; Hypertension; Japan; Male; Metabolic Syndrome; Mice; Mice, Knockout; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2012 |
Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Captopril; Chi-Square Distribution; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hypertrophy, Left Ventricular; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Prospective Studies; Renin-Angiotensin System; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Valine; Valsartan | 2012 |
[Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients].
Topics: Aged; Amlodipine; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Ramipril; Tetrazoles; Valine; Valsartan | 2012 |
Effects of exercise therapy alone and in combination with a calcium channel blocker or an angiotensin receptor blocker in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Therapy, Combination; Exercise Therapy; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Female; Humans; Hypertension; Insulin Resistance; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; PPAR gamma; Subcutaneous Fat; Telmisartan; Tetrazoles; Tomography, X-Ray Computed; Treatment Outcome; Valine; Valsartan; Waist Circumference | 2013 |
Amlodipine/valsartan 5/160 mg versus valsartan 160 mg in Chinese hypertensives.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Asian People; Blood Pressure; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2013 |
Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Area Under Curve; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Dinoprost; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Humans; Hypertension; Insulin; Insulin Resistance; Irbesartan; Luminescent Measurements; Male; Middle Aged; Oxidative Stress; Radioligand Assay; Receptors, Angiotensin; Tetrazoles; Time Factors; Valine; Valsartan; Young Adult | 2013 |
Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial.
Topics: Adipocytes; Adipose Tissue; Antihypertensive Agents; Biomarkers; Blood Pressure; Capillaries; Cell Hypoxia; Cell Size; Chemotactic Factors; Double-Blind Method; Fasting; Female; Gene Expression Regulation; Glucose; Humans; Inflammation; Insulin; Lipolysis; Macrophages; Male; Middle Aged; Placebos; Postprandial Period; Tetrazoles; Valine; Valsartan | 2012 |
Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Topics: Aged; Albuminuria; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Prospective Studies; Taiwan; Tetrazoles; Time Factors; Treatment Outcome; Uric Acid; Valine; Valsartan | 2012 |
Post-marketing surveillance study of valsartan/amlodipine combination in Taiwanese hypertensive patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Blood Pressure; Female; Humans; Hypertension; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Taiwan; Tetrazoles; Time Factors; Valine; Valsartan | 2012 |
The effect of valsartan versus non-RAAS treatment on autoregulation of cerebral blood flow.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cerebrovascular Circulation; Female; Humans; Hypertension; Male; Middle Aged; Pulse Wave Analysis; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2012 |
Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise.
Topics: Adult; Aged; Amides; Arginine; Blood Pressure; Demography; Endpoint Determination; Exercise; Female; Fumarates; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Renin; Renin-Angiotensin System; Systole; Tetrazoles; Valine; Valsartan | 2013 |
Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin Receptor Antagonists; Biopterins; Blood Pressure; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Hemodynamics; Humans; Kidney; Male; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Receptors, Angiotensin; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2013 |
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valine; Valsartan | 2012 |
Efficacy and safety of valsartan in reducing blood pressure and albuminuria in Chinese patients with essential hypertension: a multicenter prospective open-label observational study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Asian People; Blood Pressure; China; Diabetes Complications; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2012 |
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Postmenopause; Pulse Wave Analysis; Tetrazoles; Valine; Valsartan; Vascular Stiffness | 2012 |
Efficacy of aliskiren and valsartan in hypertensive patients with albuminuria: a randomized parallel-group study.
Topics: Albuminuria; Amides; Antihypertensive Agents; Demography; Female; Fumarates; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Pulse Wave Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Improved blood pressure control with nifedipine GITS/valsartan combination versus high-dose valsartan monotherapy in mild-to-moderate hypertensive patients from Asia: results from the ADVISE study, a randomized trial.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Asian People; Blood Pressure; Comorbidity; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; Nifedipine; Prospective Studies; Tetrazoles; Valine; Valsartan; Young Adult | 2012 |
Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis.
Topics: Adult; Aged; Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Female; Fumarates; Humans; Hypertension; Hypertension, Renal; Male; Middle Aged; Nephritis; Nephrosclerosis; Tetrazoles; Valine; Valsartan | 2013 |
The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Female; Humans; Hypertension; Inflammation Mediators; Male; Middle Aged; Prospective Studies; Risk Factors; Serum Amyloid P-Component; Tetrazoles; Valine; Valsartan; Vasculitis | 2013 |
Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Blood Pressure; Comorbidity; Creatinine; Disease Progression; Female; Humans; Hypertension; Japan; Male; Middle Aged; Proteinuria; Renal Insufficiency, Chronic; Renal Replacement Therapy; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
An additional LDL-lowering effect of amlodipine; not only an antihypertensive?
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Essential Hypertension; Female; Humans; Hypertension; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Tetrazoles; Triglycerides; Valine; Valsartan | 2013 |
Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Exercise Tolerance; Female; Follow-Up Studies; Heart Defects, Congenital; Heart Ventricles; Humans; Magnetic Resonance Imaging; Male; Multidetector Computed Tomography; Outcome Assessment, Health Care; Pilot Projects; Quality of Life; Stroke Volume; Tetrazoles; Transposition of Great Vessels; Valine; Valsartan; Ventricular Dysfunction, Right | 2013 |
Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
Topics: Adult; Diet, Sodium-Restricted; Female; Humans; Lipoproteins; Lisinopril; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Proteinuria; Serine Endopeptidases; Tetrazoles; Valine; Valsartan | 2013 |
Effect of valsartan with bedtime dosing on chronic kidney disease patients with nondipping blood pressure pattern.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chi-Square Distribution; Drug Chronotherapy; Echocardiography; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; Calcium Channel Blockers; Essential Hypertension; Female; Humans; Hypertension; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prospective Studies; Tetrazoles; Valine; Valsartan; von Willebrand Factor | 2013 |
Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Galectin 3; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
Amlodipine seems to be superior to valsartan in decreasing microalbuminuria in newly diagnosed hypertensive patients: a novel effect to be explained with hyperfiltration?
Topics: Adult; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2013 |
Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Drug Substitution; Female; Heart Rate; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Prospective Studies; Telmisartan; Tetrazoles; Valine; Valsartan | 2013 |
Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus.
Topics: Aged; Amides; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Comorbidity; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Fumarates; Humans; Hypertension; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
Topics: Adiposity; Aged; Albuminuria; Biomarkers; Blood Glucose; Creatinine; Cyclohexanes; Double-Blind Method; Female; Glucose Metabolism Disorders; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Linear Models; Male; Middle Aged; Multivariate Analysis; Nateglinide; Nonlinear Dynamics; Obesity, Abdominal; Phenylalanine; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Waist Circumference | 2013 |
Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
Topics: Antihypertensive Agents; Biomarkers; Cyclohexanes; Diabetes Mellitus; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Potassium; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Child, Preschool; Double-Blind Method; Female; Humans; Hypertension; Infant; Male; Tetrazoles; Valine; Valsartan | 2013 |
The effects of long-term valsartan treatment on skeletal muscle fatty acid handling in humans with impaired glucose metabolism.
Topics: Angiotensin II Type 1 Receptor Blockers; Biopsy; Carbon Radioisotopes; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Forearm; Gene Expression Regulation; Glucose Metabolism Disorders; Humans; Lipid Metabolism; Male; Muscle Proteins; Muscle, Skeletal; Oxidation-Reduction; Postprandial Period; RNA, Messenger; Tetrazoles; Tritium; Valine; Valsartan | 2013 |
Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Double-Blind Method; Electrocardiography; Female; Fibrinolytic Agents; Guideline Adherence; Hemorrhage; Humans; Incidence; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Telemetry; Tetrazoles; Thromboembolism; Time Factors; Treatment Outcome; Valine; Valsartan; Warfarin | 2013 |
Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Combined Modality Therapy; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Humans; Hypertension; Image Interpretation, Computer-Assisted; Imidazoles; Long-Term Care; Male; Middle Aged; Tetrazoles; Ultrasonography, Interventional; Valine; Valsartan | 2013 |
Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arterial Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Continuous Positive Airway Pressure; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Manometry; Middle Aged; Polysomnography; Predictive Value of Tests; Pulse Wave Analysis; Risk Factors; Russia; Severity of Illness Index; Sleep Apnea, Obstructive; Tetrazoles; Treatment Outcome; Valine; Valsartan; Vascular Stiffness | 2013 |
Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Demography; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Valine; Valsartan; Young Adult | 2013 |
Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial.
Topics: Adult; Aged; Diabetic Nephropathies; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Male; Middle Aged; Phytotherapy; Plant Extracts; Prospective Studies; Tetrazoles; Treatment Outcome; Tripterygium; Valine; Valsartan | 2013 |
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Pharmacokinetic interactions of valsartan and hydrochlorothiazide: an open-label, randomized, 4-period crossover study in healthy Egyptian male volunteers.
Topics: Administration, Oral; Antihypertensive Agents; Cross-Over Studies; Drug Therapy, Combination; Egypt; Healthy Volunteers; Humans; Hydrochlorothiazide; Male; Patient Compliance; Tetrazoles; Valine; Valsartan | 2013 |
Efficacy of newer versus older antihypertensive drugs in black patients living in sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Amlodipine; Antihypertensive Agents; Bisoprolol; Black People; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Body Mass Index; Brachial Artery; C-Reactive Protein; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Phenotype; Pravastatin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Pharmacokinetic comparison of 2 fixed-dose combination tablets of amlodipine and valsartan in healthy male Korean volunteers: a randomized, open-label, 2-period, single-dose, crossover study.
Topics: Administration, Oral; Adult; Amlodipine; Asian People; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Healthy Volunteers; Humans; Male; Middle Aged; Tablets; Tetrazoles; Valine; Valsartan; Young Adult | 2013 |
Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients.
Topics: Acetaminophen; Adult; Aged; Amides; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Fumarates; Humans; Hypertension; Male; Middle Aged; Naproxen; Ramipril; Tetrazoles; Valine; Valsartan | 2013 |
Efficacy and safety of valsartan and amlodipine single-pill combination in hypertensive patients (PEAK study).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; Patient Compliance; Tetrazoles; Treatment Outcome; Turkey; Valine; Valsartan | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Female; Glucuronidase; Hospitals, University; Humans; Hydrochlorothiazide; Hypertension; Klotho Proteins; London; Male; Middle Aged; Phosphates; Pulse Wave Analysis; Renin-Angiotensin System; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Drug Administration Schedule; Essential Hypertension; Female; Headache; Humans; Hypertension; Korea; Male; Middle Aged; Pyrimidines; Republic of Korea; Tetrazoles; Valine; Valsartan; Young Adult | 2013 |
Determinants of achieving early blood pressure control with monotherapy in a primary care setting.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Disease Management; Female; Humans; Hypertension; Male; Middle Aged; Primary Health Care; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Chemical Analysis; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; Endpoint Determination; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Sleep; Telmisartan; Tetrazoles; Valine; Valsartan | 2014 |
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Atrial Fibrillation; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2013 |
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Echocardiography, Doppler, Color; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Neprilysin; Prognosis; Prospective Studies; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2014 |
Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antioxidants; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Humans; Male; Middle Aged; Probucol; Tetrazoles; Valine; Valsartan | 2014 |
Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Pulse Wave Analysis; Tetrazoles; Valine; Valsartan; Vascular Stiffness | 2014 |
Intranasal angiotensin II in humans reduces blood pressure when angiotensin II type 1 receptors are blocked.
Topics: Administration, Intranasal; Adult; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Humans; Hydrocortisone; Male; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers.
Topics: Administration, Oral; Adult; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Humans; Male; Republic of Korea; Tablets; Tetrazoles; Therapeutic Equivalency; Valine; Valsartan; Young Adult | 2014 |
Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Female; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Receptors, Cell Surface; Regression Analysis; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Female; Glomerular Filtration Rate; Heart Atria; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
More rigorous protocol adherence to intensive structured management improves blood pressure control in primary care: results from the Valsartan Intensified Primary carE Reduction of Blood Pressure study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Female; Humans; Hypertension; Male; Middle Aged; Patient Compliance; Primary Health Care; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2014 |
Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzopyrans; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Ethanolamines; Female; Humans; Hypertension; Male; Middle Aged; Nebivolol; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult | 2014 |
Randomized trial comparing the effects of a low-dose combination of nifedipine GITS and valsartan versus high-dose monotherapy on central hemodynamics in patients with inadequately controlled hypertension: FOCUS study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension; Male; Manometry; Middle Aged; Nifedipine; Prospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult | 2014 |
Effect of add-on aliskiren to type 1 angiotensin receptor blocker therapy on endothelial function and autonomic nervous system in hypertensive patients with ischemic heart disease.
Topics: Aged; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Autonomic Nervous System; Comorbidity; Drug Therapy, Combination; Endothelium, Vascular; Female; Fumarates; Heart Rate; Humans; Hypertension; Male; Middle Aged; Myocardial Ischemia; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan; Vasodilation | 2014 |
[The influence of citoflavin on molecular mechanisms of hypertensive encephalopathy development in patients with systolic arterial hypertension].
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Atorvastatin; Blood Pressure; Blood Proteins; Drug Combinations; Drug Therapy, Combination; Echocardiography; Female; Flavin Mononucleotide; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Hypertensive Encephalopathy; Inosine Diphosphate; Male; Neuroprotective Agents; Niacinamide; Pyrroles; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Succinates; Systole; Tetrazoles; Valine; Valsartan | 2014 |
Inhibition of angiotensin-converting enzyme increases oestradiol production in ewes submitted to oestrous synchronization protocol.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Enalapril; Estradiol; Estrus Synchronization; Female; Sheep; Tetrazoles; Valine; Valsartan | 2014 |
Short-term administration of an angiotensin II receptor blocker in patients with long-term hemodialysis patients improves insulin resistance.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Glucose; Female; Humans; Insulin Resistance; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2014 |
[Optimization of arterial hypertension management by the use of two- and three-drugs fixed dose combinations at the daily stay department].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Day Care, Medical; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Drug Synergism; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Tetrazoles; Troponin T; Valine; Valsartan | 2014 |
[Treatment of stage 3b diabetic kidney disease patients with macroalbuminuria by qizhi jiangtang capsule: a multicenter randomized control clinical study].
Topics: Adult; Albumins; Albuminuria; Blood Pressure; Creatinine; Diabetic Nephropathies; Drugs, Chinese Herbal; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers.
Topics: Adult; Cross-Over Studies; Dihydropyridines; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Healthy Volunteers; Humans; Male; Tetrazoles; Valine; Valsartan; Young Adult | 2014 |
Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; China; Clopidogrel; Creatinine; Disease Progression; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Immunosuppressive Agents; Isoxazoles; Kidney; Leflunomide; Male; Platelet Aggregation Inhibitors; Proteinuria; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome; Valine; Valsartan | 2015 |
Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Endothelium, Vascular; Essential Hypertension; Female; Humans; Hypertension; Male; Middle Aged; Neoplasm Proteins; Proteoglycans; Tetrazoles; Valine; Valsartan | 2015 |
Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Confidence Intervals; Cyclohexanes; Female; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Prevalence; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan; Venous Thromboembolism | 2015 |
Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study.
Topics: Antihypertensive Agents; Benzopyrans; Drug Combinations; Ethanolamines; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Nebivolol; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Valsartan decreases platelet activity and arterial thrombotic events in elderly patients with hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Blood Platelets; Blotting, Western; Cell Line; Cyclooxygenase 2; Female; Humans; Hypertension; Male; Platelet Aggregation; Real-Time Polymerase Chain Reaction; Tetrazoles; Thrombosis; Thromboxane B2; Valine; Valsartan | 2015 |
Choice of Antihypertensive Combination Therapy Based on Daily Salt Intake.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Combinations; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Male; Metabolic Syndrome; Middle Aged; Potassium; Prospective Studies; Sodium; Sodium Chloride, Dietary; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2015 |
Comparative effects of valsartan plus cilnidipine or hydrochlorothiazide on nocturnal home blood pressure.
Topics: Antihypertensive Agents; Blood Pressure; Dihydropyridines; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2021 |
990 other study(ies) available for valsartan and valine
| Article | Year |
|---|---|
Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Glucose; Blood Pressure; Body Weight; Drug Tolerance; Glucose Intolerance; Hypertension; Insulin Resistance; Lipids; Rats; Rats, Inbred SHR; Tetrazoles; Valine; Valsartan | 1995 |
Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Diabetes Mellitus, Experimental; Glomerular Filtration Rate; Hemodynamics; Kinins; Male; Ramipril; Rats; Rats, Sprague-Dawley; Renal Circulation; Tetrazoles; Time Factors; Valine; Valsartan | 1995 |
Expression of components of the RAS during prolonged blockade at different levels in primates.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Animals; Antibodies, Monoclonal; Benzazepines; Blood Pressure; Callithrix; Female; Kidney; Liver; Male; Oligopeptides; Renin; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Time Factors; Valine; Valsartan | 1994 |
Characterization of contractile endothelin and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Azepines; Benzazepines; Bosentan; Endothelin Receptor Antagonists; Endothelins; Humans; In Vitro Techniques; Indoles; Mammary Arteries; Muscle Contraction; Plasmids; Receptors, Angiotensin; Receptors, Endothelin; Sulfonamides; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents; Viper Venoms | 1994 |
Postjunctional regulation by angiotensin II of alpha 1-adrenoceptor-mediated pressor responses in the rat.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Heart Rate; Imidazoles; Male; Neuromuscular Junction; Nitroprusside; Phenylephrine; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Sympathectomy; Synaptic Transmission; Tetrazoles; Valine; Valsartan | 1994 |
Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arginine; Coronary Vessels; Endothelium, Vascular; Hypertension; Muscle, Smooth, Vascular; Nitric Oxide; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 1994 |
Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cattle; Female; Humans; Imidazoles; In Vitro Techniques; Losartan; Male; Rabbits; Rats; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 1993 |
Kidney is an important target for the antihypertensive action of an angiotensin II receptor antagonist in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Infusions, Intravenous; Injections; Kidney; Male; Rats; Rats, Inbred SHR; Renin; Tetrazoles; Valine; Valsartan | 1993 |
Binding of valsartan to mammalian angiotensin AT1 receptors.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Adrenal Glands; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Binding Sites; Binding, Competitive; Biphenyl Compounds; Callithrix; Cell Membrane; Dogs; Humans; Imidazoles; Liver; Losartan; Molecular Structure; Muscle, Smooth, Vascular; Protein Binding; Rats; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 1995 |
Left ventricular wall stress and sarcoplasmic reticulum Ca(2+)-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and AT1-receptor blockade.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Benzazepines; Blotting, Northern; Calcium-Transporting ATPases; Dose-Response Relationship, Drug; Heart Ventricles; Hypertension, Renal; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Rats; Rats, Inbred WKY; Sarcoplasmic Reticulum; Tetrazoles; Valine; Valsartan | 1996 |
Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Body Weight; Hemodynamics; Hypertension; Male; Microcirculation; Muscle, Skeletal; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Tetrazoles; Time Factors; Valine; Valsartan | 1996 |
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Capillary Permeability; Cardiomegaly; Coloring Agents; Coronary Vessels; Diabetes Mellitus, Experimental; Dihydropyridines; Evans Blue; Hypertension; Hypertrophy; Kidney; Male; Mesenteric Arteries; Ramipril; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Serum Albumin; Tetrazoles; Valine; Valsartan | 1996 |
Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester.
Topics: Antihypertensive Agents; Chromatography, High Pressure Liquid; Esters; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism; Tetrazoles; Tosyl Compounds; Valine; Valsartan | 1996 |
Blockade of angiotensin converting enzyme but not of angiotensin AT1 receptors improves glucose tolerance.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Glucose; Blood Pressure; Body Composition; Glucose Tolerance Test; Insulin; Male; Rats; Rats, Inbred SHR; Tetrazoles; Valine; Valsartan; Weight Gain | 1997 |
Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biotransformation; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Feces; Fluorometry; Humans; Male; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 1997 |
Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Proteins; Callithrix; Dialysis; Dogs; Humans; In Vitro Techniques; Mice; Protein Binding; Rabbits; Rats; Tetrazoles; Valine; Valsartan | 1997 |
Drug-induced antisynthetase syndrome.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Inflammatory Agents; Arthritis; Autoantibodies; Autoimmune Diseases; Cytoskeleton; Humans; Male; Prednisolone; Pulmonary Fibrosis; Raynaud Disease; Skin Diseases; Syndrome; Tetrazoles; Valine; Valsartan | 1997 |
Valsartan for hypertension.
Topics: Adult; Antihypertensive Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypertension; Tetrazoles; Valine; Valsartan | 1997 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Dogs; Enalapril; Heart Rate; Hypertension; Hypertension, Renal; Male; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Tetrazoles; Valine; Valsartan | 1997 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Body Weight; Cardiomegaly; Cerebrovascular Disorders; Enalapril; Heart Rate; Hypertension; Male; Mesentery; Muscle Contraction; Organ Size; Rats; Rats, Inbred SHR; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 1997 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Circulation; Blood Pressure; Bradykinin; Cardiac Output; Dogs; Enalapril; Female; Heart Rate; Hemodynamics; Male; Rats; Rats, Inbred SHR; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renal Circulation; Tetrazoles; Valine; Valsartan; Vascular Resistance | 1997 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Enalapril; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Organ Size; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1997 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication: hemodynamic effects of valsartan in dog heart failure models.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Coronary Vessels; Dogs; Enalaprilat; Female; Heart Rate; Hemodynamics; Male; Myocardial Ischemia; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Stroke Volume; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1997 |
Role of kinins and angiotensin II in the vasodilating action of angiotensin converting enzyme inhibition in rat renal vessels.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Bradykinin Receptor Antagonists; Drug Synergism; Female; Isoquinolines; Kidney; Kinins; Quinapril; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Renin-Angiotensin System; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan; Vasodilation | 1997 |
Myocardial electrophysiological properties in the presence of an AT1 angiotensin II receptor antagonist.
Topics: Angiotensin Receptor Antagonists; Animals; Electrophysiology; Guinea Pigs; Heart; Osmolar Concentration; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 1997 |
Secreted protein acidic and rich in cysteine expression after subtotal nephrectomy and blockade of the renin-angiotensin system.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Autoradiography; Fluorescent Antibody Technique, Indirect; Gene Expression; Hypertension; In Situ Hybridization; Male; Microscopy, Fluorescence; Nephrectomy; Osteonectin; Postoperative Period; Ramipril; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Valine; Valsartan | 1997 |
Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Bradykinin Receptor Antagonists; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Kidney Glomerulus; Male; Organ Size; Ramipril; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 1997 |
Pharmacokinetics of valsartan in patients with liver disease.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Bile; Biotransformation; Drainage; Female; Humans; Injections, Intravenous; Liver Diseases; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1997 |
[AT1 receptor antagonists in treatment of hypertension].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1997 |
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardiac Output; Cardiac Pacing, Artificial; Diastole; Disease Models, Animal; Endothelins; Epinephrine; Heart Failure; Heart Rate; Hemodynamics; Norepinephrine; Pulmonary Artery; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1997 |
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Calcium Channels; Calcium Channels, L-Type; Calcium-Binding Proteins; Calcium-Transporting ATPases; Cardiac Pacing, Artificial; Cell Membrane; Cells, Cultured; Dihydropyridines; Heart Failure; Myocardial Contraction; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin-Angiotensin System; Sarcoplasmic Reticulum; Sodium-Potassium-Exchanging ATPase; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1997 |
Interactions between nitric oxide and angiotensin II on renal cortical and papillary blood flow.
Topics: Angiotensin II; Animals; Blood Pressure; Denervation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Homeostasis; Imidazoles; Kidney; Kidney Cortex; Kidney Medulla; Laser-Doppler Flowmetry; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pyridines; Rats; Rats, Wistar; Regional Blood Flow; Tetrazoles; Valine; Valsartan | 1997 |
Effect of interactions between nitric oxide and angiotensin II on pressure diuresis and natriuresis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Diuresis; Glomerular Filtration Rate; Imidazoles; Kidney; Natriuresis; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pressure; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Regional Blood Flow; Renal Circulation; Tetrazoles; Valine; Valsartan | 1997 |
Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decerebrate State; Electric Stimulation; Imidazoles; Irbesartan; Losartan; Male; Rats; Rats, Sprague-Dawley; Sympathetic Nervous System; Tetrazoles; Thiophenes; Valine; Valsartan | 1997 |
[Differential therapy of hypertension becomes more specific. Interview by Dr. R.-G. Sommer].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1997 |
Structural adaptation to ischemia in skeletal muscle: effects of blockers of the renin-angiotensin system.
Topics: Adaptation, Physiological; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Heart Rate; Hindlimb; Imidazoles; Ischemia; Male; Muscle, Skeletal; Muscles; Pyridines; Rats; Rats, Inbred SHR; Renin; Renin-Angiotensin System; Skin; Tetrazoles; Valine; Valsartan | 1997 |
Effects of valsartan and hydrochlorothiazide alone and in combination on blood pressure and heart rate in conscious-telemetered spontaneously hypertensive rats (SHR).
Topics: Animals; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Heart Rate; Hydrochlorothiazide; Hypertension; Male; Rats; Rats, Inbred SHR; Telemetry; Tetrazoles; Valine; Valsartan | 1998 |
The effect of age on the pharmacokinetics of valsartan.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aging; Analysis of Variance; Antihypertensive Agents; Area Under Curve; Female; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1998 |
Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Heart Rate; Hypertension; Male; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Telemetry; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1998 |
Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiac Pacing, Artificial; Endothelins; Epinephrine; Heart Failure; Hemodynamics; Male; Norepinephrine; Physical Exertion; Regional Blood Flow; Renin; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1998 |
Angiotensin II and insulin induce growth of ciliary artery smooth muscle: effects of AT1/AT2 antagonists.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cell Count; Cell Division; Cell Movement; Cells, Cultured; Ciliary Arteries; DNA; DNA Replication; Dose-Response Relationship, Drug; Drug Combinations; Insulin; Muscle, Smooth, Vascular; Oligopeptides; Swine; Tetrazoles; Valine; Valsartan | 1998 |
Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cerebrovascular Disorders; Genetic Predisposition to Disease; Heart Rate; Hypertension; Infusion Pumps; Kidney; Myocardium; Proteinuria; Rats; Rats, Inbred SHR; Renin; Renin-Angiotensin System; Sodium Chloride; Tetrazoles; Valine; Valsartan | 1998 |
The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cytokines; Humans; Hypertension; Interleukin-1; Interleukin-6; Lipopolysaccharides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 1998 |
Design and synthesis of nonpeptide angiotensin II receptor antagonists featuring acyclic imidazole-mimicking structural units.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Design; Humans; Imidazoles; Kinetics; Losartan; Models, Molecular; Molecular Conformation; Molecular Structure; Static Electricity; Stereoisomerism; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan | 1998 |
AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiac Pacing, Artificial; Coronary Vessels; Disease Models, Animal; Exercise Test; Heart Failure; Hemodynamics; Male; Regional Blood Flow; Swine; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1998 |
Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure.
Topics: Angiotensin Receptor Antagonists; Animals; Cardiac Output, Low; Disease Progression; Dogs; Dose-Response Relationship, Drug; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 1999 |
Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Thoracic; Arteriosclerosis; Benzazepines; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Immunohistochemistry; Male; Muscle, Smooth, Vascular; Rabbits; Reference Values; Tetrazoles; Valine; Valsartan | 1999 |
Expression, secretion, and inhibition of angiotensin-converting enzyme in cultured human bronchial epithelial cells.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bradykinin; Bronchi; Cells, Cultured; Drug Interactions; Enalaprilat; Epithelial Cells; Humans; Peptidyl-Dipeptidase A; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Valine; Valsartan | 1999 |
[Myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of formation of angiotensin II and its interaction with specific receptors].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiomegaly; Hypertension, Renovascular; Hypertrophy, Left Ventricular; Male; Myocardium; Rabbits; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 1999 |
Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic; Reference Values; Research Design; Severity of Illness Index; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
[Morphofunctional characteristics of myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of angiotensin II].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Heart Ventricles; Hypertension, Renovascular; Hypertrophy, Left Ventricular; Male; Organ Size; Rabbits; Tetrazoles; Valine; Valsartan | 1999 |
Valsartan inhibits angiotensin II-stimulated proliferation of smooth muscle cells from human coronary artery.
Topics: Angiotensin II; Antihypertensive Agents; Arteriosclerosis; Cell Count; Cell Division; Cells, Cultured; Coronary Vessels; Female; Humans; Muscle, Smooth, Vascular; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 1999 |
Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Quality of Life; Tetrazoles; Valine; Valsartan | 1999 |
AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Arteriosclerosis; Endothelium, Vascular; Male; Rabbits; Receptors, Angiotensin; Tetrazoles; Tunica Intima; Valine; Valsartan | 1999 |
Effects of angiotensin type-I receptor blockade on pericardial fibrosis.
Topics: Angiotensin Receptor Antagonists; Animals; Cardiac Surgical Procedures; Collagen; Fibrosis; Hydroxyproline; Male; Pericardium; Postoperative Complications; Receptors, Angiotensin; Reoperation; Swine; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Volume; Cyclic GMP; Diuresis; Heart Failure; Male; Myocardium; Ramipril; Rats; Rats, Wistar; Renin-Angiotensin System; Statistics, Nonparametric; Tetrazoles; Valine; Valsartan | 1999 |
Efficacy of angiotensin II antagonists in hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diuretics; Drug Interactions; Drug Therapy, Combination; Humans; Hypertension; Irbesartan; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
Valsartan. Just a second-line antihypertensive drug.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Male; Pregnancy; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
Blockade of the renin angiotensin system in heart failure: the potential place of angiotensin II receptor blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Losartan; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
Valsartan and coronary haemodynamics in early post-myocardial infarction in rats.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Body Weight; Cardiomegaly; Coronary Vessels; Dipyridamole; Dose-Response Relationship, Drug; Fibrosis; Hemodynamics; Male; Myocardial Infarction; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 1999 |
By the way, doctor... I am 87 and have been taking blood pressure medications for years. In the past, side effects were a problem, but for about the last year I've done very well taking valsartan (Diovan) and hydrochlorothiazide (Esidrex). Now My blood pr
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Systole; Tetrazoles; Valine; Valsartan | 2000 |
AT1-receptor blockers.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Tetrazoles; Valine; Valsartan | 2000 |
[Effects of an angiotensin II receptor antagonist (valsartan) on macro- and microcirculatory hemodynamics of the arm in hypertensive patients].
Topics: Antihypertensive Agents; Arm; Female; Hemodynamics; Humans; Male; Microcirculation; Middle Aged; Tetrazoles; Valine; Valsartan | 1999 |
Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Fosinopril; Heart Failure; Humans; Lisinopril; Male; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Treatment Failure; Valine; Valsartan | 2000 |
Endogenous renin and related short-term blood pressure variability in the conscious rat.
Topics: Adrenergic beta-Agonists; Animals; Antihypertensive Agents; Aorta, Abdominal; Blood Pressure; Carotid Arteries; Catecholamines; Heart Rate; Infusions, Intra-Arterial; Isoproterenol; Male; Rats; Rats, Wistar; Renin; Signal Processing, Computer-Assisted; Tetrazoles; Valine; Valsartan | 2000 |
Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats.
Topics: Animals; Antihypertensive Agents; Hypotension; Microdialysis; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Vasodilation | 2000 |
Potential drug interaction between lithium and valsartan.
Topics: Antihypertensive Agents; Antimanic Agents; Bipolar Disorder; Drug Interactions; Female; Humans; Lithium; Middle Aged; Tetrazoles; Valine; Valsartan | 2000 |
Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antibodies, Monoclonal; Benzimidazoles; Benzoates; Binding, Competitive; Biphenyl Compounds; Blood Platelets; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Platelet Activation; Pyridines; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Telmisartan; Tetrazoles; Thromboxane A2; Time Factors; Valine; Valsartan | 2000 |
[Angioedema and urticarial reaction induced by valsartan].
Topics: Angioedema; Anti-Allergic Agents; Antihypertensive Agents; Antipruritics; Drug Eruptions; Female; Follow-Up Studies; Histamine H1 Antagonists; Humans; Loratadine; Middle Aged; Tetrazoles; Time Factors; Urticaria; Valine; Valsartan | 2000 |
Enalapril and valsartan improve cyclosporine A-induced vascular dysfunction in spontaneously hypertensive rats.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cyclosporine; Dose-Response Relationship, Drug; Enalapril; Hypertension; Male; Mesenteric Arteries; Nitroprusside; Norepinephrine; Rats; Rats, Inbred SHR; Renal Artery; Systole; Tetrazoles; Valine; Valsartan; Vasoconstriction; Vasodilation | 2000 |
Effects of valsartan and 17 beta-estradiol on the oxidation of low-density lipoprotein in vitro.
Topics: Antihypertensive Agents; Cholesterol, LDL; Drug Synergism; Drug Therapy, Combination; Estradiol; Female; Humans; Postmenopause; Tetrazoles; Valine; Valsartan | 2000 |
Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Dose-Response Relationship, Drug; Heart; Imidazoles; Irbesartan; Losartan; Male; Norepinephrine; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha; Receptors, Angiotensin; Sympathetic Nervous System; Tetrazoles; Thiophenes; Valine; Valsartan | 2000 |
In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Imidazoles; In Vitro Techniques; Inhibitory Concentration 50; Irbesartan; Losartan; Microsomes, Liver; Protein Isoforms; Tetrazoles; Thiophenes; Valine; Valsartan | 2000 |
Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood Coagulation Factors; Blood Pressure; Cell Line; CHO Cells; Coronary Disease; Coronary Vessels; Cricetinae; Extracellular Matrix Proteins; Heart Ventricles; Humans; Inflammation; Integrin alpha4beta1; Integrins; NF-kappa B; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Lymphocyte Homing; RNA, Messenger; Tetrazoles; Thromboplastin; Transcription Factor AP-1; Valine; Valsartan; Vascular Resistance | 2000 |
Basilar artery remodelling in the genetically hypertensive rat: effects of nitric oxide synthase inhibition and treatment with valsartan and enalapril.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Basilar Artery; Blood Pressure; Brain; Enalapril; Enzyme Inhibitors; Hypertension; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Rats; Rats, Inbred SHR; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2000 |
Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykinin; Bradykinin Receptor Antagonists; Cyclosporine; Dose-Response Relationship, Drug; Drinking; Eating; Electrolytes; Enalapril; Heart Rate; Hypertension; Hypertrophy, Left Ventricular; Kallikreins; Kidney; Kidney Diseases; Male; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Renin; Sodium, Dietary; Tetrazoles; Urination; Valine; Valsartan | 2000 |
Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aorta; Arteries; Blood Pressure; Brachial Artery; Drug Resistance; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Pulse; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Regional Blood Flow; Tetrazoles; Valine; Valsartan | 2000 |
[Contribution of the renin-angiotensin system to blood pressure variability in hyperthyroid rats].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cardiomegaly; Chronic Disease; Disease Models, Animal; Fever; Fourier Analysis; Heart Rate; Hypertension; Hyperthyroidism; Injections, Intraperitoneal; Male; Rats; Rats, Wistar; Renin; Renin-Angiotensin System; Signal Processing, Computer-Assisted; Tachycardia; Tetrazoles; Thyroid Hormones; Thyrotoxicosis; Thyroxine; Valine; Valsartan; Weight Loss | 2000 |
[Activation of the renin-angiotensin system and blood pressure variability in rats].
Topics: Adrenergic beta-Agonists; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Carotid Arteries; Catecholamines; Catheters, Indwelling; Femoral Artery; Fourier Analysis; Heart Rate; Infusions, Intravenous; Isoproterenol; Male; Rats; Rats, Wistar; Receptors, Adrenergic, beta; Renin; Renin-Angiotensin System; Signal Processing, Computer-Assisted; Tachycardia; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2000 |
Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Cardiac Pacing, Artificial; Combined Modality Therapy; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Myocardial Contraction; Norepinephrine; Receptor, Endothelin A; Renin; Sulfonamides; Swine; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2000 |
Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Blotting, Northern; Disease Models, Animal; Gene Expression; In Situ Hybridization; Kidney; Macrophages; Male; Nephrectomy; Nephritis, Interstitial; Osteopontin; Ramipril; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sialoglycoproteins; Tetrazoles; Valine; Valsartan | 2000 |
Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cause of Death; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Myocardial Infarction; Odds Ratio; Patient Selection; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Sample Size; Tetrazoles; Valine; Valsartan | 2000 |
Effect of valsartan, an angiotensin II AT(1) receptor blocker, on the glomerular fibrosis of IgA nephropathy in ddY mice.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Fibrosis; Glomerulonephritis, IGA; Kidney Glomerulus; Mice; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2000 |
Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Chemokine CCL2; Chemotaxis, Leukocyte; Gene Expression; Hypertension, Renal; Kidney; Kidney Failure, Chronic; Macrophages; Monocytes; Nephrosclerosis; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Mutant Strains; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2000 |
Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis.
Topics: Age Factors; Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Autoradiography; Blood Pressure; Cell Division; Gene Expression; Guanosine 5'-O-(3-Thiotriphosphate); Imidazoles; In Situ Nick-End Labeling; Iodine Radioisotopes; Kidney; Male; Oligopeptides; Organ Size; Osteopontin; Proliferating Cell Nuclear Antigen; Pyridines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Sialoglycoproteins; Tetrazoles; Valine; Valsartan | 2000 |
[Creatively revised quotation on sale arguments concerning Diovan (valsartan].
Topics: Advertising; Angiotensin II; Antihypertensive Agents; Diuretics; Drug Information Services; Humans; Tetrazoles; Valine; Valsartan | 2000 |
Effects of valsartan on angiotensin II-induced migration of human coronary artery smooth muscle cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Arteries; Cell Count; Cell Movement; Cells, Cultured; Coronary Vessels; Humans; Muscle, Smooth, Vascular; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2000 |
Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Catecholamines; Collagen; Diastole; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Endothelin-1; Gene Expression; Heart Failure; Heart Function Tests; Hydroxyproline; Myocardium; Myosin Heavy Chains; Organ Size; Rats; Rats, Inbred Dahl; Receptors, Angiotensin; RNA, Messenger; Sodium Chloride, Dietary; Survival Rate; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2001 |
[AT1-blocker in heart failure. Patients are readmitted more infrequently to the clinic].
Topics: Angiotensin Receptor Antagonists; Chronic Disease; Drug Therapy, Combination; Heart Failure; Humans; Patient Readmission; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2000 |
Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction--effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Calcium-Binding Proteins; Calpain; Disease Models, Animal; Gene Expression Regulation; Heart; Heart Rate; Imidazoles; Male; Myocardial Infarction; Protein Biosynthesis; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Transcription, Genetic; Valine; Valsartan | 2001 |
Efficacy and tolerability of angiotensin II type 1 receptor antagonists in dialysis patients using AN69 dialysis membranes.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Drug Tolerance; Female; Humans; Hypertension; Male; Membranes, Artificial; Middle Aged; Renal Dialysis; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 2001 |
Do ACE inhibitors or ARBs limit restenosis after stenting? --assimilating the data.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Coronary Disease; Humans; Recurrence; Tetrazoles; Valine; Valsartan | 2001 |
Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition.
Topics: Antihypertensive Agents; Blood Platelets; Collagen; Humans; Imidazoles; Losartan; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Thromboxane; Tetrazoles; Thromboxane-A Synthase; Valine; Valsartan | 2000 |
[Info-congress. COPERNICUS and Val-HEFT studies].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Coronary Disease; Heart Failure; Humans; Propanolamines; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Valine; Valsartan | 2000 |
Renin-angiotensin system contribution to cardiac hypertrophy in experimental hyperthyroidism: an echocardiographic study.
Topics: Animals; Echocardiography; Hyperthyroidism; Hypertrophy, Left Ventricular; Male; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2001 |
Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes.
Topics: Acetylcholine; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensive Agents; Dinoprost; Disease Models, Animal; Endothelium, Vascular; F2-Isoprostanes; Humans; Hypertension; Ketone Oxidoreductases; Male; Nitrates; Nitrites; Nitroprusside; Norepinephrine; Rats; Rats, Sprague-Dawley; Renal Artery; Renin; Superoxide Dismutase; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents; Vasodilation | 2001 |
Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Diabetes Mellitus, Type 1; Endothelium, Vascular; Heart Rate; Hypertension; In Vitro Techniques; Mesenteric Arteries; Neprilysin; Nitroprusside; Norepinephrine; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Sodium, Dietary; Tetrazoles; Valine; Valsartan | 2001 |
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Body Weight; Cardiovascular Diseases; Fibroblast Growth Factor 2; Heart; Immunohistochemistry; Mineralocorticoid Receptor Antagonists; NF-kappa B; Organ Size; Platelet-Derived Growth Factor; Rats; Receptors, Mineralocorticoid; Renin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Transcription Factor AP-1; Transforming Growth Factor beta; Valine; Valsartan | 2001 |
Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Cells, Cultured; Fibrinolysis; Humans; Mammary Arteries; Muscle, Smooth, Vascular; Plasminogen Activator Inhibitor 1; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Tissue Plasminogen Activator; Umbilical Arteries; Valine; Valsartan | 2001 |
[Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation].
Topics: Angiotensin Receptor Antagonists; Animals; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2001 |
Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?
Topics: Acrylates; Angioedema; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Black or African American; Clinical Trials as Topic; Cough; Female; Humans; Imidazoles; Irbesartan; Losartan; Male; Randomized Controlled Trials as Topic; Sex Factors; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2001 |
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Platelets; Blood Pressure; Humans; Hypertension; Losartan; P-Selectin; Platelet Activation; Platelet Adhesiveness; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Tetrazoles; Thromboxane A2; Valine; Valsartan | 2001 |
Salt sensitivity in genetically hypertensive rats of the Lyon strain.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Drug Resistance; Hypertension; Kidney; Male; Perindopril; Rats; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2001 |
Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).
Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Northern; Bosentan; Collagen; Endothelin Receptor Antagonists; Female; Fibroblasts; Hemodynamics; Hypertrophy, Left Ventricular; Immunohistochemistry; Macrophages; Monocytes; Myocardial Infarction; Myocardium; Procollagen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Dysfunction, Left | 2001 |
Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture.
Topics: Adipose Tissue; Adolescent; Adult; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cells, Cultured; Female; Humans; Middle Aged; Plasminogen Activator Inhibitor 1; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2001 |
Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC.
Topics: Antihypertensive Agents; Chromatography, High Pressure Liquid; Diuretics; Drug Combinations; Hydrochlorothiazide; Reproducibility of Results; Sodium Chloride Symporter Inhibitors; Spectrophotometry, Ultraviolet; Tablets; Tetrazoles; Valine; Valsartan | 2001 |
Angiotensin-II-receptor inhibitors in pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Humans; Hypertension; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Prenatal Care; Risk Assessment; Sensitivity and Specificity; Tetrazoles; Time Factors; Valine; Valsartan | 2001 |
[Heart failure. With the AT1-blocker less frequent rehospitalization].
Topics: Angiotensin Receptor Antagonists; Heart Failure; Humans; Patient Readmission; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2001 |
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Humans; Lisinopril; Potassium; Renal Insufficiency; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2001 |
Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Female; Heterozygote; Kidney; Perindopril; Rats; Renin; Tetrazoles; Valine; Valsartan | 2001 |
Neutral effect of valsartan on serum uric acid and renal function tests.
Topics: Antihypertensive Agents; Humans; Kidney Function Tests; Tetrazoles; Uric Acid; Valine; Valsartan | 2001 |
Alterations of load-induced p38 MAP kinase activation in failing rat hearts.
Topics: Animals; Antihypertensive Agents; Body Weight; Diastole; Enzyme Activation; Heart; Heart Failure; Hemodynamics; In Vitro Techniques; Mitogen-Activated Protein Kinases; Myocardial Contraction; Myocardium; Organ Size; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Inbred Dahl; Reference Values; Systole; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Weight-Bearing | 2001 |
[The taboo topic of sexual activity in hypertensive patients. Pioneer study from Pavia proves: potency is not impaired].
Topics: Adult; Antihypertensive Agents; Carbazoles; Carvedilol; Cross-Over Studies; Double-Blind Method; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Propanolamines; Randomized Controlled Trials as Topic; Risk Factors; Taboo; Tetrazoles; Valine; Valsartan | 2001 |
Haemodynamic effects of valsartan in acute renal ischaemia/reperfusion injury.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Female; Hemodynamics; Ischemia; Kidney Glomerulus; Microcirculation; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renal Circulation; Reperfusion Injury; Tetrazoles; Valine; Valsartan | 2001 |
Fetal toxic effects and angiotensin-II-receptor antagonists.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Female; Humans; Hypertension; Losartan; Pregnancy; Pregnancy Complications, Cardiovascular; Tetrazoles; Valine; Valsartan | 2001 |
Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Drug Therapy, Combination; Hypertension; Hypertrophy, Left Ventricular; Male; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2000 |
Effect of valsartan and fosinopril on catecholamine-induced cardiac hypertrophy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Calcium-Transporting ATPases; Collagen; Female; Fosinopril; Hypertrophy, Left Ventricular; Male; Myocardium; Norepinephrine; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2000 |
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Basement Membrane; Blood Pressure; Diabetes Mellitus, Experimental; Disease Models, Animal; Disease Progression; Humans; Kidney; Kidney Glomerulus; Male; Organ Size; Ramipril; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2001 |
Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Bradykinin; Cyclic GMP; Drug Synergism; Extracellular Space; Imidazoles; Kidney; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sodium; Tetrazoles; Valine; Valsartan | 2001 |
[Effects of pathogenetic therapy on blood cholesterol in patients with glomerulonephritis].
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anticholesteremic Agents; Antihypertensive Agents; Azathioprine; Captopril; Cholesterol; Creatinine; Cyclophosphamide; Data Interpretation, Statistical; Enalapril; Female; Glomerulonephritis; Humans; Immunosuppressive Agents; Lovastatin; Male; Nephrotic Syndrome; Prednisolone; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan | 2001 |
Effects of nitric oxide synthase inhibition and low-salt diet on blood pressure and mesenteric resistance artery remodelling in genetically hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Enzyme Inhibitors; Heart Ventricles; Hypertension; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Systole; Tetrazoles; Valine; Valsartan; Vascular Resistance | 2001 |
Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Malignant; Hypertension, Renovascular; Immunohistochemistry; Kidney; Macrophages; Male; Nephritis; Organ Size; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Survival Rate; Tetrazoles; Valine; Valsartan | 2001 |
Effect of valsartan on angiotensin II- and vasopressin-degrading activities in the kidney of normotensive and hypertensive rats.
Topics: Aminopeptidases; Angiotensin II; Animals; Antihypertensive Agents; Arginine Vasopressin; Blood Pressure; Cystinyl Aminopeptidase; Drinking; Glutamyl Aminopeptidase; Hypertension, Renovascular; Kidney; Male; Placebos; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2001 |
Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Enalapril; Heart Failure; Male; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2001 |
Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Body Weight; Carotid Arteries; Dose-Response Relationship, Drug; Fibronectins; Hypertension; Immunohistochemistry; Male; Protein Isoforms; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2001 |
Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Collagen; Drug Combinations; Fibrosis; Fosinopril; Male; Myocardial Infarction; Myocardium; Random Allocation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Remodeling | 2001 |
Angiotensin II type 1 receptor blockers and congestive heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Receptor, Angiotensin, Type 1; Sample Size; Selection Bias; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2001 |
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Canada; Cardiovascular Agents; Drug Approval; Heart Failure; Humans; Hyperkalemia; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renal Insufficiency; Spironolactone; Survival Rate; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2001 |
Inhibition of the formation or action of angiotensin II reverses attenuated K+ currents in type 1 and type 2 diabetes.
Topics: Action Potentials; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Electric Conductivity; Isoquinolines; Mutation; Potassium Channels; Quinapril; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Angiotensin, Type 2; Receptors, Cell Surface; Receptors, Leptin; Saralasin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2001 |
[Acute hepatitis induced by valsartan].
Topics: Acute Disease; Angiotensin Receptor Antagonists; Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Middle Aged; Tetrazoles; Valine; Valsartan | 2001 |
Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cell Division; Chemokine CCL2; Femoral Artery; Inflammation; Interleukin-1; Interleukin-6; Leukocyte Common Antigens; Leukocytes; Macrophages; Male; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Tetrazoles; Tumor Necrosis Factor-alpha; Tunica Intima; Valine; Valsartan | 2001 |
Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.
Topics: Acrylates; Adrenergic alpha-Agonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Decerebrate State; Dihydropyridines; Dose-Response Relationship, Drug; Imidazoles; Male; Norepinephrine; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Sympathetic Nervous System; Synaptic Transmission; Tetrazoles; Thiophenes; Valine; Valsartan | 2001 |
Blockade of angiotensin II type 1 receptors suppressed free radical production and preserved coronary endothelial function in the rabbit heart after myocardial infarction.
Topics: Acetylcholine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Endothelium, Vascular; Enzyme Inhibitors; Free Radicals; Hemodynamics; In Vitro Techniques; Lipid Peroxides; Male; Myocardial Infarction; Myocardium; Nitroprusside; omega-N-Methylarginine; Oxygen; Rabbits; Receptor, Angiotensin, Type 1; Tetrazoles; Tiopronin; Valine; Valsartan; Vasodilator Agents; Ventricular Remodeling | 2002 |
Are angiotensin II receptor blockers indicated in chronic heart failure?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |
Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure Determination; Diet, Sodium-Restricted; Hypotension; Losartan; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Oligopeptides; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan; Vasodilation | 2001 |
Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Apoptosis; Atrophy; Autoradiography; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epidermal Growth Factor; Female; Fibrosis; Gene Expression; In Situ Hybridization; In Situ Nick-End Labeling; Kidney Tubules; Nephritis, Interstitial; Perindopril; Rats; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2002 |
Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice.
Topics: Angiotensin Receptor Antagonists; Animals; Cardiomegaly; Coronary Vessels; Male; Mice; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2002 |
[Heart failure. Who benefits from an AT1 blocker?].
Topics: Angiotensin Receptor Antagonists; Clinical Trials as Topic; Heart Failure; Humans; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2001 |
[Renal protective effect of valsartan in diabetic rats].
Topics: Animals; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Fibronectins; Kidney; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan | 1999 |
Valsartan improves fibrinolytic balance in atherosclerotic rabbits.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Arteriosclerosis; Biomarkers; Blood Pressure; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Dose-Response Relationship, Drug; Factor VIII; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysis; Hypercholesterolemia; Male; Myocardial Contraction; Rabbits; Tetrazoles; Time; Treatment Outcome; Valine; Valsartan | 2002 |
High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Chromatography, High Pressure Liquid; Humans; Receptors, Angiotensin; Reference Standards; Reproducibility of Results; Spectrometry, Fluorescence; Tetrazoles; Valine; Valsartan | 2002 |
Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists.
Topics: Acrylates; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Chemical Fractionation; Electrophoresis, Capillary; Imidazoles; Irbesartan; Losartan; Mathematical Computing; Molecular Structure; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2002 |
[ESC guidelines for therapy of heart failure. AT1 blockers are now also included].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Heart Failure; Humans; Practice Guidelines as Topic; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Captopril; Carotid Artery Injuries; Cell Division; Endothelin-1; Female; Male; Rabbits; Renin-Angiotensin System; Tetrazoles; Thromboxane B2; Tunica Intima; Valine; Valsartan | 2001 |
Valsartan and candesartan can inhibit deteriorating effects of angiotensin II on coronary endothelial function.
Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cells, Cultured; Collagenases; Coronary Vessels; Endothelins; Endothelium, Vascular; Enzyme Precursors; Humans; Male; Matrix Metalloproteinase 1; Plasminogen Activator Inhibitor 1; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2001 |
[Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Spironolactone; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2002 |
Inhibitory effects of angiotensin II on barosensitive rostral ventrolateral medulla neurons of the rat.
Topics: Adrenergic alpha-Agonists; Anesthesia; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Glutamic Acid; Imidazoles; Medulla Oblongata; Neurons; Phenylephrine; Pressoreceptors; Pyridines; Rats; Rats, Wistar; Tetrazoles; Time Factors; Valine; Valsartan; Vasoconstrictor Agents | 2001 |
Myocardial bradykinin following acute angiotensin-converting enzyme inhibition, AT1 receptor blockade, or combined inhibition in congestive heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Bradykinin; Heart Failure; Male; Myocardium; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Swine; Tetrazoles; Valine; Valsartan | 2001 |
Influence of Valsartan on myocardial apoptosis in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Apoptosis; Cardiomegaly; Hypertension; Myocardium; Rats; Rats, Inbred SHR; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Hypotension; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Risk; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Drug Combinations; Enalapril; Endothelium, Vascular; Hypertension; Male; Rats; Rats, Inbred SHR; Survival Analysis; Tetrazoles; Valine; Valsartan | 2000 |
Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan.
Topics: Adenosine Diphosphate; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Blood Platelets; Cells, Cultured; Drug Interactions; Humans; Losartan; Male; Platelet Activation; Platelet Aggregation Inhibitors; Receptor, Angiotensin, Type 1; Tetrazoles; Thromboxane A2; Valine; Valsartan | 2000 |
Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cyclic GMP; Extracellular Space; Female; Imidazoles; Injections, Intravenous; Kidney; Losartan; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
[Sartans for lowering blood pressure. Hypertensive patients need not fear potency].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Erectile Dysfunction; Humans; Hypertension; Male; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients.
Topics: Analysis of Variance; Antioxidants; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypertension; Indoles; Lipoproteins, LDL; Oxidation-Reduction; Tetrazoles; Valine; Valsartan | 2002 |
Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Female; Immunoenzyme Techniques; Immunohistochemistry; Kidney; Organ Size; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2002 |
Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Body Weight; Cytoprotection; Diuresis; Gene Expression; Imidazoles; Kidney; Kidney Diseases; Male; Membrane Proteins; Nephrectomy; Organ Size; Proteins; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Ask the doctor. I have had heart failure since my heart attack a year ago. My physician initially prescribed lisinopril, an angiotensin-converting enzyme (ACE) inhibitor. Unfortunately, I was one of the unlucky people who got a cough with this drug that w
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cough; Heart Failure; Humans; Lisinopril; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2002 |
Effect of angiotensin II antagonism on the regression of kidney disease in the rat.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Body Weight; Collagen Type III; Disease Progression; Kidney Diseases; Kidney Glomerulus; Lisinopril; Macrophages; Male; Monocytes; Proteinuria; Rats; Rats, Wistar; Renal Circulation; Tetrazoles; Valine; Valsartan | 2002 |
[24-hour arterial hypertension profile and heart rhythm variability in patients with arterial hypertension and NIDDM].
Topics: Angiotensin-Converting Enzyme Inhibitors; Circadian Rhythm; Diabetes Mellitus, Type 2; Enalapril; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2002 |
Comparison of UV- and second derivative-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Spectrophotometry, Ultraviolet; Tetrazoles; Valine; Valsartan | 2002 |
[Fixed combination of AT1 blocker and diuretic. Stroke preventive combination for hypertension].
Topics: Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiotonic Agents; Collagen; Enalapril; Heart Rate; Hemodynamics; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Survival Analysis; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2002 |
Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release.
Topics: Angiotensin Receptor Antagonists; Blood Platelets; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Imidazoles; Kinetics; Losartan; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2002 |
Ventrolateral medulla AT1 receptors support blood pressure in hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Brain Stem; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Hypertension; Injections; Kynurenic Acid; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2002 |
[Therapy of heart failure. 2 neurohormone blockers are enough].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |
Angiotensin receptor blockers in heart failure: a work in progress.
Topics: Angiotensin II; Heart Failure; Humans; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Progression; Echocardiography; Enzyme Activation; Heart Failure; Hypertension; Male; Myocardium; Organ Size; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-epsilon; Protein Transport; Rats; Rats, Inbred Dahl; Stress, Mechanical; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2002 |
Haemodynamic effects of an angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist during hypovolaemia in the anaesthetized pig.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Enalaprilat; Female; Hemodynamics; Hypovolemia; Renin-Angiotensin System; Swine; Tetrazoles; Valine; Valsartan | 2002 |
Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Receptors, Angiotensin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Combination of low-dose valsartan and enalapril improves endothelial dysfunction and coronary reserve in Nomega-nitro-L-arginine methyl ester-treated spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Coronary Circulation; Drug Therapy, Combination; Enalapril; Endothelium, Vascular; Enzyme Inhibitors; Kidney; Male; NG-Nitroarginine Methyl Ester; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2002 |
Biphasic regulation of Na+-HCO3- cotransporter by angiotensin II type 1A receptor.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arachidonic Acid; Bicarbonates; Calcium; Dose-Response Relationship, Drug; Enzyme Activators; Fluorescent Dyes; Imidazoles; In Vitro Techniques; Intracellular Fluid; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Sodium; Sodium-Bicarbonate Symporters; Tetrazoles; Valine; Valsartan | 2002 |
BP drug approved for heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Approval; Heart Failure; Humans; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2002 |
Release of preformed Ang II from myocytes mediates angiotensinogen and ET-1 gene overexpression in vivo via AT1 receptor.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Aortic Valve Stenosis; Cardiac Catheterization; Cytoplasm; Disease Models, Animal; Endothelin-1; Gene Expression Regulation; Heart; Insulin-Like Growth Factor I; Microscopy, Confocal; Myocardium; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Renin-Angiotensin System; RNA, Messenger; Stress, Mechanical; Swine; Systole; Tetrazoles; Valine; Valsartan | 2002 |
[Sartan as a new therapy option. When heart failure patients cannot tolerate an ACE inhibitor].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Heart Failure; Humans; Randomized Controlled Trials as Topic; Survival Rate; Tetrazoles; Treatment Outcome; United States; United States Food and Drug Administration; Valine; Valsartan | 2002 |
The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Cohort Studies; Dizziness; Drug Monitoring; England; Female; Headache; Humans; Hypertension; Male; Middle Aged; Nausea; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Product Surveillance, Postmarketing; Tetrazoles; Valine; Valsartan | 2002 |
Irbesartan substitution for valsartan or losartan in treating hypertension.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Retrospective Studies; Tetrazoles; Therapeutic Equivalency; Valine; Valsartan | 2002 |
Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Base Sequence; Benzimidazoles; Biphenyl Compounds; Coronary Vessels; Culture Techniques; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Losartan; Male; Middle Aged; Molecular Sequence Data; Probability; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Valine; Valsartan; Vasoconstriction | 2002 |
Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Gene Expression Regulation; Hemodynamics; Hypertrophy, Left Ventricular; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Elasticity; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan; Vascular Resistance | 2002 |
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Evaluation Studies as Topic; Heart Failure; Humans; Incidence; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
[Preclinical and clinical profile of Valsartan, a selective angiotensin II type-1 receptor blocker].
Topics: Adult; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Male; Rats; Rats, Inbred SHR; Tetrazoles; Valine; Valsartan | 2002 |
Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Apoptosis; Cell Nucleus; Cells, Cultured; Down-Regulation; Heart Ventricles; Male; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
Topics: Angiotensin Receptor Antagonists; Animals; Arterial Occlusive Diseases; Cell Division; Cells, Cultured; DNA; DNA-Binding Proteins; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Genes, fos; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Phosphorylation; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Valine; Valsartan | 2003 |
[Lowering blood pressure with sartans. Are there differences?].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Cross-Over Studies; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Telmisartan; Tetrazoles; Valine; Valsartan | 2002 |
The effect of inhibition of renin-angiotensin system by valsartan during hypovolemic shock and low flow sigmoideal ischaemia in pigs.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Rupture; Colon, Sigmoid; Hemodynamics; Hemoglobins; Ischemia; Oximetry; Renin-Angiotensin System; Shock; Swine; Tetrazoles; Valine; Valsartan | 2003 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Hypertension; Kidney Glomerulus; Male; Membrane Proteins; Proteins; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Sclerosis; Systole; Tetrazoles; Valine; Valsartan; Verapamil | 2003 |
Aminopeptidase activity in renovascular hypertension.
Topics: Aminopeptidases; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Down-Regulation; Heart Atria; Heart Ventricles; Hypertension; Hypertension, Renovascular; Lung; Male; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2003 |
Valsartan-induced hepatotoxicity in a HBs-Ag-Positive patient.
Topics: Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Female; Hepatitis B Surface Antigens; Humans; Hypertension; Middle Aged; Tetrazoles; Valine; Valsartan | 2003 |
Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Apoptosis; Enalapril; Fibroblasts; Heart Ventricles; Hyperplasia; Hypertension; Hypertrophy, Left Ventricular; In Situ Nick-End Labeling; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2003 |
[High dose sartan plus thiazide. Power duo in hypertension].
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Tetrazoles; Valine; Valsartan | 2003 |
Differential regulation of osteopontin expression in the clipped and nonclipped kidney of two-kidney, one-clip hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Gene Expression; Hypertension, Renal; Kidney; Male; Monocytes; Osteopontin; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; RNA, Messenger; Sialoglycoproteins; Surgical Instruments; Tetrazoles; Valine; Valsartan | 2003 |
Ventrolateral medulla AT1 receptors support arterial pressure in Dahl salt-sensitive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Hypertension; Male; Medulla Oblongata; Paraventricular Hypothalamic Nucleus; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Sodium Chloride; Tetrazoles; Valine; Valsartan | 2003 |
Are angiotensin II receptor antagonists indicated in chronic heart failure?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Functional antagonism of different angiotensin II type I receptor blockers in human arteries.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Dose-Response Relationship, Drug; Humans; Imidazoles; In Vitro Techniques; Losartan; Mammary Arteries; Muscle Contraction; Muscle, Smooth, Vascular; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2002 |
Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Topics: Alanine; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Captopril; Cardiomegaly; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Enzyme Inhibitors; Hypertension; Hypertrophy; Male; Mesenteric Arteries; Neprilysin; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2003 |
Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucose; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; Glucose Transporter Type 4; Hyperglycemia; Liver; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Nicorandil; Nifedipine; Phosphoenolpyruvate Carboxykinase (GTP); Rats; Rats, Wistar; RNA, Messenger; Saralasin; Tetrazoles; Valine; Valsartan | 2003 |
[Hypertension therapy. Does AT-1 blocker help love life?].
Topics: Angiotensin Receptor Antagonists; Angiotensins; Antihypertensive Agents; Clinical Trials as Topic; Erectile Dysfunction; Humans; Hypertension; Male; Orgasm; Penile Erection; Sex; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
VEGF-mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathies; Cricetinae; Enalapril; Endothelial Growth Factors; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Neovascularization, Pathologic; Receptor, Angiotensin, Type 1; RNA, Messenger; Tetrazoles; Time Factors; Valine; Valsartan; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
[High dose sartan plus diuretic. More power in hypertension and its sequelae].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diuretics; Drug Combinations; Heart Rate; Hydrochlorothiazide; Hypertension; Receptor, Angiotensin, Type 1; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan | 2003 |
Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis.
Topics: Angiotensin Receptor Antagonists; Animals; Autoimmune Diseases; Cardiomyopathies; Endomyocardial Fibrosis; Heart Ventricles; Male; Myocarditis; Rats; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan; Ventricular Function | 2003 |
[Successful treatment of combination therapy using an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker in a patient with IgA nephropathy].
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Humans; Hypertension, Renal; Renin-Angiotensin System; Tetrazoles; Thiazepines; Treatment Outcome; Valine; Valsartan | 2003 |
Angioedema due to valsartan.
Topics: Aged; Angioedema; Angiotensin Receptor Antagonists; Antihypertensive Agents; Female; Humans; Tetrazoles; Valine; Valsartan | 2003 |
Angiotensin receptor subtypes in thin and muscular juxtamedullary efferent arterioles of rat kidney.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arterioles; Calcium; Gene Expression Regulation; Juxtaglomerular Apparatus; Male; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2003 |
The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-alpha in diabetic rats.
Topics: Albuminuria; Animals; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Space; Hypertension, Renal; Kidney; Male; Microdialysis; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2003 |
Enhanced angiotensin-mediated responses in the nucleus tractus solitarii of spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensins; Animals; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Interactions; Functional Laterality; Glutamic Acid; Heart Rate; Hypertension; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Solitary Nucleus; Species Specificity; Tetrazoles; Valine; Valsartan | 2003 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Diuretics; Dizziness; Drug Combinations; Drug Interactions; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Olmesartan Medoxomil; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2003 |
Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Antagonism; Humans; Imidazoles; In Vitro Techniques; Irbesartan; Losartan; Muscle Contraction; Muscle, Smooth, Vascular; Receptors, Thromboxane A2, Prostaglandin H2; Saphenous Vein; Tetrazoles; Valine; Valsartan | 2003 |
Interruption of signal transduction between G protein and PKC-epsilon underlies the impaired myocardial response to ischemic preconditioning in postinfarct remodeled hearts.
Topics: Adenosine; Angiotensin II Type 1 Receptor Blockers; Animals; Cytosol; GTP-Binding Proteins; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion; Protein Kinase C; Protein Kinase C-epsilon; Protein Transport; Rabbits; Receptors, Purinergic P1; Signal Transduction; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2003 |
[Fast-acting sartan. High blood pressure therapy without long waiting time].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Rats; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antioxidants; Blood Pressure; Creatinine; Cyclic N-Oxides; Cyclosporine; Hypertension; Immunosuppressive Agents; Male; Proteinuria; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Spin Labels; Tetrazoles; Valine; Valsartan | 2003 |
[Mucocutaneous bullous pemphigoid induced by valsartan. A clinical case].
Topics: Aged; Antihypertensive Agents; Drug Eruptions; Humans; Male; Pemphigoid, Benign Mucous Membrane; Pemphigoid, Bullous; Tetrazoles; Valine; Valsartan | 2003 |
Lymphomatoid drug eruption mimicking digitate dermatosis: cross reactivity between two drugs that suppress angiotensin II function.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diagnosis, Differential; Drug Eruptions; Hand Dermatoses; Humans; Lisinopril; Male; Pseudolymphoma; Tetrazoles; Valine; Valsartan | 2003 |
Effects of fosinopril and valsartan on expressions of ICAM-1 and NO in human umbilical vein endothelial cells.
Topics: Arteriosclerosis; Cells, Cultured; Endothelium, Vascular; Fosinopril; Humans; Intercellular Adhesion Molecule-1; Lipoproteins, LDL; Nitric Oxide; Nitric Oxide Synthase; Tetrazoles; Umbilical Veins; Valine; Valsartan | 2003 |
Angiotensinase activities in the kidney of renovascular hypertensive rats.
Topics: Adrenal Cortex; Adrenal Medulla; Aminopeptidases; Angiotensin II Type 1 Receptor Blockers; Animals; CD13 Antigens; Cell Membrane; Endopeptidases; Glutamyl Aminopeptidase; Hypertension, Renovascular; Kidney; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2003 |
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
Topics: Aged; Angiotensin Receptor Antagonists; Captopril; Double-Blind Method; Female; Glyceraldehyde-3-Phosphate Dehydrogenases; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptide Fragments; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cyclic GMP; Extracellular Space; Imidazoles; Kidney; Mice; Mice, Knockout; Nitrates; Nitric Oxide; Nitrites; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Receptors, Angiotensin; Receptors, Bradykinin; Sodium; Tetrazoles; Valine; Valsartan | 2003 |
Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Binding, Competitive; Cell Line; Cells, Cultured; COS Cells; Female; Heart Rate; Heterotrimeric GTP-Binding Proteins; Humans; Isoproterenol; Macromolecular Substances; Mice; Mice, Inbred C57BL; Myocardial Contraction; Myocytes, Cardiac; Propranolol; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, beta; Receptors, Angiotensin; Signal Transduction; Tetrazoles; Valine; Valsartan | 2003 |
[The treatment of diabetes at Vals-les-bains].
Topics: Diabetes Mellitus; Humans; Mineral Waters; Tetrazoles; Valine; Valsartan | 1952 |
[Congress of diabetes mellitus; Vals-les-Bains, 15-18 September 1952].
Topics: Diabetes Mellitus; Humans; Tetrazoles; Valine; Valsartan | 1952 |
[Diabetes Congress at Vals].
Topics: Diabetes Mellitus; Humans; Tetrazoles; Valine; Valsartan | 1952 |
[Diabetes; Vals-les-Bains, September 14-18, 1952].
Topics: Diabetes Mellitus; Humans; Tetrazoles; Valine; Valsartan | 1953 |
[Conference on diabetes in Vals-les-Bains, 14-18 September, 1952].
Topics: Diabetes Mellitus; Humans; Tetrazoles; Valine; Valsartan | 1953 |
[Diabetes in 1953; the Congress of Vals].
Topics: Burns; Diabetes Mellitus; Tetrazoles; Valine; Valsartan | 1953 |
[Diabetic center at the Vals-les-Bains Hospital].
Topics: Diabetes Mellitus; Health Facilities; Hospitals; Humans; Tetrazoles; Valine; Valsartan | 1955 |
[Mineral water cure Vals-les-Bains in the treatment of diabetes mellitus].
Topics: Bicarbonates; Diabetes Mellitus; Humans; Mineral Waters; Tetrazoles; Valine; Valsartan | 1955 |
Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Biphenyl Compounds; Electrocardiography; Irbesartan; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Up-Regulation; Valine; Valsartan; Ventricular Function, Left | 2003 |
[Double profit for hypertensive patients. Blood pressure decreases--frequency of coitus increases].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Coitus; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2003 |
Effect of valsartan on hospitalization in Val-HeFT.
Topics: Heart Failure; Humans; Length of Stay; Patient Readmission; Prognosis; Tetrazoles; Valine; Valsartan | 2003 |
Short term effects of valsartan on portal blood flow in cirrhotic patients.
Topics: Adolescent; Adult; Aged; Biopsy, Needle; Blood Flow Velocity; Cohort Studies; Female; Follow-Up Studies; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Portal System; Prospective Studies; Risk Assessment; Severity of Illness Index; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler; Valine; Valsartan | 2003 |
[Dosage equivalents of AT1-receptor antagonists available in Germany].
Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Germany; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Placebos; Telmisartan; Tetrazoles; Therapeutic Equivalency; Thiophenes; Time Factors; Valine; Valsartan | 2003 |
Role of superoxide in modulating the renal effects of angiotensin II.
Topics: Acetophenones; Angiotensin II; Animals; Cyclic N-Oxides; Electrodes; Enzyme Inhibitors; Free Radical Scavengers; Kidney; Kidney Cortex; Male; NADPH Oxidases; Nitric Oxide; Rats; Rats, Sprague-Dawley; Sodium; Spin Labels; Superoxides; Tetrazoles; Valine; Valsartan | 2003 |
Effects of angiotensin II on nitric oxide generation in growing and resting rat aortic endothelial cells.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Calcimycin; Cell Division; Cells, Cultured; Endothelium, Vascular; Imidazoles; In Vitro Techniques; Ionophores; Male; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyridines; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents; Vasodilation | 2003 |
[ACE inhibitors and/or sartans in heart failure: is there a difference?].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Losartan; Tetrazoles; Valine; Valsartan | 2003 |
Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
Effect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathy.
Topics: Adult; Aged; Antihypertensive Agents; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Potassium; Proteinuria; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
Effects of angiotensin II on nitric oxide generation in proliferating and quiescent rat coronary microvascular endothelial cells.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blotting, Northern; Blotting, Western; Calcimycin; Coronary Vessels; Endothelial Cells; Imidazoles; Male; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyridines; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2003 |
Successful treatment of severe hypertension with the combination of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hypertension; Male; Severity of Illness Index; Tetrazoles; Thiazepines; Valine; Valsartan | 2003 |
[Quadritherapy with cyclosporine for membranous lupus nephropathy].
Topics: Adult; Angiotensin Receptor Antagonists; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Female; Glomerulonephritis, Membranous; Humans; Methylprednisolone; Middle Aged; Prednisolone; Pulse Therapy, Drug; Remission Induction; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2003 |
Nitric oxide-dependent antiplatelet action of AT1-receptor antagonists in a pulmonary thromboembolism in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Imidazoles; Injections, Intraperitoneal; Losartan; Mice; Platelet Aggregation Inhibitors; Pulmonary Embolism; Rats; Tetrazoles; Valine; Valsartan | 2003 |
[Episodes of depression with attempted suicide after taking valsartan with hydrochlorothiazide].
Topics: Adult; Antihypertensive Agents; Depression; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Suicide, Attempted; Tetrazoles; Valine; Valsartan | 2003 |
[Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Survival Rate; Tetrazoles; Valine; Valsartan | 2003 |
Effects of angiotensin II on sustained outward currents in rat ventricular myocytes.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Action Potentials; Angiotensin II; Animals; Antihypertensive Agents; Calcium Channel Agonists; Heart Ventricles; Inhibitory Concentration 50; Male; Muscle Cells; Patch-Clamp Techniques; Protein Kinase C; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2004 |
[Coronary stenting. Does AT-1 blocker protect from restenosis?].
Topics: Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Controlled Clinical Trials as Topic; Coronary Restenosis; Humans; Placebos; Stents; Tetrazoles; Valine; Valsartan | 2003 |
Calcineurin promotes the expression of monocyte chemoattractant protein-1 in vascular myocytes and mediates vascular inflammation.
Topics: Angiotensin II; Animals; Calcineurin; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomyopathy, Hypertrophic; Cells, Cultured; Chemokine CCL2; Cyclosporine; Femoral Artery; Gene Expression Regulation; Humans; Hyperplasia; Imidazoles; Macrophages; MAP Kinase Kinase 6; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Promoter Regions, Genetic; Protein Biosynthesis; Proteins; Pyridines; Rats; Recombinant Fusion Proteins; RNA, Messenger; Signal Transduction; Tetrazoles; Transcription, Genetic; Tunica Intima; Valine; Valsartan; Vasculitis | 2004 |
Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen Type I; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Heart; In Situ Hybridization; Infusions, Parenteral; Male; Myocardium; Nephrectomy; NF-kappa B; Rats; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan an alternative to ACE inhibitor in high-risk MI.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Valsartan restores sarcoplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Calcium-Transporting ATPases; Cardiac Pacing, Artificial; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dobutamine; Dogs; Drug Evaluation, Preclinical; Heart Failure; Myocardial Contraction; Norepinephrine; Phosphorylation; Protein Processing, Post-Translational; Receptors, Adrenergic, beta; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Tachycardia, Ventricular; Tacrolimus Binding Proteins; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2004 |
[Diabetes cure at Vals-les-Bains, based on recent research].
Topics: Balneology; Diabetes Mellitus; Humans; Tetrazoles; Valine; Valsartan | 1951 |
[Vals-les-Bains cure in diabetics].
Topics: Diabetes Mellitus; Humans; Mineral Waters; Tetrazoles; Valine; Valsartan | 1951 |
An analytical application of Valser's reagent. I. A general method for the assay of organic bases in certain pharmaceutical products.
Topics: Biological Assay; Indicators and Reagents; Organic Chemicals; Pharmaceutical Preparations; Tetrazoles; Valine; Valsartan | 1952 |
[When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[New options against undertreatment].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Heart Failure; Hospitalization; Humans; Losartan; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
Implications of recent clinical trials for heart failure performance measures.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Practice Guidelines as Topic; Quality of Health Care; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2004 |
Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat models of in vivo reperfused myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dogs; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Treatment Outcome; Up-Regulation; Valine; Valsartan; Ventricular Function, Left | 2004 |
These drugs are an ACE in the hole. Angiotensin receptor blockers prove okay when an ACE inhibitor causes problems.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Cardiac Output, Low; Cough; Humans; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan, captopril, or both in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Ethics, Clinical; Heart Failure; Humans; Myocardial Infarction; Placebos; Research Design; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Valsartan, captopril, or both in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Humans; Kidney Diseases; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan, captopril, or both in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Humans; Hypotension; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2004 |
Short-term effects of exogenous angiotensin II on plasma fibrinolytic balance in normal subjects.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; Circadian Rhythm; Diastole; Dose-Response Relationship, Drug; Fibrinolysis; Fibrinolytic Agents; Germany; Heart Rate; Humans; Hydrocortisone; Male; Plasminogen Activator Inhibitor 1; Receptor, Angiotensin, Type 1; Reference Values; Renin; Renin-Angiotensin System; Serine Proteinase Inhibitors; Systole; Tetrazoles; Time Factors; Tissue Plasminogen Activator; Valine; Valsartan; Vasoconstrictor Agents | 2004 |
The role of nitric oxide in the regulation of glomerular haemodynamics in humans.
Topics: Adult; Amlodipine; Angiotensin Receptor Antagonists; Calcium Channel Blockers; Glomerular Filtration Rate; Hemodynamics; Humans; Kidney Glomerulus; Middle Aged; Nitric Oxide; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2004 |
Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.
Topics: Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Carotid Artery Injuries; Disease Models, Animal; Hypertension; Nitric Oxide; Oxidative Stress; Rats; Rats, Sprague-Dawley; Tetrazoles; Tunica Intima; Valine; Valsartan | 2004 |
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Cell Differentiation; Cells, Cultured; Chlorocebus aethiops; Drug Evaluation, Preclinical; Gene Expression Regulation; Imidazoles; Insulin; Irbesartan; Losartan; Male; Mice; Models, Molecular; Myoblasts; Protein Conformation; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Telmisartan; Tetrazoles; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Triglycerides; Valine; Valsartan; Weight Gain | 2004 |
Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Aquaporin 2; Aquaporins; Drug Therapy, Combination; Fosinopril; Gene Expression; Heart Failure; Kidney Cortex; Kidney Medulla; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2004 |
VALIANT and EUROPA.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Crosses, Genetic; Deoxyglucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Energy Intake; Gene Expression Regulation; Glucose Transporter Type 4; Imidazoles; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mice, Obese; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Phosphoproteins; Phosphorylation; Protein Processing, Post-Translational; Protein Transport; Pyridines; Signal Transduction; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2004 |
The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Schedule; Echocardiography; Female; Glycated Hemoglobin; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2004 |
Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Platelets; Cardiovascular Diseases; Dual Specificity Phosphatase 2; Female; Flow Cytometry; Humans; In Vitro Techniques; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Protein Phosphatase 2; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Tetrazoles; Valine; Valsartan | 2004 |
Aldosterone levels after angiotensin receptor blocker treatment.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Disease Progression; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2004 |
Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex.
Topics: Aged; Angioedema; Angiotensin Receptor Antagonists; Antihypertensive Agents; Female; Humans; Losartan; Sex Factors; Tetrazoles; Valine; Valsartan | 2004 |
[AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diuretics; Double-Blind Method; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Losartan; Meta-Analysis as Topic; Placebos; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Stroke; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Cells, Cultured; Cyclic AMP; Cyclic GMP; Hypertension; Muscle, Smooth, Vascular; Prazosin; Rats; Rats, Inbred SHR; Rats, Inbred WKY; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Stroke; Tetrazoles; Valine; Valsartan | 2004 |
Effects of angiotensin II receptor antagonist on expression of collagen III, collagen V, and transforming growth factor beta1 in the airway walls of sensitized rats.
Topics: Angiotensin Receptor Antagonists; Animals; Asthma; Bronchi; Collagen Type III; Collagen Type V; Immunization; Male; Ovalbumin; Random Allocation; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2004 |
Valsartan treatment of hypertension--does VALUE add value?
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Endpoint Determination; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan | 2004 |
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Cardiac angiotensin is upregulated in the hearts of unstable angina patients.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Electrocardiography; Humans; Male; Middle Aged; Models, Cardiovascular; Myocardium; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2004 |
High-dose exposure to valsartan with suicidal intention.
Topics: Adult; Antihypertensive Agents; Female; Humans; Suicide, Attempted; Tetrazoles; Valine; Valsartan | 2004 |
AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Dogs; Heart Rate; Heart Ventricles; Hemodynamics; Irbesartan; Myocardial Infarction; Myocardial Reperfusion Injury; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Remodeling | 2004 |
Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Glomerular Filtration Rate; Humans; Hypertension; Microcirculation; Receptor, Angiotensin, Type 1; Renal Circulation; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Fluid; Kidney; Losartan; Nitric Oxide; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2004 |
["An extraordinary initiative"].
Topics: Antihypertensive Agents; Drug Costs; Drug Information Services; Humans; Tetrazoles; Valine; Valsartan | 2004 |
Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Brain Chemistry; Brain Ischemia; Cerebrovascular Circulation; Infarction, Middle Cerebral Artery; Laser-Doppler Flowmetry; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Oxidative Stress; Receptor, Angiotensin, Type 2; Superoxides; Tetrazoles; Valine; Valsartan | 2004 |
Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Central Venous Pressure; Chromatography, High Pressure Liquid; Collagen; Heart; Hydroxyproline; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Organ Size; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2004 |
Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Blood Pressure; Body Weight; Brain; Chemokine CCL2; Immunohistochemistry; Interleukin-1; Kidney; Magnetic Resonance Imaging; Male; Proteinuria; Rats; Rats, Inbred SHR; RNA, Messenger; Stroke; Survival Analysis; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2004 |
[The value of VALUE--a hypertension study which compared valsartan with amlodipine. New data support early, optimal blood pressure control for high-risk patients].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; Risk Factors; Tetrazoles; Valine; Valsartan | 2004 |
[Effects of the combined use of benazepril and valsartan on apoptosis in the kidney of rats with adriamycin-induced nephritic glomerulosclerosis].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Benzazepines; Doxorubicin; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Glomerulosclerosis, Focal Segmental; Kidney; Male; Membrane Glycoproteins; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles; Tumor Necrosis Factors; Valine; Valsartan | 2004 |
[First fixed combination of sartan and high-dosage diuretic. A strong duo against high blood pressure].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Patient Compliance; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan | 2004 |
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperkalemia; Hypertension; Male; Middle Aged; Muscle Weakness; Spironolactone; Tetrazoles; Valine; Valsartan | 2004 |
Systemic hemodynamics in non-anesthetized L-NAME- and DOCA-salt-treated mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Desoxycorticosterone; Drug Synergism; Enzyme Inhibitors; Hemodynamics; Hypertension; Mice; Mice, Inbred Strains; NG-Nitroarginine Methyl Ester; Sodium Chloride; Tetrazoles; Time Factors; Valine; Valsartan; Vascular Resistance | 2004 |
Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Humans; Hypertension; Telmisartan; Tetrazoles; Valine; Valsartan | 2004 |
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Life Tables; Male; Medical Records; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
[New combination of high dosage sartan and 25 mg HCT. Systolic blood pressure lowered by 21 mmHg].
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2004 |
[The effect of valsartan on hepatic stellate cell proliferation and collagen synthesis].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Proliferation; Cells, Cultured; Collagen Type I; Hepatocytes; Tetrazoles; Valine; Valsartan | 2004 |
[Angiotensin type 1 receptor blocker reduced proteinuria in patients of focal glomerular sclerosis].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diet, Protein-Restricted; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Humans; Immunosuppressive Agents; Losartan; Male; Methylprednisolone; Middle Aged; Prednisolone; Proteinuria; Remission Induction; Ribonucleosides; Tetrazoles; Valine; Valsartan | 2004 |
Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Mice; Mice, Knockout; Oxidative Stress; Tetrazoles; Valine; Valsartan | 2004 |
Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Blotting, Western; Densitometry; Disease Models, Animal; Dogs; Electrocardiography; Electrophoresis, Gel, Two-Dimensional; Heart Rate; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardial Infarction; Myocardial Reperfusion; Random Allocation; Tetrazoles; Tissue Inhibitor of Metalloproteinase-3; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Sartans for hypertension--implications of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Tetrazoles; Valine; Valsartan | 2004 |
The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Coronary Artery Disease; Coronary Vessels; Heart Transplantation; Male; Mice; Mice, Inbred DBA; Tetrazoles; Valine; Valsartan | 2005 |
Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression.
Topics: Administration, Oral; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cyclic N-Oxides; Disease Models, Animal; Glucose; Hypertension; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Spin Labels; Tetrazoles; Valine; Valsartan | 2005 |
[The effect of angiotensin II type 1 receptor blocker valsartan in preventing hepatic fibrosis induced by dimethylnitrosamine in rats].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dimethylnitrosamine; Female; Liver Cirrhosis, Experimental; Male; Random Allocation; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2004 |
Hypovolaemia-induced vasodilatation during angiotensin AT1 receptor blockade: role of the AT2 receptor.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Female; Hypovolemia; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Swine; Tetrazoles; Valine; Valsartan; Vasodilation | 2005 |
AT1 receptor blockade alters metabolic, functional and structural proteins after reperfused myocardial infarction: detection using proteomics.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; ATP Synthetase Complexes; Biphenyl Compounds; Creatine Kinase; Dogs; Hemodynamics; Irbesartan; Isocitrate Dehydrogenase; Myocardial Infarction; Myocardial Reperfusion Injury; Myosin Light Chains; Proteins; Proteomics; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2004 |
[Despite drug treatment, ever second hypertensive patient with morning blood pressure too high].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Circadian Rhythm; Clinical Trials as Topic; Drug Administration Schedule; Humans; Hypertension; Losartan; Telmisartan; Tetrazoles; Valine; Valsartan | 2004 |
[Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice?].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cardiovascular Diseases; Cause of Death; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Survival Rate; Tetrazoles; Valine; Valsartan | 2004 |
[Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2004 |
VALUE in hypertension treatment.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
[AT1 blocker or calcium antagonist in treatment of hypertension. What protects the heart better?].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Hypertension; Risk Factors; Tetrazoles; Valine; Valsartan | 2004 |
[VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Sodium Chloride Symporter Inhibitors; Tetrazoles; Time Factors; Valine; Valsartan | 2004 |
Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Consciousness; Depression, Chemical; Female; Imidazoles; Injections; Juxtaglomerular Apparatus; Kidney Cortex; Kidney Tubules; Natriuresis; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Renin; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium, Dietary; Systole; Tetrazoles; Valine; Valsartan | 2005 |
Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Antibodies, Monoclonal; Benzimidazoles; Biphenyl Compounds; Cells, Cultured; Collagen Type I; Endoglin; Fibroblasts; Flavonoids; Gene Expression Regulation; Imidazoles; Intracellular Signaling Peptides and Proteins; Losartan; MAP Kinase Signaling System; Matrix Metalloproteinase 1; Myocardium; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Transforming Growth Factor beta; RNA, Messenger; Signal Transduction; Tetrazoles; Valine; Valsartan | 2004 |
[VALUE study underscores the importance of reaching goal blood pressure values for minimization of cardiovascular risks].
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Prospective Studies; Randomized Controlled Trials as Topic; Reference Values; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan | 2004 |
Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Humans; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Angiotensin receptor blockers and myocardial infarction.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Myocardial Infarction; Tetrazoles; Truth Disclosure; Valine; Valsartan | 2004 |
Valuable lessons from VALUE.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Humans; Hypertension; Tetrazoles; Valine; Valsartan | 2004 |
The value of VALUE: the importance of lowering blood pressure quickly.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Middle Aged; Risk Factors; Tetrazoles; Valine; Valsartan | 2004 |
Transient receptor potential melastatin 7 ion channels regulate magnesium homeostasis in vascular smooth muscle cells: role of angiotensin II.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Division; Cells, Cultured; DNA Replication; Gene Expression Regulation; Homeostasis; Humans; Ion Channels; Ion Transport; Magnesium; Membrane Proteins; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Protein Biosynthesis; Protein Kinases; Protein Serine-Threonine Kinases; Rats; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Tetrazoles; Transfection; TRPM Cation Channels; Valine; Valsartan | 2005 |
Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; PPAR gamma; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 2005 |
[Effects of perindopril and valsartan on the expression of TGF beta 1 and TGF beta receptor II mRNA, Smad3 and Smad7 in experimental hepatic fibrotic rats].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Carbon Tetrachloride; Carbon Tetrachloride Poisoning; Female; Liver Cirrhosis, Experimental; Male; Perindopril; Random Allocation; Rats; Rats, Wistar; Receptors, Transforming Growth Factor beta; RNA, Messenger; Smad3 Protein; Smad7 Protein; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan | 2004 |
Automated office and home phone-transmitted blood pressure recordings in uncontrolled hypertension treated with valsartan and hydrochlorothiazide.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Automation; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Oscillometry; Telephone; Tetrazoles; Time Factors; Valine; Valsartan | 2004 |
[The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Male; Mice; Random Allocation; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2004 |
Effects of volsartan on transmural heterogeneous changes of transient outward potassium currents in hypertrophic cardiomyocytes in rabbits.
Topics: Animals; Antihypertensive Agents; Biological Transport, Active; Female; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium Channels; Rabbits; Tetrazoles; Valine; Valsartan | 2004 |
Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
Topics: Administration, Oral; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Callithrix; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Female; Fumarates; Heart Rate; Imidazoles; Injections, Intravenous; Male; Piperazines; Rats; Rats, Inbred SHR; Renin; Telemetry; Tetrazoles; Thiazoles; Valine; Valsartan | 2005 |
Valsartan versus ACE inhibition after bare metal stent implantation--results of the VALVACE trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Coronary Restenosis; Coronary Stenosis; Female; Humans; Male; Middle Aged; Stents; Tetrazoles; Valine; Valsartan | 2005 |
Characteristics of attenuated endothelium-dependent relaxation seen in rabbit intrapulmonary vein following chronic nitroglycerine administration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Apamin; Calcium Channel Blockers; Charybdotoxin; Drug Interactions; Drug Tolerance; Endothelium, Vascular; Hydrazines; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Nitric Oxide Donors; Nitric Oxide Synthase; Nitroarginine; Nitroglycerin; Pulmonary Veins; Rabbits; Receptor, Angiotensin, Type 1; Superoxides; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2005 |
[Effects of angiotensin II on peripheral blood endothelial progenitor cells].
Topics: Angiotensin II; Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Neovascularization, Physiologic; Stem Cells; Tetrazoles; Valine; Valsartan | 2005 |
Effect of valsartan versus lisinopril on peritoneal sclerosis in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Glucose; Lisinopril; Male; Microscopy; Peritoneum; Rats; Rats, Wistar; Sclerosis; Tetrazoles; Ultrafiltration; Urea; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2005 |
Changes in plasma lipids during renin-angiotensin system blockade by combination therapy (enalapril plus valsartan) in patients with diabetes and hypertension.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enalapril; Humans; Hypertension; Lipids; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2005 |
Is there more to life than blood pressure?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Renoprotective effect of combining angiotensin II receptor blockers and statins in diabetic rats.
Topics: Animals; Chemokine CCL2; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Kidney; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles; Transcription Factor RelA; Valine; Valsartan | 2005 |
Cumulative effects of AT1 and AT2 receptor blockade on ischaemia-reperfusion recovery in rat hearts.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Heart; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Recovery of Function; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2005 |
Increased renal production of angiotensin II and thromboxane B2 in conscious diabetic rats.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Extracellular Fluid; Kidney; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Thromboxane B2; Valine; Valsartan | 2005 |
In search of true value.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Aged; Atrial Fibrillation; Comorbidity; Electrocardiography; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Administration, Oral; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Body Weight; Deoxyguanosine; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Islets of Langerhans; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
NAD(P)H-dependent superoxide production in platelets: the role of angiotensin II and protein kinase C.
Topics: Aged; Alkaloids; Angiotensin II; Angiotensin Receptor Antagonists; Benzophenanthridines; Blood Platelets; Female; Humans; Hypertension; Male; Membrane Glycoproteins; Middle Aged; NADH, NADPH Oxidoreductases; NADPH Oxidase 2; NADPH Oxidases; Phenanthridines; Protein Kinase C; Superoxides; Tetradecanoylphorbol Acetate; Tetrazoles; Valine; Valsartan | 2005 |
[The effect and mechanism of felodipine and valsartan on a novel salt-sensitive hypertensive rat induced by sensory denervation].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Felodipine; Hypertension; Male; Rats; Rats, Wistar; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2005 |
Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
Topics: Acetylcysteine; Animals; Antihypertensive Agents; Aorta; Arteries; Blotting, Western; Body Weight; Carbazoles; Carvedilol; Down-Regulation; Doxazosin; Echocardiography; Hemodynamics; Hypertrophy; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Myocardium; Nerve Growth Factor; Organ Size; Pressure; Propanolamines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Transcription Factors; Valine; Valsartan; Vascular Endothelial Growth Factor A; Vasodilator Agents | 2005 |
[The effect of captopril and valsartan on preventing the formation of atherosclerotic plaque].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Abdominal; Arteriosclerosis; Captopril; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Male; Rabbits; Tetrazoles; Ultrasonography; Valine; Valsartan | 2005 |
Angiotensin II type 1 receptor blocker inhibits pulmonary injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antimetabolites, Antineoplastic; Bleomycin; Blotting, Western; Collagen; Connective Tissue Growth Factor; Enzyme-Linked Immunosorbent Assay; Female; Fibrosis; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lung; Macrophages; Rats; Rats, Sprague-Dawley; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan | 2005 |
Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor.
Topics: Adrenalectomy; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Cytochrome P-450 CYP11B2; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Insulin; Kidney; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; RNA, Messenger; Sodium Chloride; Steroid Hydroxylases; Tetrazoles; Tissue Distribution; Valine; Valsartan | 2005 |
[A case of drug-induced pneumonitis associated with chinese herbal drugs and valsartan].
Topics: Aged; Drugs, Chinese Herbal; Humans; Male; Pneumonia; Radiography, Thoracic; Tetrazoles; Tomography, X-Ray Computed; Valine; Valsartan | 2005 |
Valsartan improves mitochondrial function in hearts submitted to acute ischemia.
Topics: Acute Disease; Adenosine Diphosphate; Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Animals; Heart; In Vitro Techniques; Intracellular Membranes; Membrane Potentials; Mitochondria, Heart; Myocardial Ischemia; Oxidative Phosphorylation; Oxygen Consumption; Rats; Rats, Wistar; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2005 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan | 2005 |
Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.
Topics: Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Animals, Genetically Modified; Blood Pressure; Cardiomegaly; Dose-Response Relationship, Drug; Echocardiography; Fumarates; Humans; Hypertension; Kidney; Rats; Rats, Sprague-Dawley; Renin; Tetrazoles; Valine; Valsartan | 2005 |
Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Constriction, Pathologic; Dose-Response Relationship, Drug; Female; Femoral Artery; Male; Mice; Mice, Knockout; Oxidative Stress; Receptor, Angiotensin, Type 2; Sex Characteristics; Tetrazoles; Valine; Valsartan; Vasculitis; Wounds and Injuries | 2005 |
[Effects of valsartan on bleomycin-induced pulmonary fibrosis in rats and the expression of hepatocyte growth factor in lung tissue].
Topics: Animals; Hepatocyte Growth Factor; Lung; Male; Pulmonary Fibrosis; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2005 |
Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Budgets; Cost-Benefit Analysis; Heart Failure; Hospitalization; Humans; Models, Economic; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice.
Topics: Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Gene Deletion; Imidazoles; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2005 |
Modulation of 24-h blood pressure profiles: a new target for treatment?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Humans; Hypertension; Tetrazoles; Valine; Valsartan | 2005 |
Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Antihypertensive Agents; Astrocytes; Carboxypeptidases; Cells, Cultured; Cerebellum; Female; Gene Expression Regulation; Imidazoles; Losartan; Medulla Oblongata; Peptide Fragments; Peptidyl-Dipeptidase A; Pregnancy; Pyridines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2006 |
Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
Topics: Angiotensin II Type 1 Receptor Blockers; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Diclofenac; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; Kinetics; Microsomes, Liver; Proadifen; Recombinant Proteins; Tetrazoles; Valine; Valsartan | 2005 |
Angiotensin II type 1 (AT1)-receptor blocker prevents impairment of endothelium-dependent cerebral vasodilation by acute cigarette smoking in rats.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Cerebrovascular Circulation; Endothelium, Vascular; Male; Models, Animal; Nicotine; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Smoke; Smoking; Tetrazoles; Valine; Valsartan; Vasodilation | 2006 |
Left ventricular assessment in myocardial infarction: the VALIANT registry.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Cardiac Catheterization; Echocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2005 |
[Effects of angiotensin II on extracellular signal-regulated protein kinases signaling pathway in cultured vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats].
Topics: Angiotensin II; Animals; Cells, Cultured; Dual Specificity Phosphatase 1; Extracellular Signal-Regulated MAP Kinases; Hypertension; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Tetrazoles; Valine; Valsartan | 2005 |
Drug-induced isolated visceral angioneurotic edema.
Topics: Adult; Angioedema; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diagnosis, Differential; Female; Glomerulonephritis, Membranoproliferative; Humans; Lisinopril; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2005 |
How FDA currently makes decisions on clinical studies.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carbazoles; Carvedilol; Child; Clinical Trials as Topic; Diabetic Nephropathies; Evidence-Based Medicine; Heart Failure; Humans; Propanolamines; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2005 |
Valsartan abolishes most of the memory-improving effects of intracerebroventricular angiotensin II in rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Avoidance Learning; Behavior, Animal; Conditioning, Operant; Drinking; Injections, Intraventricular; Male; Maze Learning; Memory; Motor Activity; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2005 |
Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; C-Reactive Protein; Cytokines; Female; Humans; Hypertension; Interleukin-6; Male; Middle Aged; Serum Amyloid A Protein; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2005 |
Evaluation of intrarenal hemodynamics by Doppler ultrasonography for renoprotective effect of angiotensin receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Hemodynamics; Humans; Hypertension; Kidney; Kidney Diseases; Losartan; Male; Middle Aged; Tetrazoles; Ultrasonography, Doppler; Valine; Valsartan | 2005 |
Physicochemical properties of valsartan and the effect of ethyl alcohol, propylene glycol and pH on its solubility.
Topics: Antihypertensive Agents; Calibration; Chemical Phenomena; Chemistry, Physical; Ethanol; Hydrogen-Ion Concentration; Propylene Glycol; Reference Standards; Solubility; Solvents; Tetrazoles; Thermodynamics; Valine; Valsartan | 2005 |
[The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy].
Topics: Animals; Aristolochic Acids; Bosentan; Collagen Type I; Connective Tissue Growth Factor; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; Male; Plasminogen Activator Inhibitor 1; Rats; Rats, Sprague-Dawley; Sulfonamides; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Valine; Valsartan | 2005 |
[Hypertension and diabetic nephropathy, a dangerous duo].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Hypertension; Male; Metabolic Syndrome; Ramipril; Tetrazoles; Valine; Valsartan | 2005 |
Biphasic effects of angiotensin II and receptor antagonism on aggregability and protein kinase C phosphorylation in human platelets.
Topics: Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Platelets; Female; Humans; Imidazoles; In Vitro Techniques; Isoenzymes; Male; Middle Aged; Phosphorylation; Platelet Aggregation; Protein Kinase C; Pyridines; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2005 |
[Acute renal failure and hypertension].
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Humans; Hypertension, Renovascular; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2005 |
Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Basilar Artery; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Mesenteric Arteries; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Wistar; Rosiglitazone; Simvastatin; Tetrazoles; Thiazolidinediones; Tunica Media; Valine; Valsartan | 2005 |
[Mechanism of cardioprotection against ischemia/reperfusion injury by valsartan: an experiment with isolated rat hearts].
Topics: Animals; Bradykinin; Bradykinin B2 Receptor Antagonists; Cardiotonic Agents; Creatine Kinase, MB Form; Disease Models, Animal; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B2; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2005 |
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Cholesterol, Dietary; Diet, Atherogenic; Enzyme Activation; Eplerenone; Inflammation; Male; Mice; Muscle, Smooth, Vascular; NADPH Oxidases; Oxidative Stress; Spironolactone; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography.
Topics: Angiotensin Receptor Antagonists; Blood Proteins; Calibration; Chemical Precipitation; Chromatography, High Pressure Liquid; Humans; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan | 2006 |
Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Disease Progression; Echocardiography; Heart Failure; Heart Ventricles; Humans; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stroke Volume; Survival Rate; Tetrazoles; Valine; Valsartan | 2006 |
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Benzimidazoles; Benzoates; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Endothelium, Vascular; Humans; Hypertension; Middle Aged; Multicenter Studies as Topic; Oxidative Stress; Randomized Controlled Trials as Topic; Renal Insufficiency; Telmisartan; Tetrazoles; Valine; Valsartan | 2005 |
[Dilation of the brachial artery in response to sublingual nitroglycerin can predict the antihypertensive effects of valsartan: a study using novel high-frequency high-frame-rate ultrasound imaging].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Brachial Artery; Female; Humans; Hypertension; Male; Middle Aged; Nitroglycerin; Predictive Value of Tests; Tetrazoles; Ultrasonography; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2006 |
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Captopril; Cardiovascular Diseases; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Valine; Valsartan | 2006 |
Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cohort Studies; Electrocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Blood pressure control with valsartan and hydrochlorothiazide in clinical practice: the MACHT Observational Study.
Topics: Aged; Blood Pressure; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2006 |
[Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Long-Term Care; Myocardial Infarction; Secondary Prevention; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Relationship between adhesion molecules with hs-CRP and changes therein after ARB (Valsartan) administration in patients with obstructive sleep apnea syndrome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; C-Reactive Protein; Case-Control Studies; Female; Humans; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Myocardial Ischemia; Sleep Apnea, Obstructive; Tetrazoles; Valine; Valsartan | 2006 |
[Biliary stenosis, hepatitis A and valsartan: multifactorial hepatotoxicity in a surgical patient].
Topics: Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Cholestasis; Hepatitis A; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2006 |
Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cell Count; Cell Size; Energy Metabolism; Fatty Liver; Gene Expression; Male; Mitochondria; Rats; Rats, Sprague-Dawley; Telmisartan; Tetrazoles; Valine; Valsartan; Weight Gain | 2006 |
Effect of valsartan-eluting stents on the expression of angiotensin II type 2 receptor.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Coronary Angiography; Coronary Restenosis; Coronary Vessels; Drug Delivery Systems; Immunohistochemistry; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Reverse Transcriptase Polymerase Chain Reaction; Stents; Tetrazoles; Valine; Valsartan | 2006 |
Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
Topics: Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Animals; Bile; Cell Line; Cell Membrane; Disease Models, Animal; Estrone; Hepatocytes; Humans; Hyperbilirubinemia; Liver-Specific Organic Anion Transporter 1; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Rats; Rats, Sprague-Dawley; Sincalide; Solute Carrier Organic Anion Transporter Family Member 1B3; Tetrazoles; Transfection; Valine; Valsartan | 2006 |
[Effect of valsartan on Tribble 3 gene expression in rats with experimental diabetic cardiomyopathy].
Topics: Animals; Cardiomyopathy, Dilated; Diabetes Mellitus, Experimental; Gene Expression; Male; Protein Kinases; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2006 |
Effects of valsartan on stress-induced changes of serum vascular endothelial growth factor and nitric oxide in mice.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Chi-Square Distribution; Enzyme-Linked Immunosorbent Assay; Male; Mice; Mice, Inbred BALB C; Nitric Oxide; Restraint, Physical; Stress, Physiological; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2006 |
Solubilization of valsartan by aqueous glycerol, polyethylene glycol and micellar solutions.
Topics: Antihypertensive Agents; Glycerol; Micelles; Pharmaceutical Vehicles; Polyethylene Glycols; Polysorbates; Reference Standards; Sodium Dodecyl Sulfate; Solubility; Solutions; Solvents; Surface-Active Agents; Tetrazoles; Thermodynamics; Valine; Valsartan | 2006 |
[Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Blotting, Western; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Experimental; Fibrosis; Heart; Male; Myocardium; Random Allocation; Rats; Rats, Wistar; Receptors, Angiotensin; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tetrazoles; Thrombospondin 1; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-kappaB-dependent pathway in rat preadipocytes.
Topics: Adipocytes; Adipose Tissue; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cell Differentiation; Chemokine CCL2; Humans; Male; NF-kappa B; Nitriles; Obesity; Promoter Regions, Genetic; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfones; Tetrazoles; Thiocarbamates; Transcription, Genetic; Valine; Valsartan | 2006 |
[Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combination; Evidence-Based Medicine; Family Practice; Germany; Heart Failure; Humans; Hypertension; Myocardial Infarction; Product Surveillance, Postmarketing; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glycosylation; Humans; Hypertension; Japan; Tetrazoles; Thiobarbituric Acid Reactive Substances; Valine; Valsartan | 2006 |
Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2.
Topics: Angiotensin II; Animals; Brain Ischemia; Cell Differentiation; Cells, Cultured; Cognition; Mice; Mice, Inbred C57BL; Neurons; Receptor, Angiotensin, Type 2; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tetrazoles; Transcriptional Activation; Ubiquitin-Conjugating Enzymes; Valine; Valsartan | 2006 |
Intracellular angiotensin II induces cell proliferation independent of AT1 receptor.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cattle; Cell Proliferation; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Rats; Receptor, Angiotensin, Type 1; Tetrazoles; Transfection; Valine; Valsartan | 2006 |
Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Enalapril; Female; Glycation End Products, Advanced; Mice; Mice, Inbred C57BL; Mice, Obese; Pyridoxamine; Tetrazoles; Valine; Valsartan; Vitamin B Complex | 2006 |
[Valsartan eluting-stents inhibited neointimal hyperplasia by decreasing collagen deposition in rabbits].
Topics: Animals; Collagen; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Hyperplasia; Male; Rabbits; Tetrazoles; Tunica Intima; Valine; Valsartan | 2006 |
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Animals, Genetically Modified; Blood Pressure; Disease Models, Animal; Hypertension, Renal; Kidney Glomerulus; Male; Malondialdehyde; Mice; Microscopy, Electron, Transmission; NADPH Oxidases; Neprilysin; Oxidative Stress; Peptidyl-Dipeptidase A; Podocytes; Rats; Rats, Sprague-Dawley; Renin; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2006 |
Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Flow Velocity; Blood Pressure; Creatinine; Cystatin C; Cystatins; Female; Humans; Hypertension; Japan; Kidney; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Pulsatile Flow; Renal Circulation; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler; Valine; Valsartan; Vascular Resistance | 2006 |
Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion.
Topics: Acute Disease; Animals; Antihypertensive Agents; Blood Flow Velocity; Chemoprevention; Endothelium; Fosinopril; H(+)-K(+)-Exchanging ATPase; Models, Animal; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Swine; Tetrazoles; Time Factors; Valine; Valsartan | 2006 |
[Angiotensin II AT1 receptor antagonists as antiinflammatory and gastric protection drugs].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Benzimidazoles; Biphenyl Compounds; Carrageenan; Disease Models, Animal; Edema; Female; Gastric Mucosa; Indomethacin; Losartan; Rats; Rats, Wistar; Stomach Ulcer; Tetrazoles; Valine; Valsartan | 2006 |
The Valsartan Antihypertensive Long-Term Use Evaluation trial: a study in contrasts.
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Drug Administration Schedule; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2006 |
Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Topics: Animals; Anticholesteremic Agents; Azetidines; Choline Deficiency; Drug Therapy, Combination; Ezetimibe; Fats; Fatty Liver; Hypoglycemic Agents; Lipid Peroxidation; Liver; Male; Metformin; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rosiglitazone; Tetrazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
Hematuria in a patient with class IV lupus nephritis.
Topics: Antihypertensive Agents; Biopsy; Cyclophosphamide; El Salvador; Female; Follow-Up Studies; Glomerular Basement Membrane; Glomerular Mesangium; Glucocorticoids; Hematuria; Hispanic or Latino; Humans; Hydrochlorothiazide; Hydroxychloroquine; Hypertension; Immunosuppressive Agents; Kidney Glomerulus; Lisinopril; Lupus Nephritis; Middle Aged; Nifedipine; Prednisone; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2006 |
Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats.
Topics: Animals; Antihypertensive Agents; Gene Expression; Immunohistochemistry; Liver; Liver Cirrhosis, Experimental; Perindopril; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Smad3 Protein; Smad7 Protein; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2006 |
Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Comorbidity; Diastole; Double-Blind Method; Echocardiography, Doppler; Humans; Hypertension; Randomized Controlled Trials as Topic; Research Design; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction | 2006 |
Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Hypertension; Myocardial Infarction; Research Design; Tetrazoles; Valine; Valsartan | 2006 |
Prevention of adipose tissue depletion during food deprivation in angiotensin type 2 receptor-deficient mice.
Topics: Adipocytes; Adipose Tissue; Animals; Fasting; Fatty Acids, Nonesterified; Food Deprivation; Lipolysis; Liver; Male; Mice; Mice, Inbred C57BL; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2006 |
Determination and validation of ketoprofen, pantoprazole and valsartan together in human plasma by high performance liquid chromatography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antihypertensive Agents; Benzimidazoles; Chromatography, High Pressure Liquid; Humans; Indicators and Reagents; Ketoprofen; Omeprazole; Pantoprazole; Reference Standards; Reproducibility of Results; Sulfoxides; Tetrazoles; Valine; Valsartan | 2006 |
Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Dendritic Cells; Disease Models, Animal; Disease Progression; Fibrosis; Immunohistochemistry; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Membrane Glycoproteins; Proteinuria; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2006 |
[Lowering blood pressure substantially--and the diabetes risk as well?].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitors; Circadian Rhythm; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Humans; Hypertension; Sodium Chloride Symporter Inhibitors; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Aged; Captopril; Drug Therapy, Combination; Female; Humans; Internationality; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Proliferation; Disease Models, Animal; Diuretics; Fibrosis; Glomerulonephritis, Membranoproliferative; Ki-67 Antigen; Kidney; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Spironolactone; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
[The effect of angiotensin II type 1 receptor blocker valsartan in rats with portal hypertensive gastropathy].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Gastric Mucosa; Hypertension, Portal; Male; Propranolol; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2006 |
Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting inflammation and progenitor cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Biomarkers; Blood Pressure; Blood Vessels; Cell Differentiation; Constriction, Pathologic; Iliac Artery; Imidazoles; Inflammation; Inflammation Mediators; Isoenzymes; Macaca fascicularis; Male; Monocytes; Myocytes, Smooth Muscle; NADPH Oxidases; Oxidative Stress; Rabbits; Recurrence; Renin-Angiotensin System; Stem Cells; Stents; Tetrazoles; Tunica Intima; Valine; Valsartan | 2006 |
Endothelial progenitor cell differentiation and senescence in an angiotensin II-infusion rat model.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cellular Senescence; Endothelium, Vascular; Hydralazine; Male; Rats; Rats, Wistar; Stem Cells; Telomerase; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2006 |
Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade.
Topics: Amlodipine; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Carotid Artery, Common; Cyclic GMP; Male; Rats; Rats, Inbred BN; Receptor, Angiotensin, Type 2; Tetrazoles; Tunica Intima; Tunica Media; Valine; Valsartan | 2006 |
Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Progression; Drug Implants; Female; Gene Expression Regulation; Glomerulonephritis; Isoantibodies; Kidney Glomerulus; Microcirculation; Nephrectomy; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2006 |
Use of valsartan in post-myocardial infarction and heart failure patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Body Weight; Male; Mice; Mice, Knockout; Myocardial Infarction; Organ Size; Receptor, Angiotensin, Type 2; Survival Rate; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2006 |
[Dilemma of antihypertensive therapy: high blood pressure diminishes, potency sometimes, too].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Diuretics; Erectile Dysfunction; Humans; Hypertension; Male; Myocardial Infarction; Tetrazoles; Time Factors; Valine; Valsartan | 2006 |
Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Female; Imidazoles; Losartan; Organic Anion Transporters; Organic Cation Transport Proteins; Pyrazinamide; Tetrazoles; Uric Acid; Valine; Valsartan; Xenopus laevis | 2007 |
Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.
Topics: Aged; Antihypertensive Agents; C-Reactive Protein; Cholesterol; Chronic Disease; Creatinine; Databases, Factual; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morbidity; Prognosis; Retrospective Studies; Tetrazoles; Valine; Valsartan | 2007 |
Effects of angiotensin II on NO bioavailability evaluated using a catheter-type NO sensor.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Catheterization; Cyclic N-Oxides; Disease Models, Animal; Hydralazine; Male; Nitric Oxide; Oxidants; Oxidative Stress; Rabbits; Spin Labels; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents; Vasodilator Agents | 2006 |
Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes.
Topics: Adipocytes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensins; Cell Differentiation; Gene Expression; Humans; Imidazoles; Mesenchymal Stem Cells; Pyridines; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2006 |
Angiotensin II-induced neural differentiation via angiotensin II type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1.
Topics: Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Carrier Proteins; Cell Differentiation; Cell Nucleus; Cells, Cultured; DNA Repair; Imidazoles; Inhibitor of Differentiation Protein 1; Ligases; Mice; Nerve Tissue Proteins; Neurites; Neurons; Oligopeptides; Protein Phosphatase 1; Protein Transport; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 2; Signal Transduction; Synapses; Tetrazoles; Transcriptional Activation; Tumor Suppressor Proteins; Valine; Valsartan; Vanadates | 2007 |
Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Topics: Adolescent; Adult; Amides; Amlodipine; Antihypertensive Agents; Drug Interactions; Drug Therapy, Combination; Female; Fumarates; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Ramipril; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2006 |
Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cyclic GMP-Dependent Protein Kinases; Hypertension; Nitric Oxide; Rats; Receptors, Angiotensin; Stroke; Tetrazoles; Valine; Valsartan; Vasodilation | 2006 |
Combined treatment with valsartan and spironolactone prevents cardiovascular remodeling in renovascular hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Physiological Phenomena; Hypertension, Renovascular; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Rats; Rats, Wistar; Spironolactone; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2006 |
Optimization via experimental design of an SPE-HPLC-UV-fluorescence method for the determination of valsartan and its metabolite in human plasma samples.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Humans; Solid Phase Extraction; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Tetrazoles; Valine; Valsartan | 2006 |
Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4.
Topics: Acetates; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biological Transport; Biphenyl Compounds; Blotting, Western; Cell Line; Chromones; Cyclopropanes; Dose-Response Relationship, Drug; Estrone; Humans; Imidazoles; Indoles; Leukotriene Antagonists; Losartan; Molecular Structure; Organic Anion Transporters, Sodium-Independent; Phenylcarbamates; Quinolines; Structure-Activity Relationship; Sulfides; Sulfonamides; Tetrazoles; Tosyl Compounds; Transfection; Tritium; Valine; Valsartan | 2006 |
Valsartan improves the lower limit of cerebral autoregulation in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Basilar Artery; Cerebral Arteries; Endothelium, Vascular; Homeostasis; Male; Myocytes, Smooth Muscle; Rats; Rats, Inbred SHR; Receptors, Angiotensin; Regional Blood Flow; Telencephalon; Tetrazoles; Valine; Valsartan | 2006 |
Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study.
Topics: Aged; Antihypertensive Agents; Comorbidity; Echocardiography; Female; Heart Failure; Humans; Internationality; Male; Middle Aged; Myocardial Infarction; Prevalence; Prognosis; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Effects of valsartan therapy on protein glycoxidation.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Arginine; Dinoprost; Female; Glycation End Products, Advanced; Glycosylation; Humans; Hypertension; Lysine; Male; Malondialdehyde; Middle Aged; Oxidation-Reduction; Proteins; Tetrazoles; Valine; Valsartan | 2006 |
Retinopathy and choroidopathy as the initial signs of hypertensive brainstem encephalopathy.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Brain Stem; Choroid Diseases; Drug Therapy, Combination; Female; Fluorescein Angiography; Humans; Hypertensive Encephalopathy; Magnetic Resonance Imaging; Metoprolol; Middle Aged; Retinal Diseases; Tetrazoles; Valine; Valsartan | 2006 |
[Effect of valsatan on hepatocyte growth factor in the airways of asthmatic rats].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Asthma; Bronchi; Hepatocyte Growth Factor; Immunohistochemistry; Male; Rats; Rats, Sprague-Dawley; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2006 |
AT(1) and glutamatergic receptors in paraventricular nucleus support blood pressure during water deprivation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Excitatory Amino Acid Antagonists; Injections, Intraventricular; Kynurenic Acid; Male; Microinjections; Models, Biological; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Receptors, Glutamate; Tetrazoles; Valine; Valsartan; Water Deprivation | 2007 |
Effects of angiotensin II type 1 receptor blockade on beta-cell function in humans.
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2007 |
Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats.
Topics: Adrenal Medulla; Adrenalectomy; Angiotensin II Type 1 Receptor Blockers; Animals; beta-Endorphin; Blood Glucose; Diabetes Mellitus, Experimental; Gene Expression Regulation; Glucose Transporter Type 4; Glutathione Peroxidase; Liver; Male; Mice; Mice, Knockout; Muscle, Skeletal; Rats; Rats, Wistar; Receptors, Opioid, mu; RNA, Messenger; Streptozocin; Tetrazoles; Tissue Culture Techniques; Valine; Valsartan | 2007 |
[Effects of valsartan and captopril on expressions and activities of tissue factor and tissue factor pathway inhibitor].
Topics: Animals; Captopril; Cells, Cultured; Endothelium, Vascular; Male; Proton-Translocating ATPases; Rabbits; RNA, Messenger; Tetrazoles; Thromboplastin; Valine; Valsartan | 2006 |
Early lung injury contributes to lung fibrosis via AT1 receptor in rats.
Topics: Angiotensin II; Animals; Apoptosis; Collagen; Lipid Peroxidation; Male; Peptidyl-Dipeptidase A; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2007 |
Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Antihypertensive Agents; Atenolol; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Electroretinography; Female; Hypertension; Neuroglia; Photic Stimulation; Rats; Retina; Tetrazoles; Valine; Valsartan | 2007 |
Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cytokines; Endothelium; Humans; Hyperglycemia; Inflammation Mediators; Leukocytes; Male; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2007 |
The effects of cilazapril and valsartan on the mRNA and protein expressions of atrial calpains and atrial structural remodeling in atrial fibrillation dogs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Fibrillation; Blotting, Western; Calpain; Cilazapril; Disease Models, Animal; Dogs; Female; Gene Expression; Gene Expression Regulation; Heart Atria; Male; Myocytes, Cardiac; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Ultrasonography; Valine; Valsartan | 2007 |
Added VALUE of an ancillary study on ambulatory blood pressure monitoring.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Heart Rate; Humans; Hypertrophy, Left Ventricular; Randomized Controlled Trials as Topic; Reproducibility of Results; Research; Sample Size; Tetrazoles; Valine; Valsartan | 2007 |
Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Antihypertensive Agents; Chromatography, Liquid; Drug Stability; Humans; Molecular Structure; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Temperature; Tetrazoles; Valine; Valsartan | 2007 |
Angiotensin II mediates postischemic leukocyte-endothelial interactions: role of calcitonin gene-related peptide.
Topics: Acetophenones; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcitonin Gene-Related Peptide; Captopril; Cell Adhesion; Chymases; Disease Models, Animal; Endothelial Cells; Imidazoles; Intestines; Ischemia; Leukocyte Rolling; Leukocytes; Male; Mice; Mice, Inbred C57BL; Microscopy, Video; NADPH Oxidases; Pyridines; Pyrimidinones; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Calcitonin Gene-Related Peptide; Reperfusion Injury; Tetrazoles; Valine; Valsartan; Venules | 2007 |
Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Databases, Factual; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Assessment; Risk Factors; Risk Reduction Behavior; Tetrazoles; Time Factors; Treatment Outcome; United States; Valine; Valsartan | 2007 |
The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Homocysteine; Hyperhomocysteinemia; Hypertrophy, Left Ventricular; Male; Organ Size; Rats; Rats, Inbred F344; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2006 |
Contribution of different Nox homologues to cardiac remodeling in two-kidney two-clip renovascular hypertensive rats: effect of valsartan.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Ventricles; Hypertension, Renovascular; Ligation; Male; Malondialdehyde; Membrane Glycoproteins; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Rats; Rats, Sprague-Dawley; Renal Artery; Superoxides; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2007 |
Sodium, arterial stiffness, and cardiovascular mortality in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Carotid Arteries; Compliance; Disease Models, Animal; Hypertension; Male; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Tetrazoles; Time Factors; Valine; Valsartan | 2007 |
A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma.
Topics: Chromatography, High Pressure Liquid; Humans; Hydrochlorothiazide; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tetrazoles; Valine; Valsartan | 2007 |
Left bundle branch block is not good for your heart.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Heart Failure; Humans; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Biphenyl Compounds; Cardiac Surgical Procedures; Cohort Studies; Female; Humans; Irbesartan; Lisinopril; Male; Postoperative Complications; Ramipril; Retrospective Studies; Tetrazoles; Valine; Valsartan | 2007 |
Lithium intoxication after valsartan treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antimanic Agents; Bipolar Disorder; Female; Humans; Lithium Chloride; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; British Columbia; Drug Prescriptions; Female; Heart Failure; Hospital Information Systems; Humans; Irbesartan; Losartan; Male; Ontario; Proportional Hazards Models; Quebec; Retrospective Studies; Survival Analysis; Survival Rate; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Atenolol; Blood Pressure; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelial Cells; Female; Glycated Hemoglobin; Rats; Rats, Sprague-Dawley; Renin; Retinal Vessels; Tetrazoles; Valine; Valsartan | 2007 |
Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity.
Topics: Adipocytes; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Calcium Channel Blockers; Cell Size; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Intra-Abdominal Fat; Male; Obesity; PPAR gamma; Random Allocation; Rats; Rats, Long-Evans; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Urea Nitrogen; Blotting, Western; Creatinine; Disease Models, Animal; DNA; Heart Failure; Immunohistochemistry; Kidney Failure, Chronic; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Nephrectomy; Oxidative Stress; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Treatment Outcome; Up-Regulation; Valine; Valsartan; Ventricular Function, Left | 2007 |
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blotting, Western; Collagen Type I; Disease Models, Animal; Disease Progression; Fatty Liver; Hypoglycemic Agents; Immunohistochemistry; Male; Pioglitazone; PPAR gamma; Rats; Rats, Inbred F344; Spectrophotometry; Telmisartan; Tetrazoles; Thiazolidinediones; Treatment Outcome; Valine; Valsartan | 2007 |
Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Antioxidants; Blood Pressure; Cyclic N-Oxides; Lipid Peroxidation; Male; Mitochondria, Heart; NADPH Oxidases; Oxidative Stress; Protein Subunits; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Renin; Spin Labels; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2007 |
[Effect of cilazapril and valsartan on the levels of cardiac interstitial water content in rats with acute myocardial infarction].
Topics: Animals; Antihypertensive Agents; Cilazapril; Disease Models, Animal; Male; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2007 |
[Activation of transforming growth factor-beta1/Smads signal pathway in diabetic cardiomyopathy and effects of valsartan thereon: experiment with rats].
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blotting, Western; Cardiomyopathies; Cholesterol; Diabetes Mellitus, Experimental; Fasting; Insulin; Male; Random Allocation; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Smad Proteins; Smad2 Protein; Smad3 Protein; Smad7 Protein; Tetrazoles; Transforming Growth Factor beta1; Triglycerides; Valine; Valsartan | 2007 |
Novel mechanisms of valsartan on the treatment of acute myocardial infarction through inhibition of the antiadhesion molecule periostin.
Topics: Acute Disease; Angiotensin II; Animals; Antihypertensive Agents; Cell Adhesion Molecules; Cell Communication; Cells, Cultured; Disease Models, Animal; Fibroblasts; Gene Expression Regulation; Male; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Random Allocation; Rats; Rats, Inbred Lew; Rats, Wistar; Stress, Mechanical; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2007 |
Valsartan reverses post-translational modifications of the delta-subunit of ATP synthase during in vivo canine reperfused myocardial infarction.
Topics: Amino Acids; Angiotensin II Type 2 Receptor Blockers; Animals; Apoptosis; Dogs; Mitochondrial Proton-Translocating ATPases; Myocardial Infarction; Myocardial Reperfusion Injury; Necrosis; Phosphorylation; Protein Processing, Post-Translational; Protein Subunits; Proteomics; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Delayed-Action Preparations; Female; Humans; Hypertension; Insurance Claim Review; Kidney Diseases; Lisinopril; Male; Metoprolol; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Tetrazoles; Valine; Valsartan | 2007 |
NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Blood Pressure; Blotting, Western; C-Reactive Protein; Cells, Cultured; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Insulin Resistance; Male; Muscle, Smooth, Vascular; NADPH Oxidases; Probability; Random Allocation; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sensitivity and Specificity; Superoxide Dismutase; Tetrazoles; Valine; Valsartan; Vasculitis | 2007 |
[Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Female; Humans; Hypertension; Infant, Newborn; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 2007 |
VALIDD should not invalidate angiotensin-receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Myocardial Infarction; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2007 |
[Valsartan: arguments for the high dose concept].
Topics: Angiotensin II Type 1 Receptor Blockers; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Humans; Hypertension, Renal; Proteinuria; Tetrazoles; Valine; Valsartan | 2006 |
[Convincing results from the JIKEI Study].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Controlled Clinical Trials as Topic; Coronary Disease; Heart Failure; Humans; Hypertension; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Cardioprotective effect of angiotensin II type 1 receptor antagonist associated with bradykinin-endothelial nitric oxide synthase and oxidative stress in Dahl salt-sensitive hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Bradykinin; Bradykinin B2 Receptor Antagonists; Cardiotonic Agents; Hydralazine; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; Pyridines; Rats; Rats, Inbred Dahl; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2007 |
[Blood pressure lowering and risk reduction under treatment with valsartan and its combination with hydrochlorothiazide (HCT)].
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Prospective Studies; Risk Factors; Tetrazoles; Valine; Valsartan | 2006 |
Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
Topics: Animals; Chemokine CCL2; Desmin; Diabetic Nephropathies; Drug Therapy, Combination; Immunohistochemistry; Male; Membrane Proteins; Mycophenolic Acid; Podocytes; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2007 |
Angiotensin II type 1 receptor blocker reduces monocyte adhesion to endothelial cells in spontaneously hypertensive rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Atherosclerosis; Blood Pressure; Cell Adhesion; Deoxyguanosine; Endothelial Cells; Hydralazine; Hypertension; Male; Monocytes; Rats; Rats, Inbred SHR; Tetrazoles; Tunica Intima; Tunica Media; Valine; Valsartan | 2007 |
Dual inhibition of the renin system by aliskiren and valsartan.
Topics: Amides; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Fumarates; Humans; Randomized Controlled Trials as Topic; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2007 |
New-onset diabetes, antihypertensive treatment, and outcome.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Drug Administration Schedule; Humans; Hypertension; Prognosis; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2007 |
Angiotensin II type 1 receptor blockade prevents decrease in adult stem-like cells in kidney after ureteral obstruction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Female; Fibrosis; Flow Cytometry; Injections, Intraperitoneal; Kidney; Leukocyte Common Antigens; Mice; Mice, Inbred C57BL; Stem Cells; Tetrazoles; Ureteral Obstruction; Valine; Valsartan | 2007 |
Biovalidation of an SPE-HPLC-UV-fluorescence method for the determination of valsartan and its metabolite valeryl-4-hydroxy-valsartan in human plasma.
Topics: Aged; Antihypertensive Agents; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Female; Humans; Male; Middle Aged; Reference Standards; Solid Phase Extraction; Spectrophotometry, Ultraviolet; Tetrazoles; Valine; Valsartan | 2007 |
[Case report of cholesterol crystal embolism 1 month after carotid stenting].
Topics: Aged; Angioplasty, Balloon, Coronary; Carotid Stenosis; Drug Therapy, Combination; Early Diagnosis; Embolism, Cholesterol; Humans; Male; Pravastatin; Prednisolone; Stents; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2007 |
Angiotensin AT1 receptor blockers suppress ischemia/reperfusion-induced gastric injury in rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Capillary Permeability; Gastric Mucosa; Hydrogen Peroxide; Losartan; Male; Microcirculation; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Tetrazoles; Valine; Valsartan | 2007 |
Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Thoracic; beta-Galactosidase; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Male; Muscle, Smooth, Vascular; Oxidative Stress; Proto-Oncogene Proteins p21(ras); Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Renin-Angiotensin System; RNA, Small Interfering; Spironolactone; Tetrazoles; Tumor Suppressor Protein p53; Valine; Valsartan | 2007 |
Synthesis of valsartan via decarboxylative biaryl coupling.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzene Derivatives; Tetrazoles; Valine; Valsartan | 2007 |
[Signal transductional mechanism of calpain involved in the regulation of rat hypertrophy myocardium mediated by overloaded pressure].
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Calcineurin; Calcium; Calpain; Gene Expression Regulation; Heart; Hypertrophy; Imidazoles; Male; Myocardium; Phosphorylation; Pyridines; Rats; Rats, Wistar; Receptors, Angiotensin; RNA, Messenger; Signal Transduction; Tetrazoles; Valine; Valsartan; Vasoconstriction; Ventricular Myosins | 2007 |
Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Cell Communication; Cell Proliferation; Cells, Cultured; Collagen Type I; Culture Media; Disease Models, Animal; Dogs; Extracellular Matrix; Fibroblasts; Fibronectins; Heterocyclic Compounds, 4 or More Rings; Muscle Contraction; Myocytes, Cardiac; Tachycardia; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2007 |
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Benzamides; Blotting, Western; Cell Adhesion; Chemokine CCL2; Cyclohexanones; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Imidazoles; Intercellular Adhesion Molecule-1; Leukocytes; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Pyridines; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Retinitis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Thiazolidines; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2007 |
Antihypertensive therapies.
Topics: Amides; Antihypertensive Agents; Blood Pressure; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diuretics; Drug Design; Drug Industry; Fumarates; Humans; Hydrochlorothiazide; Hypertension; Renin; Tetrazoles; Valine; Valsartan | 2007 |
Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Diabetes Complications; Diabetes Mellitus, Experimental; Hypertension; Male; Metoprolol; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Streptozocin; Tetrazoles; Valine; Valsartan | 2007 |
Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Aryl Hydrocarbon Hydroxylases; Chemical Phenomena; Chemistry, Physical; Cytochrome P-450 CYP2C9; Humans; Hydrogen-Ion Concentration; Hydroxylation; Imidazoles; Microsomes, Liver; Models, Biological; Protein Binding; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan; Warfarin | 2007 |
Successful treatment of refractory angina pectoris due to multivessel coronary spasm with valsartan.
Topics: Aged; Angina, Unstable; Angiotensin II Type 1 Receptor Blockers; Coronary Angiography; Coronary Vasospasm; Dose-Response Relationship, Drug; Humans; Male; Recurrence; Tetrazoles; Valine; Valsartan | 2007 |
Novel regulatory effect of angiotensin II type 1 receptor-interacting molecule on vascular smooth muscle cells.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Fluorescence Resonance Energy Transfer; Gene Transfer Techniques; Immunoprecipitation; Muscle, Smooth, Vascular; Protein Binding; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; RNA, Small Interfering; Signal Transduction; Tetrazoles; Transcription, Genetic; Valine; Valsartan | 2007 |
Dynamic NMR study and theoretical calculations on the conformational exchange of valsartan and related compounds.
Topics: Antihypertensive Agents; Butyrates; Kinetics; Models, Molecular; Molecular Conformation; Morpholines; Nuclear Magnetic Resonance, Biomolecular; Quantum Theory; Tetrazoles; Thermodynamics; Valine; Valsartan | 2007 |
Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study.
Topics: Administration, Oral; Antihypertensive Agents; Benzopyrans; Chromatography, Liquid; Drug Combinations; Ethanolamines; Humans; Nebivolol; Reproducibility of Results; Tandem Mass Spectrometry; Tetrazoles; Valine; Valsartan | 2007 |
[Expression of angiotensin II type 1 receptor in cervical squamous cell carcinoma and its clinical significance].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cervix Uteri; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lymphatic Metastasis; Neoplasm Staging; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2007 |
Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Binding Sites; Chlorocebus aethiops; Computer Simulation; COS Cells; Imidazoles; Losartan; Lysine; Molecular Structure; Mutation; Protein Structure, Secondary; Protein Structure, Tertiary; Rats; Receptor, Angiotensin, Type 1; Serine; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan | 2008 |
Dual inhibition of the renin system by aliskiren and valsartan.
Topics: Amides; Antihypertensive Agents; Drug Therapy, Combination; Fumarates; Humans; Hyperkalemia; Hypertension; Renin; Tetrazoles; Valine; Valsartan | 2007 |
Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure.
Topics: Acetophenones; Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Apoptosis; Biopterins; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Endothelium, Vascular; Heart Failure, Diastolic; Hydralazine; Hypertension; Male; MAP Kinase Kinase Kinase 5; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Nitric Oxide Synthase Type III; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Signal Transduction; Sodium Chloride, Dietary; Superoxides; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilation | 2007 |
Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; C-Reactive Protein; Calcium Channel Blockers; Calcium Channels, L-Type; Drug Interactions; Inflammation; Male; Nitrendipine; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan; Verapamil | 2008 |
Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antihypertensive Agents; Behavior, Animal; Brain; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Memory; Mice; Mice, Transgenic; Protein Structure, Quaternary; Random Allocation; Space Perception; Tetrazoles; Valine; Valsartan | 2007 |
[Effect of valsartan on neointimal proliferation and expression of vWF after balloon angioplasty in rabbits].
Topics: Angioplasty, Balloon; Animals; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; Hyperplasia; Male; Postoperative Period; Rabbits; Random Allocation; Tetrazoles; Tunica Intima; Valine; Valsartan; von Willebrand Factor | 2007 |
An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Colitis; Cytokines; Disease Models, Animal; Humans; Immunohistochemistry; Inflammatory Bowel Diseases; Male; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2008 |
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
The JIKEI trial.
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Japan; Randomized Controlled Trials as Topic; Stroke; Tetrazoles; Valine; Valsartan | 2007 |
[New effective dosage of valsartan. High dosage--effective against high blood pressure].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Nephropathies; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Prognosis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
[Risk oriented therapy of hypertension. Lowering blood pressure and risk].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetic Nephropathies; Humans; Hypertension; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan | 2007 |
Valsartan ingestions among adults reported to Texas poison control centers, 2000 to 2005.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Female; Guidelines as Topic; Humans; Male; Middle Aged; Poison Control Centers; Poisoning; Retrospective Studies; Tetrazoles; Texas; Triage; Valine; Valsartan | 2007 |
Two amlodipine/ARB combinations for hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Drug Combinations; Humans; Hypertension; Imidazoles; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Blood Pressure; Dose-Response Relationship, Drug; Endothelium, Vascular; Heart Failure; In Vitro Techniques; Male; Myocardial Infarction; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2007 |
[Effects of benazepril and valsartan alone or in combination on proteinuria in chronic glomerular disease].
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Chronic Disease; Drug Therapy, Combination; Female; Glomerulonephritis; Humans; Male; Middle Aged; Proteinuria; Tetrazoles; Valine; Valsartan; Young Adult | 2007 |
Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models.
Topics: Adipocytes, White; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Cell Differentiation; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Gene Deletion; Gene Expression; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; PPAR gamma; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2008 |
Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blotting, Western; Body Weight; Diabetes Mellitus, Experimental; Imidazoles; Immunohistochemistry; Kidney Glomerulus; Kidney Tubules; NADPH Oxidases; Onium Compounds; Prorenin Receptor; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Up-Regulation; Valine; Valsartan | 2008 |
Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Endomyocardial Fibrosis; Endothelium, Vascular; Hydralazine; Hypertension; Male; Mesenteric Arteries; Neprilysin; Rats; Rats, Inbred SHR; Rats, Wistar; Stroke; Tetrazoles; Tyrosine; Valine; Valsartan | 2008 |
Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cost-Benefit Analysis; Drug Costs; Humans; Hypertension; Irbesartan; Losartan; Markov Chains; Tetrazoles; Valine; Valsartan | 2008 |
Higher persistence with valsartan compared with enalapril in daily practice.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Drug Prescriptions; Enalapril; Female; Humans; Hypertension; Male; Medicine; Middle Aged; Multivariate Analysis; Netherlands; Registries; Sex Factors; Specialization; Tetrazoles; Valine; Valsartan | 2007 |
Determination of ecabet in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Topics: Abietanes; Area Under Curve; Chromatography, High Pressure Liquid; Humans; Hydrophobic and Hydrophilic Interactions; Methanol; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tetrazoles; Valine; Valsartan | 2008 |
Interplay of angiotensin II and angiotensin(1-7) in the regulation of matrix metalloproteinases of human cardiocytes.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blotting, Western; Cells, Cultured; DNA; Fibroblasts; Gene Expression Regulation, Enzymologic; Humans; Indicators and Reagents; Matrix Metalloproteinases; Myocytes, Cardiac; Peptide Fragments; Reverse Transcriptase Polymerase Chain Reaction; RNA; Tetrazoles; Tissue Inhibitor of Metalloproteinases; Transcription, Genetic; Valine; Valsartan | 2008 |
Angiotensin receptor blockers: dose does matter.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Male; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method.
Topics: Acrylates; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Chromatography, High Pressure Liquid; Female; Humans; Imidazoles; Irbesartan; Male; Middle Aged; Solid Phase Extraction; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2008 |
Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Topics: Aged; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Fumarates; Humans; Hydrochlorothiazide; Hyperkalemia; Hypertension; Male; Middle Aged; Renin; Renin-Angiotensin System; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Dimerization; Eplerenone; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Receptor, Angiotensin, Type 1; Spironolactone; Tetrazoles; Transglutaminases; Valine; Valsartan; Vasoconstriction; Vasodilation | 2008 |
Angiotensin II receptor blocker inhibits tumour necrosis factor-alpha-induced cell damage in human renal proximal tubular epithelial cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Apoptosis; Caspase 3; Caspase 7; Cell Survival; Cells, Cultured; Cytoprotection; Dose-Response Relationship, Drug; Enzyme Activation; Epithelial Cells; Glucosamine; Humans; Imidazoles; Kidney Tubules, Proximal; L-Lactate Dehydrogenase; NADPH Oxidases; Pyridines; Receptor, Angiotensin, Type 2; Receptors, Tumor Necrosis Factor, Type I; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2008 |
Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
Topics: Adrenal Cortex; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cell Line; Cytochrome P-450 CYP11B2; Dihydropyridines; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Humans; Membrane Potentials; Patch-Clamp Techniques; Potassium Chloride; RNA, Messenger; Steroid 11-beta-Hydroxylase; Tetrazoles; Valine; Valsartan | 2008 |
Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats.
Topics: Acetylcholine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Carotid Arteries; Disease Models, Animal; Hypertension; Male; NADPH Oxidases; Peptidyl-Dipeptidase A; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renin; Telmisartan; Tetrazoles; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2007 |
ACE inhibitors in cardiovascular disease--unbeatable?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Research Design; Telmisartan; Tetrazoles; Valine; Valsartan | 2008 |
Decreased expression of angiotensin II type 1 and type 2 receptors in the brain after long-term administration of antihypertensive drugs in stroke-prone spontaneously hypertensive rat.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Brain Stem; Calcium Channel Blockers; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Enalapril; Hypertension; Male; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Stroke; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
[The study of the effect of Cilazapril and valsartan on angiotensin 1 and angiotensin 2 receptors mRNA expression and myocardial interstitial collagen metabolism after myocardial infarction in rats].
Topics: Animals; Cilazapril; Collagen; Disease Models, Animal; Male; Myocardial Infarction; Myocardium; Random Allocation; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2008 |
Temporary pretreatment with the angiotensin II type 1 receptor blocker, valsartan, prevents ischemic brain damage through an increase in capillary density.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Brain; Brain Injuries; Brain Ischemia; Capillaries; Chemokine CCL2; DNA Damage; Infarction, Middle Cerebral Artery; Mice; Mice, Inbred C57BL; Oxidative Stress; Receptor, Angiotensin, Type 1; Superoxides; Tetrazoles; Valine; Valsartan | 2008 |
Study of valsartan interaction with micelles as a model system for biomembranes.
Topics: Angiotensin II Type 1 Receptor Blockers; Cetrimonium; Cetrimonium Compounds; Chromatography, Liquid; Membranes, Artificial; Micelles; Spectrophotometry, Ultraviolet; Tetrazoles; Valine; Valsartan | 2008 |
AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygen-induced retinopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Astrocytes; Neovascularization, Physiologic; Oxygen; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Retinal Degeneration; Retinal Vessels; Tetrazoles; Valine; Valsartan | 2008 |
Neuroprotective role of angiotensin II type 2 receptor after transient focal ischemia in mice brain.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Apoptosis; Brain; Gene Expression Regulation; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuroprotective Agents; Proto-Oncogene Proteins c-bcl-2; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Reperfusion; Signal Transduction; STAT3 Transcription Factor; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
Peritubular capillary loss is ameliorated by ramipril or valsartan treatment.
Topics: Animals; Antihypertensive Agents; Capillaries; Gene Expression Regulation; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Tubules; Male; Microcirculation; Ramipril; Rats; Rats, Sprague-Dawley; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2008 |
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Black or African American; Captopril; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Systole; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People | 2008 |
From black and white to shades of gray: race and renin-angiotensin system blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African American; Captopril; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People | 2008 |
Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Antioxidants; Apoptosis; Blood Pressure; Cyclic N-Oxides; Disease Models, Animal; Fatty Liver; Lipid Peroxidation; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Renin; Renin-Angiotensin System; Spin Labels; Tetrazoles; Valine; Valsartan | 2008 |
Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cell Line; Diabetes Mellitus, Experimental; Extracellular Signal-Regulated MAP Kinases; Immunoblotting; Mice; Mice, Inbred C57BL; Neurons; Oncogene Protein v-akt; Phosphorylation; Receptor, Angiotensin, Type 1; Retina; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Synaptophysin; Telmisartan; Tetrazoles; Ubiquitination; Valine; Valsartan | 2008 |
Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biopsy; Creatinine; Female; Fibrosis; Glomerulonephritis, Membranoproliferative; Humans; Immunoglobulin A; Kidney Glomerulus; Losartan; Male; Middle Aged; Receptor, Angiotensin, Type 1; Retrospective Studies; Telmisartan; Tetrazoles; Valine; Valsartan; Vasodilation | 2008 |
Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Blood Pressure; DNA Primers; Endothelin-1; Female; Hypertension; Kidney Tubules, Collecting; Male; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2008 |
Stripping voltammetric determination of valsartan in bulk and pharmaceutical products.
Topics: Angiotensin II Type 1 Receptor Blockers; Drug Stability; Electrochemistry; Electrodes; Hydrogen-Ion Concentration; Indicators and Reagents; Mercury; Tablets; Tetrazoles; Valine; Valsartan | 2008 |
Prolonged severe hypotension following combined amlodipine and valsartan ingestion.
Topics: Aged; Amlodipine; Antidotes; Antihypertensive Agents; Blood Glucose; Calcium Channel Blockers; Cardiac Catheterization; Drug Interactions; Drug Overdose; Female; Glucagon; Humans; Hypotension; Insulin; Naloxone; Severity of Illness Index; Suicide, Attempted; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
Transdermal delivery of valsartan: I. Effect of various terpenes.
Topics: Adjuvants, Pharmaceutic; Administration, Cutaneous; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cadaver; Calorimetry, Differential Scanning; Drug Carriers; Drug Evaluation, Preclinical; Humans; In Vitro Techniques; Male; Permeability; Rats; Rats, Wistar; Skin Absorption; Spectroscopy, Fourier Transform Infrared; Terpenes; Tetrazoles; Valine; Valsartan | 2008 |
Can changing antihypertensive administration time alone reduce the risk for CVD in nondipper patients with CKD?
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chronotherapy; Follow-Up Studies; Humans; Hypertension; Incidence; Renal Insufficiency, Chronic; Risk Assessment; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2008 |
Antihypertensive therapy in children: implications for future studies.
Topics: Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Male; Randomized Controlled Trials as Topic; Severity of Illness Index; Tetrazoles; Valine; Valsartan | 2008 |
Homocysteine, renin and aldosterone in patients with Cushing's syndrome.
Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Chromatography, High Pressure Liquid; Cushing Syndrome; Female; Fluorescence Polarization Immunoassay; Homocysteine; Humans; Male; Metabolic Syndrome; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2008 |
Significance of pulsatility of brachial artery pressure for blood pressure control.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Brachial Artery; Calcium Channel Blockers; Female; Humans; Hypertension; Male; Middle Aged; Pulsatile Flow; Pulse; Tetrazoles; Valine; Valsartan | 2008 |
Deletion of angiotensin II type 2 receptor attenuates protective effects of bone marrow stromal cell treatment on ischemia-reperfusion brain injury in mice.
Topics: Animals; Antihypertensive Agents; Bone Marrow Transplantation; Brain Infarction; Brain Ischemia; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Reperfusion Injury; Stromal Cells; Survival Rate; Tetrazoles; Treatment Outcome; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2008 |
[Changes of c-fos, c-jun mRNA expressions in cardiomyocyte hypertrophy induced by angiotensin II and effects of tanshinone II A].
Topics: Abietanes; Angiotensin II; Animals; Cardiomegaly; Gene Expression Regulation; Genes, fos; Genes, jun; Myocytes, Cardiac; Phenanthrenes; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2008 |
Application in the STRATHE trial of a score system to compare the efficacy and the tolerability of different therapeutic strategies in the management of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Double-Blind Method; Drug Therapy, Combination; France; Humans; Hydrochlorothiazide; Hypertension; Indapamide; Losartan; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
[Effects of valsartan on the renal vascular endothelial growth factor and its receptor flk-1 of diabetic rats].
Topics: Animals; Antihypertensive Agents; Blotting, Western; Diabetes Mellitus, Experimental; Immunohistochemistry; Kidney; Male; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Flow Velocity; Carotid Artery, Common; Elasticity; Female; Humans; Hypertension; Male; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Tunica Media; Ultrasonography; Valine; Valsartan; Vascular Resistance | 2008 |
Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect.
Topics: Adverse Drug Reaction Reporting Systems; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Approval; Humans; Irbesartan; Losartan; Tetrazoles; Time Factors; United States; Valine; Valsartan | 2008 |
Suppression of lipoprotein lipase expression in 3T3-L1 cells by inhibition of adipogenic differentiation through activation of the renin-angiotensin system.
Topics: 3T3-L1 Cells; Adipocytes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Azo Compounds; Blotting, Western; Cell Differentiation; Lipoprotein Lipase; Mice; Microscopy, Phase-Contrast; Pioglitazone; PPAR gamma; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Thiazolidinediones; Valine; Valsartan | 2008 |
Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
Topics: Acetylcholine; Amides; Animals; Antihypertensive Agents; Atherosclerosis; Biopterins; Blood Pressure; Drug Therapy, Combination; Endothelium, Vascular; Fumarates; Heart Rate; HSP90 Heat-Shock Proteins; Hyperlipidemias; Inflammation Mediators; Lipids; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rabbits; Renin; Tetrazoles; Tyrosine; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2008 |
[Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
Topics: Animals; Antihypertensive Agents; Apoptosis; Apoptosis Regulatory Proteins; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Immunosuppressive Agents; Kidney; Male; Mycophenolic Acid; NF-kappa B; Random Allocation; Rats; Rats, Wistar; Tetrazoles; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Valine; Valsartan | 2008 |
Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation.
Topics: Acetophenones; Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Astrocytes; Blood Pressure; Cerebral Cortex; Enzyme Activation; Enzyme Inhibitors; Humans; Hydralazine; Hypertension; Inflammation; Male; NADPH Oxidases; Neurons; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Sodium Chloride; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
Effects of angiotensin II type 1 receptor blocker on albumin-induced cell damage in human renal proximal tubular epithelial cells.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylglucosaminidase; Albumins; Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Cells, Cultured; Deoxyguanosine; Dose-Response Relationship, Drug; Humans; Imidazoles; Kidney Tubules, Proximal; NADPH Oxidases; Oxidative Stress; Tetrazoles; Valine; Valsartan | 2009 |
Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Biological Availability; Drug Therapy, Combination; Echocardiography; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Nitric Oxide; Quinolines; Rabbits; Reactive Oxygen Species; Tetrazoles; Tyrosine; Valine; Valsartan | 2008 |
[The effects of renin-angiotensin system blockade on the liver steatosis in rats on long-term high-fat diet].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Dietary Fats; Fatty Liver; Immunohistochemistry; Insulin Resistance; Ion Channels; Liver; Male; Mitochondrial Proteins; Perindopril; Rats; Rats, Wistar; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Time Factors; Transforming Growth Factor beta1; Uncoupling Protein 2; Valine; Valsartan | 2008 |
Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Coronary Artery Disease; Disease Models, Animal; Endothelium, Vascular; Inflammation; Lipids; Male; Rabbits; Risk; Simvastatin; Stress, Mechanical; Tetrazoles; Valine; Valsartan | 2009 |
Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]
Topics: Adamantane; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Drug Therapy, Combination; Fibrosis; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Pyrrolidines; Reactive Oxygen Species; Tetrazoles; Valine; Valsartan | 2008 |
Improved analytical validation and pharmacokinetics of valsartan using HPLC with UV detection.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Proteins; Calibration; Capsules; Chromatography, High Pressure Liquid; Humans; Male; Protein Binding; Reference Standards; Reproducibility of Results; Solvents; Spectrophotometry, Ultraviolet; Tetrazoles; Valine; Valsartan | 2008 |
Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Imidazoles; In Vitro Techniques; Insulin; Kidney; Male; Microdialysis; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2008 |
Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database.
Topics: Adolescent; Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Insurance Claim Review; Male; Managed Care Programs; Middle Aged; Patient Compliance; Tetrazoles; United States; Valine; Valsartan | 2008 |
Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cohort Studies; Diuretics; Drug Combinations; Drug Costs; Female; Humans; Hydrochlorothiazide; Male; Middle Aged; Patient Compliance; Retrospective Studies; Tetrazoles; Valine; Valsartan | 2008 |
Electrochemical behavior of valsartan and its determination in capsules.
Topics: Capsules; Electrochemistry; Tetrazoles; Valine; Valsartan | 2008 |
Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cells, Cultured; Extracellular Matrix; Glomerulosclerosis, Focal Segmental; Mesangial Cells; PPAR gamma; Rats; Telmisartan; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2008 |
Cost-effectiveness analysis: controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study.
Topics: Amlodipine; Cost-Benefit Analysis; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension; Japan; Nifedipine; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2008 |
Ameliorative effect of Captopril and Valsartan on an animal model of diabetic cardiomyopathy.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cardiomyopathies; Creatine Kinase, MB Form; Diabetes Mellitus, Experimental; Female; Isoenzymes; L-Lactate Dehydrogenase; Male; Microscopy, Electron; Myocardium; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2008 |
The effects of renin-angiotensin system inhibition on regression of encapsulating peritoneal sclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Chlorhexidine; Disease Models, Animal; Enalapril; Female; Peritoneal Dialysis; Peritoneum; Rats; Rats, Wistar; Sclerosis; Tetrazoles; Valine; Valsartan | 2008 |
Analysis of angiotensin II receptor antagonist and protein markers at microliter level plasma by LC-MS/MS.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Blood Proteins; Chromatography, Liquid; Drug Monitoring; Humans; Molecular Structure; Nanotechnology; Sensitivity and Specificity; Tandem Mass Spectrometry; Tetrazoles; Valine; Valsartan | 2009 |
Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Blood Pressure; Disease Models, Animal; Disease Progression; Gene Expression Regulation; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neutrophil Infiltration; NF-kappa B; Pancreatic Elastase; Rats; Rats, Wistar; Tetrazoles; Ultrasonography; Valine; Valsartan | 2008 |
Angiotensin inhibition stimulates PPARgamma and the release of visfatin.
Topics: Adipocytes; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blotting, Western; Endothelial Cells; Humans; Intra-Abdominal Fat; Lisinopril; Muscle, Skeletal; Nicotinamide Phosphoribosyltransferase; PPAR gamma; Receptor, IGF Type 1; Rosiglitazone; Telmisartan; Tetrazoles; Thiazolidinediones; Umbilical Veins; Valine; Valsartan | 2008 |
Exaggeration of focal cerebral ischemia in transgenic mice carrying human Renin and human angiotensinogen genes.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Brain Chemistry; Brain Ischemia; Capillaries; Cerebrovascular Circulation; Humans; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Transgenic; Oxidative Stress; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Reverse Transcriptase Polymerase Chain Reaction; Superoxides; Tetrazoles; Valine; Valsartan | 2009 |
Valsartan improves L-NAME-exacerbated cardiac fibrosis with TGF-ß inhibition and apoptosis induction in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Caspase 3; Fibrosis; Hypertension; Male; Myocardium; NG-Nitroarginine Methyl Ester; Rats; Rats, Inbred SHR; RNA; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan; Ventricular Remodeling | 2008 |
Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; Cardiomegaly; Cyclic AMP Response Element Modulator; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 3; Gene Expression Regulation; Heart; Heart Failure; Myocardial Infarction; Myocardium; Rats; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2009 |
Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology.
Topics: Aldosterone; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Cattle; Cells, Cultured; Cytokines; Endothelial Cells; Eye Proteins; Glucosephosphate Dehydrogenase; Leukostasis; Mineralocorticoid Receptor Antagonists; NADPH Oxidase 4; NADPH Oxidases; Neovascularization, Pathologic; Oxidative Stress; Oxygen; Pericytes; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Renin-Angiotensin System; Retinal Vasculitis; Sodium Chloride; Spironolactone; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2009 |
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Collagen; Disease Models, Animal; Female; Heart Rate; Hypertrophy, Left Ventricular; Ligation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocytes, Cardiac; Ramipril; Receptor, Bradykinin B1; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2009 |
Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adiponectin; Aged; Albuminuria; Antihypertensive Agents; Aryldialkylphosphatase; Biomarkers; C-Reactive Protein; Carotid Arteries; Diabetes Mellitus, Type 2; Dinoprost; Female; Glycation End Products, Advanced; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Tetrazoles; Valine; Valsartan | 2008 |
Effect of valsartan on the expression of angiotensin II receptors in the lung of chronic antigen exposure rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Asthma; Blotting, Western; Bronchoalveolar Lavage Fluid; Enzyme-Linked Immunosorbent Assay; Gene Expression; Lung; Male; Ovalbumin; Platelet-Derived Growth Factor; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2008 |
[Renin-angiotensin system blocking agents reverse the myocardial hypertrophy in experimental hyperthyroid cardiomyopathy via altering intracellular calcium handling].
Topics: Animals; Calcium; Calcium Channels; Cardiomyopathies; Disease Models, Animal; Hyperthyroidism; Imidazolidines; Myocardium; Rabbits; Renin-Angiotensin System; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tetrazoles; Thyroxine; Valine; Valsartan | 2008 |
[Effects of valsartan on sarcoplasmic reticulum calcium adenosine triphosphatase, protein kinase A and protein phosphatase 1 alpha in a rabbit model of heart failure].
Topics: Animals; Cyclic AMP-Dependent Protein Kinases; Female; Heart Failure; Male; Protein Phosphatase 1; Rabbits; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tetrazoles; Valine; Valsartan | 2008 |
[Valsartan improves symptoms and quality of life in patients with chronic heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Multicenter Studies as Topic; Prospective Studies; Quality of Life; Tetrazoles; Valine; Valsartan | 2008 |
Telmisartan and carotid intima-media thickness regression: a class effect of angiotensin-receptor blockers?
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Carotid Arteries; Humans; Irbesartan; Losartan; Telmisartan; Tetrazoles; Tunica Intima; Tunica Media; Valine; Valsartan | 2008 |
Primary CNS lymphoma presenting as fever of unknown origin.
Topics: Antihypertensive Agents; Antineoplastic Agents; Antitubercular Agents; Aspirin; Brain Neoplasms; Cranial Irradiation; Diagnosis, Differential; Fatal Outcome; Fever of Unknown Origin; Humans; Hypertension; Indapamide; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Tetrazoles; Tuberculosis; Valine; Valsartan | 2009 |
Chronic treatment with angiotensin AT1 receptor antagonists reduced serum but not bone TGF-beta1 levels in ovariectomized rats.
Topics: Acid Phosphatase; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Bone and Bones; Bone Density; Female; Humans; Isoenzymes; Osteocalcin; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Tartrate-Resistant Acid Phosphatase; Telmisartan; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2009 |
An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Data Collection; Decision Making; Humans; Kaplan-Meier Estimate; Marketing; Markov Chains; Models, Economic; Models, Statistical; Myocardial Infarction; Psychometrics; Quality-Adjusted Life Years; Tetrazoles; Time Factors; United Kingdom; Valine; Valsartan | 2009 |
Effects of metronidazole, tinidazole, captopril and valsartan on taste and serum levels of zinc and magnesium.
Topics: Amebicides; Animals; Antihypertensive Agents; Captopril; Humans; Magnesium; Male; Metronidazole; Rabbits; Random Allocation; Taste; Taste Buds; Tetrazoles; Tinidazole; Valine; Valsartan; Zinc | 2009 |
Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cohort Studies; Databases, Factual; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult | 2008 |
High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin.
Topics: Angiotensin II; Gene Expression Regulation; Glucose; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Inflammation; Kidney; Mesangial Cells; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Tetrazoles; Valine; Valsartan | 2009 |
Chronotherapeutic drug delivery for early morning surge in blood pressure: a programmable delivery system.
Topics: Blood Pressure; Drug Chronotherapy; Drug Delivery Systems; Hypertension; Solubility; Tablets, Enteric-Coated; Tetrazoles; Valine; Valsartan | 2009 |
Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Blotting, Western; Cyclic N-Oxides; DNA, Mitochondrial; Fatty Acids; Fatty Liver; Gene Expression; Immunohistochemistry; Male; Microscopy, Electron, Transmission; Mitochondria; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Reverse Transcriptase Polymerase Chain Reaction; Spin Labels; Tetrazoles; Valine; Valsartan | 2009 |
Antihypertensive drug valsartan in solution and at the AT1 receptor: conformational analysis, dynamic NMR spectroscopy, in silico docking, and molecular dynamics simulations.
Topics: Antihypertensive Agents; Lipid Bilayers; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2009 |
Direct analysis of valsartan or candesartan in human plasma and urines by on-line solid phase extraction coupled to electrospray tandem mass spectrometry.
Topics: Benzimidazoles; Biphenyl Compounds; Humans; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Tetrazoles; Valine; Valsartan | 2009 |
Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study.
Topics: Acetonitriles; Amlodipine; Antihypertensive Agents; Chromatography, High Pressure Liquid; Humans; Male; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tetrazoles; Time Factors; Valine; Valsartan | 2009 |
Telmisartan, an angiotensin II type 1 receptor antagonist, attenuates T-type Ca2+ channel expression in neonatal rat cardiomyocytes.
Topics: Action Potentials; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Benzimidazoles; Benzoates; Calcium Channels, T-Type; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Electrophysiology; Extracellular Signal-Regulated MAP Kinases; F-Box Proteins; Flavonoids; Gene Expression Regulation; Heart Rate; Imidazoles; JNK Mitogen-Activated Protein Kinases; Membrane Potentials; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; Patch-Clamp Techniques; Pyridines; Rats; Rats, Wistar; RNA, Messenger; Telmisartan; Tetrazoles; Time Factors; Valine; Valsartan; Zebrafish Proteins | 2009 |
Investigation of effects of Lacidipine, Ramipril and Valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats.
Topics: Animals; Antihypertensive Agents; Biomarkers; Dihydropyridines; DNA Damage; Guanine; Isoproterenol; Myocardial Infarction; Nitric Oxide; Oxidative Stress; Ramipril; Rats; Tetrazoles; Valine; Valsartan | 2009 |
Interesting findings in the VALERIA trial.
Topics: Albuminuria; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hypertension, Renal; Lisinopril; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2009 |
Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling.
Topics: Animals; Antihypertensive Agents; Aorta; Cattle; Cells, Cultured; Endothelial Cells; Humans; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Angiotensin, Type 1; Signal Transduction; src-Family Kinases; Tetrazoles; Valine; Valsartan | 2009 |
Combination of ARB and ACE inhibitors in heart failure patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2009 |
Acetylcholine-regulated K+ current remodelling in the atrium after myocardial infarction and valsartan administration.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Appendage; Atrial Fibrillation; Heart Atria; Myocardial Infarction; Patch-Clamp Techniques; Potassium Channels; Rabbits; Tetrazoles; Valine; Valsartan | 2009 |
Angiotensin-receptor blockers for prevention of atrial fibrillation--a matter of timing or target?
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Humans; Tetrazoles; Valine; Valsartan | 2009 |
Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Inflammation Mediators; Ischemic Preconditioning, Myocardial; Myocardial Reperfusion Injury; NF-kappa B; Rats; Signal Transduction; Tetrazoles; Toll-Like Receptor 4; Treatment Outcome; Valine; Valsartan | 2009 |
Are treatment effects of ACEI and ARB in post-MI patients homogeneous?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asian People; Disease Progression; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Design, optimization, preparation and evaluation of dispersion granules of valsartan and formulation into tablets.
Topics: Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Drug Stability; Models, Statistical; Solubility; Spectroscopy, Fourier Transform Infrared; Tablets; Technology, Pharmaceutical; Tetrazoles; Valine; Valsartan; X-Ray Diffraction | 2009 |
Late lumen loss and follow-up percent diameter stenosis at different doses of oral valsartan six months after bare-metal stent implantation in type B2/C coronary lesions.
Topics: Administration, Oral; Aged; Cohort Studies; Coronary Restenosis; Coronary Stenosis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Metals; Middle Aged; Postoperative Complications; Stents; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Population pharmacokinetics of valsartan in pediatrics.
Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Humans; Infant; Metabolic Clearance Rate; Models, Biological; Pediatrics; Population Groups; Tetrazoles; Valine; Valsartan | 2009 |
AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Cell Count; Cell Differentiation; Cholesterol, Dietary; Insulin Receptor Substrate Proteins; Male; Mice; Mice, Knockout; NADPH Oxidases; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2009 |
Determination of losartan, telmisartan, and valsartan by direct injection of human urine into a column-switching liquid chromatographic system with fluorescence detection.
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Chromatography, High Pressure Liquid; Humans; Losartan; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Binding Sites; Biphenyl Compounds; Cell Line; Humans; Losartan; Models, Molecular; Protein Conformation; Radioligand Assay; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2009 |
Linear lichenoid drug eruption induced by valsartan.
Topics: Antihypertensive Agents; Drug Eruptions; Female; Humans; Lichen Planus; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2009 |
Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Coronary Angiography; Coronary Vessels; Female; Glomerular Filtration Rate; Heart Rate; Humans; Imidazoles; Male; Middle Aged; Serum Amyloid P-Component; Stents; Tetrazoles; Valine; Valsartan | 2009 |
Triple fixed-dose combination therapy: back to the past.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Silica in oral drugs as a possible sarcoidosis-inducing antigen.
Topics: Administration, Oral; Antigens; Antihypertensive Agents; Bisoprolol; Causality; Chemistry, Pharmaceutical; Doxazosin; Humans; Hypertension; Male; Middle Aged; Pharmaceutical Vehicles; Sarcoidosis, Pulmonary; Silicon Dioxide; Tetrazoles; Valine; Valsartan | 2009 |
First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents.
Topics: Aged; Coronary Vessels; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Sirolimus; Tetrazoles; Valine; Valsartan | 2009 |
Exforge HCT.
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Diuretics; Drug Combinations; Drug Costs; Humans; Hydrochlorothiazide; Hypertension; Tetrazoles; Valine; Valsartan | 2009 |
Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Contamination; Magnetic Resonance Spectroscopy; Mass Spectrometry; Spectrophotometry, Infrared; Tetrazoles; Valine; Valsartan | 2009 |
Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Cardiovascular System; Drug Synergism; Drug Therapy, Combination; Fumarates; Gene Expression; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Nitric Oxide Synthase Type III; Receptor, Angiotensin, Type 1; Renin; RNA, Messenger; Superoxides; Tetrazoles; Tunica Intima; Valine; Valsartan | 2009 |
Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Apolipoproteins E; Bezafibrate; Child; Child, Preschool; Enalapril; Female; Hematuria; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Failure, Chronic; Kidney Glomerulus; Nephrotic Syndrome; Probucol; Tetrazoles; Valine; Valsartan | 2009 |
Re: Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.
Topics: Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Dosage Forms; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Tablets; Tetrazoles; Treatment Failure; Treatment Outcome; Valine; Valsartan | 2009 |
Role of angiotensin II type 1 receptor in cerebral aneurysm formation in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chemokine CCL2; Gene Expression Regulation, Enzymologic; Intracranial Aneurysm; Macrophages; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; NF-kappa B; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2009 |
Valsartan and recurrent atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Cardiomegaly; Drug Administration Schedule; Humans; Secondary Prevention; Tetrazoles; Valine; Valsartan | 2009 |
Valsartan and recurrent atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Humans; Secondary Prevention; Tetrazoles; Valine; Valsartan | 2009 |
Validation of a fast liquid chromatography-UV method for the analysis of drugs used in combined cardiovascular therapy in human plasma.
Topics: Cardiovascular Agents; Chlorthalidone; Chromatography, Liquid; Drug Stability; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tetrazoles; Time Factors; Valine; Valsartan | 2009 |
Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats.
Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Carotid Arteries; Hypertension; Imidazoles; Immunohistochemistry; In Vitro Techniques; Male; Muscle Relaxation; NADPH Oxidases; Peptidyl-Dipeptidase A; Protective Agents; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Renin; Reverse Transcriptase Polymerase Chain Reaction; Sodium-Hydrogen Exchanger 3; Sodium-Hydrogen Exchangers; Tetrazoles; Valine; Valsartan; Vascular Diseases | 2009 |
AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Calcitonin Gene-Related Peptide; Capsaicin; Cells, Cultured; Ganglia, Spinal; Hypertension; Imidazoles; Insulin-Like Growth Factor I; Kidney; Losartan; Male; Myocardium; Nifedipine; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; RNA, Messenger; Sensory Receptor Cells; Telmisartan; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2009 |
Valsartan inhibits NPC cell line CNE-2 proliferation and invasion and promotes its sensitivity to radiation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Apoptosis; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Cobalt Radioisotopes; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gamma Rays; Humans; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Radiation Tolerance; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Tumor Cells, Cultured; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2009 |
Angiotensin II receptor blockade improves matrix metalloproteinases/tissue inhibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardium.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Fibronectins; Imidazoles; Male; Matrix Metalloproteinases; Myocardial Infarction; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2009 |
Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Hypertension; Linear Models; Male; Proteinuria; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2009 |
Angiotensin receptor blockers: baseline therapy in hypertension?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Humans; Hypertension; Risk Factors; Tetrazoles; Valine; Valsartan | 2009 |
Enantiomeric LC separation of valsartan on amylose based stationary phase.
Topics: Amylose; Angiotensin II Type 1 Receptor Blockers; Chromatography, High Pressure Liquid; Indicators and Reagents; Regression Analysis; Reproducibility of Results; Stereoisomerism; Tablets; Tetrazoles; Valine; Valsartan | 2009 |
Angiotensin II receptor blocker, valsartan, increases myocardial blood volume and regresses hypertrophy in hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Volume; Case-Control Studies; Echocardiography, Doppler; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2009 |
[On angiotensin II receptor distribution after myocardial infarction in dogs].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dogs; Female; Male; Myocardial Infarction; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2009 |
Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Cells, Cultured; Cyclooxygenase 2; Dose-Response Relationship, Drug; Glucose; Interleukin-1beta; Mesangial Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prorenin Receptor; Rats; Receptors, Cell Surface; Renin; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tetrazoles; Time Factors; Transcription Factor RelA; Valine; Valsartan | 2009 |
Angiotensin type-1 receptor inhibition is neuroprotective to amacrine cells in a rat model of retinopathy of prematurity.
Topics: Amacrine Cells; Amino Acids; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Color Vision; gamma-Aminobutyric Acid; Glycine; Humans; Infant, Newborn; Neuroprotective Agents; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Retina; Retinopathy of Prematurity; Tetrazoles; Valine; Valsartan | 2010 |
The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial.
Topics: Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Effects of angiotensin-II receptor blockers on experimental autoimmune myocarditis.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Autoimmune Diseases; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Male; Myocarditis; Rats; Rats, Inbred Lew; Tetrazoles; Th1 Cells; Th2 Cells; Valine; Valsartan | 2009 |
Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Fluorescence Resonance Energy Transfer; Humans; Molecular Dynamics Simulation; Protein Binding; Serum Albumin; Static Electricity; Telmisartan; Tetrazoles; Valine; Valsartan | 2010 |
Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin; Diabetes Mellitus, Type 2; Enkephalin, Leucine-2-Alanine; Erythropoietin; Immunosuppressive Agents; Ischemic Preconditioning, Myocardial; Janus Kinase 2; Losartan; Male; Myocardial Reperfusion Injury; Myocardium; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred OLETF; Receptor, Angiotensin, Type 1; Receptors, Opioid, delta; Signal Transduction; Species Specificity; Tacrolimus; Tetrazoles; Up-Regulation; Valine; Valsartan | 2010 |
The surge of Japanese studies supporting the use of angiotensin receptor blockers in hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Humans; Hypertension; Japan; Tetrazoles; Valine; Valsartan | 2009 |
[Effects of valsartan on myocardial calcium/calmodulin-dependent protein kinase-II expression and activity in a rabbit model of heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Disease Models, Animal; Female; Heart Failure; Male; Myocardium; Rabbits; Tetrazoles; Valine; Valsartan | 2009 |
The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Topics: Age Factors; Aged; Antihypertensive Agents; Chronic Disease; Computer Simulation; Cost-Benefit Analysis; Drug Costs; Female; Heart Failure; Hospital Costs; Humans; Italy; Male; Markov Chains; Middle Aged; Models, Statistical; Quality of Life; Quality-Adjusted Life Years; Sex Factors; Tetrazoles; Valine; Valsartan | 2009 |
Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Tetrazoles; Valine; Valsartan | 2009 |
Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data.
Topics: Administration, Oral; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Animals; Bile; Biological Transport, Active; CHO Cells; Cricetinae; Cricetulus; Cross-Over Studies; Drug Interactions; Female; Hepatocytes; Humans; Injections, Intravenous; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Models, Biological; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reproducibility of Results; Solute Carrier Organic Anion Transporter Family Member 1B3; Species Specificity; Tetrazoles; Transfection; Valine; Valsartan | 2009 |
Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data.
Topics: Algorithms; Angiotensin II Type 1 Receptor Blockers; Animals; Bile; Biological Transport, Active; Cell Line; Computer Simulation; Data Interpretation, Statistical; Forecasting; Hepatocytes; Humans; Liver-Specific Organic Anion Transporter 1; Models, Biological; Organ Size; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Rats; Solute Carrier Organic Anion Transporter Family Member 1B3; Tetrazoles; Tissue Distribution; Transfection; Valine; Valsartan | 2009 |
Involvement of Rho-kinase in collar-induced vasoconstriction and vascular hypersensitivity to serotonin in rat carotid.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II Type 1 Receptor Blockers; Animals; Carotid Artery Diseases; Cerebrovascular Circulation; Disease Models, Animal; Male; Protein Kinase Inhibitors; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; rho-Associated Kinases; rhoA GTP-Binding Protein; Serotonin; Silicones; Tetrazoles; Valine; Valsartan; Vasoconstriction | 2011 |
Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Stroke; Tetrazoles; Valine; Valsartan | 2010 |
[Intermedin (IMD) gene expression in hypertrophic cardiac myocyte of renal vascular hypertension rats and the intervention of Valsartan, Amlodipine and Enalapril in the expression].
Topics: Adrenomedullin; Amlodipine; Animals; Antihypertensive Agents; Cardiomegaly; Enalapril; Hypertension, Renovascular; Male; Myocardium; Neuropeptides; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2009 |
[The effect of valsartan and fluvastatin on the connective tissue growth factor expression in experimental diabetic cardiomyopathy].
Topics: Animals; Cardiomyopathies; Connective Tissue; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Male; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2009 |
HOTLINE III: KYOTO shows ARBs have efficacy in Asian populations.
Topics: Antihypertensive Agents; Humans; Hypertension; Japan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2009 |
Continuous positive airway pressure treatment in addition to optimal medical therapy for ventricular ectopy in a patient with heart failure and sleep-related breathing disorder.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Continuous Positive Airway Pressure; Coronary Artery Disease; Heart Failure; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Propanolamines; Radiography; Sleep Apnea, Obstructive; Tachycardia, Ventricular; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Premature Complexes | 2013 |
Celiac artery dissection presenting with abdominal and chest pain.
Topics: Abdominal Pain; Adult; Angiography; Antihypertensive Agents; Aortic Dissection; Bisoprolol; Celiac Artery; Chest Pain; Humans; Male; Tetrazoles; Tomography, X-Ray Computed; Valine; Valsartan | 2010 |
Effect of renin angiotensin system blockade on the islet microvessel density of diabetic rats and its relationship with islet function.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Islets of Langerhans; Male; Microvessels; Perindopril; Random Allocation; Rats; Rats, Wistar; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2009 |
Metabolomics in angiotensin II-induced cardiac hypertrophy.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Biomarkers; Cardiomegaly; Disease Models, Animal; Fatty Acids; Female; Humans; Hypoxanthine; Linoleic Acids; Male; Metabolomics; Mitochondria, Heart; Oxidative Stress; Probability; Random Allocation; Rats; Rats, Sprague-Dawley; Reference Values; Sirtuin 1; Survival Rate; Tetrazoles; Valine; Valsartan | 2010 |
HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Evidence-Based Medicine; Heart Failure; Humans; Losartan; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Effect of Renin-Angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance.
Topics: Adiponectin; Adult; Angiotensin II Type 1 Receptor Blockers; C-Reactive Protein; Glucose Intolerance; Humans; Insulin Resistance; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Retinol-Binding Proteins, Plasma; Tetrazoles; Valine; Valsartan | 2010 |
Endothelin-1 receptor blockade induces upregulation of renin-angiotensin-aldosterone system expression in terms of blood pressure regulation.
Topics: Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Blotting, Northern; Endothelin A Receptor Antagonists; Kidney; Liver; Lung; Mice; Mice, Inbred C57BL; Peptidyl-Dipeptidase A; Receptor, Endothelin A; Renin; Renin-Angiotensin System; Systole; Tetrazoles; Up-Regulation; Valine; Valsartan | 2010 |
Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animal Feed; Animals; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Gene Expression; Glucose Intolerance; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Macrophages; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mitochondria; Tetrazoles; Valine; Valsartan | 2010 |
Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization.
Topics: Adult; Biological Availability; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Dosage Forms; Excipients; Freeze Drying; Humans; Male; Middle Aged; Tablets; Tetrazoles; Valine; Valsartan | 2010 |
Dominant conformation of valsartan in sodium dodecyl sulfate micelle environment.
Topics: Micelles; Molecular Conformation; Molecular Dynamics Simulation; Molecular Structure; Sodium Dodecyl Sulfate; Stereoisomerism; Surface-Active Agents; Tetrazoles; Thermodynamics; Valine; Valsartan | 2010 |
Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cost-Benefit Analysis; Deductibles and Coinsurance; Drugs, Generic; Fees, Pharmaceutical; Female; Health Care Costs; Health Services; Humans; Hypertension; Male; Matched-Pair Analysis; Medication Adherence; Middle Aged; Tetrazoles; United States; Valine; Valsartan | 2010 |
Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention.
Topics: Angiotensin II Type 1 Receptor Blockers; Cost Control; Cost-Benefit Analysis; Drugs, Generic; Europe; Fees, Pharmaceutical; Health Care Costs; Humans; Hypertension; Medication Adherence; Patient Preference; Tetrazoles; Therapeutic Equivalency; United Kingdom; United States; Valine; Valsartan | 2010 |
Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
Topics: Aged; Analog-Digital Conversion; Angiotensin II Type 1 Receptor Blockers; Death; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Motion; Myocardial Contraction; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stress, Mechanical; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left; Video Recording | 2010 |
Preparation and bioavailability assessment of SMEDDS containing valsartan.
Topics: Animals; Biological Availability; Caprylates; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Diffusion; Drug Delivery Systems; Glycerides; Male; Oils; Particle Size; Polyethylene Glycols; Rabbits; Solubility; Surface-Active Agents; Tetrazoles; Valine; Valsartan | 2010 |
Blood pressure lowering with valsartan is associated with maintenance of cerebral blood flow and cerebral perfusion reserve in hypertensive patients with cerebral small vessel disease.
Topics: Acetazolamide; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cerebral Arteries; Cerebrovascular Circulation; Diuretics; Female; Humans; Hypertension; Intracranial Arteriosclerosis; Male; Microcirculation; Middle Aged; Nerve Fibers, Myelinated; Positron-Emission Tomography; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Effects of renin-angiotensin system blockade on islet function in diabetic rats.
Topics: Angiotensinogen; Animals; Apoptosis; Diabetes Mellitus, Experimental; Glucose Tolerance Test; In Situ Nick-End Labeling; Islets of Langerhans; Male; Nitric Oxide Synthase Type II; Perindopril; Rats; Rats, Wistar; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2010 |
Regulation of adrenal aldosterone production by serine protease prostasin.
Topics: Adrenal Cortex; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Channel Blockers; Cell Line; Cytochrome P-450 CYP11B2; Dihydropyridines; Gene Expression Regulation; Gene Silencing; Humans; Nitrophenols; Organophosphorus Compounds; Promoter Regions, Genetic; Rats; Receptors, Proteinase-Activated; Recombinant Proteins; Serine Endopeptidases; Tetrazoles; Transfection; Valine; Valsartan | 2010 |
Navigating the choices for diabetes prevention.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Tetrazoles; Valine; Valsartan | 2010 |
Blood-pressure reduction with LCZ696.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypertension; Neprilysin; Tetrazoles; Valine; Valsartan | 2010 |
The effects of water intake from Vals Perles no. 3 on the urinary reaction to di-chlorophenol 1-6 indophenol of pulmonary tuberculosis patients.
Topics: France; Humans; Mineral Waters; Minerals; Tetrazoles; Valine; Valsartan; Water | 1946 |
Valsartan alleviates atherosclerotic lesions in pulmonary arteries of rabbits via an endothelium-dependent mechanism.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Endothelium, Vascular; Lipids; Male; Nitric Oxide; Pulmonary Artery; Rabbits; Tetrazoles; Treatment Outcome; Valine; Valsartan; Vasodilation | 2010 |
Internalization of constitutively active N111G MUTANT of AT1 receptor induced by angiotensin II-receptor antagonists candesartan, losartan, and telmisartan: comparison with valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Chlorocebus aethiops; COS Cells; Losartan; Mutagenesis, Site-Directed; Mutation; Receptor, Angiotensin, Type 1; Telmisartan; Tetrazoles; Valine; Valsartan | 2010 |
[Effect of valsartan on ultrastructure in the brain tissue and expression of Klotho gene in spontaneously hypertensive rats].
Topics: Animals; Antihypertensive Agents; Brain; Glucuronidase; Hypertension; Intercellular Adhesion Molecule-1; Klotho Proteins; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan; Vascular Cell Adhesion Molecule-1 | 2010 |
Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Area Under Curve; Biological Availability; Capsules; Crystallization; Drug Delivery Systems; Drug Stability; Drug Storage; Excipients; Gelatin; Hypromellose Derivatives; Male; Methylcellulose; Rats; Rats, Sprague-Dawley; Solubility; Temperature; Tetrazoles; Valine; Valsartan | 2010 |
RILLKKMPSV influences the vasculature, neurons and glia, and (pro)renin receptor expression in the retina.
Topics: Animals; Animals, Newborn; Cell Survival; Chymosin; Disease Models, Animal; Enzyme Precursors; Neovascularization, Physiologic; Neuroglia; Neurons; Oligopeptides; Probability; Prorenin Receptor; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Reference Values; Retina; Retinal Diseases; Retinal Vessels; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2010 |
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.
Topics: Albuminuria; Amides; Animals; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Synergism; Fumarates; Kidney Glomerulus; Losartan; Male; Mice; Mice, Inbred C57BL; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2010 |
Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells.
Topics: Antiviral Agents; Bosentan; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Down-Regulation; Endothelial Cells; Enterovirus B, Human; Epithelial Cells; Gene Expression; HeLa Cells; Humans; Receptors, Virus; RNA, Messenger; Sulfonamides; Tetrazoles; Valine; Valsartan; Viral Load; Virus Replication | 2010 |
Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Tetrazoles; Valine; Valsartan | 2010 |
Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Female; Greece; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Male; Markov Chains; Middle Aged; Models, Economic; Quality of Life; Sex Factors; Tetrazoles; Valine; Valsartan | 2011 |
Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats.
Topics: Acetamides; Animals; Biomarkers; Cardiac Volume; Cellular Senescence; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure; Inflammation; Mitochondria, Heart; Myocardial Infarction; Myocytes, Cardiac; Pyridazines; Random Allocation; Rats; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilator Agents; Ventricular Pressure | 2010 |
Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calpain; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Inflammation; Kidney Glomerulus; Male; NF-kappa B; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Streptozocin; Tetrazoles; Transcription Factor RelA; Valine; Valsartan | 2010 |
Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb.
Topics: Angiopoietin-1; Angiopoietin-2; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Endothelial Cells; Eplerenone; Hindlimb; Immediate-Early Proteins; Ischemia; Male; Mineralocorticoid Receptor Antagonists; Monocytes; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Spironolactone; Stem Cells; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factors | 2010 |
[The effect of angiotensin II on phosphoinositide-3 kinase/Akt cascade in cultured fibroblasts derived from patients with hypertrophic scars].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Cells, Cultured; Cicatrix, Hypertrophic; Fibroblasts; Humans; Imidazoles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Valine; Valsartan | 2010 |
A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.
Topics: Alanine; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Chlorocebus aethiops; COS Cells; Humans; Imidazoles; Inositol Phosphates; Irbesartan; Losartan; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Telmisartan; Tetrazoles; Threonine; Valine; Valsartan | 2010 |
Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob/ob mouse.
Topics: Angiopoietin-Like Protein 4; Angiopoietins; Angiotensin II Type 1 Receptor Blockers; Animals; Cerebral Cortex; Diabetes Mellitus; Disease Models, Animal; Gene Expression Regulation; Hypothalamus; Intra-Abdominal Fat; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Pituitary Gland; Resistin; RNA, Messenger; Subcutaneous Fat; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Body Weight; Chemokine CCL2; Desmin; Diabetic Nephropathies; Diterpenes; Epoxy Compounds; Glomerular Filtration Rate; Immunohistochemistry; Kidney; Lipids; Liver; Mice; Mice, Inbred C57BL; Microscopy, Electron; Phenanthrenes; Podocytes; Reactive Oxygen Species; T-Lymphocytes; Tetrazoles; Valine; Valsartan | 2010 |
Effect of experimental hyperglycaemia on renal haemodynamics in prediabetic patients with and without AT1 receptor blockade.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Case-Control Studies; Glomerular Filtration Rate; Glucose Tolerance Test; Humans; Hyperglycemia; Male; Middle Aged; Prospective Studies; Receptor, Angiotensin, Type 1; Renal Circulation; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult | 2010 |
Role of Fosinopril and Valsartan on Klotho Gene Expression Induced by Angiotensin II in Rat Renal Tubular Epithelial Cells.
Topics: Angiotensin II; Animals; Cell Line; Epithelial Cells; Fosinopril; Gene Expression Regulation; Glucuronidase; Kidney Tubules; Klotho Proteins; Rats; Tetrazoles; Valine; Valsartan | 2010 |
Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension.
Topics: Abietanes; Animals; Blood Pressure; Cardiovascular Agents; Collagen; Drugs, Chinese Herbal; Fibrosis; Gene Expression; Heart; Hypertension, Renovascular; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardium; Phytotherapy; Rats; Rats, Sprague-Dawley; RNA, Messenger; Salvia miltiorrhiza; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2010 |
Stability-indicating UPLC method for determination of Valsartan and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms.
Topics: Angiotensin II Type 1 Receptor Blockers; Chromatography, High Pressure Liquid; Dosage Forms; Drug Stability; Limit of Detection; Tetrazoles; Valine; Valsartan | 2010 |
Pharmaceutical composition of valsartan: beta-cyclodextrin: physico-chemical characterization and anti-hypertensive evaluation.
Topics: Animals; Antihypertensive Agents; Cyclodextrins; Hypertension; Magnetic Resonance Spectroscopy; Male; Molecular Structure; Rats; Rats, Wistar; Spectroscopy, Fourier Transform Infrared; Tetrazoles; Valine; Valsartan | 2010 |
Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Female; Health Services; Humans; Hypertension; Male; Medical Audit; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Tetrazoles; Valine; Valsartan | 2010 |
Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Comorbidity; Down-Regulation; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Retrospective Studies; Tablets; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren.
Topics: Actins; Amides; Anatomy, Cross-Sectional; Animals; Antihypertensive Agents; Blood Pressure; Blotting, Western; Collagen; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Fumarates; Immunohistochemistry; Kidney; Kidney Diseases; Kidney Function Tests; Male; Neutrophil Infiltration; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Snail Family Transcription Factors; Tetrazoles; Transcription Factors; Ureteral Obstruction; Valine; Valsartan | 2010 |
Valsartan inefficacy or ill-effects of concomitant medications!
Topics: Angiotensin II Type 1 Receptor Blockers; Drug Interactions; Humans; Tetrazoles; Valine; Valsartan | 2010 |
Effect of valsartan on the incidence of diabetes.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Diuretics; Humans; Hypertension; Incidence; Tetrazoles; Valine; Valsartan | 2010 |
Therapeutic implications of high-dose angiotensin receptor blocker monotherapy in mild-to-moderate hypertensive patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Dose-Response Relationship, Drug; Humans; Hypertension; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Area Under Curve; Biological Availability; Chemistry, Pharmaceutical; Drug Carriers; Hydrogen-Ion Concentration; Male; Poloxamer; Rats; Rats, Sprague-Dawley; Solubility; Solvents; Tetrazoles; Valine; Valsartan | 2010 |
Naloxone, but not valsartan, preserves responses to hypoglycemia after antecedent hypoglycemia: role of metabolic reprogramming in counterregulatory failure.
Topics: Angiopoietin-Like Protein 4; Angiopoietins; Animals; Antihypertensive Agents; Apoptosis Regulatory Proteins; Blood Glucose; Carrier Proteins; Cyclin-Dependent Kinase Inhibitor p21; Glucose Transporter Type 2; Glycerolphosphate Dehydrogenase; Homeostasis; Hypoglycemia; Insulin; Membrane Proteins; Mice; Naloxone; Narcotic Antagonists; Perilipin-4; Protein Serine-Threonine Kinases; Pure Autonomic Failure; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Transcription Factors; Valine; Valsartan | 2011 |
Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption.
Topics: Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Antihypertensive Agents; Betamethasone; Biopsy; Combined Modality Therapy; Drug Eruptions; Humans; Immunohistochemistry; Ki-1 Antigen; Male; Prednisolone; Pseudolymphoma; Skin; Tetrazoles; Treatment Outcome; Ultraviolet Therapy; Valine; Valsartan | 2010 |
Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.
Topics: Angiotensin II Type 1 Receptor Blockers; Antipsychotic Agents; Benzimidazoles; Benzoates; Benzodiazepines; Female; Humans; Hyperinsulinism; Insulin Resistance; Male; Middle Aged; Olanzapine; Receptor, Angiotensin, Type 1; Schizophrenia; Telmisartan; Tetrazoles; Valine; Valsartan | 2011 |
Local angiotensin II aggravates cardiac remodeling in hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Collagen; Desoxycorticosterone; Dinoprost; Disease Models, Animal; Heart Rate; Hypertension; Male; Membrane Glycoproteins; Mice; Mice, Transgenic; Myocardium; Myocytes, Cardiac; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2010 |
Simultaneous spectrofluorimetric determination of amlodipine besylate and valsartan in their combined tablets.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Drug Combinations; Limit of Detection; Spectrophotometry; Tablets; Tetrazoles; Valine; Valsartan | 2010 |
Strategy for identification and characterization of small quantities of drug degradation products using LC and LC-MS: application to valsartan, a model drug.
Topics: Chemistry, Pharmaceutical; Chromatography, Liquid; Drug Stability; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tetrazoles; Valine; Valsartan | 2010 |
The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Glomerulonephritis; Hypertension; Kidney; Kidney Diseases; Male; Organ Size; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Development and evaluation of a monolithic drug-in-adhesive patch for valsartan.
Topics: Administration, Cutaneous; Angiotensin II Type 1 Receptor Blockers; Animals; Dioctyl Sulfosuccinic Acid; Excipients; Female; Humans; Male; Mice; Mice, Hairless; Myristates; Permeability; Rats; Rats, Hairless; Skin Absorption; Species Specificity; Swine; Swine, Miniature; Tetrazoles; Transdermal Patch; Valine; Valsartan | 2010 |
Treatment with valsartan stimulates endothelial progenitor cells and renal label-retaining cells in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Base Sequence; Cell Movement; DNA Primers; Endothelium, Vascular; Kidney Medulla; Male; Oxidative Stress; PAX2 Transcription Factor; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stem Cells; Tetrazoles; Thiobarbituric Acid Reactive Substances; Valine; Valsartan | 2011 |
Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atrial Natriuretic Factor; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Echocardiography; Gene Expression; Hemodynamics; Imidazoles; Losartan; Male; Mice; Myocardium; Reverse Transcriptase Polymerase Chain Reaction; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Fibrosis; Fosinopril; Glucuronidase; Hypertension; Kidney; Klotho Proteins; Male; Matrix Metalloproteinase 9; Plasminogen Activator Inhibitor 1; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2010 |
[CCB uptitration is superior to ARB uptitration in CKD patients who do not reach target blood pressure with ARB/CCB combined therapy].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Chronic Disease; Drug Therapy, Combination; Glomerular Filtration Rate; Hypertension; Kidney Diseases; Nifedipine; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Radionuclide imaging of angiotensin II type 1 receptor upregulation after myocardial ischemia-reperfusion injury.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Autoradiography; Enalapril; Feasibility Studies; Male; Myocardial Reperfusion Injury; Myocardium; Positron-Emission Tomography; Pyridines; Radiopharmaceuticals; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Tissue Distribution; Valine; Valsartan | 2010 |
Determinants of masked hypertension in hypertensive patients treated in a primary care setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Comorbidity; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Masked Hypertension; Middle Aged; Obesity; Prevalence; Primary Health Care; Quebec; Risk; Tetrazoles; Valine; Valsartan; White Coat Hypertension | 2012 |
Valsartan decreases TGF-β1 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats.
Topics: Animals; Blood Pressure; Chlorhexidine; Glucose; Heart Rate; Immunohistochemistry; Liver Cirrhosis; Male; Peritoneal Dialysis; Peritoneal Fibrosis; Peritoneum; Protective Agents; Rats; Rats, Sprague-Dawley; Staining and Labeling; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2011 |
Estimation of financial burden due to oversupply of medications for chronic diseases.
Topics: Aged; Atorvastatin; Chronic Disease; Clopidogrel; Drug Costs; Female; Heptanoic Acids; Hospitals, University; Humans; Male; Middle Aged; Pharmaceutical Preparations; Phenylcarbamates; Pyrroles; Retrospective Studies; Rivastigmine; Rosiglitazone; Tetrazoles; Thailand; Thiazolidinediones; Ticlopidine; Valine; Valsartan | 2012 |
Ask the doctor. I read that angiotensin-receptor blockers cause cancer. I take one (Diovan) for my blood pressure. Should I stop?
Topics: Angiotensin II Type 1 Receptor Blockers; Health Knowledge, Attitudes, Practice; Humans; Neoplasms; Risk Assessment; Tetrazoles; Valine; Valsartan | 2010 |
Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade.
Topics: Animals; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose; Hyperglycemia; Male; Mesangial Cells; Oligopeptides; Prorenin Receptor; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; RNA, Small Interfering; Signal Transduction; Tetrazoles; Transforming Growth Factor beta1; Up-Regulation; Valine; Valsartan | 2011 |
Angiotensin II receptor blocker induced fetopathy: 7 cases.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Apgar Score; Benzimidazoles; Biphenyl Compounds; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; Hypertension, Pulmonary; Imidazoles; Infant, Newborn; Kidney; Lung; Male; Oligohydramnios; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Renal Insufficiency; Skull; Tetrazoles; Ultrasonography, Prenatal; Valine; Valsartan | 2011 |
Effects of an N-type calcium antagonist on angiotensin II-renin feedback.
Topics: Amlodipine; Angiotensin II; Animals; Calcium Channel Blockers; Calcium Channels, N-Type; Dihydropyridines; Dose-Response Relationship, Drug; Male; Models, Biological; Rats; Renin; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2011 |
Temporary treatment with AT1 receptor blocker, valsartan, from early stage of hypertension prevented vascular remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Arteries; Blood Vessels; Disease Models, Animal; Hydralazine; Hypertension; Mice; Mice, Inbred C57BL; NADPH Oxidases; Neointima; Oxidative Stress; Renin; Tetrazoles; Valine; Valsartan | 2011 |
Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
Topics: Angioedema; Animals; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Indans; Male; Neprilysin; Propionates; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Thiazepines; Valine; Valsartan | 2011 |
Renoprotective efficacy of valsartan in chronic non-diabetic proteinuric nephropathies with renin-angiotensin system gene polymorphisms.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Chronic Disease; Female; Genotype; Humans; Kidney; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Prospective Studies; Protective Agents; Proteinuria; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2011 |
Interactions of the AT1 antagonist valsartan with dipalmitoyl-phosphatidylcholine bilayers.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Algorithms; Angiotensin II Type 1 Receptor Blockers; Binding, Competitive; Calorimetry, Differential Scanning; Kinetics; Lipid Bilayers; Models, Chemical; Models, Molecular; Molecular Structure; Scattering, Small Angle; Spectrum Analysis, Raman; Temperature; Tetrazoles; Thermodynamics; Valine; Valsartan; X-Ray Diffraction | 2011 |
Valsartan protects against ER stress-induced myocardial apoptosis via CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Endoplasmic Reticulum; Fluorescent Antibody Technique; Male; Myocardium; Oxidative Stress; Rats; Rats, Wistar; Signal Transduction; Tetrazoles; Transcription Factor CHOP; Valine; Valsartan; Ventricular Remodeling | 2011 |
[Protective effect of valsartan or/and ligustrazine on hippocampal neuronal loss in rats with vascular dementia].
Topics: Animals; Dementia, Vascular; Drug Synergism; Hippocampus; Male; Maze Learning; Memory; Neurons; Neuroprotective Agents; Pyrazines; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2011 |
Do placebo based validation standards mimic real batch products behaviour? Case studies.
Topics: Calibration; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Hydrochlorothiazide; Metformin; Parabens; Pharmaceutical Preparations; Placebos; Quality Control; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tablets; Tetrazoles; Valine; Valsartan | 2011 |
Valsartan, an angiotensin II receptor blocker, attenuates cardiac dysfunction and oxidative stress in isoproterenol-induced cardiotoxicity.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cardiotonic Agents; Cardiotoxins; Heart Diseases; Heart Rate; Isoproterenol; Male; Oxidative Stress; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2011 |
Simultaneous spectrophotometric determination of valsartan and hydrochlorothiazide by H-point standard addition method and partial least squares regression.
Topics: Antihypertensive Agents; Calibration; Hydrochlorothiazide; Least-Squares Analysis; Spectrophotometry, Ultraviolet; Tetrazoles; Valine; Valsartan | 2011 |
Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Body Weight; Dietary Fats; Disease Models, Animal; Hypertension; Kidney Diseases; Male; Metabolic Syndrome; PPAR gamma; Rats; Rats, Inbred SHR; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
[Effect of valsartan on vasoconstriction induced by the chronic injury of the adventitia in the rat collared carotid artery].
Topics: Angiotensin II; Animals; Carotid Arteries; Connective Tissue; Male; Oxidative Stress; Rats; Rats, Inbred WKY; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan; Vasoconstriction | 2011 |
Role of novel terpenes in transcutaneous permeation of valsartan: effectiveness and mechanism of action.
Topics: Administration, Cutaneous; Animals; Cadaver; Drug Delivery Systems; Humans; Permeability; Rats; Rats, Wistar; Skin; Skin Absorption; Terpenes; Tetrazoles; Valine; Valsartan | 2011 |
Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism.
Topics: Aldosterone; Angiotensin II; Animals; Astrocytes; Cells, Cultured; DNA Damage; Eplerenone; Ganglia, Spinal; Mice; Mice, Inbred C57BL; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone; Tetrazoles; Valine; Valsartan | 2011 |
Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats.
Topics: Acetylcholine; Angiotensin II; Animals; Enalapril; Endothelium, Vascular; Estrogens; Female; Free Radical Scavengers; NADPH Oxidases; Nitric Oxide; Ovariectomy; Oxidative Stress; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Vasodilation | 2011 |
Efficacy, safety, and tolerability of valsartan/hydrochlorothiazide in Asian patients with essential hypertension.
Topics: Adult; Antihypertensive Agents; Asia; Asian People; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Pacific Islands; Tetrazoles; Valine; Valsartan; Young Adult | 2011 |
Effects of valsartan on neuroprotection and neurogenesis after ischemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blotting, Western; Brain Ischemia; Immunohistochemistry; In Situ Nick-End Labeling; Male; Neurogenesis; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2011 |
Characterization of two new potential impurities of Valsartan obtained under photodegradation stress condition.
Topics: Angiotensin II Type 1 Receptor Blockers; Azirines; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stability; Magnetic Resonance Spectroscopy; Molecular Structure; Phenanthridines; Photolysis; Spectroscopy, Fourier Transform Infrared; Tetrazoles; Valine; Valsartan | 2011 |
Amlodipine + valsartan + hydrochlorothiazide. A 3-drug fixed-dose combination for hypertension: too many drawbacks.
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Packaging; Humans; Hydrochlorothiazide; Hypertension; Medication Errors; Tetrazoles; Valine; Valsartan | 2011 |
Antioxidant and cardioprotective effects of Danshensu (3-(3, 4-dihydroxyphenyl)-2-hydroxy-propanoic acid from Salvia miltiorrhiza) on isoproterenol-induced myocardial hypertrophy in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Arrhythmias, Cardiac; Cardiomegaly; Cardiotonic Agents; Connexins; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Electrocardiography; Hemodynamics; Isoproterenol; Lactates; Male; Phytotherapy; Rats; Rats, Sprague-Dawley; Salvia miltiorrhiza; Tetrazoles; Valine; Valsartan | 2011 |
[Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].
Topics: Aged; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Drug Therapy, Combination; Enalapril; Female; Fumarates; Humans; Hypertension; Indapamide; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2011 |
Emerging benefits of AT1 receptor antagonists with pleiotropic anti-inflammatory activity.
Topics: Animals; Benzimidazoles; Benzoates; Hypertension; Kidney Diseases; Male; Metabolic Syndrome; Telmisartan; Tetrazoles; Valine; Valsartan | 2011 |
Safety concerns of angiotensin II receptor blockers in preschool children.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Child, Preschool; Clinical Trials as Topic; Female; Gastroenteritis; Humans; Infant; Male; Nephrotic Syndrome; Tetrazoles; Valine; Valsartan; Virus Diseases | 2011 |
Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.
Topics: Adiponectin; Adipose Tissue; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Gene Expression Regulation; Glucose Transporter Type 4; Hypertension; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Irbesartan; Male; Metabolic Syndrome; Pioglitazone; PPAR gamma; Rats; Rats, Inbred SHR; RNA, Messenger; Tetrazoles; Thiazolidinediones; Valine; Valsartan | 2011 |
Role of angiotensin-(1-7) in rostral ventrolateral medulla in blood pressure regulation via sympathetic nerve activity in Wistar-Kyoto and spontaneous hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Disease Models, Animal; Hypertension; Male; Medulla Oblongata; Microinjections; Peptide Fragments; Peptides; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan | 2011 |
Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
Topics: Albuminuria; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glomerular Filtration Rate; Heart Rate; Humans; Hypertension; Indoles; Kidney; Lipids; Male; Middle Aged; Pilot Projects; Prospective Studies; Regression Analysis; Tetrazoles; Valine; Valsartan | 2011 |
Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan.
Topics: Administration, Cutaneous; Animals; Antihypertensive Agents; Disease Models, Animal; Drug Delivery Systems; Humans; Hypertension; Liposomes; Nanospheres; Particle Size; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2012 |
[The significance of generic valsartan in the treatment of patients].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drugs, Generic; Humans; Hypertension; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2011 |
Dissolution-enhancing mechanism of alkalizers in poloxamer-based solid dispersions and physical mixtures containing poorly water-soluble valsartan.
Topics: Calorimetry, Differential Scanning; Carbonates; Chemistry, Pharmaceutical; Electrodes; Hydrogen-Ion Concentration; Poloxamer; Solubility; Spectroscopy, Fourier Transform Infrared; Tetrazoles; Valine; Valsartan; Water; X-Ray Diffraction | 2011 |
Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Drug Combinations; Female; Health Care Costs; Health Services; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Retrospective Studies; Tetrazoles; United States; Valine; Valsartan | 2011 |
[Effect of valsartan and carnitine on cardiomyocyte Calpain-1 and Bcl-xl expressions of dogs with chronic alcohol intake-induced cardiomyopathy].
Topics: Animals; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Calpain; Cardiomyopathy, Alcoholic; Carnitine; Disease Models, Animal; Dogs; Myocytes, Cardiac; Tetrazoles; Valine; Valsartan | 2011 |
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Confounding Factors, Epidemiologic; Electronic Health Records; Female; Heart Failure; Hospitalization; Humans; Irbesartan; Losartan; Male; Models, Structural; Proportional Hazards Models; Retrospective Studies; Risk; Tetrazoles; Treatment Outcome; United States; Valine; Valsartan | 2012 |
Antioxidant effect of valsartan in experimental model of myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aspartate Aminotransferases; Creatine Kinase, MB Form; Epinephrine; Erythrocytes; Female; Glutathione; Male; Malondialdehyde; Models, Animal; Myocardial Infarction; Oxidative Stress; Rats; Tetrazoles; Valine; Valsartan | 2011 |
Beneficial effects of combination of valsartan and amlodipine on salt-induced brain injury in hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Brain; Calcium Channel Blockers; Calcium Channels; Carotid Arteries; Drug Therapy, Combination; Endothelial Cells; Hypertension; Hypoxia-Ischemia, Brain; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Random Allocation; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Sodium Chloride, Dietary; Tetrazoles; Tyrosine; Valine; Valsartan | 2011 |
Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Drug Synergism; Fumarates; Heart; Lipid Peroxidation; Male; Mice; Myocardial Infarction; Myocardium; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2012 |
[A case of valsartan-induced pneumonitis with marked elevation of serum KL-6].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Humans; Male; Middle Aged; Mucin-1; Pneumonia; Tetrazoles; Valine; Valsartan | 2011 |
Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Diet, Sodium-Restricted; Echocardiography; Heart; Heart Failure; Heart Rate; Hydrazones; Hypertension; Kidney; Male; Myocytes, Cardiac; Pyridazines; Rats; Rats, Inbred Dahl; RNA, Messenger; Simendan; Sodium Chloride, Dietary; Sodium, Dietary; Tetrazoles; Valine; Valsartan; Vasodilator Agents; Ventricular Remodeling | 2011 |
To PRESERVE and protect: targeting the microcirculation in prevention of diabetes and its complications.
Topics: Angiotensin II Type 1 Receptor Blockers; Female; Humans; Insulin Resistance; Male; Microvessels; Tetrazoles; Valine; Valsartan | 2011 |
Resistance to antihypertensive treatment: reality or artifact of reasoning?
Topics: Angiotensin II Type 1 Receptor Blockers; Female; Humans; Insulin Resistance; Male; Microvessels; Tetrazoles; Valine; Valsartan | 2011 |
Valsartan attenuated oxidative stress, decreased MCP-1 and TGF-β1 expression in glomerular mesangial and epithelial cells induced by high-glucose levels.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Culture Techniques; Cells, Cultured; Chemokine CCL2; Culture Media; Diabetic Nephropathies; Epithelial Cells; Glucose; Glutathione; Malondialdehyde; Mesangial Cells; Oxidative Stress; Rats; Reactive Oxygen Species; Superoxide Dismutase; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2011 |
[Effect of valsartan on cyclooxygenase-2 expression in cultured human umbilical vein endothelial cells stimulated by ox-LDL].
Topics: Cells, Cultured; Cyclooxygenase 2; Human Umbilical Vein Endothelial Cells; Humans; Lipoproteins, LDL; Tetrazoles; Valine; Valsartan | 2011 |
Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Belgium; Blood Pressure; Body Mass Index; Body Weight; Clinical Competence; Female; Guideline Adherence; Humans; Hypertension; Linear Models; Logistic Models; Male; Medication Adherence; Middle Aged; Odds Ratio; Overweight; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Linear Models; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2011 |
Cardiovascular protection with danshensu in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Body Weight; Cardiotonic Agents; Cardiovascular System; Chronic Disease; Drug Administration Schedule; Drug Evaluation, Preclinical; Heart; Heart Function Tests; Hypertension; Lactates; Large-Conductance Calcium-Activated Potassium Channels; Male; Mesenteric Arteries; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Nitric Oxide Synthase Type II; Patch-Clamp Techniques; Phytotherapy; Plant Preparations; Plant Roots; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Salvia miltiorrhiza; Tetrazoles; Valine; Valsartan | 2011 |
Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker.
Topics: 3T3 Cells; Adipocytes; Adipogenesis; Adiponectin; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biomarkers; Cell Differentiation; Cell Proliferation; Complement Factor D; Gene Expression; Leptin; Mice; Oxadiazoles; PPAR alpha; PPAR delta; Tetrazoles; Valine; Valsartan | 2011 |
Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.
Topics: Administration, Oral; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Fumarates; Hemodynamics; Immunoblotting; Male; Mice; Mice, Inbred Strains; Myocardial Infarction; Myocardial Reperfusion Injury; Receptor, Angiotensin, Type 1; Renin; Tetrazoles; Valine; Valsartan | 2011 |
Evolutionary cost analysis of valsartan initiation among patients with hypertension: a time series approach.
Topics: Adolescent; Adult; Antihypertensive Agents; Costs and Cost Analysis; Databases, Factual; Female; Humans; Hypertension; Male; Middle Aged; Retrospective Studies; Tetrazoles; United States; Valine; Valsartan; Young Adult | 2012 |
Synthesis of angiotensin II receptor blockers by means of a catalytic system for C-H activation.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Catalysis; Chelating Agents; Humans; Losartan; Magnetic Resonance Spectroscopy; Ruthenium; Tetrazoles; Tetrazolium Salts; Valine; Valsartan | 2011 |
Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study).
Topics: Aged; Blood Pressure; Drug Combinations; Drug Substitution; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Valsartan, independently of AT1 receptor or PPARγ, suppresses LPS-induced macrophage activation and improves insulin resistance in cocultured adipocytes.
Topics: 3T3-L1 Cells; Adipocytes, White; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cells, Cultured; Coculture Techniques; Humans; Insulin Resistance; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Receptor, Angiotensin, Type 1; RNA Interference; RNA, Small Interfering; Tetrazoles; Valine; Valsartan | 2012 |
Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan.
Topics: Adhesiveness; Administration, Intranasal; Angiotensin II Type 1 Receptor Blockers; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Diffusion; Drug Carriers; Microscopy, Electron, Scanning; Microspheres; Particle Size; Tetrazoles; Valine; Valsartan; X-Ray Diffraction | 2012 |
Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Black or African American; Blood Pressure; Diabetes Mellitus; Electronic Health Records; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Obesity; Primary Health Care; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People; Young Adult | 2011 |
Cost-effectiveness analysis of valsartan versus losartan and the effect of switching.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Substitution; Fees, Pharmaceutical; Humans; Hypertension; Insurance, Health, Reimbursement; Losartan; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Tetrazoles; United States; Valine; Valsartan | 2012 |
Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biological Availability; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Crystallization; Crystallography, X-Ray; Drug Carriers; Drug Compounding; Hydrophobic and Hydrophilic Interactions; Hypromellose Derivatives; Male; Methylcellulose; Microscopy, Electron, Scanning; Powders; Rats; Rats, Sprague-Dawley; Sodium Dodecyl Sulfate; Solubility; Surface Properties; Technology, Pharmaceutical; Tetrazoles; Valine; Valsartan; Water | 2012 |
[The effect of valsartan on the expression of the receptor for advanced glycation end products in human glomerular mesangial cells].
Topics: Angiotensin II Type 1 Receptor Blockers; Antioxidants; Glycation End Products, Advanced; Humans; Mesangial Cells; Oxidative Stress; Receptor for Advanced Glycation End Products; Receptors, Immunologic; RNA, Messenger; Serum Albumin, Bovine; Tetrazoles; Valine; Valsartan | 2011 |
Cardioplegia and angiotensin II receptor antagonists modulate signal transducers and activators of transcription activation in neonatal rat myocytes.
Topics: Angiotensin Receptor Antagonists; Animals; Cells, Cultured; Heart Arrest, Induced; Imidazoles; Muscle Cells; Pyridines; Rats; Rats, Wistar; STAT Transcription Factors; STAT2 Transcription Factor; STAT3 Transcription Factor; STAT5 Transcription Factor; Tetrazoles; Transcriptional Activation; Valine; Valsartan | 2011 |
MDSC parameter optimization for the determination of glass transitions using a design of experiments approach.
Topics: Angiotensin II Type 1 Receptor Blockers; Calorimetry, Differential Scanning; Models, Statistical; Phase Transition; Pyrrolidines; Reproducibility of Results; Research Design; Signal-To-Noise Ratio; Sodium Chloride; Technology, Pharmaceutical; Tetrazoles; Time Factors; Transition Temperature; Valine; Valsartan; Vinyl Compounds | 2012 |
Effects of valsartan on ventricular arrhythmia induced by programmed electrical stimulation in rats with myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Connexin 43; Down-Regulation; Electric Stimulation; Female; Myocardial Infarction; Rats; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 1; Tetrazoles; Up-Regulation; Valine; Valsartan | 2012 |
Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.
Topics: Adrenergic alpha-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; Dose-Response Relationship, Drug; Doxazosin; Imidazoles; In Vitro Techniques; Losartan; Male; Molecular Structure; Prazosin; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2012 |
Angiotensin receptor blockade attenuates glomerulosclerosis progression by promoting VEGF expression and bone marrow-derived cells recruitment.
Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Western; Bone Marrow; Bone Marrow Transplantation; Disease Progression; Female; Fluorescent Antibody Technique; Glomerulosclerosis, Focal Segmental; Green Fluorescent Proteins; Immunoenzyme Techniques; Isoantibodies; Kidney Glomerulus; Male; Nephrectomy; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptors, Angiotensin; Tetrazoles; Thy-1 Antigens; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2012 |
Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Collagen Type I; Collagen Type III; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Hydroxyproline; Insulin Resistance; Male; Myocardium; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2010 |
Dinuclear copper(II) complexes with valsartan. Synthesis, characterization and cytotoxicity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Shape; Coordination Complexes; Copper; Drug Stability; Electron Spin Resonance Spectroscopy; Inhibitory Concentration 50; Mice; Models, Molecular; Molecular Conformation; Rats; Spectroscopy, Fourier Transform Infrared; Tetrazoles; Thermogravimetry; Valine; Valsartan | 2012 |
Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Disease Models, Animal; Drug Therapy, Combination; Fumarates; Heart Rate; Male; Motor Activity; Random Allocation; Rats; Rats, Inbred Lew; Rats, Transgenic; Receptors, Angiotensin; Renin; Tetrazoles; Valine; Valsartan | 2012 |
The crossroad of RAAS modulation, inflammation, and oxidative stress in dialysis patients: light at the end of the tunnel?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Inflammation; Male; Ramipril; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2012 |
Effects of renin-angiotensin-aldosterone system blockade on chlorhexidine gluconate-induced sclerosing encapsulated peritonitis in rats.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Chlorhexidine; Fumarates; Matrix Metalloproteinase 2; Peritoneum; Peritonitis; Rats; Rats, Wistar; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2012 |
Exanthematous drug eruption due to valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Eruptions; Erythema; Exanthema; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2012 |
Synthesis, pharmacokinetics, and pharmacodynamics studies of valsartan peptide derivatives.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Drug Stability; Female; Intestinal Absorption; Male; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2012 |
Neovascularization is attenuated with aldosterone synthase inhibition in rats with retinopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cytochrome P-450 CYP11B2; Disease Models, Animal; Drug Therapy, Combination; Fadrozole; Follow-Up Studies; Microglia; Oxygen; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells; Retinal Neovascularization; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Valsartan inhibits angiotensin II-induced proliferation of vascular smooth muscle cells via regulating the expression of mitofusin 2.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Proliferation; Cells, Cultured; Drug Interactions; Gene Expression Regulation; GTP Phosphohydrolases; Male; MAP Kinase Signaling System; Membrane Proteins; Mitochondrial Proteins; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Rats; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2012 |
Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Cells, Cultured; Female; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Losartan; Nitric Oxide; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Telmisartan; Tetrazoles; Umbilical Veins; Valine; Valsartan; Vasodilation | 2012 |
The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomechanical Phenomena; Blood Pressure; Echocardiography, Doppler; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Contraction; Prospective Studies; Recovery of Function; Tetrazoles; Time Factors; Treatment Outcome; Turkey; Valine; Valsartan; Ventricular Function, Left | 2012 |
Comparing effects of lacidipine, ramipril, and valsartan against experimentally induced myocardial infarcted rats.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Dihydropyridines; Dose-Response Relationship, Drug; Isoproterenol; Male; Myocardial Infarction; Ramipril; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2012 |
[Effects of valsartan and U0126 on atrial fibrosis and connexin40 remodeling in rats].
Topics: Animals; Butadienes; Connexins; Fibrosis; Gap Junction alpha-5 Protein; Heart Atria; Male; Myocardium; Nitriles; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2011 |
Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomyopathy, Dilated; Cricetinae; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Fumarates; Male; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2012 |
Valsartan inhibited HIF-1α pathway and attenuated renal interstitial fibrosis in streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Blotting, Western; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin-1; Gene Expression; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kidney; Male; Nephritis, Interstitial; Proteinuria; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Streptozocin; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2012 |
Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPARγ activation.
Topics: Angiotensin II; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Benzimidazoles; Benzoates; Cell Differentiation; Cell Line; Dose-Response Relationship, Drug; Down-Regulation; Humans; Macrophages; Monocytes; PPAR gamma; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Telmisartan; Tetrazoles; Valine; Valsartan | 2012 |
Valsartan, an angiotensin receptor blocker treats sexual dysfunction in a female hypertensive: a case report.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Middle Aged; Orgasm; Sexual Dysfunction, Physiological; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Valsartan: in children and adolescents with hypertension.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Child; Enalapril; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2012 |
Cardioprotective effects of zofenopril, enalapril and valsartan against ischaemia/reperfusion injury as well as doxorubicin cardiotoxicity.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Doxorubicin; Enalapril; Heart Diseases; Hemodynamics; Humans; Male; Rats; Rats, Wistar; Reperfusion Injury; Tetrazoles; Valine; Valsartan | 2012 |
Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Carotid Artery Diseases; Carotid Artery, Common; CD36 Antigens; Disease Models, Animal; Disease Progression; Focal Adhesion Kinase 1; Gene Deletion; JNK Mitogen-Activated Protein Kinases; Lipids; Lipoproteins, LDL; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Plaque, Atherosclerotic; Receptor, Angiotensin, Type 1; Rupture, Spontaneous; Superoxides; Tetrazoles; Time Factors; Valine; Valsartan | 2012 |
Protective effects of valsartan against cigarette smoke-induced left ventricular systolic dysfunction in rats.
Topics: Animals; Cardiotonic Agents; Inflammation Mediators; Male; Oxidative Stress; Random Allocation; Rats; Rats, Wistar; Smoking; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2013 |
Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.
Topics: Acute Kidney Injury; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Fumarates; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Renin; Tetrazoles; Valine; Valsartan | 2012 |
Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Diuretics; Drug Therapy, Combination; Guideline Adherence; Guidelines as Topic; Humans; Hydrochlorothiazide; Reproducibility of Results; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2012 |
The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice.
Topics: Adamantane; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Endothelial Cells; Endothelium, Vascular; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Inflammation; Intercellular Adhesion Molecule-1; Mice; NADPH Oxidases; Oxidative Stress; Pyrrolidines; Receptors, Glucagon; Tetrazoles; Valine; Valsartan; Vascular Cell Adhesion Molecule-1 | 2012 |
Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chronic Disease; Etidronic Acid; Fluorobenzenes; France; Humans; Middle Aged; Pioglitazone; Prescription Drugs; Pyrimidines; Randomized Controlled Trials as Topic; Risedronic Acid; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Thiazolidinediones; Valine; Valsartan | 2012 |
Aquaporin changes during diabetic retinopathy in rats are accelerated by systemic hypertension and are linked to the renin-angiotensin system.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aquaporins; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Glial Fibrillary Acidic Protein; Hypertension; Metoprolol; Nerve Fibers; Neuroglia; Rats; Rats, Inbred WKY; Renin-Angiotensin System; Retina; Tetrazoles; Valine; Valsartan | 2012 |
Subtle issues in model specification and estimation of marginal structural models.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; Humans; Irbesartan; Losartan; Male; Tetrazoles; Valine; Valsartan | 2012 |
Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis.
Topics: Adult; Aged; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fumarates; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Gene Expression Regulation; Hepatocytes; In Situ Nick-End Labeling; Liver Cirrhosis, Experimental; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2012 |
Determining the feasibility of objective adherence measurement with blister packaging smart technology.
Topics: Angiotensin II Type 1 Receptor Blockers; Drug Labeling; Drug Monitoring; Drug Packaging; Equipment Design; Feasibility Studies; Humans; Netherlands; Patient Compliance; Pharmacies; Reproducibility of Results; Technology, Pharmaceutical; Tetrazoles; Valine; Valsartan | 2012 |
Angiotensin-receptor-blocker-induced refractory hypotension responds to methylene blue.
Topics: Aged; Angiotensin Receptor Antagonists; Carbazoles; Carvedilol; Citalopram; Crystalloid Solutions; Diabetes Mellitus, Type 2; Drug Resistance; Female; Gastric Bypass; Humans; Hypotension; Isotonic Solutions; Obesity, Morbid; Phenylephrine; Preoperative Care; Propanolamines; Tetrazoles; Valine; Valsartan | 2012 |
Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biological Transport; Bosentan; Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Fluorobenzenes; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Kinetics; Models, Biological; Organic Anion Transporters; Piperidines; Pravastatin; Pyrimidines; Quinolines; Rats; Rosuvastatin Calcium; Species Specificity; Sulfonamides; Telmisartan; Tetrazoles; Valine; Valsartan | 2012 |
Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Drug Interactions; Intestinal Absorption; Male; Organ Culture Techniques; Quercetin; Random Allocation; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2013 |
Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan.
Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fumarates; Kidney; Male; Mice; Mice, Inbred C57BL; Renin; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2012 |
Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique.
Topics: Acrylic Resins; Adhesiveness; Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Biological Availability; Chemistry, Pharmaceutical; Drug Compounding; Drug Delivery Systems; Excipients; Gastrointestinal Transit; Hypromellose Derivatives; Male; Methylcellulose; Powders; Rats; Rats, Sprague-Dawley; Solubility; Spectroscopy, Fourier Transform Infrared; Tetrazoles; Valine; Valsartan | 2012 |
The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Arginine; Benzopyrans; C-Reactive Protein; Ethanolamines; Female; Humans; Hypertension; Male; Middle Aged; Nebivolol; Serum Amyloid P-Component; Tetrazoles; Valine; Valsartan | 2012 |
Understanding the interaction between valsartan and detergents by NMR techniques and molecular dynamics simulation.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cell Membrane; Cetrimonium; Cetrimonium Compounds; Detergents; Magnetic Resonance Spectroscopy; Micelles; Models, Molecular; Molecular Conformation; Molecular Dynamics Simulation; Phosphorylcholine; Polysorbates; Sodium Dodecyl Sulfate; Tetrazoles; Thermodynamics; Valine; Valsartan | 2012 |
Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; Drug Therapy, Combination; Female; Gene Expression Regulation, Enzymologic; Heart; Hemodynamics; Immunohistochemistry; Myocardial Infarction; Myocardium; Organ Size; Peptidyl-Dipeptidase A; Ramipril; Rats; Rats, Sprague-Dawley; Renin; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Valine; Valsartan | 2012 |
Ionic liquids dispersive liquid-liquid microextraction and high-performance liquid chromatographic determination of irbesartan and valsartan in human urine.
Topics: Acetone; Biphenyl Compounds; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Humans; Irbesartan; Liquid Phase Microextraction; Reproducibility of Results; Tetrazoles; Time Factors; Valine; Valsartan | 2013 |
Does response of RAS blockade on serum K+ levels influence its glycemic-mitigating response when combined with hydrochlorothiazide?
Topics: Aged; Antihypertensive Agents; Blood Glucose; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; Hydrochlorothiazide; Hypertension; Insulin; Male; Middle Aged; Obesity, Abdominal; Outpatients; Postprandial Period; Potassium; Renin-Angiotensin System; Statistics as Topic; Tetrazoles; Valine; Valsartan | 2012 |
A comparison of the effects of fixed dose vs. single-agent combinations on 24-h blood pressure variability.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Time Factors; Valine; Valsartan | 2012 |
Presence and physiologic function of the renin-angiotensin system in mouse lacrimal gland.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensinogen; Animals; Cells, Cultured; Female; Fibroblasts; Imidazoles; Immunohistochemistry; Lacrimal Apparatus; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Peptidyl-Dipeptidase A; Pyridines; Receptors, Angiotensin; Renin; Renin-Angiotensin System; RNA, Messenger; Tears; Tetrazoles; Valine; Valsartan | 2012 |
Valsartan, a specific angiotensin II receptor blocker, inhibits pancreatic fluid secretion via vagal afferent pathway in conscious rats.
Topics: Afferent Pathways; Amylases; Angiotensin II Type 1 Receptor Blockers; Animals; Atropine; Bicarbonates; Capsaicin; Cholecystokinin; Male; Muscarinic Antagonists; Pancreas; Pancreatic Juice; Proteins; Rats; Rats, Wistar; Renin-Angiotensin System; Secretin; Sensory System Agents; Tetrazoles; Vagus Nerve; Valine; Valsartan | 2012 |
Thermal behavior and phase identification of Valsartan by standard and temperature-modulated differential scanning calorimetry.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calorimetry, Differential Scanning; Drug Stability; Hot Temperature; Phase Transition; Powder Diffraction; Powders; Reproducibility of Results; Tetrazoles; Thermogravimetry; Valine; Valsartan | 2013 |
Valsartan impairs angiogenesis of mesenchymal stem cells through Akt pathway.
Topics: Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Human Umbilical Vein Endothelial Cells; Humans; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred ICR; Mice, Transgenic; Proto-Oncogene Proteins c-akt; Signal Transduction; Tetrazoles; Valine; Valsartan | 2013 |
Effects of solvents and crystallization conditions on the polymorphic behaviors and dissolution rates of valsartan.
Topics: Acetone; Acetonitriles; Angiotensin II Type 1 Receptor Blockers; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Crystallization; Crystallography, X-Ray; Ethanol; Hot Temperature; Kinetics; Microscopy, Electron, Scanning; Powder Diffraction; Powders; Solubility; Solvents; Technology, Pharmaceutical; Tetrazoles; Valine; Valsartan; Water | 2012 |
Different effects of telmisartan and valsartan on human aortic vascular smooth muscle cell proliferation.
Topics: Benzimidazoles; Benzoates; Cell Proliferation; Humans; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; PPAR gamma; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Telmisartan; Tetrazoles; Valine; Valsartan | 2012 |
Comparative study of the AT₁ receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cell Membrane; Imidazoles; Lipid Bilayers; Molecular Conformation; Receptor, Angiotensin, Type 1; Tetrazoles; Thermodynamics; Valine; Valsartan | 2012 |
Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Imidazoles; Liver Cirrhosis; Losartan; Male; Microscopy, Electron; Rats; Tetrazoles; Valine; Valsartan | 2012 |
[Role of valsartan on myocardial Calpain I, calcineurin and Ca/calmodulin-dependent protein kinase IIδ expression of renovascular hypertensive rats].
Topics: Animals; Calcineurin; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calpain; Hypertension, Renovascular; Male; Myocardium; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Tetrazoles; Valine; Valsartan | 2012 |
[2 promising substances for diastolic heart failure].
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure, Diastolic; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Spironolactone; Tetrazoles; Valine; Valsartan | 2012 |
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dihydropyridines; Disease Progression; Drug Therapy, Combination; Glomerulonephritis; Glucagon; Glucose Transporter Type 1; Glycated Hemoglobin; Glycogen; Hypertension; Kidney; Male; Norepinephrine; Proteinuria; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2013 |
Characterization of new organic nitrate hybrid drugs covalently bound to valsartan and cilostazol.
Topics: Animals; Cilostazol; Male; Nitrates; Oxidative Stress; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan; Vasoconstriction; Vasodilator Agents | 2012 |
Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive β1-adrenergic and anti-angiotensin II type 1 receptor antibody.
Topics: Aged; Autoantibodies; Diabetic Nephropathies; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Metoprolol; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, beta-1; Tetrazoles; Valine; Valsartan | 2012 |
Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers.
Topics: Absorption; Animals; Antihypertensive Agents; Biological Availability; Chemistry, Pharmaceutical; Drug Carriers; Drug Delivery Systems; Drug Stability; Emulsifying Agents; Glycerides; Male; Nanoparticles; Oils; Organic Chemicals; Particle Size; Polysorbates; Porosity; Rats; Rats, Wistar; Solubility; Surface-Active Agents; Tablets; Tetrazoles; Valine; Valsartan; Viscosity | 2012 |
Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Health Care Costs; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Prospective Studies; Retrospective Studies; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor.
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Diabetes Mellitus, Experimental; Fumarates; Heart; Humans; Male; Mice; Mice, Inbred C57BL; Myocardium; Oxidative Stress; Prorenin Receptor; Receptors, Cell Surface; Renin; Tetrazoles; Valine; Valsartan | 2013 |
Formulation, characterization and optimization of valsartan self-microemulsifying drug delivery system using statistical design of experiment.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Area Under Curve; Emulsions; Male; Oils; Pharmaceutical Vehicles; Rats; Rats, Sprague-Dawley; Solubility; Surface-Active Agents; Tetrazoles; Valine; Valsartan | 2012 |
[Effects of valsartan on aortic angiotensin converting enzyme 2 expression after aortic balloon injury in rats].
Topics: Angiotensin I; Angiotensin-Converting Enzyme 2; Animals; Intra-Aortic Balloon Pumping; Male; Muscle, Smooth, Vascular; Peptide Fragments; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2012 |
Hypertension and the J-curve phenomenon: implications for tight blood pressure control.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hypertension; Male; Product Surveillance, Postmarketing; Tetrazoles; Valine; Valsartan | 2013 |
Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats.
Topics: Aldehydes; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Carotid Arteries; Cysteine Proteinase Inhibitors; Dihydropyridines; Heart; Immunohistochemistry; Male; Muscle Relaxation; Muscle, Smooth, Vascular; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Nitric Oxide Synthase Type III; Organ Size; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Real-Time Polymerase Chain Reaction; Tetrazoles; Valine; Valsartan; Vascular Diseases | 2013 |
Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice.
Topics: Adiponectin; Adipose Tissue; Animals; Benzimidazoles; Benzoates; Body Weight; Diabetes Mellitus; Eating; Fatty Acid Synthases; Fatty Acid-Binding Proteins; Gene Expression Regulation; Homeostasis; Insulin Resistance; Interleukin-6; Male; Mice; Mice, Obese; PPAR gamma; RNA, Messenger; Telmisartan; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2013 |
[Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation].
Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Arterial Pressure; Arteries; Atrial Fibrillation; Combined Modality Therapy; Drug Monitoring; Female; Fluorobenzenes; Humans; Hypertension; Male; Myocardial Infarction; Perindopril; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler, Duplex; Valine; Valsartan; Vascular Resistance | 2012 |
Comparison of different linear calibration approaches for LC-MS bioanalysis.
Topics: Calibration; Chromatography, Liquid; Computer Simulation; Fluorobenzenes; Humans; Linear Models; Mass Spectrometry; Models, Chemical; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Triamcinolone Acetonide; Valine; Valsartan | 2012 |
Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Fibrosis; Glomerulonephritis; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Function Tests; Male; Membrane Proteins; Podocytes; Proteinuria; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2014 |
Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Fumarates; Heart Rate; Hemodynamics; Hypertension; Kidney; Male; Rats; Renin; Renin-Angiotensin System; Telemetry; Tetrazoles; Valine; Valsartan | 2013 |
Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: a retrospective observational study in Oman.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes Complications; Diabetes Mellitus; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Male; Middle Aged; Oman; Retrospective Studies; Tetrazoles; Valine; Valsartan | 2013 |
Right ventricle: wrong targets? Another blow for pharmacotherapy in congenital heart diseases.
Topics: Angiotensin II Type 1 Receptor Blockers; Female; Heart Ventricles; Humans; Male; Stroke Volume; Tetrazoles; Valine; Valsartan | 2013 |
Adenylyl cyclase VI mediates vasopressin-stimulated ENaC activity.
Topics: Adenylyl Cyclases; Aldosterone; Animals; Antidiuretic Agents; Antihypertensive Agents; Aquaporin 2; Arginine Vasopressin; Blood Pressure; Epithelial Sodium Channels; Female; Heart Rate; Kidney Tubules, Collecting; Male; Mice; Mice, Knockout; Patch-Clamp Techniques; Renin; Sodium; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2013 |
Uniform nano-sized valsartan for dissolution and bioavailability enhancement: influence of particle size and crystalline state.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Biological Availability; Calorimetry, Differential Scanning; Crystallization; Drug Stability; Drug Storage; Hydrogen-Ion Concentration; Male; Microspheres; Nanoparticles; Particle Size; Rats; Rats, Sprague-Dawley; Solubility; Tetrazoles; Time Factors; Valine; Valsartan | 2013 |
Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Topics: Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Aspirin; Carcinoma, Renal Cell; Cyclooxygenase 2 Inhibitors; Esophagitis; Humans; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Tetrazoles; Valine; Valsartan | 2013 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, Animal; Down-Regulation; Heart Failure; Isoproterenol; Male; Myocytes, Cardiac; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Valine; Valsartan | 2013 |
Concurrent estimation of amlodipine besylate, hydrochlorothiazide and valsartan by RP-HPLC, HPTLC and UV-spectrophotometry.
Topics: Amlodipine; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Combinations; Hydrochlorothiazide; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tablets; Tetrazoles; Valine; Valsartan | 2014 |
Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization, characterization and pharmacokinetic assessment.
Topics: Administration, Cutaneous; Animals; Antihypertensive Agents; Biological Availability; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Ethanol; Microscopy, Confocal; Microscopy, Electron, Transmission; Molecular Structure; Nanoparticles; Particle Size; Phospholipids; Rats; Rats, Wistar; Regression Analysis; Skin; Skin Absorption; Sonication; Surface Properties; Tetrazoles; Valine; Valsartan | 2013 |
Intracellular renin alters the electrical properties of the intact heart ventricle of adult Sprague Dawley rats.
Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Animals; Dialysis; Heart Ventricles; Indoles; Maleimides; Microelectrodes; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium; Primary Cell Culture; Protein Kinase C; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Renin; Tetrazoles; Tissue Culture Techniques; Valine; Valsartan | 2013 |
Design and development of ethosomal transdermal drug delivery system of valsartan with preclinical assessment in Wistar albino rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chromatography, High Pressure Liquid; Drug Delivery Systems; Microscopy, Electron, Scanning; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2013 |
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cell Size; Drug Interactions; Fibrosis; Fumarates; Mice; Myocardium; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Renin; Signal Transduction; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2013 |
[Angiotensin II activates large-conductance Ca(2+)-activated potassium channels in human mesenteric artery smooth muscle cells].
Topics: Angiotensin II; Humans; Large-Conductance Calcium-Activated Potassium Channels; Mesenteric Arteries; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Patch-Clamp Techniques; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vasodilation | 2013 |
Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA.
Topics: Base Sequence; Cells, Cultured; Cytochrome P-450 CYP3A; Drug Interactions; Estrone; Female; Fluorobenzenes; Hepatocytes; Humans; Imidazoles; Liver-Specific Organic Anion Transporter 1; Male; Molecular Sequence Data; Organic Anion Transporters; Pyrimidines; Quinolines; RNA, Small Interfering; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Valine; Valsartan; Xenobiotics | 2013 |
Valsartan attenuates oxidative stress and NF-κB activation and reduces myocardial apoptosis after ischemia and reperfusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Caspase 3; Male; Malondialdehyde; Myocardial Reperfusion Injury; NADPH Oxidases; NF-kappa B; Oxidative Stress; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2013 |
Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial.
Topics: Acute Coronary Syndrome; Aldosterone; Amides; Angiotensin-Converting Enzyme Inhibitors; Down-Regulation; Female; Fumarates; Humans; Male; Middle Aged; Renin-Angiotensin System; Retrospective Studies; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2013 |
Pill burden in hypertensive patients treated with single-pill combination therapy--an observational study.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Cost of Illness; Drug Combinations; Drug Therapy, Combination; Female; Germany; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2013 |
Pharmacokinetics of angiotensin II receptor blockers in the dog following a single oral administration.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Benzimidazoles; Benzoates; Chromatography, Liquid; Dogs; Dose-Response Relationship, Drug; Half-Life; Losartan; Male; Models, Biological; Tandem Mass Spectrometry; Telmisartan; Tetrazoles; Tissue Distribution; Valine; Valsartan | 2013 |
Amlodipine increases vitamin D levels more than valsartan in newly diagnosed hypertensive patients: pointing to an additional effect on bone metabolism or a novel marker of inflammation?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biomarkers; Bone Remodeling; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan; Vitamin D | 2013 |
Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Belgium; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Chi-Square Distribution; Comparative Effectiveness Research; Female; General Practice; Humans; Hypertension; Kidney Diseases; Linear Models; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
Adaptive appetites for salted and unsalted food in rats: differential effects of sodium depletion, DOCA, and dehydration.
Topics: Acetazolamide; Adaptation, Psychological; Animal Feed; Animals; Appetite; Behavior, Animal; Dehydration; Desoxycorticosterone; Diuretics; Eating; Furosemide; Homeostasis; Male; Mineralocorticoids; Models, Animal; Rats; Rats, Sprague-Dawley; Sodium; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2013 |
Angiotensin receptor blockade has protective effects on the poststenotic porcine kidney.
Topics: Acute Kidney Injury; Angiotensin Receptor Antagonists; Animals; Constriction, Pathologic; Disease Models, Animal; Female; Glomerular Filtration Rate; Hemodynamics; Kidney; Microcirculation; Oxidative Stress; Receptors, Angiotensin; Renal Artery Obstruction; Swine; Tetrazoles; Valine; Valsartan | 2013 |
Microparticles-entrapped micelles: a novel delivery system to improve solubility and dissolution rate of poorly water-soluble valsartan.
Topics: Antihypertensive Agents; Excipients; Humans; Micelles; Solubility; Surface-Active Agents; Tablets; Tetrazoles; Valine; Valsartan; Water | 2013 |
Effects of angiotensin II type 1 receptor antagonist and temperature on prolonged cardioplegic arrest in neonatal rat myocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardioplegic Solutions; Cells, Cultured; Heart; Heart Arrest, Induced; Muscle Cells; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; STAT Transcription Factors; Temperature; Tetrazoles; Valine; Valsartan | 2013 |
Hepatosteatosis and hepatic insulin resistance are blunted by argirein, an anti-inflammatory agent, through normalizing endoplasmic reticulum stress and apoptosis in diabetic liver.
Topics: Animals; Anthraquinones; Anti-Inflammatory Agents; Apoptosis; Arginine; Diabetes Mellitus, Experimental; Diet, High-Fat; Drug Combinations; eIF-2 Kinase; Endoplasmic Reticulum Stress; Glucose; Glucose Transporter Type 4; Glutathione Peroxidase; Glycogen; Heat-Shock Proteins; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Male; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Receptors, Leptin; Tetrazoles; Transcription Factor CHOP; Valine; Valsartan | 2013 |
Male hypogonadism induced by high fat diet and low dose streptozotocin is mediated by activated endoplasmic reticulum stress and IκBβ and attenuated by argirein and valsartan.
Topics: Animals; Anthraquinones; Anti-Inflammatory Agents; Arginine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Combinations; Endoplasmic Reticulum Stress; Hypogonadism; I-kappa B Proteins; Male; Rats; Rats, Sprague-Dawley; Sexual Behavior, Animal; Streptozocin; Tetrazoles; Valine; Valsartan | 2013 |
Valsartan inhibits transient receptor potential canonical-3 channel in canine atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Disease Models, Animal; Dogs; Tetrazoles; TRPC Cation Channels; Valine; Valsartan | 2013 |
Comparative study between derivative spectrophotometry and multivariate calibration as analytical tools applied for the simultaneous quantitation of Amlodipine, Valsartan and Hydrochlorothiazide.
Topics: Amlodipine; Calibration; Chemistry Techniques, Analytical; Chromatography, High Pressure Liquid; Hydrochlorothiazide; Least-Squares Analysis; Multivariate Analysis; Reproducibility of Results; Spectrophotometry; Spectrophotometry, Ultraviolet; Tablets; Tetrazoles; Valine; Valsartan | 2013 |
Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Gene Expression Regulation, Enzymologic; Kidney; Male; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2013 |
Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Gene Expression; Graft vs Host Disease; Histocompatibility Testing; Humans; Imidazoles; Lacrimal Apparatus; Liver; Lung; Male; Mice; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2013 |
Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Blood Pressure; Carotid Arteries; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Indoles; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Bone Morphogenetic Proteins; Carrier Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Male; Mice; Mice, Mutant Strains; Reactive Oxygen Species; Tetrazoles; Valine; Valsartan; Vasculitis | 2013 |
Valsartan in the treatment of hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult | 2013 |
[General molecular and cellular mechanisms for renal and cardiac remodeling in chronic kidney disease: a target for nephrocardioprotection].
Topics: Angiotensin II Type 1 Receptor Blockers; Biomarkers; Cardiotonic Agents; Fibrosis; Humans; Kidney; Myocardium; Myofibroblasts; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2013 |
Japan. Tampered data cast shadow on drug trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomedical Research; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Japan; Scientific Misconduct; Tetrazoles; Valine; Valsartan | 2013 |
Enhanced solubility and modified release of poorly water-soluble drugs via self-assembled gelatin-oleic acid nanoparticles.
Topics: Benzimidazoles; Benzoates; Diclofenac; Gelatin; Nanoparticles; Oleic Acid; Particle Size; Powder Diffraction; Solubility; Spectroscopy, Fourier Transform Infrared; Telmisartan; Tetrazoles; Valine; Valsartan; Water; X-Ray Diffraction | 2013 |
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Antihypertensive Agents; Comorbidity; Controlled Clinical Trials as Topic; Cyclohexanes; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Predictive Value of Tests; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2013 |
Second study on valsartan is threatened with retraction over alleged data manipulation.
Topics: Adverse Drug Reaction Reporting Systems; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Eruptions; Female; Humans; Male; Practice Patterns, Physicians'; Retraction of Publication as Topic; Tetrazoles; Valine; Valsartan | 2013 |
3-nitrotyrosine, a biomarker for cardiomyocyte apoptosis induced by diabetic cardiomyopathy in a rat model.
Topics: Animals; Apoptosis; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Male; Myocardium; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Tetrazoles; Tyrosine; Valine; Valsartan | 2013 |
A comparison between use of spray and freeze drying techniques for preparation of solid self-microemulsifying formulation of valsartan and in vitro and in vivo evaluation.
Topics: Administration, Oral; Animals; Desiccation; Drug Compounding; Emulsions; Freeze Drying; Gases; Male; Metabolic Clearance Rate; Particle Size; Rats; Rats, Sprague-Dawley; Solubility; Tetrazoles; Valine; Valsartan | 2013 |
Platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Carotid Intima-Media Thickness; Essential Hypertension; Exercise; Female; Humans; Hypertension; Male; Middle Aged; Platelet Activation; Tetrazoles; Valine; Valsartan | 2014 |
Antihypertensive drug Valsartan promotes dendritic spine density by altering AMPA receptor trafficking.
Topics: Animals; Antihypertensive Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclin-Dependent Kinase 5; Dendritic Spines; Hippocampus; Phosphorylation; Protein Transport; Rats; Rats, Wistar; Receptors, AMPA; Synaptophysin; Tetrazoles; Valine; Valsartan | 2013 |
Dietary salt intake regulates WNK3-SPAK-NKCC1 phosphorylation cascade in mouse aorta through angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Mesenteric Arteries; Mice; Mice, Knockout; Phosphorylation; Protein Serine-Threonine Kinases; Sodium, Dietary; Solute Carrier Family 12, Member 2; Tetrazoles; Valine; Valsartan | 2013 |
Research misconduct and scientific integrity: a call for a global forum.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Hypertension; Japan; Scientific Misconduct; Tetrazoles; Valine; Valsartan | 2013 |
Hierarchical modeling of patient and physician determinants of blood pressure outcomes in adherent vs nonadherent hypertensive patients: pooled analysis of 6 studies with 14,646 evaluable patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cohort Studies; Female; Humans; Hypertension; Linear Models; Logistic Models; Male; Middle Aged; Models, Statistical; Patient Compliance; Physician-Patient Relations; Practice Patterns, Physicians'; Self Report; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Scleroderma renal crisis in an elderly patient with overlap syndrome.
Topics: Aged; Biopsy; Enalapril; Female; Humans; Hypertension; Kidney; Renal Dialysis; Renal Insufficiency; Scleroderma, Systemic; Sjogren's Syndrome; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Japanese Society of Hypertension official comment on valsartan papers.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Retraction of Publication as Topic; Scientific Misconduct; Societies; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Occurrence and fate of the angiotensin II receptor antagonist transformation product valsartan acid in the water cycle--a comparative study with selected β-blockers and the persistent anthropogenic wastewater indicators carbamazepine and acesulfame.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Carbamazepine; Drinking Water; Geography; Germany; Groundwater; Human Activities; Humans; Surface Properties; Tetrazoles; Thiazines; Valine; Valsartan; Wastewater; Water Cycle; Water Pollutants, Chemical | 2013 |
Induction of autophagy contributes to the myocardial protection of valsartan against ischemia‑reperfusion injury.
Topics: Adenine; Animals; Autophagy; Cardiotonic Agents; Hemodynamics; Ischemic Preconditioning; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases; Signal Transduction; Tetrazoles; TOR Serine-Threonine Kinases; Valine; Valsartan | 2013 |
Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Substitution; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Mycophenolate mofetil and valsartan inhibit podocyte apoptosis in streptozotocin-induced diabetic rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Diabetes Mellitus, Experimental; Kidney; Male; Membrane Proteins; Mycophenolic Acid; Podocytes; Protective Agents; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan; WT1 Proteins | 2013 |
Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Non-Small-Cell Lung; Female; Humans; Imidazoles; Lisinopril; Lung; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Radiation Pneumonitis; Retrospective Studies; Risk; Sex Factors; Tetrazoles; Valine; Valsartan | 2013 |
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Logistic Models; Losartan; Male; Middle Aged; Multivariate Analysis; Olmesartan Medoxomil; Retrospective Studies; Telmisartan; Tetrazoles; Treatment Outcome; Uric Acid; Valine; Valsartan | 2013 |
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Topics: Adamantane; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Homeodomain Proteins; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Phlorhizin; Pyrrolidines; Tetrazoles; Trans-Activators; Valine; Valsartan; Vildagliptin | 2013 |
Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Extracellular Matrix Proteins; Fibronectins; Gene Expression Regulation; Inflammation; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Cortex; Kidney Glomerulus; Membrane Proteins; Mice; Oxidative Stress; Plasminogen Activator Inhibitor 1; Podocytes; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta1; Treatment Outcome; Valine; Valsartan; WT1 Proteins | 2014 |
Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Disease Models, Animal; Down-Regulation; Fumarates; Kallikreins; Kininogens; Kinins; Mice; Mice, Knockout; Myocytes, Cardiac; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Tetrazoles; Ultrasonography; Valine; Valsartan | 2013 |
Angiotensin II downregulates ACE2-mediated enhancement of MMP-2 activity in human cardiofibroblasts.
Topics: ADAM Proteins; ADAM17 Protein; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Fibroblasts; Gene Expression Regulation; Genetic Vectors; Humans; Lentivirus; Matrix Metalloproteinase 2; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardium; Peptidyl-Dipeptidase A; Primary Cell Culture; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2013 |
Lowering effect of valsartan on fetuin-A in type 1 diabetes mellitus.
Topics: Adult; Albuminuria; alpha-2-HS-Glycoprotein; Angiotensin II Type 1 Receptor Blockers; Cholesterol, LDL; Creatine; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Female; Glycated Hemoglobin; Humans; Male; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Young Adult | 2013 |
Plasma renin activity testing to guide triple antirenin system drug therapy in a patient with difficult-to-treat hypertension.
Topics: Aged; Amides; Antihypertensive Agents; Carbazoles; Carvedilol; Fumarates; Humans; Hypertension; Male; Propanolamines; Renin; Tetrazoles; Valine; Valsartan | 2014 |
Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Age Factors; Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Child; Child, Preschool; Dilatation, Pathologic; Female; Humans; Male; Marfan Syndrome; Metoprolol; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Plasma renin activity testing to guide triple antirenin system drug therapy in a patient with difficult-to-treat hypertension.
Topics: Aged; Amides; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Drug Therapy, Combination; Fumarates; Humans; Hypertension; Male; Practice Guidelines as Topic; Precision Medicine; Predictive Value of Tests; Propanolamines; Renin; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Investigation of antihypertensive activity of carbopol valsartan transdermal gel containing 1,8-cineole.
Topics: Acrylic Resins; Administration, Cutaneous; Animals; Antihypertensive Agents; Blood Pressure; Chemistry, Pharmaceutical; Cyclohexanols; Disease Models, Animal; Eucalyptol; Gels; Monoterpenes; Rats; Skin; Tetrazoles; Valine; Valsartan | 2014 |
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Models, Statistical; Nateglinide; Phenylalanine; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Inhibitory effect of valsartan on the intestinal absorption and renal excretion of bestatin in rats.
Topics: Administration, Intravenous; Administration, Oral; Algorithms; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Bacterial Agents; Area Under Curve; Cells, Cultured; Chromatography, High Pressure Liquid; Drug Interactions; HEK293 Cells; HeLa Cells; Humans; Intestinal Absorption; Leucine; Male; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Peptide Transporter 1; Rats; Rats, Wistar; Symporters; Tandem Mass Spectrometry; Tetrazoles; Valine; Valsartan | 2014 |
Preconditioning via angiotensin type 2 receptor activation improves therapeutic efficacy of bone marrow mononuclear cells for cardiac repair.
Topics: Angiotensin II; Animals; Apoptosis; Bone Marrow Cells; Cell Transplantation; Coculture Techniques; Echocardiography; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Inflammation; Leukocytes, Mononuclear; Male; Myocardial Infarction; Myocytes, Cardiac; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Oligopeptides; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Stem Cell Transplantation; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2013 |
Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Antihypertensive Agents; Diuresis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hematocrit; Humans; Hypertension, Renal; Kidney; Male; Nephritis; Pyridines; Pyrimidines; Rats; Rats, Transgenic; Renin; Tetrazoles; Valine; Valsartan | 2014 |
Temporal association as a prerequisite factor of valsartan-induced lithium toxicity.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antimanic Agents; Bipolar Disorder; Creatinine; Drug Synergism; Female; Humans; Lithium Chloride; Tetrazoles; Valine; Valsartan | 2014 |
Different approaches in Partial Least Squares and Artificial Neural Network models applied for the analysis of a ternary mixture of Amlodipine, Valsartan and Hydrochlorothiazide.
Topics: Amlodipine; Antihypertensive Agents; Dosage Forms; Hydrochlorothiazide; Least-Squares Analysis; Neural Networks, Computer; Principal Component Analysis; Spectrophotometry, Ultraviolet; Tetrazoles; Valine; Valsartan | 2014 |
Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Topics: Amides; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykinin; Bradykinin B2 Receptor Antagonists; Cardiotonic Agents; Drug Therapy, Combination; Female; Fumarates; Imidazoles; Models, Animal; Myocardial Infarction; Myocardial Reperfusion Injury; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Tetrazoles; Valine; Valsartan | 2014 |
Novartis faces charges in Japan over promotion of valsartan to doctors.
Topics: Advertising; Drug Approval; Drug Industry; Humans; Intellectual Property; Japan; Tetrazoles; Valine; Valsartan | 2014 |
Angiotensin II induces Fat1 expression/activation and vascular smooth muscle cell migration via Nox1-dependent reactive oxygen species generation.
Topics: Acetophenones; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cadherins; Cell Movement; Cells, Cultured; Flavonoids; Gene Expression Regulation; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Oxidation-Reduction; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Tetrazoles; Valine; Valsartan | 2014 |
Effects of the angiotensin receptor blocker Valsartan (Valsacor®) on arterial pressure, indices of myocardial diastolic function and global longitudinal strain in patients with uncontrolled arterial hypertension.
Topics: Adult; Aged; Aged, 80 and over; Arterial Pressure; Drug Therapy, Combination; Echocardiography; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure, Diastolic; Humans; Hypertension; Male; Middle Aged; Myocardial Contraction; Tetrazoles; Valine; Valsartan | 2013 |
Opiorphin increases blood pressure of conscious rats through renin-angiotensin system (RAS).
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Captopril; Hypotension; Hypoxia; Male; Oligopeptides; Rats, Wistar; Renin-Angiotensin System; Salivary Proteins and Peptides; Tetrazoles; Valine; Valsartan | 2014 |
Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Proportional Hazards Models; Registries; Retrospective Studies; Survival Rate; Taiwan; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blotting, Western; Cells, Cultured; Endothelium, Vascular; Extracellular Signal-Regulated MAP Kinases; Immunoenzyme Techniques; Male; Phosphorylation; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2014 |
Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.
Topics: Aged; Cyclohexanes; Diet; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Motor Activity; Nateglinide; Phenylalanine; Placebos; Tetrazoles; Valine; Valsartan | 2014 |
Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: a role for inverse agonism of the angiotensin II type 1 receptor in obesity.
Topics: 3T3-L1 Cells; Active Transport, Cell Nucleus; Adipocytes; Adipokines; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Chlorocebus aethiops; COS Cells; Drug Inverse Agonism; Interleukin-6; Mice; NF-kappa B; Obesity; PPAR gamma; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2014 |
Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-κB pathways.
Topics: Administration, Oral; Angiotensin II; Animals; Antioxidants; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypertrophy, Left Ventricular; Isoflavones; Male; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; NF-kappa B; Oxidation-Reduction; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Reactive Oxygen Species; Signal Transduction; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Remodeling | 2014 |
The effects of valsartan on cognitive deficits induced by aluminum trichloride and d-galactose in mice.
Topics: Acetylcholinesterase; Aluminum Chloride; Aluminum Compounds; Animals; Cerebral Cortex; Chlorides; Cognition Disorders; Dementia; Disease Models, Animal; Galactose; Glutathione Peroxidase; Hippocampus; Malondialdehyde; Maze Learning; Memory Disorders; Mice; Nootropic Agents; Oxidative Stress; Random Allocation; Superoxide Dismutase; Tetrazoles; Valine; Valsartan | 2014 |
Angiotensin II type 1 receptor blockade suppresses light-induced neural damage in the mouse retina.
Topics: Acetylcysteine; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Apoptosis; Benzimidazoles; Biphenyl Compounds; Dose-Response Relationship, Drug; Fas Ligand Protein; Gene Expression Regulation; Light; Losartan; Male; Mice; Mice, Inbred BALB C; Proto-Oncogene Proteins c-fos; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Retinal Degeneration; Retinal Photoreceptor Cell Outer Segment; Signal Transduction; Tetrazoles; Valine; Valsartan | 2014 |
Differential effects of angiotensin II receptor blockers on Aβ generation.
Topics: Amyloid beta-Peptides; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Cells, Cultured; Fibroblasts; Imidazoles; Losartan; Mice, Inbred C57BL; Mice, Knockout; Peptide Fragments; Phosphatidylinositol 3-Kinases; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan; Tetrazoles; Valine; Valsartan | 2014 |
Valsartan-induced acute pancreatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Cholangiopancreatography, Endoscopic Retrograde; Cholangiopancreatography, Magnetic Resonance; Diagnosis, Differential; Humans; Hypertension; Male; Middle Aged; Pancreatitis, Acute Necrotizing; Sphincterotomy, Endoscopic; Tetrazoles; Valine; Valsartan | 2014 |
Parkinsonism and severe hypothyroidism in an elderly patient: a case of lithium toxicity due to pharmacological interactions.
Topics: Aged; Antimanic Agents; Drug Combinations; Drug Interactions; Female; Humans; Hydrochlorothiazide; Hypothyroidism; Lithium Carbonate; Parkinsonian Disorders; Severity of Illness Index; Tetrazoles; Valine; Valsartan | 2014 |
Spectroscopic investigations of the interaction of the anti‑hypertension drug valsartan with human serum albumin.
Topics: Antihypertensive Agents; Circular Dichroism; Fluorescence Resonance Energy Transfer; Humans; Protein Binding; Serum Albumin; Serum Albumin, Human; Spectrometry, Fluorescence; Tetrazoles; Valine; Valsartan | 2014 |
Investigation of drug-polymer interaction in solid dispersions by vapour sorption methods.
Topics: Adsorption; Crystallography, X-Ray; Hydrogen Bonding; Kinetics; Microscopy, Electron, Scanning; Models, Chemical; Polyethylene Glycols; Polymers; Polymethacrylic Acids; Polyvinyls; Povidone; Solubility; Technology, Pharmaceutical; Tetrazoles; Valine; Valsartan; Volatilization; Water | 2014 |
Valsartan regulates myocardial autophagy and mitochondrial turnover in experimental hypertension.
Topics: Animals; Antihypertensive Agents; Autophagy; Blood Pressure; Heart; Hypertension, Renovascular; Mitochondria; Mitochondrial Turnover; Myocardium; Swine; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2014 |
Valsartan improves the electrophysiological characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Heart Ventricles; Hypertrophy, Left Ventricular; Male; Myocardium; Rats; Rats, Inbred SHR; Shal Potassium Channels; Tetrazoles; Valine; Valsartan | 2014 |
Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects.
Topics: Amides; Animals; Antihypertensive Agents; Drug Therapy, Combination; Extracellular Matrix; Female; Fumarates; Gene Expression; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Stroke Volume; Survival Analysis; Systole; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2014 |
[Case of drug-induced angioedema (DIAE) on induction of anesthesia with difficult ventilation due to oropharyngeal edema].
Topics: Aged; Anesthesia, Epidural; Anesthesia, General; Angioedema; Angiotensin Receptor Antagonists; Edema; Humans; Intubation, Intratracheal; Male; Pharyngeal Diseases; Prostatectomy; Prostatic Neoplasms; Severity of Illness Index; Tetrazoles; Valine; Valsartan | 2014 |
Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells.
Topics: AMP-Activated Protein Kinases; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Benzoates; Cyclic GMP; Enzyme Activation; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Signal Transduction; Telmisartan; Tetrazoles; Valine; Valsartan | 2014 |
Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: preclinical assessment of pharmacokinetics in Wistar albino rats.
Topics: Administration, Cutaneous; Angiotensin II Type 1 Receptor Blockers; Animals; Biological Availability; Chemistry, Pharmaceutical; Cyclohexanols; Drug Compounding; Drug Delivery Systems; Eucalyptol; Gels; Humans; Monoterpenes; Rats; Rats, Wistar; Skin; Skin Absorption; Solvents; Tetrazoles; Valine; Valsartan; Viscosity | 2014 |
Renin-angiotensin system blockade and exercise-induced increase in aortic stiffness.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Essential Hypertension; Exercise; Female; Humans; Hypertension; Male; Tetrazoles; Valine; Valsartan; Vascular Stiffness | 2014 |
Valsartan reverses depressive/anxiety-like behavior and induces hippocampal neurogenesis and expression of BDNF protein in unpredictable chronic mild stress mice.
Topics: Animals; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Enzyme-Linked Immunosorbent Assay; Hippocampus; Male; Mice; Mice, Inbred C57BL; Neurogenesis; Stress, Psychological; Tetrazoles; Valine; Valsartan | 2014 |
Exercise-induced pulse wave velocity changes in untreated patients with essential hypertension: the effect of an angiotensin receptor antagonist.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Blood Pressure; Blood Pressure Determination; Electrocardiography; Essential Hypertension; Exercise; Female; Humans; Hypertension; Male; Middle Aged; Pulse Wave Analysis; Tetrazoles; Valine; Valsartan; Vascular Stiffness | 2014 |
Isolation, characterization and investigation of Plantago ovata husk polysaccharide as superdisintegrant.
Topics: Drug Carriers; Kinetics; Patient Compliance; Plantago; Polysaccharides; Tetrazoles; Valine; Valsartan | 2014 |
Clinical trial rigging: again!
Topics: Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Humans; Hypertension; Retraction of Publication as Topic; Scientific Misconduct; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Oral absorption of a valsartan-loaded spray-dried emulsion based on hydroxypropylmethyl cellulose.
Topics: Absorption, Physicochemical; Administration, Oral; Animals; Desiccation; Drug Carriers; Emulsions; Hypromellose Derivatives; Male; Oils; Rats; Rats, Sprague-Dawley; Surface-Active Agents; Tetrazoles; Valine; Valsartan; Water | 2014 |
Nebivolol and valsartan: useful treatment for hypertension?
Topics: Antihypertensive Agents; Benzopyrans; Ethanolamines; Female; Humans; Hypertension; Male; Nebivolol; Tetrazoles; Valine; Valsartan | 2014 |
The vasoneuronal effects of AT1 receptor blockade in a rat model of retinopathy of prematurity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Disease Models, Animal; Electroretinography; Female; Fluorescent Antibody Technique, Indirect; Microglia; Microscopy, Confocal; Oxygen; Photic Stimulation; Photoreceptor Cells, Vertebrate; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Retinal Neovascularization; Retinal Vessels; Retinopathy of Prematurity; Tetrazoles; Valine; Valsartan | 2014 |
Behavior of sartans (antihypertensive drugs) in wastewater treatment plants, their occurrence and risk for the aquatic environment.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biodegradation, Environmental; Biphenyl Compounds; Chromatography, Liquid; Environmental Monitoring; Germany; Imidazoles; Irbesartan; Mass Spectrometry; Molecular Structure; Rivers; Tetrazoles; Thiophenes; Valine; Valsartan; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2014 |
Efficacy and safety of valsartan/amlodipine single-pill combination in patients with essential hypertension (PEAK LOW).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Turkey; Valine; Valsartan | 2014 |
Impaired regulator of G protein signaling 2 transcription facilitates vascular remodeling in injured rat aorta.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Male; Muscle, Smooth, Vascular; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Tetrazoles; Valine; Valsartan; Vascular Remodeling; Vascular System Injuries | 2014 |
Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy.
Topics: Angiomyolipoma; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium; Cell Line, Tumor; Cell Proliferation; Humans; In Vitro Techniques; Kidney; Kidney Neoplasms; Pericytes; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Signal Transduction; Tetrazoles; Tuberous Sclerosis; Valine; Valsartan | 2014 |
Valsartan prevents neointimal hyperplasia after carotid artery stenting by suppressing endothelial cell injuries.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Calcium Channel Blockers; Carotid Arteries; Carotid Stenosis; Endothelial Cells; Female; Humans; Hyperplasia; Hypertension; Male; Prospective Studies; Stents; Tetrazoles; Treatment Outcome; Ultrasonography; Valine; Valsartan | 2015 |
Former Novartis employee arrested over valsartan data.
Topics: Antihypertensive Agents; Drug Industry; Fraud; Scientific Misconduct; Tetrazoles; Tokyo; Valine; Valsartan | 2014 |
Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Denmark; Female; Heart Failure; Humans; Insurance, Health, Reimbursement; Losartan; Male; Tetrazoles; Valine; Valsartan | 2014 |
Plasma abnormalities following overdose.
Topics: Color; Diltiazem; Drug Overdose; Fat Emulsions, Intravenous; Female; Food-Drug Interactions; Hemolysis; Humans; Hyperlipidemias; Middle Aged; Off-Label Use; Plasma; Poisoning; Tetrazoles; Valine; Valsartan | 2014 |
Biomedicine. Faulty drug trials tarnish Japan's clinical research.
Topics: Alzheimer Disease; Antihypertensive Agents; Biomedical Research; Brain; Clinical Trials as Topic; Drug Evaluation; Drug Industry; Humans; Japan; Positron-Emission Tomography; Product Surveillance, Postmarketing; Scientific Misconduct; Tetrazoles; Valine; Valsartan | 2014 |
[Process monitoring of dissolution of valsartan and hydrochlorothiazide tablets by fiber-chemical sensor assisted by mathematical separation model of linear equations].
Topics: Chromatography, High Pressure Liquid; Hydrochlorothiazide; Models, Theoretical; Solubility; Tablets; Tetrazoles; Valine; Valsartan | 2014 |
Valsartan decreases neointimal hyperplasia in balloon-injured rat aortic arteries by upregulating HO-1 and inhibiting angiotensin II type 1 receptor.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Animals; Aorta, Thoracic; Bilirubin; DNA Primers; Gene Expression Regulation; Heme Oxygenase-1; Hyperplasia; Male; Neointima; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Valine; Valsartan | 2014 |
Blood pressure variability, impaired autonomic function and vascular senescence in aged spontaneously hypertensive rats are ameliorated by angiotensin blockade.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Autonomic Nervous System; Baroreflex; beta-Galactosidase; Blood Pressure; Drug Evaluation, Preclinical; Endothelium, Vascular; Hypertension; Imidazoles; Myocardium; NADPH Oxidases; NG-Nitroarginine Methyl Ester; Norepinephrine; Organ Size; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reflex, Abnormal; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Vasodilation | 2014 |
Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
Topics: Albumins; Amides; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Fumarates; Inflammation; Lipid Metabolism; Male; Membrane Proteins; Mesangial Cells; Mice, Inbred DBA; Podocytes; Protective Agents; Proteinuria; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Carbon; Drug Carriers; HT29 Cells; Humans; Porosity; Rats, Sprague-Dawley; Solubility; Tetrazoles; Valine; Valsartan; Water | 2014 |
Valsartan independent of AT₁ receptor inhibits tissue factor, TLR-2 and -4 expression by regulation of Egr-1 through activation of AMPK in diabetic conditions.
Topics: AMP-Activated Protein Kinases; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Cells, Cultured; Chromatin Immunoprecipitation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Early Growth Response Protein 1; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Glucose Tolerance Test; Humans; Male; Mice; Mice, Inbred C57BL; Monocytes; Receptor, Angiotensin, Type 1; RNA, Small Interfering; Tetrazoles; Thromboplastin; Toll-Like Receptor 2; Toll-Like Receptor 4; Valine; Valsartan | 2014 |
Bisoprolol and bisoprolol-valsartan compatibility studied by differential scanning calorimetry, nuclear magnetic resonance and X-ray powder diffractometry.
Topics: Bisoprolol; Calorimetry, Differential Scanning; Magnetic Resonance Spectroscopy; Tetrazoles; Valine; Valsartan; X-Ray Diffraction | 2015 |
Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Dihydropyridines; Drug Evaluation, Preclinical; Drug Therapy, Combination; Heart; Hypertension; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Oxidative Stress; Rats, Inbred Dahl; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2015 |
First principles calculation of electron ionization mass spectra for selected organic drug molecules.
Topics: Chemistry, Pharmaceutical; Erythromycin; Humans; Lovastatin; Paclitaxel; Prescription Drugs; Simvastatin; Spectrometry, Mass, Electrospray Ionization; Tetrazoles; Valine; Valsartan | 2014 |
The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Diet, Atherogenic; Drug Therapy, Combination; Female; Guinea Pigs; Heptanoic Acids; Interleukin-1beta; Male; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Protective Agents; Pyrroles; Tetrazoles; Valine; Valsartan | 2014 |
The impact of different proportions of a treated effluent on the biotransformation of selected micro-contaminants in river water microcosms.
Topics: Acetaminophen; Biotransformation; Caffeine; Carbamazepine; Metoprolol; Pharmaceutical Preparations; Rivers; Sewage; Tetrazoles; Valine; Valsartan; Waste Disposal, Fluid; Water Pollutants, Chemical | 2014 |
Autoantibodies against β1 receptor and AT1 receptor in type 2 diabetes patients with left ventricular dilatation.
Topics: Aged; Antihypertensive Agents; Autoantibodies; Biomarkers; Diabetes Mellitus, Type 2; Dilatation, Pathologic; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Metoprolol; Middle Aged; Predictive Value of Tests; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, beta-1; Risk Factors; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan | 2014 |
Valsartan blocked alcohol-induced, Toll-like receptor 2 signaling-mediated inflammation in human vascular endothelial cells.
Topics: Angiotensin Receptor Antagonists; Apoptosis; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Ethanol; Humans; In Vitro Techniques; Inflammation; Interleukin-6; NF-kappa B; Receptor, Angiotensin, Type 1; RNA, Small Interfering; Signal Transduction; Tetrazoles; TNF Receptor-Associated Factor 6; Toll-Like Receptor 2; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2014 |
In vitro dissolution and physicochemical characterizations of novel PVP-based solid dispersions containing valsartan prepared by a freeze-drying method.
Topics: Freeze Drying; Povidone; Solubility; Spectroscopy, Fourier Transform Infrared; Tetrazoles; Valine; Valsartan; X-Ray Diffraction | 2014 |
Fabrication and evaluation of valsartan-polymer- surfactant composite nanoparticles by using the supercritical antisolvent process.
Topics: Administration, Oral; Animals; Biological Availability; Hypromellose Derivatives; Male; Nanocomposites; Nanotechnology; Poloxamer; Rats; Rats, Sprague-Dawley; Solubility; Surface-Active Agents; Tetrazoles; Valine; Valsartan | 2014 |
Angiotensin II acting on brain AT1 receptors induces adrenaline secretion and pressor responses in the rat.
Topics: Adrenal Medulla; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Brain; Epinephrine; Injections, Intraventricular; Male; Norepinephrine; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2014 |
Isolation, characterization and investigation of Cordia dichotoma fruit polysaccharide as a herbal excipient.
Topics: Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Cordia; Excipients; Polysaccharides; Powders; Spectroscopy, Fourier Transform Infrared; Tablets; Tetrazoles; Valine; Valsartan; X-Ray Diffraction | 2015 |
Effects and underlying mechanisms of human opiorphin on cardiovascular activity in anesthetized rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Heart Rate; Humans; Male; Naloxone; Narcotic Antagonists; Oligopeptides; Phentolamine; Propranolol; Rats, Sprague-Dawley; Renin-Angiotensin System; Reserpine; Salivary Proteins and Peptides; Tetrazoles; Valine; Valsartan | 2015 |
Elevated pressure causes endothelial dysfunction in mouse carotid arteries by increasing local angiotensin signaling.
Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Carotid Arteries; Endothelium, Vascular; Hydrazines; Hypertension; Indoles; Losartan; Male; Mice; Mice, Inbred C57BL; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Reactive Oxygen Species; Signal Transduction; Tetrazoles; Valine; Valsartan; Vasodilation | 2015 |
Unraveling regulatory mechanisms of atrial remodeling of mitral regurgitation pigs by gene expression profiling analysis: role of type I angiotensin II receptor antagonist.
Topics: Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Remodeling; Down-Regulation; Female; Gene Expression Profiling; Heart Atria; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Renin-Angiotensin System; Swine; Swine, Miniature; Tetrazoles; Translational Research, Biomedical; Up-Regulation; Valine; Valsartan | 2015 |
Angiotensin II-mediated GFR decline in subtotal nephrectomy is due to acid retention associated with reduced GFR.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animal Feed; Animals; Disease Models, Animal; Female; Glomerular Filtration Rate; Kidney; Male; Microdialysis; Nephrectomy; Protons; Rats; Rats, Wistar; Sodium Bicarbonate; Tetrazoles; Valine; Valsartan | 2015 |
Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Chemistry, Pharmaceutical; Child; Drug Compounding; Drug Stability; Drug Storage; Humans; Hydrogen-Ion Concentration; Polysaccharides, Bacterial; Sucrose; Temperature; Tetrazoles; Time Factors; Valine; Valsartan; Viscosity | 2014 |
Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Hyperaldosteronism; Myocardial Infarction; Rats; Tetrazoles; Valine; Valsartan | 2014 |
Suppression of adrenal βarrestin1-dependent aldosterone production by ARBs: head-to-head comparison.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arrestins; Benzimidazoles; beta-Arrestins; Biphenyl Compounds; CHO Cells; Cricetinae; Cricetulus; GTP-Binding Proteins; Humans; Phosphoproteins; Rats; Receptor, Angiotensin, Type 1; Tetrazoles; Up-Regulation; Valine; Valsartan; Zona Glomerulosa | 2015 |
Novel spectrophotometric methods for simultaneous determination of Amlodipine, Valsartan and Hydrochlorothiazide in their ternary mixture.
Topics: Amlodipine; Antihypertensive Agents; Hydrochlorothiazide; Limit of Detection; Spectrophotometry; Tetrazoles; Valine; Valsartan | 2015 |
Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asia; Blood Pressure; Calcium Channel Blockers; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Middle East; Prospective Studies; Tablets; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2015 |
Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
Topics: Angiotensin II; Animals; Atorvastatin; Benzazepines; C-Reactive Protein; Cardio-Renal Syndrome; Case-Control Studies; Drug Synergism; Heptanoic Acids; Lipids; Male; Natriuretic Peptide, Brain; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2015 |
Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Health Knowledge, Attitudes, Practice; Heart Failure, Systolic; Humans; Male; Middle Aged; Neprilysin; Tetrazoles; Valine; Valsartan | 2015 |
MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Disease Models, Animal; Endoglin; Fibrosis; Gene Expression Regulation; Hemodynamics; Heptanoic Acids; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; MicroRNAs; Muscle Cells; Myocardial Infarction; Polymerase Chain Reaction; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2015 |
[Sleep apnea: RR lowering drugs need to be administered in the evening].
Topics: Amlodipine; Blood Pressure; Cross-Over Studies; Drug Chronotherapy; Drug Therapy, Combination; Humans; Hypertension; Sleep Apnea, Obstructive; Tetrazoles; Valine; Valsartan | 2015 |
Tetrahydrobiopterin reverse left ventricular hypertrophy and diastolic dysfunction through the PI3K/p-Akt pathway in spontaneously hypertensive rats.
Topics: Animals; Biopterins; Blood Pressure; Body Weight; Diastole; Hypertension; Hypertrophy, Left Ventricular; Male; Organ Size; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2015 |
Modulation of oxidative stress by enalapril and valsartan in adrenaline treated rats: a comparative study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Enalapril; Epinephrine; Female; Male; Oxidative Stress; Rats; Rats, Long-Evans; Tetrazoles; Valine; Valsartan | 2014 |
Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in isolated ischaemia and reperfused rat hearts.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Coronary Circulation; Disease Models, Animal; Gene Expression Regulation; Male; Myocardial Reperfusion Injury; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Up-Regulation; Valine; Valsartan | 2015 |
Simultaneous determination of valsartan, amlodipine besylate and hydrochlorothiazide using capillary zone electrophoresis (CZE).
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Calibration; Diuretics; Drug Combinations; Electrophoresis, Capillary; Hydrochlorothiazide; Limit of Detection; Reference Standards; Reproducibility of Results; Tablets; Tetrazoles; Valine; Valsartan | 2015 |
New Drug Entresto for Heart Failure Drums Up a Lot of Enthusiasm.
Topics: Angiotensin Receptor Antagonists; Drug Approval; Drug Combinations; Drug Costs; Heart Failure; Humans; Managed Care Programs; Neprilysin; Tetrazoles; Valine; Valsartan | 2015 |
Effectiveness evaluation of cardiovascular drugs based on CYP2C9 target protein.
Topics: Cardiovascular Agents; Cytochrome P-450 CYP2C9; Fuzzy Logic; Humans; Tetrazoles; Valine; Valsartan | 2015 |
Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Male; Physicians; Prospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2021 |
Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; Neoplasms; Tetrazoles; Valine; Valsartan | 2022 |
Understanding the dosing-time-dependent antihypertensive effect of valsartan and aspirin through mathematical modeling.
Topics: Antihypertensive Agents; Aspirin; Humans; Hypertension; Tetrazoles; Valine; Valsartan | 2023 |
Effect of Fixed-dose Combination Amlodipine/Valsartan in Comparison to Two Drug Combination Nebivolol/Valsartan on 24-Hour Ambulatory Blood Pressure.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Combinations; Humans; Hypertension; Nebivolol; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2023 |
Effects of 5-fluorouracil Co-administration on Blood Pressure in Patients Maintained on Antihypertensives: a Retrospective Case Series.
Topics: Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Blood Pressure; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Fluorouracil; Humans; Hypertension; Nifedipine; Retrospective Studies; Tetrazoles; Valine; Valsartan | 2023 |